Frequencies for pmc_commitments dataset : by Jean Roth , jroth@nber.org , 3 Feb 2017 Frequencies for cmt_id variable in pmc_commitments dataset : Commitment | ID | Freq. Percent Cum. ------------+----------------------------------- 283222 | 1 0.04 0.04 283223 | 1 0.04 0.08 283224 | 1 0.04 0.12 283225 | 1 0.04 0.15 283226 | 1 0.04 0.19 283227 | 1 0.04 0.23 283228 | 1 0.04 0.27 283229 | 1 0.04 0.31 283230 | 1 0.04 0.35 283231 | 1 0.04 0.38 283232 | 1 0.04 0.42 283233 | 1 0.04 0.46 283234 | 1 0.04 0.50 283235 | 1 0.04 0.54 283236 | 1 0.04 0.58 283237 | 1 0.04 0.61 283238 | 1 0.04 0.65 283239 | 1 0.04 0.69 283240 | 1 0.04 0.73 283241 | 1 0.04 0.77 283242 | 1 0.04 0.81 283243 | 1 0.04 0.84 283244 | 1 0.04 0.88 283245 | 1 0.04 0.92 283246 | 1 0.04 0.96 283247 | 1 0.04 1.00 283248 | 1 0.04 1.04 283249 | 1 0.04 1.07 283250 | 1 0.04 1.11 283251 | 1 0.04 1.15 283252 | 1 0.04 1.19 283253 | 1 0.04 1.23 283254 | 1 0.04 1.27 283255 | 1 0.04 1.30 283256 | 1 0.04 1.34 283257 | 1 0.04 1.38 283258 | 1 0.04 1.42 283259 | 1 0.04 1.46 283260 | 1 0.04 1.50 283261 | 1 0.04 1.53 283262 | 1 0.04 1.57 283263 | 1 0.04 1.61 283264 | 1 0.04 1.65 283265 | 1 0.04 1.69 283266 | 1 0.04 1.73 283267 | 1 0.04 1.76 283268 | 1 0.04 1.80 283269 | 1 0.04 1.84 283270 | 1 0.04 1.88 283271 | 1 0.04 1.92 283272 | 1 0.04 1.96 283273 | 1 0.04 1.99 283274 | 1 0.04 2.03 283275 | 1 0.04 2.07 283276 | 1 0.04 2.11 283277 | 1 0.04 2.15 283278 | 1 0.04 2.19 283279 | 1 0.04 2.22 283280 | 1 0.04 2.26 283281 | 1 0.04 2.30 283282 | 1 0.04 2.34 283283 | 1 0.04 2.38 283284 | 1 0.04 2.42 283285 | 1 0.04 2.45 283286 | 1 0.04 2.49 283287 | 1 0.04 2.53 283288 | 1 0.04 2.57 283289 | 1 0.04 2.61 283290 | 1 0.04 2.65 283291 | 1 0.04 2.69 283292 | 1 0.04 2.72 283293 | 1 0.04 2.76 283294 | 1 0.04 2.80 283295 | 1 0.04 2.84 283296 | 1 0.04 2.88 283297 | 1 0.04 2.92 283298 | 1 0.04 2.95 283299 | 1 0.04 2.99 283300 | 1 0.04 3.03 283301 | 1 0.04 3.07 283302 | 1 0.04 3.11 283303 | 1 0.04 3.15 283304 | 1 0.04 3.18 283305 | 1 0.04 3.22 283306 | 1 0.04 3.26 283307 | 1 0.04 3.30 283308 | 1 0.04 3.34 283309 | 1 0.04 3.38 283310 | 1 0.04 3.41 283311 | 1 0.04 3.45 283312 | 1 0.04 3.49 283313 | 1 0.04 3.53 283314 | 1 0.04 3.57 283315 | 1 0.04 3.61 283316 | 1 0.04 3.64 283317 | 1 0.04 3.68 283318 | 1 0.04 3.72 283319 | 1 0.04 3.76 283320 | 1 0.04 3.80 283321 | 1 0.04 3.84 283322 | 1 0.04 3.87 283323 | 1 0.04 3.91 283324 | 1 0.04 3.95 283325 | 1 0.04 3.99 283326 | 1 0.04 4.03 283327 | 1 0.04 4.07 283328 | 1 0.04 4.10 283329 | 1 0.04 4.14 283330 | 1 0.04 4.18 283331 | 1 0.04 4.22 283332 | 1 0.04 4.26 283333 | 1 0.04 4.30 283334 | 1 0.04 4.33 283335 | 1 0.04 4.37 283336 | 1 0.04 4.41 283337 | 1 0.04 4.45 283338 | 1 0.04 4.49 283339 | 1 0.04 4.53 283340 | 1 0.04 4.56 283341 | 1 0.04 4.60 283342 | 1 0.04 4.64 283343 | 1 0.04 4.68 283344 | 1 0.04 4.72 283345 | 1 0.04 4.76 283346 | 1 0.04 4.79 283347 | 1 0.04 4.83 283348 | 1 0.04 4.87 283349 | 1 0.04 4.91 283350 | 1 0.04 4.95 283351 | 1 0.04 4.99 283352 | 1 0.04 5.02 283353 | 1 0.04 5.06 283354 | 1 0.04 5.10 283355 | 1 0.04 5.14 283356 | 1 0.04 5.18 283357 | 1 0.04 5.22 283358 | 1 0.04 5.26 283359 | 1 0.04 5.29 283360 | 1 0.04 5.33 283361 | 1 0.04 5.37 283362 | 1 0.04 5.41 283363 | 1 0.04 5.45 283364 | 1 0.04 5.49 283365 | 1 0.04 5.52 283366 | 1 0.04 5.56 283367 | 1 0.04 5.60 283368 | 1 0.04 5.64 283369 | 1 0.04 5.68 283370 | 1 0.04 5.72 283371 | 1 0.04 5.75 283372 | 1 0.04 5.79 283373 | 1 0.04 5.83 283374 | 1 0.04 5.87 283375 | 1 0.04 5.91 283376 | 1 0.04 5.95 283377 | 1 0.04 5.98 283378 | 1 0.04 6.02 283379 | 1 0.04 6.06 283380 | 1 0.04 6.10 283381 | 1 0.04 6.14 283382 | 1 0.04 6.18 283383 | 1 0.04 6.21 283384 | 1 0.04 6.25 283385 | 1 0.04 6.29 283386 | 1 0.04 6.33 283387 | 1 0.04 6.37 283388 | 1 0.04 6.41 283389 | 1 0.04 6.44 283390 | 1 0.04 6.48 283391 | 1 0.04 6.52 283392 | 1 0.04 6.56 283393 | 1 0.04 6.60 283394 | 1 0.04 6.64 283395 | 1 0.04 6.67 283396 | 1 0.04 6.71 283397 | 1 0.04 6.75 283398 | 1 0.04 6.79 283399 | 1 0.04 6.83 283400 | 1 0.04 6.87 283401 | 1 0.04 6.90 283402 | 1 0.04 6.94 283403 | 1 0.04 6.98 283404 | 1 0.04 7.02 283405 | 1 0.04 7.06 283406 | 1 0.04 7.10 283407 | 1 0.04 7.13 283408 | 1 0.04 7.17 283409 | 1 0.04 7.21 283410 | 1 0.04 7.25 283411 | 1 0.04 7.29 283412 | 1 0.04 7.33 283413 | 1 0.04 7.36 283414 | 1 0.04 7.40 283415 | 1 0.04 7.44 283416 | 1 0.04 7.48 283417 | 1 0.04 7.52 283418 | 1 0.04 7.56 283419 | 1 0.04 7.59 283420 | 1 0.04 7.63 283421 | 1 0.04 7.67 283422 | 1 0.04 7.71 283423 | 1 0.04 7.75 283424 | 1 0.04 7.79 283425 | 1 0.04 7.83 283426 | 1 0.04 7.86 283427 | 1 0.04 7.90 283428 | 1 0.04 7.94 283429 | 1 0.04 7.98 283430 | 1 0.04 8.02 283431 | 1 0.04 8.06 283432 | 1 0.04 8.09 283433 | 1 0.04 8.13 283434 | 1 0.04 8.17 283435 | 1 0.04 8.21 283436 | 1 0.04 8.25 283437 | 1 0.04 8.29 283438 | 1 0.04 8.32 283439 | 1 0.04 8.36 283440 | 1 0.04 8.40 283441 | 1 0.04 8.44 283442 | 1 0.04 8.48 283443 | 1 0.04 8.52 283444 | 1 0.04 8.55 283445 | 1 0.04 8.59 283446 | 1 0.04 8.63 283447 | 1 0.04 8.67 283448 | 1 0.04 8.71 283449 | 1 0.04 8.75 283450 | 1 0.04 8.78 283451 | 1 0.04 8.82 283452 | 1 0.04 8.86 283453 | 1 0.04 8.90 283454 | 1 0.04 8.94 283455 | 1 0.04 8.98 283456 | 1 0.04 9.01 283457 | 1 0.04 9.05 283458 | 1 0.04 9.09 283459 | 1 0.04 9.13 283460 | 1 0.04 9.17 283461 | 1 0.04 9.21 283462 | 1 0.04 9.24 283463 | 1 0.04 9.28 283464 | 1 0.04 9.32 283465 | 1 0.04 9.36 283466 | 1 0.04 9.40 283467 | 1 0.04 9.44 283468 | 1 0.04 9.47 283469 | 1 0.04 9.51 283470 | 1 0.04 9.55 283471 | 1 0.04 9.59 283472 | 1 0.04 9.63 283473 | 1 0.04 9.67 283474 | 1 0.04 9.70 283475 | 1 0.04 9.74 283476 | 1 0.04 9.78 283477 | 1 0.04 9.82 283478 | 1 0.04 9.86 283479 | 1 0.04 9.90 283480 | 1 0.04 9.93 283481 | 1 0.04 9.97 283482 | 1 0.04 10.01 283483 | 1 0.04 10.05 283484 | 1 0.04 10.09 283485 | 1 0.04 10.13 283486 | 1 0.04 10.16 283487 | 1 0.04 10.20 283488 | 1 0.04 10.24 283489 | 1 0.04 10.28 283490 | 1 0.04 10.32 283491 | 1 0.04 10.36 283492 | 1 0.04 10.40 283493 | 1 0.04 10.43 283494 | 1 0.04 10.47 283495 | 1 0.04 10.51 283496 | 1 0.04 10.55 283497 | 1 0.04 10.59 283498 | 1 0.04 10.63 283499 | 1 0.04 10.66 283500 | 1 0.04 10.70 283501 | 1 0.04 10.74 283502 | 1 0.04 10.78 283503 | 1 0.04 10.82 283504 | 1 0.04 10.86 283505 | 1 0.04 10.89 283506 | 1 0.04 10.93 283507 | 1 0.04 10.97 283508 | 1 0.04 11.01 283509 | 1 0.04 11.05 283510 | 1 0.04 11.09 283511 | 1 0.04 11.12 283512 | 1 0.04 11.16 283513 | 1 0.04 11.20 283514 | 1 0.04 11.24 283515 | 1 0.04 11.28 283516 | 1 0.04 11.32 283517 | 1 0.04 11.35 283518 | 1 0.04 11.39 283519 | 1 0.04 11.43 283520 | 1 0.04 11.47 283521 | 1 0.04 11.51 283522 | 1 0.04 11.55 283523 | 1 0.04 11.58 283524 | 1 0.04 11.62 283525 | 1 0.04 11.66 283526 | 1 0.04 11.70 283527 | 1 0.04 11.74 283528 | 1 0.04 11.78 283529 | 1 0.04 11.81 283530 | 1 0.04 11.85 283531 | 1 0.04 11.89 283532 | 1 0.04 11.93 283533 | 1 0.04 11.97 283534 | 1 0.04 12.01 283535 | 1 0.04 12.04 283536 | 1 0.04 12.08 283537 | 1 0.04 12.12 283538 | 1 0.04 12.16 283539 | 1 0.04 12.20 283540 | 1 0.04 12.24 283541 | 1 0.04 12.27 283542 | 1 0.04 12.31 283543 | 1 0.04 12.35 283544 | 1 0.04 12.39 283545 | 1 0.04 12.43 283546 | 1 0.04 12.47 283547 | 1 0.04 12.50 283548 | 1 0.04 12.54 283549 | 1 0.04 12.58 283550 | 1 0.04 12.62 283551 | 1 0.04 12.66 283552 | 1 0.04 12.70 283553 | 1 0.04 12.73 283554 | 1 0.04 12.77 283555 | 1 0.04 12.81 283556 | 1 0.04 12.85 283557 | 1 0.04 12.89 283558 | 1 0.04 12.93 283559 | 1 0.04 12.97 283560 | 1 0.04 13.00 283561 | 1 0.04 13.04 283562 | 1 0.04 13.08 283563 | 1 0.04 13.12 283564 | 1 0.04 13.16 283565 | 1 0.04 13.20 283566 | 1 0.04 13.23 283567 | 1 0.04 13.27 283568 | 1 0.04 13.31 283569 | 1 0.04 13.35 283570 | 1 0.04 13.39 283571 | 1 0.04 13.43 283572 | 1 0.04 13.46 283573 | 1 0.04 13.50 283574 | 1 0.04 13.54 283575 | 1 0.04 13.58 283576 | 1 0.04 13.62 283577 | 1 0.04 13.66 283578 | 1 0.04 13.69 283579 | 1 0.04 13.73 283580 | 1 0.04 13.77 283581 | 1 0.04 13.81 283582 | 1 0.04 13.85 283583 | 1 0.04 13.89 283584 | 1 0.04 13.92 283585 | 1 0.04 13.96 283586 | 1 0.04 14.00 283587 | 1 0.04 14.04 283588 | 1 0.04 14.08 283589 | 1 0.04 14.12 283590 | 1 0.04 14.15 283591 | 1 0.04 14.19 283592 | 1 0.04 14.23 283593 | 1 0.04 14.27 283594 | 1 0.04 14.31 283595 | 1 0.04 14.35 283596 | 1 0.04 14.38 283597 | 1 0.04 14.42 283598 | 1 0.04 14.46 283599 | 1 0.04 14.50 283600 | 1 0.04 14.54 283601 | 1 0.04 14.58 283602 | 1 0.04 14.61 283603 | 1 0.04 14.65 283604 | 1 0.04 14.69 283605 | 1 0.04 14.73 283606 | 1 0.04 14.77 283607 | 1 0.04 14.81 283608 | 1 0.04 14.84 283609 | 1 0.04 14.88 283610 | 1 0.04 14.92 283611 | 1 0.04 14.96 283612 | 1 0.04 15.00 283613 | 1 0.04 15.04 283614 | 1 0.04 15.07 283615 | 1 0.04 15.11 283616 | 1 0.04 15.15 283617 | 1 0.04 15.19 283618 | 1 0.04 15.23 283619 | 1 0.04 15.27 283620 | 1 0.04 15.30 283621 | 1 0.04 15.34 283622 | 1 0.04 15.38 283623 | 1 0.04 15.42 283624 | 1 0.04 15.46 283625 | 1 0.04 15.50 283626 | 1 0.04 15.54 283627 | 1 0.04 15.57 283628 | 1 0.04 15.61 283629 | 1 0.04 15.65 283630 | 1 0.04 15.69 283631 | 1 0.04 15.73 283632 | 1 0.04 15.77 283633 | 1 0.04 15.80 283634 | 1 0.04 15.84 283635 | 1 0.04 15.88 283636 | 1 0.04 15.92 283637 | 1 0.04 15.96 283638 | 1 0.04 16.00 283639 | 1 0.04 16.03 283640 | 1 0.04 16.07 283641 | 1 0.04 16.11 283642 | 1 0.04 16.15 283643 | 1 0.04 16.19 283644 | 1 0.04 16.23 283645 | 1 0.04 16.26 283646 | 1 0.04 16.30 283647 | 1 0.04 16.34 283648 | 1 0.04 16.38 283649 | 1 0.04 16.42 283650 | 1 0.04 16.46 283651 | 1 0.04 16.49 283652 | 1 0.04 16.53 283653 | 1 0.04 16.57 283654 | 1 0.04 16.61 283655 | 1 0.04 16.65 283656 | 1 0.04 16.69 283657 | 1 0.04 16.72 283658 | 1 0.04 16.76 283659 | 1 0.04 16.80 283660 | 1 0.04 16.84 283661 | 1 0.04 16.88 283662 | 1 0.04 16.92 283663 | 1 0.04 16.95 283664 | 1 0.04 16.99 283665 | 1 0.04 17.03 283666 | 1 0.04 17.07 283667 | 1 0.04 17.11 283668 | 1 0.04 17.15 283669 | 1 0.04 17.18 283670 | 1 0.04 17.22 283671 | 1 0.04 17.26 283672 | 1 0.04 17.30 283673 | 1 0.04 17.34 283674 | 1 0.04 17.38 283675 | 1 0.04 17.41 283676 | 1 0.04 17.45 283677 | 1 0.04 17.49 283678 | 1 0.04 17.53 283679 | 1 0.04 17.57 283680 | 1 0.04 17.61 283681 | 1 0.04 17.64 283682 | 1 0.04 17.68 283683 | 1 0.04 17.72 283684 | 1 0.04 17.76 283685 | 1 0.04 17.80 283686 | 1 0.04 17.84 283687 | 1 0.04 17.87 283688 | 1 0.04 17.91 283689 | 1 0.04 17.95 283690 | 1 0.04 17.99 283691 | 1 0.04 18.03 283692 | 1 0.04 18.07 283693 | 1 0.04 18.11 283694 | 1 0.04 18.14 283695 | 1 0.04 18.18 283696 | 1 0.04 18.22 283697 | 1 0.04 18.26 283698 | 1 0.04 18.30 283699 | 1 0.04 18.34 283700 | 1 0.04 18.37 283701 | 1 0.04 18.41 283702 | 1 0.04 18.45 283703 | 1 0.04 18.49 283704 | 1 0.04 18.53 283705 | 1 0.04 18.57 283706 | 1 0.04 18.60 283707 | 1 0.04 18.64 283708 | 1 0.04 18.68 283709 | 1 0.04 18.72 283710 | 1 0.04 18.76 283711 | 1 0.04 18.80 283712 | 1 0.04 18.83 283713 | 1 0.04 18.87 283714 | 1 0.04 18.91 283715 | 1 0.04 18.95 283716 | 1 0.04 18.99 283717 | 1 0.04 19.03 283718 | 1 0.04 19.06 283719 | 1 0.04 19.10 283720 | 1 0.04 19.14 283721 | 1 0.04 19.18 283722 | 1 0.04 19.22 283723 | 1 0.04 19.26 283724 | 1 0.04 19.29 283725 | 1 0.04 19.33 283726 | 1 0.04 19.37 283727 | 1 0.04 19.41 283728 | 1 0.04 19.45 283729 | 1 0.04 19.49 283730 | 1 0.04 19.52 283731 | 1 0.04 19.56 283732 | 1 0.04 19.60 283733 | 1 0.04 19.64 283734 | 1 0.04 19.68 283735 | 1 0.04 19.72 283736 | 1 0.04 19.75 283737 | 1 0.04 19.79 283738 | 1 0.04 19.83 283739 | 1 0.04 19.87 283740 | 1 0.04 19.91 283741 | 1 0.04 19.95 283742 | 1 0.04 19.98 283743 | 1 0.04 20.02 283744 | 1 0.04 20.06 283745 | 1 0.04 20.10 283746 | 1 0.04 20.14 283747 | 1 0.04 20.18 283748 | 1 0.04 20.21 283749 | 1 0.04 20.25 283750 | 1 0.04 20.29 283751 | 1 0.04 20.33 283752 | 1 0.04 20.37 283753 | 1 0.04 20.41 283754 | 1 0.04 20.44 283755 | 1 0.04 20.48 283756 | 1 0.04 20.52 283757 | 1 0.04 20.56 283758 | 1 0.04 20.60 283759 | 1 0.04 20.64 283760 | 1 0.04 20.68 283761 | 1 0.04 20.71 283762 | 1 0.04 20.75 283763 | 1 0.04 20.79 283764 | 1 0.04 20.83 283765 | 1 0.04 20.87 283766 | 1 0.04 20.91 283767 | 1 0.04 20.94 283768 | 1 0.04 20.98 283769 | 1 0.04 21.02 283770 | 1 0.04 21.06 283771 | 1 0.04 21.10 283772 | 1 0.04 21.14 283773 | 1 0.04 21.17 283774 | 1 0.04 21.21 283775 | 1 0.04 21.25 283776 | 1 0.04 21.29 283777 | 1 0.04 21.33 283778 | 1 0.04 21.37 283779 | 1 0.04 21.40 283780 | 1 0.04 21.44 283781 | 1 0.04 21.48 283782 | 1 0.04 21.52 283783 | 1 0.04 21.56 283784 | 1 0.04 21.60 283785 | 1 0.04 21.63 283786 | 1 0.04 21.67 283787 | 1 0.04 21.71 283788 | 1 0.04 21.75 283789 | 1 0.04 21.79 283790 | 1 0.04 21.83 283791 | 1 0.04 21.86 283792 | 1 0.04 21.90 283793 | 1 0.04 21.94 283794 | 1 0.04 21.98 283795 | 1 0.04 22.02 283796 | 1 0.04 22.06 283797 | 1 0.04 22.09 283798 | 1 0.04 22.13 283799 | 1 0.04 22.17 283800 | 1 0.04 22.21 283801 | 1 0.04 22.25 283802 | 1 0.04 22.29 283803 | 1 0.04 22.32 283804 | 1 0.04 22.36 283805 | 1 0.04 22.40 283806 | 1 0.04 22.44 283807 | 1 0.04 22.48 283808 | 1 0.04 22.52 283809 | 1 0.04 22.55 283810 | 1 0.04 22.59 283811 | 1 0.04 22.63 283812 | 1 0.04 22.67 283813 | 1 0.04 22.71 283814 | 1 0.04 22.75 283815 | 1 0.04 22.78 283816 | 1 0.04 22.82 283817 | 1 0.04 22.86 283818 | 1 0.04 22.90 283819 | 1 0.04 22.94 283820 | 1 0.04 22.98 283821 | 1 0.04 23.01 283822 | 1 0.04 23.05 283823 | 1 0.04 23.09 283824 | 1 0.04 23.13 283825 | 1 0.04 23.17 283826 | 1 0.04 23.21 283827 | 1 0.04 23.25 283828 | 1 0.04 23.28 283829 | 1 0.04 23.32 283830 | 1 0.04 23.36 283831 | 1 0.04 23.40 283832 | 1 0.04 23.44 283833 | 1 0.04 23.48 283834 | 1 0.04 23.51 283835 | 1 0.04 23.55 283836 | 1 0.04 23.59 283837 | 1 0.04 23.63 283838 | 1 0.04 23.67 283839 | 1 0.04 23.71 283840 | 1 0.04 23.74 283841 | 1 0.04 23.78 283842 | 1 0.04 23.82 283843 | 1 0.04 23.86 283844 | 1 0.04 23.90 283845 | 1 0.04 23.94 283846 | 1 0.04 23.97 283847 | 1 0.04 24.01 283848 | 1 0.04 24.05 283849 | 1 0.04 24.09 283850 | 1 0.04 24.13 283851 | 1 0.04 24.17 283852 | 1 0.04 24.20 283853 | 1 0.04 24.24 283854 | 1 0.04 24.28 283855 | 1 0.04 24.32 283856 | 1 0.04 24.36 283857 | 1 0.04 24.40 283858 | 1 0.04 24.43 283859 | 1 0.04 24.47 283860 | 1 0.04 24.51 283861 | 1 0.04 24.55 283862 | 1 0.04 24.59 283863 | 1 0.04 24.63 283864 | 1 0.04 24.66 283865 | 1 0.04 24.70 283866 | 1 0.04 24.74 283867 | 1 0.04 24.78 283868 | 1 0.04 24.82 283869 | 1 0.04 24.86 283870 | 1 0.04 24.89 283871 | 1 0.04 24.93 283872 | 1 0.04 24.97 283873 | 1 0.04 25.01 283874 | 1 0.04 25.05 283875 | 1 0.04 25.09 283876 | 1 0.04 25.12 283877 | 1 0.04 25.16 283878 | 1 0.04 25.20 283879 | 1 0.04 25.24 283880 | 1 0.04 25.28 283881 | 1 0.04 25.32 283882 | 1 0.04 25.35 283883 | 1 0.04 25.39 283884 | 1 0.04 25.43 283885 | 1 0.04 25.47 283886 | 1 0.04 25.51 283887 | 1 0.04 25.55 283888 | 1 0.04 25.58 283889 | 1 0.04 25.62 283890 | 1 0.04 25.66 283891 | 1 0.04 25.70 283892 | 1 0.04 25.74 283893 | 1 0.04 25.78 283894 | 1 0.04 25.82 283895 | 1 0.04 25.85 283896 | 1 0.04 25.89 283897 | 1 0.04 25.93 283898 | 1 0.04 25.97 283899 | 1 0.04 26.01 283900 | 1 0.04 26.05 283901 | 1 0.04 26.08 283902 | 1 0.04 26.12 283903 | 1 0.04 26.16 283904 | 1 0.04 26.20 283905 | 1 0.04 26.24 283906 | 1 0.04 26.28 283907 | 1 0.04 26.31 283908 | 1 0.04 26.35 283909 | 1 0.04 26.39 283910 | 1 0.04 26.43 283911 | 1 0.04 26.47 283912 | 1 0.04 26.51 283913 | 1 0.04 26.54 283914 | 1 0.04 26.58 283915 | 1 0.04 26.62 283916 | 1 0.04 26.66 283917 | 1 0.04 26.70 283918 | 1 0.04 26.74 283919 | 1 0.04 26.77 283920 | 1 0.04 26.81 283921 | 1 0.04 26.85 283922 | 1 0.04 26.89 283923 | 1 0.04 26.93 283924 | 1 0.04 26.97 283925 | 1 0.04 27.00 283926 | 1 0.04 27.04 283927 | 1 0.04 27.08 283928 | 1 0.04 27.12 283929 | 1 0.04 27.16 283930 | 1 0.04 27.20 283931 | 1 0.04 27.23 283932 | 1 0.04 27.27 283933 | 1 0.04 27.31 283934 | 1 0.04 27.35 283935 | 1 0.04 27.39 283936 | 1 0.04 27.43 283937 | 1 0.04 27.46 283938 | 1 0.04 27.50 283939 | 1 0.04 27.54 283940 | 1 0.04 27.58 283941 | 1 0.04 27.62 283942 | 1 0.04 27.66 283943 | 1 0.04 27.69 283944 | 1 0.04 27.73 283945 | 1 0.04 27.77 283946 | 1 0.04 27.81 283947 | 1 0.04 27.85 283948 | 1 0.04 27.89 283949 | 1 0.04 27.92 283950 | 1 0.04 27.96 283951 | 1 0.04 28.00 283952 | 1 0.04 28.04 283953 | 1 0.04 28.08 283954 | 1 0.04 28.12 283955 | 1 0.04 28.15 283956 | 1 0.04 28.19 283957 | 1 0.04 28.23 283958 | 1 0.04 28.27 283959 | 1 0.04 28.31 283960 | 1 0.04 28.35 283961 | 1 0.04 28.39 283962 | 1 0.04 28.42 283963 | 1 0.04 28.46 283964 | 1 0.04 28.50 283965 | 1 0.04 28.54 283966 | 1 0.04 28.58 283967 | 1 0.04 28.62 283968 | 1 0.04 28.65 283969 | 1 0.04 28.69 283970 | 1 0.04 28.73 283971 | 1 0.04 28.77 283972 | 1 0.04 28.81 283973 | 1 0.04 28.85 283974 | 1 0.04 28.88 283975 | 1 0.04 28.92 283976 | 1 0.04 28.96 283977 | 1 0.04 29.00 283978 | 1 0.04 29.04 283979 | 1 0.04 29.08 283980 | 1 0.04 29.11 283981 | 1 0.04 29.15 283982 | 1 0.04 29.19 283983 | 1 0.04 29.23 283984 | 1 0.04 29.27 283985 | 1 0.04 29.31 283986 | 1 0.04 29.34 283987 | 1 0.04 29.38 283988 | 1 0.04 29.42 283989 | 1 0.04 29.46 283990 | 1 0.04 29.50 283991 | 1 0.04 29.54 283992 | 1 0.04 29.57 283993 | 1 0.04 29.61 283994 | 1 0.04 29.65 283995 | 1 0.04 29.69 283996 | 1 0.04 29.73 283997 | 1 0.04 29.77 283998 | 1 0.04 29.80 283999 | 1 0.04 29.84 284000 | 1 0.04 29.88 284001 | 1 0.04 29.92 284002 | 1 0.04 29.96 284003 | 1 0.04 30.00 284004 | 1 0.04 30.03 284005 | 1 0.04 30.07 284006 | 1 0.04 30.11 284007 | 1 0.04 30.15 284008 | 1 0.04 30.19 284009 | 1 0.04 30.23 284010 | 1 0.04 30.26 284011 | 1 0.04 30.30 284012 | 1 0.04 30.34 284013 | 1 0.04 30.38 284014 | 1 0.04 30.42 284015 | 1 0.04 30.46 284016 | 1 0.04 30.49 284017 | 1 0.04 30.53 284018 | 1 0.04 30.57 284019 | 1 0.04 30.61 284020 | 1 0.04 30.65 284021 | 1 0.04 30.69 284022 | 1 0.04 30.72 284023 | 1 0.04 30.76 284024 | 1 0.04 30.80 284025 | 1 0.04 30.84 284026 | 1 0.04 30.88 284027 | 1 0.04 30.92 284028 | 1 0.04 30.96 284029 | 1 0.04 30.99 284030 | 1 0.04 31.03 284031 | 1 0.04 31.07 284032 | 1 0.04 31.11 284033 | 1 0.04 31.15 284034 | 1 0.04 31.19 284035 | 1 0.04 31.22 284036 | 1 0.04 31.26 284037 | 1 0.04 31.30 284038 | 1 0.04 31.34 284039 | 1 0.04 31.38 284040 | 1 0.04 31.42 284041 | 1 0.04 31.45 284042 | 1 0.04 31.49 284043 | 1 0.04 31.53 284044 | 1 0.04 31.57 284045 | 1 0.04 31.61 284046 | 1 0.04 31.65 284047 | 1 0.04 31.68 284048 | 1 0.04 31.72 284049 | 1 0.04 31.76 284050 | 1 0.04 31.80 284051 | 1 0.04 31.84 284052 | 1 0.04 31.88 284053 | 1 0.04 31.91 284054 | 1 0.04 31.95 284055 | 1 0.04 31.99 284056 | 1 0.04 32.03 284057 | 1 0.04 32.07 284058 | 1 0.04 32.11 284059 | 1 0.04 32.14 284060 | 1 0.04 32.18 284061 | 1 0.04 32.22 284062 | 1 0.04 32.26 284063 | 1 0.04 32.30 284064 | 1 0.04 32.34 284065 | 1 0.04 32.37 284066 | 1 0.04 32.41 284067 | 1 0.04 32.45 284068 | 1 0.04 32.49 284069 | 1 0.04 32.53 284070 | 1 0.04 32.57 284071 | 1 0.04 32.60 284072 | 1 0.04 32.64 284073 | 1 0.04 32.68 284074 | 1 0.04 32.72 284075 | 1 0.04 32.76 284076 | 1 0.04 32.80 284077 | 1 0.04 32.83 284078 | 1 0.04 32.87 284079 | 1 0.04 32.91 284080 | 1 0.04 32.95 284081 | 1 0.04 32.99 284082 | 1 0.04 33.03 284083 | 1 0.04 33.06 284084 | 1 0.04 33.10 284085 | 1 0.04 33.14 284086 | 1 0.04 33.18 284087 | 1 0.04 33.22 284088 | 1 0.04 33.26 284089 | 1 0.04 33.29 284090 | 1 0.04 33.33 284091 | 1 0.04 33.37 284092 | 1 0.04 33.41 284093 | 1 0.04 33.45 284094 | 1 0.04 33.49 284095 | 1 0.04 33.53 284096 | 1 0.04 33.56 284097 | 1 0.04 33.60 284098 | 1 0.04 33.64 284099 | 1 0.04 33.68 284100 | 1 0.04 33.72 284101 | 1 0.04 33.76 284102 | 1 0.04 33.79 284103 | 1 0.04 33.83 284104 | 1 0.04 33.87 284105 | 1 0.04 33.91 284106 | 1 0.04 33.95 284107 | 1 0.04 33.99 284108 | 1 0.04 34.02 284109 | 1 0.04 34.06 284110 | 1 0.04 34.10 284111 | 1 0.04 34.14 284112 | 1 0.04 34.18 284113 | 1 0.04 34.22 284114 | 1 0.04 34.25 284115 | 1 0.04 34.29 284116 | 1 0.04 34.33 284117 | 1 0.04 34.37 284118 | 1 0.04 34.41 284119 | 1 0.04 34.45 284120 | 1 0.04 34.48 284121 | 1 0.04 34.52 284122 | 1 0.04 34.56 284123 | 1 0.04 34.60 284124 | 1 0.04 34.64 284125 | 1 0.04 34.68 284126 | 1 0.04 34.71 284127 | 1 0.04 34.75 284128 | 1 0.04 34.79 284129 | 1 0.04 34.83 284130 | 1 0.04 34.87 284131 | 1 0.04 34.91 284132 | 1 0.04 34.94 284133 | 1 0.04 34.98 284134 | 1 0.04 35.02 284135 | 1 0.04 35.06 284136 | 1 0.04 35.10 284137 | 1 0.04 35.14 284138 | 1 0.04 35.17 284139 | 1 0.04 35.21 284140 | 1 0.04 35.25 284141 | 1 0.04 35.29 284142 | 1 0.04 35.33 284143 | 1 0.04 35.37 284144 | 1 0.04 35.40 284145 | 1 0.04 35.44 284146 | 1 0.04 35.48 284147 | 1 0.04 35.52 284148 | 1 0.04 35.56 284149 | 1 0.04 35.60 284150 | 1 0.04 35.63 284151 | 1 0.04 35.67 284152 | 1 0.04 35.71 284153 | 1 0.04 35.75 284154 | 1 0.04 35.79 284155 | 1 0.04 35.83 284156 | 1 0.04 35.86 284157 | 1 0.04 35.90 284158 | 1 0.04 35.94 284159 | 1 0.04 35.98 284160 | 1 0.04 36.02 284161 | 1 0.04 36.06 284162 | 1 0.04 36.10 284163 | 1 0.04 36.13 284164 | 1 0.04 36.17 284165 | 1 0.04 36.21 284166 | 1 0.04 36.25 284167 | 1 0.04 36.29 284168 | 1 0.04 36.33 284169 | 1 0.04 36.36 284170 | 1 0.04 36.40 284171 | 1 0.04 36.44 284172 | 1 0.04 36.48 284173 | 1 0.04 36.52 284174 | 1 0.04 36.56 284175 | 1 0.04 36.59 284176 | 1 0.04 36.63 284177 | 1 0.04 36.67 284178 | 1 0.04 36.71 284179 | 1 0.04 36.75 284180 | 1 0.04 36.79 284181 | 1 0.04 36.82 284182 | 1 0.04 36.86 284183 | 1 0.04 36.90 284184 | 1 0.04 36.94 284185 | 1 0.04 36.98 284186 | 1 0.04 37.02 284187 | 1 0.04 37.05 284188 | 1 0.04 37.09 284189 | 1 0.04 37.13 284190 | 1 0.04 37.17 284191 | 1 0.04 37.21 284192 | 1 0.04 37.25 284193 | 1 0.04 37.28 284194 | 1 0.04 37.32 284195 | 1 0.04 37.36 284196 | 1 0.04 37.40 284197 | 1 0.04 37.44 284198 | 1 0.04 37.48 284199 | 1 0.04 37.51 284200 | 1 0.04 37.55 284201 | 1 0.04 37.59 284202 | 1 0.04 37.63 284203 | 1 0.04 37.67 284204 | 1 0.04 37.71 284205 | 1 0.04 37.74 284206 | 1 0.04 37.78 284207 | 1 0.04 37.82 284208 | 1 0.04 37.86 284209 | 1 0.04 37.90 284210 | 1 0.04 37.94 284211 | 1 0.04 37.97 284212 | 1 0.04 38.01 284213 | 1 0.04 38.05 284214 | 1 0.04 38.09 284215 | 1 0.04 38.13 284216 | 1 0.04 38.17 284217 | 1 0.04 38.20 284218 | 1 0.04 38.24 284219 | 1 0.04 38.28 284220 | 1 0.04 38.32 284221 | 1 0.04 38.36 284222 | 1 0.04 38.40 284223 | 1 0.04 38.43 284224 | 1 0.04 38.47 284225 | 1 0.04 38.51 284226 | 1 0.04 38.55 284227 | 1 0.04 38.59 284228 | 1 0.04 38.63 284229 | 1 0.04 38.67 284230 | 1 0.04 38.70 284231 | 1 0.04 38.74 284232 | 1 0.04 38.78 284233 | 1 0.04 38.82 284234 | 1 0.04 38.86 284235 | 1 0.04 38.90 284236 | 1 0.04 38.93 284237 | 1 0.04 38.97 284238 | 1 0.04 39.01 284239 | 1 0.04 39.05 284240 | 1 0.04 39.09 284241 | 1 0.04 39.13 284242 | 1 0.04 39.16 284243 | 1 0.04 39.20 284244 | 1 0.04 39.24 284245 | 1 0.04 39.28 284246 | 1 0.04 39.32 284247 | 1 0.04 39.36 284248 | 1 0.04 39.39 284249 | 1 0.04 39.43 284250 | 1 0.04 39.47 284251 | 1 0.04 39.51 284252 | 1 0.04 39.55 284253 | 1 0.04 39.59 284254 | 1 0.04 39.62 284255 | 1 0.04 39.66 284256 | 1 0.04 39.70 284257 | 1 0.04 39.74 284258 | 1 0.04 39.78 284259 | 1 0.04 39.82 284260 | 1 0.04 39.85 284261 | 1 0.04 39.89 284262 | 1 0.04 39.93 284263 | 1 0.04 39.97 284264 | 1 0.04 40.01 284265 | 1 0.04 40.05 284266 | 1 0.04 40.08 284267 | 1 0.04 40.12 284268 | 1 0.04 40.16 284269 | 1 0.04 40.20 284270 | 1 0.04 40.24 284271 | 1 0.04 40.28 284272 | 1 0.04 40.31 284273 | 1 0.04 40.35 284274 | 1 0.04 40.39 284275 | 1 0.04 40.43 284276 | 1 0.04 40.47 284277 | 1 0.04 40.51 284278 | 1 0.04 40.54 284279 | 1 0.04 40.58 284280 | 1 0.04 40.62 284281 | 1 0.04 40.66 284282 | 1 0.04 40.70 284283 | 1 0.04 40.74 284284 | 1 0.04 40.77 284285 | 1 0.04 40.81 284286 | 1 0.04 40.85 284287 | 1 0.04 40.89 284288 | 1 0.04 40.93 284289 | 1 0.04 40.97 284290 | 1 0.04 41.00 284291 | 1 0.04 41.04 284292 | 1 0.04 41.08 284293 | 1 0.04 41.12 284294 | 1 0.04 41.16 284295 | 1 0.04 41.20 284296 | 1 0.04 41.24 284297 | 1 0.04 41.27 284298 | 1 0.04 41.31 284299 | 1 0.04 41.35 284300 | 1 0.04 41.39 284301 | 1 0.04 41.43 284302 | 1 0.04 41.47 284303 | 1 0.04 41.50 284304 | 1 0.04 41.54 284305 | 1 0.04 41.58 284306 | 1 0.04 41.62 284307 | 1 0.04 41.66 284308 | 1 0.04 41.70 284309 | 1 0.04 41.73 284310 | 1 0.04 41.77 284311 | 1 0.04 41.81 284312 | 1 0.04 41.85 284313 | 1 0.04 41.89 284314 | 1 0.04 41.93 284315 | 1 0.04 41.96 284316 | 1 0.04 42.00 284317 | 1 0.04 42.04 284318 | 1 0.04 42.08 284319 | 1 0.04 42.12 284320 | 1 0.04 42.16 284321 | 1 0.04 42.19 284322 | 1 0.04 42.23 284323 | 1 0.04 42.27 284324 | 1 0.04 42.31 284325 | 1 0.04 42.35 284326 | 1 0.04 42.39 284327 | 1 0.04 42.42 284328 | 1 0.04 42.46 284329 | 1 0.04 42.50 284330 | 1 0.04 42.54 284331 | 1 0.04 42.58 284332 | 1 0.04 42.62 284333 | 1 0.04 42.65 284334 | 1 0.04 42.69 284335 | 1 0.04 42.73 284336 | 1 0.04 42.77 284337 | 1 0.04 42.81 284338 | 1 0.04 42.85 284339 | 1 0.04 42.88 284340 | 1 0.04 42.92 284341 | 1 0.04 42.96 284342 | 1 0.04 43.00 284343 | 1 0.04 43.04 284344 | 1 0.04 43.08 284345 | 1 0.04 43.11 284346 | 1 0.04 43.15 284347 | 1 0.04 43.19 284348 | 1 0.04 43.23 284349 | 1 0.04 43.27 284350 | 1 0.04 43.31 284351 | 1 0.04 43.34 284352 | 1 0.04 43.38 284353 | 1 0.04 43.42 284354 | 1 0.04 43.46 284355 | 1 0.04 43.50 284356 | 1 0.04 43.54 284357 | 1 0.04 43.57 284358 | 1 0.04 43.61 284359 | 1 0.04 43.65 284360 | 1 0.04 43.69 284361 | 1 0.04 43.73 284362 | 1 0.04 43.77 284363 | 1 0.04 43.81 284364 | 1 0.04 43.84 284365 | 1 0.04 43.88 284366 | 1 0.04 43.92 284367 | 1 0.04 43.96 284368 | 1 0.04 44.00 284369 | 1 0.04 44.04 284370 | 1 0.04 44.07 284371 | 1 0.04 44.11 284372 | 1 0.04 44.15 284373 | 1 0.04 44.19 284374 | 1 0.04 44.23 284375 | 1 0.04 44.27 284376 | 1 0.04 44.30 284377 | 1 0.04 44.34 284378 | 1 0.04 44.38 284379 | 1 0.04 44.42 284380 | 1 0.04 44.46 284381 | 1 0.04 44.50 284382 | 1 0.04 44.53 284383 | 1 0.04 44.57 284384 | 1 0.04 44.61 284385 | 1 0.04 44.65 284386 | 1 0.04 44.69 284387 | 1 0.04 44.73 284388 | 1 0.04 44.76 284389 | 1 0.04 44.80 284390 | 1 0.04 44.84 284391 | 1 0.04 44.88 284392 | 1 0.04 44.92 284393 | 1 0.04 44.96 284394 | 1 0.04 44.99 284395 | 1 0.04 45.03 284396 | 1 0.04 45.07 284397 | 1 0.04 45.11 284398 | 1 0.04 45.15 284399 | 1 0.04 45.19 284400 | 1 0.04 45.22 284401 | 1 0.04 45.26 284402 | 1 0.04 45.30 284403 | 1 0.04 45.34 284404 | 1 0.04 45.38 284405 | 1 0.04 45.42 284406 | 1 0.04 45.45 284407 | 1 0.04 45.49 284408 | 1 0.04 45.53 284409 | 1 0.04 45.57 284410 | 1 0.04 45.61 284411 | 1 0.04 45.65 284412 | 1 0.04 45.68 284413 | 1 0.04 45.72 284414 | 1 0.04 45.76 284415 | 1 0.04 45.80 284416 | 1 0.04 45.84 284417 | 1 0.04 45.88 284418 | 1 0.04 45.91 284419 | 1 0.04 45.95 284420 | 1 0.04 45.99 284421 | 1 0.04 46.03 284422 | 1 0.04 46.07 284423 | 1 0.04 46.11 284424 | 1 0.04 46.14 284425 | 1 0.04 46.18 284426 | 1 0.04 46.22 284427 | 1 0.04 46.26 284428 | 1 0.04 46.30 284429 | 1 0.04 46.34 284430 | 1 0.04 46.38 284431 | 1 0.04 46.41 284432 | 1 0.04 46.45 284433 | 1 0.04 46.49 284434 | 1 0.04 46.53 284435 | 1 0.04 46.57 284436 | 1 0.04 46.61 284437 | 1 0.04 46.64 284438 | 1 0.04 46.68 284439 | 1 0.04 46.72 284440 | 1 0.04 46.76 284441 | 1 0.04 46.80 284442 | 1 0.04 46.84 284443 | 1 0.04 46.87 284444 | 1 0.04 46.91 284445 | 1 0.04 46.95 284446 | 1 0.04 46.99 284447 | 1 0.04 47.03 284448 | 1 0.04 47.07 284449 | 1 0.04 47.10 284450 | 1 0.04 47.14 284451 | 1 0.04 47.18 284452 | 1 0.04 47.22 284453 | 1 0.04 47.26 284454 | 1 0.04 47.30 284455 | 1 0.04 47.33 284456 | 1 0.04 47.37 284457 | 1 0.04 47.41 284458 | 1 0.04 47.45 284459 | 1 0.04 47.49 284460 | 1 0.04 47.53 284461 | 1 0.04 47.56 284462 | 1 0.04 47.60 284463 | 1 0.04 47.64 284464 | 1 0.04 47.68 284465 | 1 0.04 47.72 284466 | 1 0.04 47.76 284467 | 1 0.04 47.79 284468 | 1 0.04 47.83 284469 | 1 0.04 47.87 284470 | 1 0.04 47.91 284471 | 1 0.04 47.95 284472 | 1 0.04 47.99 284473 | 1 0.04 48.02 284474 | 1 0.04 48.06 284475 | 1 0.04 48.10 284476 | 1 0.04 48.14 284477 | 1 0.04 48.18 284478 | 1 0.04 48.22 284479 | 1 0.04 48.25 284480 | 1 0.04 48.29 284481 | 1 0.04 48.33 284482 | 1 0.04 48.37 284483 | 1 0.04 48.41 284484 | 1 0.04 48.45 284485 | 1 0.04 48.48 284486 | 1 0.04 48.52 284487 | 1 0.04 48.56 284488 | 1 0.04 48.60 284489 | 1 0.04 48.64 284490 | 1 0.04 48.68 284491 | 1 0.04 48.71 284492 | 1 0.04 48.75 284493 | 1 0.04 48.79 284494 | 1 0.04 48.83 284495 | 1 0.04 48.87 284496 | 1 0.04 48.91 284497 | 1 0.04 48.95 284498 | 1 0.04 48.98 284499 | 1 0.04 49.02 284500 | 1 0.04 49.06 284501 | 1 0.04 49.10 284502 | 1 0.04 49.14 284503 | 1 0.04 49.18 284504 | 1 0.04 49.21 284505 | 1 0.04 49.25 284506 | 1 0.04 49.29 284507 | 1 0.04 49.33 284508 | 1 0.04 49.37 284509 | 1 0.04 49.41 284510 | 1 0.04 49.44 284511 | 1 0.04 49.48 284512 | 1 0.04 49.52 284513 | 1 0.04 49.56 284514 | 1 0.04 49.60 284515 | 1 0.04 49.64 284516 | 1 0.04 49.67 284517 | 1 0.04 49.71 284518 | 1 0.04 49.75 284519 | 1 0.04 49.79 284520 | 1 0.04 49.83 284521 | 1 0.04 49.87 284522 | 1 0.04 49.90 284523 | 1 0.04 49.94 284524 | 1 0.04 49.98 284525 | 1 0.04 50.02 284526 | 1 0.04 50.06 284527 | 1 0.04 50.10 284528 | 1 0.04 50.13 284529 | 1 0.04 50.17 284530 | 1 0.04 50.21 284531 | 1 0.04 50.25 284532 | 1 0.04 50.29 284533 | 1 0.04 50.33 284534 | 1 0.04 50.36 284535 | 1 0.04 50.40 284536 | 1 0.04 50.44 284537 | 1 0.04 50.48 284538 | 1 0.04 50.52 284539 | 1 0.04 50.56 284540 | 1 0.04 50.59 284541 | 1 0.04 50.63 284542 | 1 0.04 50.67 284543 | 1 0.04 50.71 284544 | 1 0.04 50.75 284545 | 1 0.04 50.79 284546 | 1 0.04 50.82 284547 | 1 0.04 50.86 284548 | 1 0.04 50.90 284549 | 1 0.04 50.94 284550 | 1 0.04 50.98 284551 | 1 0.04 51.02 284552 | 1 0.04 51.05 284553 | 1 0.04 51.09 284554 | 1 0.04 51.13 284555 | 1 0.04 51.17 284556 | 1 0.04 51.21 284557 | 1 0.04 51.25 284558 | 1 0.04 51.29 284559 | 1 0.04 51.32 284560 | 1 0.04 51.36 284561 | 1 0.04 51.40 284562 | 1 0.04 51.44 284563 | 1 0.04 51.48 284564 | 1 0.04 51.52 284565 | 1 0.04 51.55 284566 | 1 0.04 51.59 284567 | 1 0.04 51.63 284568 | 1 0.04 51.67 284569 | 1 0.04 51.71 284570 | 1 0.04 51.75 284571 | 1 0.04 51.78 284572 | 1 0.04 51.82 284573 | 1 0.04 51.86 284574 | 1 0.04 51.90 284575 | 1 0.04 51.94 284576 | 1 0.04 51.98 284577 | 1 0.04 52.01 284578 | 1 0.04 52.05 284579 | 1 0.04 52.09 284580 | 1 0.04 52.13 284581 | 1 0.04 52.17 284582 | 1 0.04 52.21 284583 | 1 0.04 52.24 284584 | 1 0.04 52.28 284585 | 1 0.04 52.32 284586 | 1 0.04 52.36 284587 | 1 0.04 52.40 284588 | 1 0.04 52.44 284589 | 1 0.04 52.47 284590 | 1 0.04 52.51 284591 | 1 0.04 52.55 284592 | 1 0.04 52.59 284593 | 1 0.04 52.63 284594 | 1 0.04 52.67 284595 | 1 0.04 52.70 284596 | 1 0.04 52.74 284597 | 1 0.04 52.78 284598 | 1 0.04 52.82 284599 | 1 0.04 52.86 284600 | 1 0.04 52.90 284601 | 1 0.04 52.93 284602 | 1 0.04 52.97 284603 | 1 0.04 53.01 284604 | 1 0.04 53.05 284605 | 1 0.04 53.09 284606 | 1 0.04 53.13 284607 | 1 0.04 53.16 284608 | 1 0.04 53.20 284609 | 1 0.04 53.24 284610 | 1 0.04 53.28 284611 | 1 0.04 53.32 284612 | 1 0.04 53.36 284613 | 1 0.04 53.39 284614 | 1 0.04 53.43 284615 | 1 0.04 53.47 284616 | 1 0.04 53.51 284617 | 1 0.04 53.55 284618 | 1 0.04 53.59 284619 | 1 0.04 53.62 284620 | 1 0.04 53.66 284621 | 1 0.04 53.70 284622 | 1 0.04 53.74 284623 | 1 0.04 53.78 284624 | 1 0.04 53.82 284625 | 1 0.04 53.86 284626 | 1 0.04 53.89 284627 | 1 0.04 53.93 284628 | 1 0.04 53.97 284629 | 1 0.04 54.01 284630 | 1 0.04 54.05 284631 | 1 0.04 54.09 284632 | 1 0.04 54.12 284633 | 1 0.04 54.16 284634 | 1 0.04 54.20 284635 | 1 0.04 54.24 284636 | 1 0.04 54.28 284637 | 1 0.04 54.32 284638 | 1 0.04 54.35 284639 | 1 0.04 54.39 284640 | 1 0.04 54.43 284641 | 1 0.04 54.47 284642 | 1 0.04 54.51 284643 | 1 0.04 54.55 284644 | 1 0.04 54.58 284645 | 1 0.04 54.62 284646 | 1 0.04 54.66 284647 | 1 0.04 54.70 284648 | 1 0.04 54.74 284649 | 1 0.04 54.78 284650 | 1 0.04 54.81 284651 | 1 0.04 54.85 284652 | 1 0.04 54.89 284653 | 1 0.04 54.93 284654 | 1 0.04 54.97 284655 | 1 0.04 55.01 284656 | 1 0.04 55.04 284657 | 1 0.04 55.08 284658 | 1 0.04 55.12 284659 | 1 0.04 55.16 284660 | 1 0.04 55.20 284661 | 1 0.04 55.24 284662 | 1 0.04 55.27 284663 | 1 0.04 55.31 284664 | 1 0.04 55.35 284665 | 1 0.04 55.39 284666 | 1 0.04 55.43 284667 | 1 0.04 55.47 284668 | 1 0.04 55.50 284669 | 1 0.04 55.54 284670 | 1 0.04 55.58 284671 | 1 0.04 55.62 284672 | 1 0.04 55.66 284673 | 1 0.04 55.70 284674 | 1 0.04 55.73 284675 | 1 0.04 55.77 284676 | 1 0.04 55.81 284677 | 1 0.04 55.85 284678 | 1 0.04 55.89 284679 | 1 0.04 55.93 284680 | 1 0.04 55.96 284681 | 1 0.04 56.00 284682 | 1 0.04 56.04 284683 | 1 0.04 56.08 284684 | 1 0.04 56.12 284685 | 1 0.04 56.16 284686 | 1 0.04 56.19 284687 | 1 0.04 56.23 284688 | 1 0.04 56.27 284689 | 1 0.04 56.31 284690 | 1 0.04 56.35 284691 | 1 0.04 56.39 284692 | 1 0.04 56.43 284693 | 1 0.04 56.46 284694 | 1 0.04 56.50 284695 | 1 0.04 56.54 284696 | 1 0.04 56.58 284697 | 1 0.04 56.62 284698 | 1 0.04 56.66 284699 | 1 0.04 56.69 284700 | 1 0.04 56.73 284701 | 1 0.04 56.77 284702 | 1 0.04 56.81 284703 | 1 0.04 56.85 284704 | 1 0.04 56.89 284705 | 1 0.04 56.92 284706 | 1 0.04 56.96 284707 | 1 0.04 57.00 284708 | 1 0.04 57.04 284709 | 1 0.04 57.08 284710 | 1 0.04 57.12 284711 | 1 0.04 57.15 284712 | 1 0.04 57.19 284713 | 1 0.04 57.23 284714 | 1 0.04 57.27 284715 | 1 0.04 57.31 284716 | 1 0.04 57.35 284717 | 1 0.04 57.38 284718 | 1 0.04 57.42 284719 | 1 0.04 57.46 284720 | 1 0.04 57.50 284721 | 1 0.04 57.54 284722 | 1 0.04 57.58 284723 | 1 0.04 57.61 284724 | 1 0.04 57.65 284725 | 1 0.04 57.69 284726 | 1 0.04 57.73 284727 | 1 0.04 57.77 284728 | 1 0.04 57.81 284729 | 1 0.04 57.84 284730 | 1 0.04 57.88 284731 | 1 0.04 57.92 284732 | 1 0.04 57.96 284733 | 1 0.04 58.00 284734 | 1 0.04 58.04 284735 | 1 0.04 58.07 284736 | 1 0.04 58.11 284737 | 1 0.04 58.15 284738 | 1 0.04 58.19 284739 | 1 0.04 58.23 284740 | 1 0.04 58.27 284741 | 1 0.04 58.30 284742 | 1 0.04 58.34 284743 | 1 0.04 58.38 284744 | 1 0.04 58.42 284745 | 1 0.04 58.46 284746 | 1 0.04 58.50 284747 | 1 0.04 58.53 284748 | 1 0.04 58.57 284749 | 1 0.04 58.61 284750 | 1 0.04 58.65 284751 | 1 0.04 58.69 284752 | 1 0.04 58.73 284753 | 1 0.04 58.76 284754 | 1 0.04 58.80 284755 | 1 0.04 58.84 284756 | 1 0.04 58.88 284757 | 1 0.04 58.92 284758 | 1 0.04 58.96 284759 | 1 0.04 59.00 284760 | 1 0.04 59.03 284761 | 1 0.04 59.07 284762 | 1 0.04 59.11 284763 | 1 0.04 59.15 284764 | 1 0.04 59.19 284765 | 1 0.04 59.23 284766 | 1 0.04 59.26 284767 | 1 0.04 59.30 284768 | 1 0.04 59.34 284769 | 1 0.04 59.38 284770 | 1 0.04 59.42 284771 | 1 0.04 59.46 284772 | 1 0.04 59.49 284773 | 1 0.04 59.53 284774 | 1 0.04 59.57 284775 | 1 0.04 59.61 284776 | 1 0.04 59.65 284777 | 1 0.04 59.69 284778 | 1 0.04 59.72 284779 | 1 0.04 59.76 284780 | 1 0.04 59.80 284781 | 1 0.04 59.84 284782 | 1 0.04 59.88 284783 | 1 0.04 59.92 284784 | 1 0.04 59.95 284785 | 1 0.04 59.99 284786 | 1 0.04 60.03 284787 | 1 0.04 60.07 284788 | 1 0.04 60.11 284789 | 1 0.04 60.15 284790 | 1 0.04 60.18 284791 | 1 0.04 60.22 284792 | 1 0.04 60.26 284793 | 1 0.04 60.30 284794 | 1 0.04 60.34 284795 | 1 0.04 60.38 284796 | 1 0.04 60.41 284797 | 1 0.04 60.45 284798 | 1 0.04 60.49 284799 | 1 0.04 60.53 284800 | 1 0.04 60.57 284801 | 1 0.04 60.61 284802 | 1 0.04 60.64 284803 | 1 0.04 60.68 284804 | 1 0.04 60.72 284805 | 1 0.04 60.76 284806 | 1 0.04 60.80 284807 | 1 0.04 60.84 284808 | 1 0.04 60.87 284809 | 1 0.04 60.91 284810 | 1 0.04 60.95 284811 | 1 0.04 60.99 284812 | 1 0.04 61.03 284813 | 1 0.04 61.07 284814 | 1 0.04 61.10 284815 | 1 0.04 61.14 284816 | 1 0.04 61.18 284817 | 1 0.04 61.22 284818 | 1 0.04 61.26 284819 | 1 0.04 61.30 284820 | 1 0.04 61.33 284821 | 1 0.04 61.37 284822 | 1 0.04 61.41 284823 | 1 0.04 61.45 284824 | 1 0.04 61.49 284825 | 1 0.04 61.53 284826 | 1 0.04 61.57 284827 | 1 0.04 61.60 284828 | 1 0.04 61.64 284829 | 1 0.04 61.68 284830 | 1 0.04 61.72 284831 | 1 0.04 61.76 284832 | 1 0.04 61.80 284833 | 1 0.04 61.83 284834 | 1 0.04 61.87 284835 | 1 0.04 61.91 284836 | 1 0.04 61.95 284837 | 1 0.04 61.99 284838 | 1 0.04 62.03 284839 | 1 0.04 62.06 284840 | 1 0.04 62.10 284841 | 1 0.04 62.14 284842 | 1 0.04 62.18 284843 | 1 0.04 62.22 284844 | 1 0.04 62.26 284845 | 1 0.04 62.29 284846 | 1 0.04 62.33 284847 | 1 0.04 62.37 284848 | 1 0.04 62.41 284849 | 1 0.04 62.45 284850 | 1 0.04 62.49 284851 | 1 0.04 62.52 284852 | 1 0.04 62.56 284853 | 1 0.04 62.60 284854 | 1 0.04 62.64 284855 | 1 0.04 62.68 284856 | 1 0.04 62.72 284857 | 1 0.04 62.75 284858 | 1 0.04 62.79 284859 | 1 0.04 62.83 284860 | 1 0.04 62.87 284861 | 1 0.04 62.91 284862 | 1 0.04 62.95 284863 | 1 0.04 62.98 284864 | 1 0.04 63.02 284865 | 1 0.04 63.06 284866 | 1 0.04 63.10 284867 | 1 0.04 63.14 284868 | 1 0.04 63.18 284869 | 1 0.04 63.21 284870 | 1 0.04 63.25 284871 | 1 0.04 63.29 284872 | 1 0.04 63.33 284873 | 1 0.04 63.37 284874 | 1 0.04 63.41 284875 | 1 0.04 63.44 284876 | 1 0.04 63.48 284877 | 1 0.04 63.52 284878 | 1 0.04 63.56 284879 | 1 0.04 63.60 284880 | 1 0.04 63.64 284881 | 1 0.04 63.67 284882 | 1 0.04 63.71 284883 | 1 0.04 63.75 284884 | 1 0.04 63.79 284885 | 1 0.04 63.83 284886 | 1 0.04 63.87 284887 | 1 0.04 63.90 284888 | 1 0.04 63.94 284889 | 1 0.04 63.98 284890 | 1 0.04 64.02 284891 | 1 0.04 64.06 284892 | 1 0.04 64.10 284893 | 1 0.04 64.14 284894 | 1 0.04 64.17 284895 | 1 0.04 64.21 284896 | 1 0.04 64.25 284897 | 1 0.04 64.29 284898 | 1 0.04 64.33 284899 | 1 0.04 64.37 284900 | 1 0.04 64.40 284901 | 1 0.04 64.44 284902 | 1 0.04 64.48 284903 | 1 0.04 64.52 284904 | 1 0.04 64.56 284905 | 1 0.04 64.60 284906 | 1 0.04 64.63 284907 | 1 0.04 64.67 284908 | 1 0.04 64.71 284909 | 1 0.04 64.75 284910 | 1 0.04 64.79 284911 | 1 0.04 64.83 284912 | 1 0.04 64.86 284913 | 1 0.04 64.90 284914 | 1 0.04 64.94 284915 | 1 0.04 64.98 284916 | 1 0.04 65.02 284917 | 1 0.04 65.06 284918 | 1 0.04 65.09 284919 | 1 0.04 65.13 284920 | 1 0.04 65.17 284921 | 1 0.04 65.21 284922 | 1 0.04 65.25 284923 | 1 0.04 65.29 284924 | 1 0.04 65.32 284925 | 1 0.04 65.36 284926 | 1 0.04 65.40 284927 | 1 0.04 65.44 284928 | 1 0.04 65.48 284929 | 1 0.04 65.52 284930 | 1 0.04 65.55 284931 | 1 0.04 65.59 284932 | 1 0.04 65.63 284933 | 1 0.04 65.67 284934 | 1 0.04 65.71 284935 | 1 0.04 65.75 284936 | 1 0.04 65.78 284937 | 1 0.04 65.82 284938 | 1 0.04 65.86 284939 | 1 0.04 65.90 284940 | 1 0.04 65.94 284941 | 1 0.04 65.98 284942 | 1 0.04 66.01 284943 | 1 0.04 66.05 284944 | 1 0.04 66.09 284945 | 1 0.04 66.13 284946 | 1 0.04 66.17 284947 | 1 0.04 66.21 284948 | 1 0.04 66.24 284949 | 1 0.04 66.28 284950 | 1 0.04 66.32 284951 | 1 0.04 66.36 284952 | 1 0.04 66.40 284953 | 1 0.04 66.44 284954 | 1 0.04 66.47 284955 | 1 0.04 66.51 284956 | 1 0.04 66.55 284957 | 1 0.04 66.59 284958 | 1 0.04 66.63 284959 | 1 0.04 66.67 284960 | 1 0.04 66.71 284961 | 1 0.04 66.74 284962 | 1 0.04 66.78 284963 | 1 0.04 66.82 284964 | 1 0.04 66.86 284965 | 1 0.04 66.90 284966 | 1 0.04 66.94 284967 | 1 0.04 66.97 284968 | 1 0.04 67.01 284969 | 1 0.04 67.05 284970 | 1 0.04 67.09 284971 | 1 0.04 67.13 284972 | 1 0.04 67.17 284973 | 1 0.04 67.20 284974 | 1 0.04 67.24 284975 | 1 0.04 67.28 284976 | 1 0.04 67.32 284977 | 1 0.04 67.36 284978 | 1 0.04 67.40 284979 | 1 0.04 67.43 284980 | 1 0.04 67.47 284981 | 1 0.04 67.51 284982 | 1 0.04 67.55 284983 | 1 0.04 67.59 284984 | 1 0.04 67.63 284985 | 1 0.04 67.66 284986 | 1 0.04 67.70 284987 | 1 0.04 67.74 284988 | 1 0.04 67.78 284989 | 1 0.04 67.82 284990 | 1 0.04 67.86 284991 | 1 0.04 67.89 284992 | 1 0.04 67.93 284993 | 1 0.04 67.97 284994 | 1 0.04 68.01 284995 | 1 0.04 68.05 284996 | 1 0.04 68.09 284997 | 1 0.04 68.12 284998 | 1 0.04 68.16 284999 | 1 0.04 68.20 285000 | 1 0.04 68.24 285001 | 1 0.04 68.28 285002 | 1 0.04 68.32 285003 | 1 0.04 68.35 285004 | 1 0.04 68.39 285005 | 1 0.04 68.43 285006 | 1 0.04 68.47 285007 | 1 0.04 68.51 285008 | 1 0.04 68.55 285009 | 1 0.04 68.58 285010 | 1 0.04 68.62 285011 | 1 0.04 68.66 285012 | 1 0.04 68.70 285013 | 1 0.04 68.74 285014 | 1 0.04 68.78 285015 | 1 0.04 68.81 285016 | 1 0.04 68.85 285017 | 1 0.04 68.89 285018 | 1 0.04 68.93 285019 | 1 0.04 68.97 285020 | 1 0.04 69.01 285021 | 1 0.04 69.04 285022 | 1 0.04 69.08 285023 | 1 0.04 69.12 285024 | 1 0.04 69.16 285025 | 1 0.04 69.20 285026 | 1 0.04 69.24 285027 | 1 0.04 69.28 285028 | 1 0.04 69.31 285029 | 1 0.04 69.35 285030 | 1 0.04 69.39 285031 | 1 0.04 69.43 285032 | 1 0.04 69.47 285033 | 1 0.04 69.51 285034 | 1 0.04 69.54 285035 | 1 0.04 69.58 285036 | 1 0.04 69.62 285037 | 1 0.04 69.66 285038 | 1 0.04 69.70 285039 | 1 0.04 69.74 285040 | 1 0.04 69.77 285041 | 1 0.04 69.81 285042 | 1 0.04 69.85 285043 | 1 0.04 69.89 285044 | 1 0.04 69.93 285045 | 1 0.04 69.97 285046 | 1 0.04 70.00 285047 | 1 0.04 70.04 285048 | 1 0.04 70.08 285049 | 1 0.04 70.12 285050 | 1 0.04 70.16 285051 | 1 0.04 70.20 285052 | 1 0.04 70.23 285053 | 1 0.04 70.27 285054 | 1 0.04 70.31 285055 | 1 0.04 70.35 285056 | 1 0.04 70.39 285057 | 1 0.04 70.43 285058 | 1 0.04 70.46 285059 | 1 0.04 70.50 285060 | 1 0.04 70.54 285061 | 1 0.04 70.58 285062 | 1 0.04 70.62 285063 | 1 0.04 70.66 285064 | 1 0.04 70.69 285065 | 1 0.04 70.73 285066 | 1 0.04 70.77 285067 | 1 0.04 70.81 285068 | 1 0.04 70.85 285069 | 1 0.04 70.89 285070 | 1 0.04 70.92 285071 | 1 0.04 70.96 285072 | 1 0.04 71.00 285073 | 1 0.04 71.04 285074 | 1 0.04 71.08 285075 | 1 0.04 71.12 285076 | 1 0.04 71.15 285077 | 1 0.04 71.19 285078 | 1 0.04 71.23 285079 | 1 0.04 71.27 285080 | 1 0.04 71.31 285081 | 1 0.04 71.35 285082 | 1 0.04 71.38 285083 | 1 0.04 71.42 285084 | 1 0.04 71.46 285085 | 1 0.04 71.50 285086 | 1 0.04 71.54 285087 | 1 0.04 71.58 285088 | 1 0.04 71.61 285089 | 1 0.04 71.65 285090 | 1 0.04 71.69 285091 | 1 0.04 71.73 285092 | 1 0.04 71.77 285093 | 1 0.04 71.81 285094 | 1 0.04 71.85 285095 | 1 0.04 71.88 285096 | 1 0.04 71.92 285097 | 1 0.04 71.96 285098 | 1 0.04 72.00 285099 | 1 0.04 72.04 285100 | 1 0.04 72.08 285101 | 1 0.04 72.11 285102 | 1 0.04 72.15 285103 | 1 0.04 72.19 285104 | 1 0.04 72.23 285105 | 1 0.04 72.27 285106 | 1 0.04 72.31 285107 | 1 0.04 72.34 285108 | 1 0.04 72.38 285109 | 1 0.04 72.42 285110 | 1 0.04 72.46 285111 | 1 0.04 72.50 285112 | 1 0.04 72.54 285113 | 1 0.04 72.57 285114 | 1 0.04 72.61 285115 | 1 0.04 72.65 285116 | 1 0.04 72.69 285117 | 1 0.04 72.73 285118 | 1 0.04 72.77 285119 | 1 0.04 72.80 285120 | 1 0.04 72.84 285121 | 1 0.04 72.88 285122 | 1 0.04 72.92 285123 | 1 0.04 72.96 285124 | 1 0.04 73.00 285125 | 1 0.04 73.03 285126 | 1 0.04 73.07 285127 | 1 0.04 73.11 285128 | 1 0.04 73.15 285129 | 1 0.04 73.19 285130 | 1 0.04 73.23 285131 | 1 0.04 73.26 285132 | 1 0.04 73.30 285133 | 1 0.04 73.34 285134 | 1 0.04 73.38 285135 | 1 0.04 73.42 285136 | 1 0.04 73.46 285137 | 1 0.04 73.49 285138 | 1 0.04 73.53 285139 | 1 0.04 73.57 285140 | 1 0.04 73.61 285141 | 1 0.04 73.65 285142 | 1 0.04 73.69 285143 | 1 0.04 73.72 285144 | 1 0.04 73.76 285145 | 1 0.04 73.80 285146 | 1 0.04 73.84 285147 | 1 0.04 73.88 285148 | 1 0.04 73.92 285149 | 1 0.04 73.95 285150 | 1 0.04 73.99 285151 | 1 0.04 74.03 285152 | 1 0.04 74.07 285153 | 1 0.04 74.11 285154 | 1 0.04 74.15 285155 | 1 0.04 74.18 285156 | 1 0.04 74.22 285157 | 1 0.04 74.26 285158 | 1 0.04 74.30 285159 | 1 0.04 74.34 285160 | 1 0.04 74.38 285161 | 1 0.04 74.42 285162 | 1 0.04 74.45 285163 | 1 0.04 74.49 285164 | 1 0.04 74.53 285165 | 1 0.04 74.57 285166 | 1 0.04 74.61 285167 | 1 0.04 74.65 285168 | 1 0.04 74.68 285169 | 1 0.04 74.72 285170 | 1 0.04 74.76 285171 | 1 0.04 74.80 285172 | 1 0.04 74.84 285173 | 1 0.04 74.88 285174 | 1 0.04 74.91 285175 | 1 0.04 74.95 285176 | 1 0.04 74.99 285177 | 1 0.04 75.03 285178 | 1 0.04 75.07 285179 | 1 0.04 75.11 285180 | 1 0.04 75.14 285181 | 1 0.04 75.18 285182 | 1 0.04 75.22 285183 | 1 0.04 75.26 285184 | 1 0.04 75.30 285185 | 1 0.04 75.34 285186 | 1 0.04 75.37 285187 | 1 0.04 75.41 285188 | 1 0.04 75.45 285189 | 1 0.04 75.49 285190 | 1 0.04 75.53 285191 | 1 0.04 75.57 285192 | 1 0.04 75.60 285193 | 1 0.04 75.64 285194 | 1 0.04 75.68 285195 | 1 0.04 75.72 285196 | 1 0.04 75.76 285197 | 1 0.04 75.80 285198 | 1 0.04 75.83 285199 | 1 0.04 75.87 285200 | 1 0.04 75.91 285201 | 1 0.04 75.95 285202 | 1 0.04 75.99 285203 | 1 0.04 76.03 285204 | 1 0.04 76.06 285205 | 1 0.04 76.10 285206 | 1 0.04 76.14 285207 | 1 0.04 76.18 285208 | 1 0.04 76.22 285209 | 1 0.04 76.26 285210 | 1 0.04 76.29 285211 | 1 0.04 76.33 285212 | 1 0.04 76.37 285213 | 1 0.04 76.41 285214 | 1 0.04 76.45 285215 | 1 0.04 76.49 285216 | 1 0.04 76.52 285217 | 1 0.04 76.56 285218 | 1 0.04 76.60 285219 | 1 0.04 76.64 285220 | 1 0.04 76.68 285221 | 1 0.04 76.72 285222 | 1 0.04 76.75 285223 | 1 0.04 76.79 285224 | 1 0.04 76.83 285225 | 1 0.04 76.87 285226 | 1 0.04 76.91 285227 | 1 0.04 76.95 285228 | 1 0.04 76.99 285229 | 1 0.04 77.02 285230 | 1 0.04 77.06 285231 | 1 0.04 77.10 285232 | 1 0.04 77.14 285233 | 1 0.04 77.18 285234 | 1 0.04 77.22 285235 | 1 0.04 77.25 285236 | 1 0.04 77.29 285237 | 1 0.04 77.33 285238 | 1 0.04 77.37 285239 | 1 0.04 77.41 285240 | 1 0.04 77.45 285241 | 1 0.04 77.48 285242 | 1 0.04 77.52 285243 | 1 0.04 77.56 285244 | 1 0.04 77.60 285245 | 1 0.04 77.64 285246 | 1 0.04 77.68 285247 | 1 0.04 77.71 285248 | 1 0.04 77.75 285249 | 1 0.04 77.79 285250 | 1 0.04 77.83 285251 | 1 0.04 77.87 285252 | 1 0.04 77.91 285253 | 1 0.04 77.94 285254 | 1 0.04 77.98 285255 | 1 0.04 78.02 285256 | 1 0.04 78.06 285257 | 1 0.04 78.10 285258 | 1 0.04 78.14 285259 | 1 0.04 78.17 285260 | 1 0.04 78.21 285261 | 1 0.04 78.25 285262 | 1 0.04 78.29 285263 | 1 0.04 78.33 285264 | 1 0.04 78.37 285265 | 1 0.04 78.40 285266 | 1 0.04 78.44 285267 | 1 0.04 78.48 285268 | 1 0.04 78.52 285269 | 1 0.04 78.56 285270 | 1 0.04 78.60 285271 | 1 0.04 78.63 285272 | 1 0.04 78.67 285273 | 1 0.04 78.71 285274 | 1 0.04 78.75 285275 | 1 0.04 78.79 285276 | 1 0.04 78.83 285277 | 1 0.04 78.86 285278 | 1 0.04 78.90 285279 | 1 0.04 78.94 285280 | 1 0.04 78.98 285281 | 1 0.04 79.02 285282 | 1 0.04 79.06 285283 | 1 0.04 79.09 285284 | 1 0.04 79.13 285285 | 1 0.04 79.17 285286 | 1 0.04 79.21 285287 | 1 0.04 79.25 285288 | 1 0.04 79.29 285289 | 1 0.04 79.32 285290 | 1 0.04 79.36 285291 | 1 0.04 79.40 285292 | 1 0.04 79.44 285293 | 1 0.04 79.48 285294 | 1 0.04 79.52 285295 | 1 0.04 79.56 285296 | 1 0.04 79.59 285297 | 1 0.04 79.63 285298 | 1 0.04 79.67 285299 | 1 0.04 79.71 285300 | 1 0.04 79.75 285301 | 1 0.04 79.79 285302 | 1 0.04 79.82 285303 | 1 0.04 79.86 285304 | 1 0.04 79.90 285305 | 1 0.04 79.94 285306 | 1 0.04 79.98 285307 | 1 0.04 80.02 285308 | 1 0.04 80.05 285309 | 1 0.04 80.09 285310 | 1 0.04 80.13 285311 | 1 0.04 80.17 285312 | 1 0.04 80.21 285313 | 1 0.04 80.25 285314 | 1 0.04 80.28 285315 | 1 0.04 80.32 285316 | 1 0.04 80.36 285317 | 1 0.04 80.40 285318 | 1 0.04 80.44 285319 | 1 0.04 80.48 285320 | 1 0.04 80.51 285321 | 1 0.04 80.55 285322 | 1 0.04 80.59 285323 | 1 0.04 80.63 285324 | 1 0.04 80.67 285325 | 1 0.04 80.71 285326 | 1 0.04 80.74 285327 | 1 0.04 80.78 285328 | 1 0.04 80.82 285329 | 1 0.04 80.86 285330 | 1 0.04 80.90 285331 | 1 0.04 80.94 285332 | 1 0.04 80.97 285333 | 1 0.04 81.01 285334 | 1 0.04 81.05 285335 | 1 0.04 81.09 285336 | 1 0.04 81.13 285337 | 1 0.04 81.17 285338 | 1 0.04 81.20 285339 | 1 0.04 81.24 285340 | 1 0.04 81.28 285341 | 1 0.04 81.32 285342 | 1 0.04 81.36 285343 | 1 0.04 81.40 285344 | 1 0.04 81.43 285345 | 1 0.04 81.47 285346 | 1 0.04 81.51 285347 | 1 0.04 81.55 285348 | 1 0.04 81.59 285349 | 1 0.04 81.63 285350 | 1 0.04 81.66 285351 | 1 0.04 81.70 285352 | 1 0.04 81.74 285353 | 1 0.04 81.78 285354 | 1 0.04 81.82 285355 | 1 0.04 81.86 285356 | 1 0.04 81.89 285357 | 1 0.04 81.93 285358 | 1 0.04 81.97 285359 | 1 0.04 82.01 285360 | 1 0.04 82.05 285361 | 1 0.04 82.09 285362 | 1 0.04 82.13 285363 | 1 0.04 82.16 285364 | 1 0.04 82.20 285365 | 1 0.04 82.24 285366 | 1 0.04 82.28 285367 | 1 0.04 82.32 285368 | 1 0.04 82.36 285369 | 1 0.04 82.39 285370 | 1 0.04 82.43 285371 | 1 0.04 82.47 285372 | 1 0.04 82.51 285373 | 1 0.04 82.55 285374 | 1 0.04 82.59 285375 | 1 0.04 82.62 285376 | 1 0.04 82.66 285377 | 1 0.04 82.70 285378 | 1 0.04 82.74 285379 | 1 0.04 82.78 285380 | 1 0.04 82.82 285381 | 1 0.04 82.85 285382 | 1 0.04 82.89 285383 | 1 0.04 82.93 285384 | 1 0.04 82.97 285385 | 1 0.04 83.01 285386 | 1 0.04 83.05 285387 | 1 0.04 83.08 285388 | 1 0.04 83.12 285389 | 1 0.04 83.16 285390 | 1 0.04 83.20 285391 | 1 0.04 83.24 285392 | 1 0.04 83.28 285393 | 1 0.04 83.31 285394 | 1 0.04 83.35 285395 | 1 0.04 83.39 285396 | 1 0.04 83.43 285397 | 1 0.04 83.47 285398 | 1 0.04 83.51 285399 | 1 0.04 83.54 285400 | 1 0.04 83.58 285401 | 1 0.04 83.62 285402 | 1 0.04 83.66 285403 | 1 0.04 83.70 285404 | 1 0.04 83.74 285405 | 1 0.04 83.77 285406 | 1 0.04 83.81 285407 | 1 0.04 83.85 285408 | 1 0.04 83.89 285409 | 1 0.04 83.93 285410 | 1 0.04 83.97 285411 | 1 0.04 84.00 285412 | 1 0.04 84.04 285413 | 1 0.04 84.08 285414 | 1 0.04 84.12 285415 | 1 0.04 84.16 285416 | 1 0.04 84.20 285417 | 1 0.04 84.23 285418 | 1 0.04 84.27 285419 | 1 0.04 84.31 285420 | 1 0.04 84.35 285421 | 1 0.04 84.39 285422 | 1 0.04 84.43 285423 | 1 0.04 84.46 285424 | 1 0.04 84.50 285425 | 1 0.04 84.54 285426 | 1 0.04 84.58 285427 | 1 0.04 84.62 285428 | 1 0.04 84.66 285429 | 1 0.04 84.70 285430 | 1 0.04 84.73 285431 | 1 0.04 84.77 285432 | 1 0.04 84.81 285433 | 1 0.04 84.85 285434 | 1 0.04 84.89 285435 | 1 0.04 84.93 285436 | 1 0.04 84.96 285437 | 1 0.04 85.00 285438 | 1 0.04 85.04 285439 | 1 0.04 85.08 285440 | 1 0.04 85.12 285441 | 1 0.04 85.16 285442 | 1 0.04 85.19 285443 | 1 0.04 85.23 285444 | 1 0.04 85.27 285445 | 1 0.04 85.31 285446 | 1 0.04 85.35 285447 | 1 0.04 85.39 285448 | 1 0.04 85.42 285449 | 1 0.04 85.46 285450 | 1 0.04 85.50 285451 | 1 0.04 85.54 285452 | 1 0.04 85.58 285453 | 1 0.04 85.62 285454 | 1 0.04 85.65 285455 | 1 0.04 85.69 285456 | 1 0.04 85.73 285457 | 1 0.04 85.77 285458 | 1 0.04 85.81 285459 | 1 0.04 85.85 285460 | 1 0.04 85.88 285461 | 1 0.04 85.92 285462 | 1 0.04 85.96 285463 | 1 0.04 86.00 285464 | 1 0.04 86.04 285465 | 1 0.04 86.08 285466 | 1 0.04 86.11 285467 | 1 0.04 86.15 285468 | 1 0.04 86.19 285469 | 1 0.04 86.23 285470 | 1 0.04 86.27 285471 | 1 0.04 86.31 285472 | 1 0.04 86.34 285473 | 1 0.04 86.38 285474 | 1 0.04 86.42 285475 | 1 0.04 86.46 285476 | 1 0.04 86.50 285477 | 1 0.04 86.54 285478 | 1 0.04 86.57 285479 | 1 0.04 86.61 285480 | 1 0.04 86.65 285481 | 1 0.04 86.69 285482 | 1 0.04 86.73 285483 | 1 0.04 86.77 285484 | 1 0.04 86.80 285485 | 1 0.04 86.84 285486 | 1 0.04 86.88 285487 | 1 0.04 86.92 285488 | 1 0.04 86.96 285489 | 1 0.04 87.00 285490 | 1 0.04 87.03 285491 | 1 0.04 87.07 285492 | 1 0.04 87.11 285493 | 1 0.04 87.15 285494 | 1 0.04 87.19 285495 | 1 0.04 87.23 285496 | 1 0.04 87.27 285497 | 1 0.04 87.30 285498 | 1 0.04 87.34 285499 | 1 0.04 87.38 285500 | 1 0.04 87.42 285501 | 1 0.04 87.46 285502 | 1 0.04 87.50 285503 | 1 0.04 87.53 285504 | 1 0.04 87.57 285505 | 1 0.04 87.61 285506 | 1 0.04 87.65 285507 | 1 0.04 87.69 285508 | 1 0.04 87.73 285509 | 1 0.04 87.76 285510 | 1 0.04 87.80 285511 | 1 0.04 87.84 285512 | 1 0.04 87.88 285513 | 1 0.04 87.92 285514 | 1 0.04 87.96 285515 | 1 0.04 87.99 285516 | 1 0.04 88.03 285517 | 1 0.04 88.07 285518 | 1 0.04 88.11 285519 | 1 0.04 88.15 285520 | 1 0.04 88.19 285521 | 1 0.04 88.22 285522 | 1 0.04 88.26 285523 | 1 0.04 88.30 285524 | 1 0.04 88.34 285525 | 1 0.04 88.38 285526 | 1 0.04 88.42 285527 | 1 0.04 88.45 285528 | 1 0.04 88.49 285529 | 1 0.04 88.53 285530 | 1 0.04 88.57 285531 | 1 0.04 88.61 285532 | 1 0.04 88.65 285533 | 1 0.04 88.68 285534 | 1 0.04 88.72 285535 | 1 0.04 88.76 285536 | 1 0.04 88.80 285537 | 1 0.04 88.84 285538 | 1 0.04 88.88 285539 | 1 0.04 88.91 285540 | 1 0.04 88.95 285541 | 1 0.04 88.99 285542 | 1 0.04 89.03 285543 | 1 0.04 89.07 285544 | 1 0.04 89.11 285545 | 1 0.04 89.14 285546 | 1 0.04 89.18 285547 | 1 0.04 89.22 285548 | 1 0.04 89.26 285549 | 1 0.04 89.30 285550 | 1 0.04 89.34 285551 | 1 0.04 89.37 285552 | 1 0.04 89.41 285553 | 1 0.04 89.45 285554 | 1 0.04 89.49 285555 | 1 0.04 89.53 285556 | 1 0.04 89.57 285557 | 1 0.04 89.60 285558 | 1 0.04 89.64 285559 | 1 0.04 89.68 285560 | 1 0.04 89.72 285561 | 1 0.04 89.76 285562 | 1 0.04 89.80 285563 | 1 0.04 89.84 285564 | 1 0.04 89.87 285565 | 1 0.04 89.91 285566 | 1 0.04 89.95 285567 | 1 0.04 89.99 285568 | 1 0.04 90.03 285569 | 1 0.04 90.07 285570 | 1 0.04 90.10 285571 | 1 0.04 90.14 285572 | 1 0.04 90.18 285573 | 1 0.04 90.22 285574 | 1 0.04 90.26 285575 | 1 0.04 90.30 285576 | 1 0.04 90.33 285577 | 1 0.04 90.37 285578 | 1 0.04 90.41 285579 | 1 0.04 90.45 285580 | 1 0.04 90.49 285581 | 1 0.04 90.53 285582 | 1 0.04 90.56 285583 | 1 0.04 90.60 285584 | 1 0.04 90.64 285585 | 1 0.04 90.68 285586 | 1 0.04 90.72 285587 | 1 0.04 90.76 285588 | 1 0.04 90.79 285589 | 1 0.04 90.83 285590 | 1 0.04 90.87 285591 | 1 0.04 90.91 285592 | 1 0.04 90.95 285593 | 1 0.04 90.99 285594 | 1 0.04 91.02 285595 | 1 0.04 91.06 285596 | 1 0.04 91.10 285597 | 1 0.04 91.14 285598 | 1 0.04 91.18 285599 | 1 0.04 91.22 285600 | 1 0.04 91.25 285601 | 1 0.04 91.29 285602 | 1 0.04 91.33 285603 | 1 0.04 91.37 285604 | 1 0.04 91.41 285605 | 1 0.04 91.45 285606 | 1 0.04 91.48 285607 | 1 0.04 91.52 285608 | 1 0.04 91.56 285609 | 1 0.04 91.60 285610 | 1 0.04 91.64 285611 | 1 0.04 91.68 285612 | 1 0.04 91.71 285613 | 1 0.04 91.75 285614 | 1 0.04 91.79 285615 | 1 0.04 91.83 285616 | 1 0.04 91.87 285617 | 1 0.04 91.91 285618 | 1 0.04 91.94 285619 | 1 0.04 91.98 285620 | 1 0.04 92.02 285621 | 1 0.04 92.06 285622 | 1 0.04 92.10 285623 | 1 0.04 92.14 285624 | 1 0.04 92.17 285625 | 1 0.04 92.21 285626 | 1 0.04 92.25 285627 | 1 0.04 92.29 285628 | 1 0.04 92.33 285629 | 1 0.04 92.37 285630 | 1 0.04 92.41 285631 | 1 0.04 92.44 285632 | 1 0.04 92.48 285633 | 1 0.04 92.52 285634 | 1 0.04 92.56 285635 | 1 0.04 92.60 285636 | 1 0.04 92.64 285637 | 1 0.04 92.67 285638 | 1 0.04 92.71 285639 | 1 0.04 92.75 285640 | 1 0.04 92.79 285641 | 1 0.04 92.83 285642 | 1 0.04 92.87 285643 | 1 0.04 92.90 285644 | 1 0.04 92.94 285645 | 1 0.04 92.98 285646 | 1 0.04 93.02 285647 | 1 0.04 93.06 285648 | 1 0.04 93.10 285649 | 1 0.04 93.13 285650 | 1 0.04 93.17 285651 | 1 0.04 93.21 285652 | 1 0.04 93.25 285653 | 1 0.04 93.29 285654 | 1 0.04 93.33 285655 | 1 0.04 93.36 285656 | 1 0.04 93.40 285657 | 1 0.04 93.44 285658 | 1 0.04 93.48 285659 | 1 0.04 93.52 285660 | 1 0.04 93.56 285661 | 1 0.04 93.59 285662 | 1 0.04 93.63 285663 | 1 0.04 93.67 285664 | 1 0.04 93.71 285665 | 1 0.04 93.75 285666 | 1 0.04 93.79 285667 | 1 0.04 93.82 285668 | 1 0.04 93.86 285669 | 1 0.04 93.90 285670 | 1 0.04 93.94 285671 | 1 0.04 93.98 285672 | 1 0.04 94.02 285673 | 1 0.04 94.05 285674 | 1 0.04 94.09 285675 | 1 0.04 94.13 285676 | 1 0.04 94.17 285677 | 1 0.04 94.21 285678 | 1 0.04 94.25 285679 | 1 0.04 94.28 285680 | 1 0.04 94.32 285681 | 1 0.04 94.36 285682 | 1 0.04 94.40 285683 | 1 0.04 94.44 285684 | 1 0.04 94.48 285685 | 1 0.04 94.51 285686 | 1 0.04 94.55 285687 | 1 0.04 94.59 285688 | 1 0.04 94.63 285689 | 1 0.04 94.67 285690 | 1 0.04 94.71 285691 | 1 0.04 94.74 285692 | 1 0.04 94.78 285693 | 1 0.04 94.82 285694 | 1 0.04 94.86 285695 | 1 0.04 94.90 285696 | 1 0.04 94.94 285697 | 1 0.04 94.98 285698 | 1 0.04 95.01 285699 | 1 0.04 95.05 285700 | 1 0.04 95.09 285701 | 1 0.04 95.13 285702 | 1 0.04 95.17 285703 | 1 0.04 95.21 285704 | 1 0.04 95.24 285705 | 1 0.04 95.28 285706 | 1 0.04 95.32 285707 | 1 0.04 95.36 285708 | 1 0.04 95.40 285709 | 1 0.04 95.44 285710 | 1 0.04 95.47 285711 | 1 0.04 95.51 285712 | 1 0.04 95.55 285713 | 1 0.04 95.59 285714 | 1 0.04 95.63 285715 | 1 0.04 95.67 285716 | 1 0.04 95.70 285717 | 1 0.04 95.74 285718 | 1 0.04 95.78 285719 | 1 0.04 95.82 285720 | 1 0.04 95.86 285721 | 1 0.04 95.90 285722 | 1 0.04 95.93 285723 | 1 0.04 95.97 285724 | 1 0.04 96.01 285725 | 1 0.04 96.05 285726 | 1 0.04 96.09 285727 | 1 0.04 96.13 285728 | 1 0.04 96.16 285729 | 1 0.04 96.20 285730 | 1 0.04 96.24 285731 | 1 0.04 96.28 285732 | 1 0.04 96.32 285733 | 1 0.04 96.36 285734 | 1 0.04 96.39 285735 | 1 0.04 96.43 285736 | 1 0.04 96.47 285737 | 1 0.04 96.51 285738 | 1 0.04 96.55 285739 | 1 0.04 96.59 285740 | 1 0.04 96.62 285741 | 1 0.04 96.66 285742 | 1 0.04 96.70 285743 | 1 0.04 96.74 285744 | 1 0.04 96.78 285745 | 1 0.04 96.82 285746 | 1 0.04 96.85 285747 | 1 0.04 96.89 285748 | 1 0.04 96.93 285749 | 1 0.04 96.97 285750 | 1 0.04 97.01 285751 | 1 0.04 97.05 285752 | 1 0.04 97.08 285753 | 1 0.04 97.12 285754 | 1 0.04 97.16 285755 | 1 0.04 97.20 285756 | 1 0.04 97.24 285757 | 1 0.04 97.28 285758 | 1 0.04 97.31 285759 | 1 0.04 97.35 285760 | 1 0.04 97.39 285761 | 1 0.04 97.43 285762 | 1 0.04 97.47 285763 | 1 0.04 97.51 285764 | 1 0.04 97.55 285765 | 1 0.04 97.58 285766 | 1 0.04 97.62 285767 | 1 0.04 97.66 285768 | 1 0.04 97.70 285769 | 1 0.04 97.74 285770 | 1 0.04 97.78 285771 | 1 0.04 97.81 285772 | 1 0.04 97.85 285773 | 1 0.04 97.89 285774 | 1 0.04 97.93 285775 | 1 0.04 97.97 285776 | 1 0.04 98.01 285777 | 1 0.04 98.04 285778 | 1 0.04 98.08 285779 | 1 0.04 98.12 285780 | 1 0.04 98.16 285781 | 1 0.04 98.20 285782 | 1 0.04 98.24 285783 | 1 0.04 98.27 285784 | 1 0.04 98.31 285785 | 1 0.04 98.35 285786 | 1 0.04 98.39 285787 | 1 0.04 98.43 285788 | 1 0.04 98.47 285789 | 1 0.04 98.50 285790 | 1 0.04 98.54 285791 | 1 0.04 98.58 285792 | 1 0.04 98.62 285793 | 1 0.04 98.66 285794 | 1 0.04 98.70 285795 | 1 0.04 98.73 285796 | 1 0.04 98.77 285797 | 1 0.04 98.81 285798 | 1 0.04 98.85 285799 | 1 0.04 98.89 285800 | 1 0.04 98.93 285801 | 1 0.04 98.96 285802 | 1 0.04 99.00 285803 | 1 0.04 99.04 285804 | 1 0.04 99.08 285805 | 1 0.04 99.12 285806 | 1 0.04 99.16 285807 | 1 0.04 99.19 285808 | 1 0.04 99.23 285809 | 1 0.04 99.27 285810 | 1 0.04 99.31 285811 | 1 0.04 99.35 285812 | 1 0.04 99.39 285813 | 1 0.04 99.42 285814 | 1 0.04 99.46 285815 | 1 0.04 99.50 285816 | 1 0.04 99.54 285817 | 1 0.04 99.58 285818 | 1 0.04 99.62 285819 | 1 0.04 99.65 285820 | 1 0.04 99.69 285821 | 1 0.04 99.73 285822 | 1 0.04 99.77 285823 | 1 0.04 99.81 285824 | 1 0.04 99.85 285825 | 1 0.04 99.88 285826 | 1 0.04 99.92 285827 | 1 0.04 99.96 285828 | 1 0.04 100.00 ------------+----------------------------------- Total | 2,607 100.00 Frequencies for cmt_number variable in pmc_commitments dataset : Commitment | Number | Freq. Percent Cum. ------------+----------------------------------- 1 | 1,010 38.74 38.74 2 | 496 19.03 57.77 3 | 333 12.77 70.54 4 | 247 9.47 80.02 5 | 163 6.25 86.27 6 | 103 3.95 90.22 7 | 75 2.88 93.10 8 | 53 2.03 95.13 9 | 48 1.84 96.97 10 | 31 1.19 98.16 11 | 25 0.96 99.12 12 | 6 0.23 99.35 13 | 5 0.19 99.54 14 | 4 0.15 99.69 15 | 5 0.19 99.88 16 | 2 0.08 99.96 18 | 1 0.04 100.00 ------------+----------------------------------- Total | 2,607 100.00 Frequencies for cmt_doc_type variable in pmc_commitments dataset : Commitment Document Type | Freq. Percent Cum. ----------------------------------------+----------------------------------- Original Biologics License Application | 350 13.43 13.43 Original New Drug Application (NDA) | 1,776 68.12 81.55 Other | 6 0.23 81.78 Supplemental NDA or BLA | 475 18.22 100.00 ----------------------------------------+----------------------------------- Total | 2,607 100.00 Frequencies for cmt_doc_typestr variable in pmc_commitments dataset : Commitment | Document | Type | Freq. Percent Cum. ------------+----------------------------------- B | 350 13.43 13.43 N | 1,776 68.12 81.55 O | 6 0.23 81.78 S | 475 18.22 100.00 ------------+----------------------------------- Total | 2,607 100.00 Frequencies for cmt_doc_type_no variable in pmc_commitments dataset : Commitment | Document | Type Number | Freq. Percent Cum. ------------+----------------------------------- 0 | 137 5.26 5.26 1 | 1,981 75.99 81.24 10 | 12 0.46 81.70 101 | 2 0.08 81.78 102 | 2 0.08 81.86 1033 | 1 0.04 81.89 104 | 1 0.04 81.93 1077 | 2 0.08 82.01 11 | 7 0.27 82.28 110 | 1 0.04 82.32 114 | 1 0.04 82.36 12 | 16 0.61 82.97 122 | 1 0.04 83.01 125 | 2 0.08 83.08 127 | 3 0.12 83.20 1297 | 2 0.08 83.28 13 | 12 0.46 83.74 14 | 4 0.15 83.89 15 | 10 0.38 84.27 153 | 3 0.12 84.39 16 | 13 0.50 84.89 160 | 3 0.12 85.00 163 | 1 0.04 85.04 1668 | 2 0.08 85.12 169 | 1 0.04 85.16 17 | 8 0.31 85.46 172 | 1 0.04 85.50 18 | 10 0.38 85.88 180 | 1 0.04 85.92 184 | 3 0.12 86.04 19 | 10 0.38 86.42 192 | 2 0.08 86.50 194 | 1 0.04 86.54 2 | 42 1.61 88.15 20 | 6 0.23 88.38 21 | 2 0.08 88.45 22 | 3 0.12 88.57 226 | 1 0.04 88.61 23 | 2 0.08 88.68 232 | 6 0.23 88.91 24 | 1 0.04 88.95 242 | 1 0.04 88.99 25 | 2 0.08 89.07 253 | 2 0.08 89.14 254 | 1 0.04 89.18 259 | 1 0.04 89.22 26 | 5 0.19 89.41 262 | 1 0.04 89.45 27 | 9 0.35 89.80 28 | 2 0.08 89.87 280 | 1 0.04 89.91 286 | 1 0.04 89.95 3 | 26 1.00 90.95 30 | 9 0.35 91.29 31 | 2 0.08 91.37 32 | 1 0.04 91.41 33 | 12 0.46 91.87 34 | 2 0.08 91.94 35 | 4 0.15 92.10 36 | 3 0.12 92.21 37 | 1 0.04 92.25 375 | 1 0.04 92.29 38 | 1 0.04 92.33 393 | 1 0.04 92.37 395 | 2 0.08 92.44 4 | 14 0.54 92.98 41 | 1 0.04 93.02 42 | 1 0.04 93.06 43 | 1 0.04 93.10 45 | 1 0.04 93.13 47 | 1 0.04 93.17 5 | 12 0.46 93.63 5000 | 1 0.04 93.67 5002 | 1 0.04 93.71 5037 | 1 0.04 93.75 5047 | 1 0.04 93.79 5050 | 1 0.04 93.82 5052 | 3 0.12 93.94 5065 | 1 0.04 93.98 5074 | 1 0.04 94.02 5089 | 1 0.04 94.05 51 | 6 0.23 94.28 5129 | 1 0.04 94.32 513 | 2 0.08 94.40 5138 | 1 0.04 94.44 5139 | 4 0.15 94.59 5140 | 1 0.04 94.63 5149 | 1 0.04 94.67 5153 | 1 0.04 94.71 5175 | 1 0.04 94.74 5183 | 1 0.04 94.78 5187 | 1 0.04 94.82 5189 | 4 0.15 94.98 5215 | 2 0.08 95.05 5232 | 2 0.08 95.13 5248 | 1 0.04 95.17 5250 | 2 0.08 95.24 5251 | 1 0.04 95.28 5256 | 1 0.04 95.32 5259 | 1 0.04 95.36 5282 | 3 0.12 95.47 5301 | 4 0.15 95.63 5328 | 1 0.04 95.67 5332 | 1 0.04 95.70 5344 | 2 0.08 95.78 55 | 1 0.04 95.82 5514 | 1 0.04 95.86 5520 | 1 0.04 95.90 5574 | 1 0.04 95.93 56 | 2 0.08 96.01 565 | 3 0.12 96.13 5733 | 1 0.04 96.16 6 | 12 0.46 96.62 60 | 2 0.08 96.70 61 | 2 0.08 96.78 62 | 1 0.04 96.82 63 | 1 0.04 96.85 64 | 1 0.04 96.89 67 | 3 0.12 97.01 69 | 2 0.08 97.08 7 | 14 0.54 97.62 73 | 3 0.12 97.74 734 | 1 0.04 97.78 76 | 1 0.04 97.81 77 | 4 0.15 97.97 78 | 6 0.23 98.20 79 | 4 0.15 98.35 8 | 22 0.84 99.19 80 | 2 0.08 99.27 83 | 1 0.04 99.31 84 | 1 0.04 99.35 85 | 1 0.04 99.39 86 | 1 0.04 99.42 87 | 1 0.04 99.46 89 | 3 0.12 99.58 9 | 7 0.27 99.85 94 | 3 0.12 99.96 95 | 1 0.04 100.00 ------------+----------------------------------- Total | 2,607 100.00 Frequencies for cmt_desc variable in pmc_commitments dataset : Commitment Description | Freq. Percent Cum. ----------------------------------------+----------------------------------- (2a) If the proposed rationale submit.. | 1 0.04 0.04 A 1-month, GLP juvenile animal toxico.. | 1 0.04 0.08 A 10 year, observational study to pro.. | 1 0.04 0.12 A 10 year, observational study to pro.. | 1 0.04 0.15 A 10 year, observational study to pro.. | 1 0.04 0.19 A 10 year, observational study to pro.. | 1 0.04 0.23 A 10 year, observational study to pro.. | 1 0.04 0.27 A 10 year, observational study to pro.. | 1 0.04 0.31 A 10-year, observational study to pro.. | 1 0.04 0.35 A 10-year, observational study to pro.. | 1 0.04 0.38 A 12-week, randomized, placebo-contro.. | 1 0.04 0.42 A 2-year carcinogenicity study in a s.. | 1 0.04 0.46 A 2-year dermal rat carcinogenicity s.. | 1 0.04 0.50 A 2-year study in mice to determine t.. | 1 0.04 0.54 A 2-year subcutaneous carcinogenicity.. | 1 0.04 0.58 A 24-month oral (gavage) carcinogenic.. | 1 0.04 0.61 A 24-month oral (gavage) carcinogenic.. | 1 0.04 0.65 A 24-month oral carcinogenicity study.. | 1 0.04 0.69 A 24-week, randomized, double-blind, .. | 2 0.08 0.77 A 26-week carcinogenicity study of et.. | 1 0.04 0.81 A 26-week randomized, controlled clin.. | 1 0.04 0.84 A 26-week randomized, controlled tria.. | 1 0.04 0.88 A 26-week randomized, double-blind, p.. | 1 0.04 0.92 A 26-week randomized, double-blind, p.. | 1 0.04 0.96 A 26-week, randomized double-blind, p.. | 2 0.08 1.04 A 52-week randomized, double-blind, p.. | 1 0.04 1.07 A 52-week randomized, double-blind, p.. | 1 0.04 1.11 A 52-week, randomized, double-blind, .. | 1 0.04 1.15 A 52-week, randomized, double-blind, .. | 1 0.04 1.19 A 52-week, randomized, double-blind, .. | 1 0.04 1.23 A 52-week, randomized, double-blind, .. | 1 0.04 1.27 A 52-week, randomized, double-blind, .. | 1 0.04 1.30 A 54-week, randomized, double-blind, .. | 1 0.04 1.34 A 56-week randomized, double-blind, p.. | 1 0.04 1.38 A 56-week randomized, double-blind, p.. | 1 0.04 1.42 A 6-month carcinogenicity study in th.. | 1 0.04 1.46 A 6-week randomized, double blind, pl.. | 1 0.04 1.50 A GLP toxicology study in juvenile rats | 1 0.04 1.53 A JIA patient safety registry compris.. | 1 0.04 1.57 A PK-PD bridging simulation study mus.. | 6 0.23 1.80 A PK-PD eugylcemic glucose-clamp tria.. | 1 0.04 1.84 A PK/PD dose finding study of netupit.. | 1 0.04 1.88 A PK/PD study to characterize aprepit.. | 1 0.04 1.92 A PK/PD study to characterize aprepit.. | 1 0.04 1.96 A Pharmacokinetics/Pharmacodynamics t.. | 1 0.04 1.99 A Pregnancy Pharmacovigilance Study t.. | 1 0.04 2.03 A Pregnancy Pharmacovigilance Study t.. | 1 0.04 2.07 A Randomized, Multicenter, Double Mas.. | 1 0.04 2.11 A Syrian Hamster Embryo (SHE) cell tr.. | 1 0.04 2.15 A bioequivalence trial of Prestalia (.. | 1 0.04 2.19 A carcinogenicity study in one animal.. | 1 0.04 2.22 A carcinogenicity study of orally adm.. | 1 0.04 2.26 A carcinogenicity study of orally adm.. | 1 0.04 2.30 A case-control study of pregnancy los.. | 1 0.04 2.34 A clinical pharmacokinetic trial in p.. | 1 0.04 2.38 A clinical pharmacology (Part A) foll.. | 1 0.04 2.42 A clinical pharmacology (Part A) foll.. | 1 0.04 2.45 A clinical pharmacology study to asse.. | 1 0.04 2.49 A clinical pharmacology study to asse.. | 1 0.04 2.53 A clinical pharmacology study to eval.. | 2 0.08 2.61 A clinical pharmacology trial to asse.. | 1 0.04 2.65 A clinical pharmacology trial to asse.. | 1 0.04 2.69 A clinical pharmacology trial to asse.. | 1 0.04 2.72 A clinical trial in adults receiving .. | 1 0.04 2.76 A clinical trial in healthy adult vol.. | 6 0.23 2.99 A clinical trial in healthy subjects .. | 1 0.04 3.03 A clinical trial in healthy subjects .. | 1 0.04 3.07 A clinical trial in healthy subjects .. | 1 0.04 3.11 A clinical trial in healthy subjects .. | 1 0.04 3.15 A clinical trial in healthy subjects .. | 1 0.04 3.18 A clinical trial in healthy subjects .. | 1 0.04 3.22 A clinical trial of patients with sym.. | 1 0.04 3.26 A clinical trial to assess the effect.. | 1 0.04 3.30 A clinical trial to assess the risk o.. | 1 0.04 3.34 A clinical trial to assess the risk o.. | 2 0.08 3.41 A clinical trial to assess the risk o.. | 2 0.08 3.49 A clinical trial to assess the risk o.. | 1 0.04 3.53 A clinical trial to assess the risk o.. | 1 0.04 3.57 A clinical trial to assess the safety.. | 1 0.04 3.61 A clinical trial to assess the safety.. | 1 0.04 3.64 A clinical trial to evaluate the effe.. | 1 0.04 3.68 A clinical trial to examine pharmacok.. | 1 0.04 3.72 A clinical trial to examine pharmacok.. | 1 0.04 3.76 A commitment to conduct a registry st.. | 1 0.04 3.80 A commitment to conduct a well-contro.. | 1 0.04 3.84 A commitment to evaluate mangafodipir.. | 1 0.04 3.87 A commitment to perform a Phase 4 adr.. | 1 0.04 3.91 A controlled efficacy and safety stud.. | 2 0.08 3.99 A controlled trial to evaluate the lo.. | 4 0.15 4.14 A controlled trial to evaluate the lo.. | 2 0.08 4.22 A controlled trial to evaluate the lo.. | 1 0.04 4.26 A controlled urodynamic trial, to inc.. | 1 0.04 4.30 A dedicated clinical pharmacology tri.. | 1 0.04 4.33 A deferred pediatric study (B1971017).. | 1 0.04 4.37 A deferred pediatric study (B1971035).. | 1 0.04 4.41 A deferred pediatric study (B1971051).. | 1 0.04 4.45 A deferred pediatric study (V72_28) u.. | 1 0.04 4.49 A deferred pediatric study (V72_57) u.. | 1 0.04 4.53 A deferred pediatric study under PREA.. | 1 0.04 4.56 A deferred pediatric study under PREA.. | 1 0.04 4.60 A deferred pediatric study under PREA.. | 1 0.04 4.64 A deferred pediatric study under PREA.. | 1 0.04 4.68 A deferred pediatric study under PREA.. | 1 0.04 4.72 A deferred pediatric study under PREA.. | 1 0.04 4.76 A deferred pediatric study under PREA.. | 1 0.04 4.79 A deferred pediatric study under PREA.. | 1 0.04 4.83 A deferred pediatric study under PREA.. | 1 0.04 4.87 A deferred pediatric study under PREA.. | 1 0.04 4.91 A deferred pediatric study under PREA.. | 1 0.04 4.95 A descriptive observational cohort st.. | 1 0.04 4.99 A descriptive observational cohort st.. | 1 0.04 5.02 A descriptive study of the safety of .. | 1 0.04 5.06 A dose finding, pharmacokinetics and .. | 1 0.04 5.10 A dose-ranging clinical trial to eval.. | 1 0.04 5.14 A dose-ranging study assessing the ph.. | 1 0.04 5.18 A drug interaction trial to determine.. | 2 0.08 5.26 A drug utilization study to better ch.. | 1 0.04 5.29 A drug-drug interaction clinical tria.. | 1 0.04 5.33 A drug-use study conducted annually f.. | 1 0.04 5.37 A five-year prospective epidemiologic.. | 1 0.04 5.41 A juvenile animal study to evaluate t.. | 1 0.04 5.45 A juvenile animal study with the comb.. | 1 0.04 5.49 A juvenile animal toxicology study in.. | 1 0.04 5.52 A juvenile dog toxicology study under.. | 1 0.04 5.56 A juvenile neurotoxicity study in neo.. | 1 0.04 5.60 A juvenile rat study to support use o.. | 2 0.08 5.68 A juvenile rat toxicology study is re.. | 1 0.04 5.72 A juvenile rat toxicology study is re.. | 1 0.04 5.75 A juvenile rat toxicology study is re.. | 1 0.04 5.79 A juvenile rat toxicology study is re.. | 1 0.04 5.83 A juvenile rat toxicology study is re.. | 1 0.04 5.87 A juvenile rat toxicology study under.. | 2 0.08 5.95 A juvenile rat toxicology study. The .. | 1 0.04 5.98 A large randomized, double-blind, act.. | 1 0.04 6.02 A large randomized, double-blind, act.. | 1 0.04 6.06 A large, long-term, prospective obser.. | 1 0.04 6.10 A long term ( 24 week, 3on/off cycle).. | 1 0.04 6.14 A long-term follow-up study to evalua.. | 1 0.04 6.18 A long-term observational safety stud.. | 1 0.04 6.21 A long-term observational study in ad.. | 1 0.04 6.25 A long-term observational study in el.. | 1 0.04 6.29 A long-term observational study in th.. | 1 0.04 6.33 A long-term observational study using.. | 1 0.04 6.37 A long-term prospective observational.. | 1 0.04 6.41 A long-term prospective observational.. | 1 0.04 6.44 A long-term prospective observational.. | 1 0.04 6.48 A long-term prospective observational.. | 1 0.04 6.52 A long-term prospective observational.. | 1 0.04 6.56 A long-term rodent carcinogenicity st.. | 1 0.04 6.60 A long-term safety study in 100 pedia.. | 1 0.04 6.64 A long-term safety study in 400 pedia.. | 1 0.04 6.67 A long-term surveillance study in pos.. | 1 0.04 6.71 A long-term, open-label safety study .. | 2 0.08 6.79 A long-term, open-label, safety study.. | 1 0.04 6.83 A medullary thyroid carcinoma case se.. | 1 0.04 6.87 A medullary thyroid carcinoma case se.. | 1 0.04 6.90 A medullary thyroid carcinoma case se.. | 1 0.04 6.94 A medullary thyroid carcinoma registr.. | 1 0.04 6.98 A medullary thyroid carcinoma registr.. | 1 0.04 7.02 A milk-only lactation trial in lactat.. | 1 0.04 7.06 A multi-center clinical trial to eval.. | 1 0.04 7.10 A multi-center clinical trial to eval.. | 1 0.04 7.13 A multi-center observational study of.. | 1 0.04 7.17 A multi-center, randomized, clinical .. | 1 0.04 7.21 A multi-phase clinical trial in a hyp.. | 1 0.04 7.25 A multicenter, randomized, double-bli.. | 1 0.04 7.29 A multicenter, randomized, double-bli.. | 1 0.04 7.33 A multicenter, randomized, double-bli.. | 1 0.04 7.36 A multicenter, randomized, double-bli.. | 1 0.04 7.40 A multicenter, randomized, double-bli.. | 1 0.04 7.44 A multiple ascending dose clinical tr.. | 6 0.23 7.67 A multiple ascending dose thorough QT.. | 1 0.04 7.71 A multiple-dose pharmacokinetic trial.. | 1 0.04 7.75 A one year Pediatric Open-Label Safet.. | 1 0.04 7.79 A one year Pediatric Open-Label Safet.. | 1 0.04 7.83 A one year Pediatric Open-Label Safet.. | 1 0.04 7.86 A one year prospective, randomized, p.. | 2 0.08 7.94 A one year, prospective observational.. | 1 0.04 7.98 A pediatric study in patients aged 6 .. | 1 0.04 8.02 A pediatric study to evaluate pharmac.. | 1 0.04 8.06 A pharmacokinetic analysis to determi.. | 3 0.12 8.17 A pharmacokinetic and safety analysis.. | 3 0.12 8.29 A pharmacokinetic and safety study of.. | 1 0.04 8.32 A pharmacokinetic and tolerability st.. | 1 0.04 8.36 A pharmacokinetic study in pediatric .. | 1 0.04 8.40 A pharmacokinetic study in pediatric .. | 1 0.04 8.44 A pharmacokinetic trial in patients t.. | 1 0.04 8.48 A pharmacokinetic trial in patients w.. | 2 0.08 8.55 A pharmacokinetic trial in patients w.. | 2 0.08 8.63 A pharmacokinetic, safety, and effica.. | 1 0.04 8.67 A pharmacokinetic, safety, and effica.. | 1 0.04 8.71 A pharmacokinetic, safety, and effica.. | 1 0.04 8.75 A pharmacokinetic, safety, and effica.. | 1 0.04 8.78 A pharmacokinetic/dose ranging study .. | 1 0.04 8.82 A pharmacokinetic/dose ranging study .. | 1 0.04 8.86 A placebo-controlled clinical trial i.. | 1 0.04 8.90 A placebo-controlled, randomized with.. | 2 0.08 8.98 A placebo-controlled, randomized with.. | 2 0.08 9.05 A placebo-controlled, randomized with.. | 2 0.08 9.13 A post-marketing registry study of pe.. | 1 0.04 9.17 A post-marketing, observational epide.. | 1 0.04 9.21 A post-marketing, observational epide.. | 1 0.04 9.24 A post-marketing, observational epide.. | 1 0.04 9.28 A postmarket claims-based study to fu.. | 1 0.04 9.32 A postmarket electronic medical recor.. | 1 0.04 9.36 A postmarketing observational cohort .. | 1 0.04 9.40 A postmarketing observational prospec.. | 1 0.04 9.44 A postmarketing pharmacovigilance stu.. | 1 0.04 9.47 A postmarketing prospective, long-ter.. | 1 0.04 9.51 A postmarketing study that will allow.. | 47 1.80 11.32 A postmarketing study that will allow.. | 48 1.84 13.16 A postmarketing study that will allow.. | 84 3.22 16.38 A postmarketing study that will allow.. | 4 0.15 16.53 A postmarketing, prospective, observa.. | 1 0.04 16.57 A pre- and postnatal development (inc.. | 1 0.04 16.61 A pre-and postnatal development (incl.. | 1 0.04 16.65 A pregnancy registry must be establis.. | 1 0.04 16.69 A prospective cohort study to a) dete.. | 1 0.04 16.72 A prospective descriptive observation.. | 1 0.04 16.76 A prospective human physical dependen.. | 1 0.04 16.80 A prospective human physical dependen.. | 1 0.04 16.84 A prospective observational cohort st.. | 2 0.08 16.92 A prospective observational registry .. | 1 0.04 16.95 A prospective observational study des.. | 16 0.61 17.57 A prospective pharmacokinetic (PK) st.. | 1 0.04 17.61 A prospective safety study conducted .. | 1 0.04 17.64 A prospective study in adult patients.. | 1 0.04 17.68 A prospective study in the United Sta.. | 1 0.04 17.72 A prospective, controlled, non-interv.. | 1 0.04 17.76 A prospective, long-term observationa.. | 1 0.04 17.80 A prospective, long-term, observation.. | 1 0.04 17.84 A prospective, multi-center, long-ter.. | 3 0.12 17.95 A prospective, multi-center, long-ter.. | 1 0.04 17.99 A prospective, multiple dose, randomi.. | 1 0.04 18.03 A prospective, observational exposure.. | 1 0.04 18.07 A prospective, observational pregnanc.. | 1 0.04 18.11 A prospective, observational study de.. | 16 0.61 18.72 A prospective, observational study in.. | 1 0.04 18.76 A prospective, observational, control.. | 1 0.04 18.80 A prospective, observational, exposur.. | 1 0.04 18.83 A prospective, randomized, active-con.. | 2 0.08 18.91 A prospective, randomized, controlled.. | 1 0.04 18.95 A prospective, randomized, controlled.. | 1 0.04 18.99 A prospective, randomized, controlled.. | 1 0.04 19.03 A prospective, randomized, controlled.. | 1 0.04 19.06 A prospective, randomized, controlled.. | 1 0.04 19.10 A prospective, randomized, controlled.. | 1 0.04 19.14 A prospective, randomized, controlled.. | 1 0.04 19.18 A prospective, randomized, controlled.. | 1 0.04 19.22 A prospective, randomized, controlled.. | 3 0.12 19.33 A prospective, randomized, placebo-co.. | 1 0.04 19.37 A prospective, registry-based observa.. | 1 0.04 19.41 A randomized and controlled pediatric.. | 1 0.04 19.45 A randomized and controlled pediatric.. | 1 0.04 19.49 A randomized and controlled pediatric.. | 1 0.04 19.52 A randomized clinical trial to assess.. | 1 0.04 19.56 A randomized controlled trial in pati.. | 2 0.08 19.64 A randomized controlled trial to eval.. | 2 0.08 19.72 A randomized dose-comparison trial in.. | 1 0.04 19.75 A randomized trial comparing lapatini.. | 1 0.04 19.79 A randomized trial comparing pralatre.. | 1 0.04 19.83 A randomized trial of maintenance tre.. | 1 0.04 19.87 A randomized withdrawal, double-blind.. | 1 0.04 19.91 A randomized, controlled clinical tri.. | 1 0.04 19.95 A randomized, controlled clinical tri.. | 2 0.08 20.02 A randomized, controlled clinical tri.. | 2 0.08 20.10 A randomized, controlled trial evalua.. | 1 0.04 20.14 A randomized, controlled trial of ade.. | 1 0.04 20.18 A randomized, controlled trial to rul.. | 1 0.04 20.21 A randomized, controlled, clinical tr.. | 1 0.04 20.25 A randomized, controlled, parallel gr.. | 1 0.04 20.29 A randomized, controlled, parallel gr.. | 1 0.04 20.33 A randomized, double blind, multicent.. | 1 0.04 20.37 A randomized, double blind, placebo-c.. | 1 0.04 20.41 A randomized, double blind, placebo-c.. | 1 0.04 20.44 A randomized, double-blind study in p.. | 1 0.04 20.48 A randomized, double-blind, 26-week, .. | 1 0.04 20.52 A randomized, double-blind, 26-week, .. | 1 0.04 20.56 A randomized, double-blind, 26-week, .. | 1 0.04 20.60 A randomized, double-blind, 26-week, .. | 1 0.04 20.64 A randomized, double-blind, 26-week, .. | 1 0.04 20.68 A randomized, double-blind, adequatel.. | 1 0.04 20.71 A randomized, double-blind, adequatel.. | 1 0.04 20.75 A randomized, double-blind, adequatel.. | 1 0.04 20.79 A randomized, double-blind, adequatel.. | 1 0.04 20.83 A randomized, double-blind, controlle.. | 1 0.04 20.87 A randomized, double-blind, controlle.. | 1 0.04 20.91 A randomized, double-blind, placebo-c.. | 13 0.50 21.40 A randomized, double-blind, placebo-c.. | 1 0.04 21.44 A randomized, double-blind, placebo-c.. | 1 0.04 21.48 A randomized, double-blind, placebo-c.. | 1 0.04 21.52 A randomized, double-blind, placebo-c.. | 1 0.04 21.56 A randomized, double-blind, placebo-c.. | 2 0.08 21.63 A randomized, double-blind, placebo-c.. | 2 0.08 21.71 A randomized, double-blind, placebo-c.. | 1 0.04 21.75 A randomized, double-blind, placebo-c.. | 1 0.04 21.79 A randomized, double-blind, placebo-c.. | 1 0.04 21.83 A randomized, double-blind, placebo-c.. | 1 0.04 21.86 A randomized, double-blind, placebo-c.. | 1 0.04 21.90 A randomized, double-blind, placebo-c.. | 1 0.04 21.94 A randomized, double-blind, placebo-c.. | 1 0.04 21.98 A randomized, double-blind, placebo-c.. | 1 0.04 22.02 A randomized, placebo- and active-con.. | 1 0.04 22.06 A randomized, placebo-controlled clin.. | 1 0.04 22.09 A randomized, placebo-controlled tria.. | 1 0.04 22.13 A randomized, placebo-controlled, dos.. | 1 0.04 22.17 A randomized, single-blind, multicent.. | 1 0.04 22.21 A randomized, single-blind, multicent.. | 1 0.04 22.25 A randomized, single-blind, multicent.. | 1 0.04 22.29 A randomized, single-blind, multicent.. | 1 0.04 22.32 A randomized, single-blind, multicent.. | 1 0.04 22.36 A randomized, single-blind, multicent.. | 1 0.04 22.40 A randomized, single-blind, multicent.. | 1 0.04 22.44 A randomized, single-blind, multicent.. | 1 0.04 22.48 A registry of patients, including inf.. | 1 0.04 22.52 A registry to provide long term evalu.. | 1 0.04 22.55 A repeat dose, randomized, active-con.. | 1 0.04 22.59 A retrospective observational cohort .. | 1 0.04 22.63 A rodent carcinogenicity study in the.. | 1 0.04 22.67 A rodent carcinogenicity study in the.. | 1 0.04 22.71 A safety and efficacy study in pediat.. | 1 0.04 22.75 A safety and efficacy trial in pediat.. | 1 0.04 22.78 A safety and pharmacokinetic trial as.. | 1 0.04 22.82 A safety and pharmacokinetic trial as.. | 1 0.04 22.86 A safety assessment of deoxycholic ac.. | 1 0.04 22.90 A safety study in 100 pediatric patie.. | 1 0.04 22.94 A safety study of replacement of oral.. | 6 0.23 23.17 A simulated driving trial in healthy .. | 1 0.04 23.21 A single dose, pharmacokinetic, open-.. | 1 0.04 23.25 A single pediatric study in at least .. | 1 0.04 23.28 A single- and repeated-dose pharmacod.. | 1 0.04 23.32 A single-center randomized, placebo-c.. | 2 0.08 23.40 A single-center randomized, placebo-c.. | 2 0.08 23.48 A single-center, randomized, placebo-.. | 1 0.04 23.51 A single-dose pharmacokinetic and pha.. | 2 0.08 23.59 A single-dose, open-label, pharmacoki.. | 1 0.04 23.63 A single-dose, open-label, randomized.. | 1 0.04 23.67 A single-dose, open-label, randomized.. | 1 0.04 23.71 A single-dose, open-label, randomized.. | 1 0.04 23.74 A study analyzing data from the Regis.. | 1 0.04 23.78 A study based on routine postmarketin.. | 1 0.04 23.82 A study evaluating gallbladder ejecti.. | 1 0.04 23.86 A study evaluating gallbladder ejecti.. | 1 0.04 23.90 A study in Fischer 344 rats to ascert.. | 1 0.04 23.94 A study in adolescents and younger pe.. | 1 0.04 23.97 A study in inflammatory bowel disease.. | 1 0.04 24.01 A study in the greater than or equal .. | 1 0.04 24.05 A study of the effects of carglumic a.. | 1 0.04 24.09 A study that will examine safety and .. | 6 0.23 24.32 A study that will examine safety and .. | 6 0.23 24.55 A study to analyze samples from the P.. | 1 0.04 24.59 A study to assess for the presence of.. | 1 0.04 24.63 A study to assess the chronic dose ef.. | 1 0.04 24.66 A study to assess the effectiveness a.. | 1 0.04 24.70 A study to assess the efficacy and sa.. | 1 0.04 24.74 A study to assess the pharmacokinetic.. | 1 0.04 24.78 A study to bank samples for future ev.. | 1 0.04 24.82 A study to bank samples from inflamma.. | 3 0.12 24.93 A study to characterize guanylate cyc.. | 1 0.04 24.97 A study to determine patient complian.. | 1 0.04 25.01 A study to determine the feasibility .. | 1 0.04 25.05 A study to evaluate and compare GLP-1.. | 1 0.04 25.09 A study to evaluate dulaglutide toxic.. | 1 0.04 25.12 A study to evaluate empagliflozin tox.. | 2 0.08 25.20 A study to evaluate the PK and tolera.. | 1 0.04 25.24 A study to evaluate the dependence of.. | 1 0.04 25.28 A study to evaluate the efficacy and .. | 1 0.04 25.32 A study to evaluate the pharmacokinet.. | 1 0.04 25.35 A study to evaluate the pharmacokinet.. | 1 0.04 25.39 A study to evaluate the safety of met.. | 1 0.04 25.43 A study to evaluate: 1. patient immun.. | 1 0.04 25.47 A study to measure GC-C mRNA levels i.. | 1 0.04 25.51 A study to reanalyze banked immunogen.. | 1 0.04 25.55 A thorough QT trial designed to rule .. | 1 0.04 25.58 A thorough QTc clinical trial in pati.. | 3 0.12 25.70 A trial of the short and long-term sa.. | 1 0.04 25.74 A two-year carcinogenicity study in o.. | 1 0.04 25.78 A two-year carcinogenicity study of i.. | 1 0.04 25.82 A two-year rodent carcinogenicity stu.. | 1 0.04 25.85 Adult clinical study to address longe.. | 1 0.04 25.89 Alcohol Interaction Trial in the Targ.. | 1 0.04 25.93 Alcohol Interaction Trial in the Targ.. | 1 0.04 25.97 Alcohol Interaction Trial in the Targ.. | 1 0.04 26.01 An 8-week GLP toxicology study with f.. | 1 0.04 26.05 An 8-week randomized, double blind, p.. | 1 0.04 26.08 An Enhanced Pharmacovigilance Study t.. | 1 0.04 26.12 An actual use human factors study to .. | 1 0.04 26.16 An addition to the stability protocol.. | 1 0.04 26.20 An adequate randomized, active contro.. | 1 0.04 26.24 An adequate, placebo-controlled, doub.. | 1 0.04 26.28 An adequate, well-controlled, double-.. | 1 0.04 26.31 An adequately controlled study to ass.. | 1 0.04 26.35 An adequately controlled study to ass.. | 1 0.04 26.39 An adequately powered safety and effi.. | 1 0.04 26.43 An assessment and analysis of all for.. | 2 0.08 26.51 An assessment and analysis of all for.. | 1 0.04 26.54 An assessment and analysis of reports.. | 1 0.04 26.58 An assessment and analysis of spontan.. | 1 0.04 26.62 An assessment and analysis of spontan.. | 1 0.04 26.66 An assessment and analysis of spontan.. | 1 0.04 26.70 An assessment and analysis of spontan.. | 1 0.04 26.74 An assessment and analysis of spontan.. | 1 0.04 26.77 An assessment and analysis of spontan.. | 1 0.04 26.81 An assessment and analysis of spontan.. | 1 0.04 26.85 An assessment and analysis of spontan.. | 1 0.04 26.89 An assessment and analysis of spontan.. | 1 0.04 26.93 An efficacy and safety, dose-finding .. | 1 0.04 26.97 An efficacy, safety and dose-finding .. | 1 0.04 27.00 An enhanced pharmacovigilance study o.. | 2 0.08 27.08 An enhanced pharmacovigilance study o.. | 2 0.08 27.16 An enhanced pharmacovigilance study o.. | 3 0.12 27.27 An enhanced pharmacovigilance study o.. | 1 0.04 27.31 An epidemiological study to address w.. | 1 0.04 27.35 An evaluation of Fertility and Early .. | 1 0.04 27.39 An evaluation of Peri-and Postnatal D.. | 1 0.04 27.43 An evaluation of the potential carcin.. | 1 0.04 27.46 An evaluation of the potential carcin.. | 1 0.04 27.50 An evaluation of the potential carcin.. | 1 0.04 27.54 An ex vivo study to determine whether.. | 1 0.04 27.58 An in vitro study to evaluate the tim.. | 1 0.04 27.62 An in vitro study to evaluate whether.. | 1 0.04 27.66 An in vivo drug-drug interaction stud.. | 2 0.08 27.73 An in vivo study in human subjects to.. | 1 0.04 27.77 An observational safety study enrolli.. | 1 0.04 27.81 An observational study (N = 1200) to .. | 1 0.04 27.85 An observational study designed to me.. | 16 0.61 28.46 An observational study of pediatric p.. | 1 0.04 28.50 An observational study of pediatric p.. | 1 0.04 28.54 An observational study of pediatric p.. | 2 0.08 28.62 An observational study of pediatric p.. | 2 0.08 28.69 An observational study of pediatric p.. | 2 0.08 28.77 An observational study of pediatric p.. | 2 0.08 28.85 An observational study of pediatric p.. | 2 0.08 28.92 An observational study of pediatric p.. | 2 0.08 29.00 An observational study of pediatric p.. | 1 0.04 29.04 An observational study of pediatric p.. | 1 0.04 29.08 An observational study of the associa.. | 7 0.27 29.34 An observational study registry in ad.. | 1 0.04 29.38 An observational study to develop and.. | 16 0.61 30.00 An observational study to develop and.. | 16 0.61 30.61 An observational study to estimate th.. | 1 0.04 30.65 An observational study to estimate th.. | 1 0.04 30.69 An observational study to evaluate th.. | 16 0.61 31.30 An observational study to validate me.. | 16 0.61 31.91 An observational study using a valida.. | 16 0.61 32.53 An observational study using coded me.. | 16 0.61 33.14 An observational study using medical .. | 16 0.61 33.76 An open label pharmacokinetic and saf.. | 1 0.04 33.79 An open label pharmacokinetic and saf.. | 1 0.04 33.83 An open-label pharmacokinetic (PK), a.. | 1 0.04 33.87 An open-label pharmacokinetic and saf.. | 1 0.04 33.91 An open-label pharmacokinetic and saf.. | 1 0.04 33.95 An open-label pharmacokinetic and saf.. | 1 0.04 33.99 An open-label pharmacokinetic and saf.. | 1 0.04 34.02 An open-label pharmacokinetic and saf.. | 1 0.04 34.06 An open-label pilot study assessing t.. | 1 0.04 34.10 An open-label safety and tolerability.. | 6 0.23 34.33 An open-label study to assess the eff.. | 1 0.04 34.37 An open-label trial of the safety and.. | 1 0.04 34.41 An open-label, 16-week, randomized, c.. | 1 0.04 34.45 An open-label, 26-week, randomized, c.. | 1 0.04 34.48 An open-label, long-term safety study.. | 1 0.04 34.52 Analyze and submit the remainder of t.. | 1 0.04 34.56 Analyze anti-elosulfase alfa neutrali.. | 1 0.04 34.60 Analyze the polyethylene oxide (PEO) .. | 1 0.04 34.64 Applicant Holder commits to conduct o.. | 1 0.04 34.68 Applicant to conduct a Phase 4 study .. | 1 0.04 34.71 As part of the ongoing Pompe Registry.. | 1 0.04 34.75 Assess apixaban pharmacokinetics and .. | 1 0.04 34.79 Assess data anticipated from adults i.. | 1 0.04 34.83 Assess development of anti-drug antib.. | 1 0.04 34.87 Assess possible cobicistat protease i.. | 1 0.04 34.91 Assess the long-term efficacy (and sa.. | 2 0.08 34.98 Assess the long-term safety of Exjade.. | 2 0.08 35.06 Assess the long-term safety of Trulan.. | 1 0.04 35.10 Assess the pharmacokinetics, safety, .. | 1 0.04 35.14 Assess the safety and effectiveness o.. | 1 0.04 35.17 Assess the safety and efficacy of Peg.. | 1 0.04 35.21 Assess the systemic exposure and phar.. | 1 0.04 35.25 Assess the systemic exposure and phar.. | 1 0.04 35.29 Assessment of Amjevita (adalimumab-at.. | 1 0.04 35.33 Assessment of Amjevita (adalimumab-at.. | 1 0.04 35.37 Assessment of Amjevita (adalimumab-at.. | 1 0.04 35.40 Assessment of efficacy and safety of .. | 1 0.04 35.44 Assessment of efficacy and safety of .. | 1 0.04 35.48 Assessment of pharmacokinetic (PK/PD).. | 1 0.04 35.52 Azelaic acid pre-foam emulsion: 104-w.. | 1 0.04 35.56 Based on the data obtained in PMR #18.. | 1 0.04 35.60 Based on the results of the Phase 1 p.. | 1 0.04 35.63 Based on the results of the pilot stu.. | 1 0.04 35.67 Baxter commits to conducting an evalu.. | 1 0.04 35.71 Baxter commits to establish and maint.. | 1 0.04 35.75 BioMarin commits to designing and imp.. | 1 0.04 35.79 BioMarin commits to designing and imp.. | 1 0.04 35.83 BioMarin commits to developing an ass.. | 1 0.04 35.86 BioMarin is required to conduct the f.. | 1 0.04 35.90 CONFIRMATORY TRIAL - A randomized pha.. | 1 0.04 35.94 CONFIRMATORY TRIAL- A randomized phas.. | 1 0.04 35.98 CSL Behring will conduct phase 4 stud.. | 1 0.04 36.02 Centocor agrees to conduct a prospect.. | 1 0.04 36.06 Centocor commits to designing and imp.. | 1 0.04 36.10 Characterize complications after allo.. | 1 0.04 36.13 Characterize safety of long-term use .. | 1 0.04 36.17 Characterize the PK and safety of bel.. | 1 0.04 36.21 Characterize the PK and safety of bel.. | 1 0.04 36.25 Characterize the PK of belinostat in .. | 1 0.04 36.29 Characterize the comparative efficacy.. | 1 0.04 36.33 Characterize the comparative efficacy.. | 1 0.04 36.36 Characterize the comparative safety a.. | 1 0.04 36.40 Characterize the mass balance informa.. | 1 0.04 36.44 Clarify the possible effects on devel.. | 1 0.04 36.48 Clinical trial (existing trial or new.. | 1 0.04 36.52 Clinical trial to assess the risk of .. | 1 0.04 36.56 Clinical trial to evaluate the effect.. | 1 0.04 36.59 Clinical trial to evaluate the safety.. | 1 0.04 36.63 Cnduct a non-interventional, open-lab.. | 1 0.04 36.67 Collaborate with the cancer registrie.. | 1 0.04 36.71 Collect additional safety and efficac.. | 1 0.04 36.75 Collect additional safety and efficac.. | 1 0.04 36.79 Collect and analyze all cases of acut.. | 1 0.04 36.82 Collect and analyze data from individ.. | 1 0.04 36.86 Collect and analyze data regarding pr.. | 1 0.04 36.90 Collect and analyze data related to t.. | 1 0.04 36.94 Collect and analyze long-term safety .. | 1 0.04 36.98 Collect and analyze long-term safety .. | 1 0.04 37.02 Collect and analyze long-term safety .. | 1 0.04 37.05 Collect and analyze long-term safety .. | 1 0.04 37.09 Collect long-term safety data for sub.. | 1 0.04 37.13 Collect, analyze, and submit addition.. | 1 0.04 37.17 Collect, analyze, and submit data fro.. | 1 0.04 37.21 Collect, analyze, and submit data on .. | 3 0.12 37.32 Collect, analyze, and submit data on .. | 1 0.04 37.36 Combine all available pharmacokinetic.. | 1 0.04 37.40 Commitment to conduct a limited pharm.. | 1 0.04 37.44 Commitment to conduct a study to inve.. | 1 0.04 37.48 Commitment to continue to collect com.. | 1 0.04 37.51 Commitment to determine whether Quadr.. | 1 0.04 37.55 Commitment to perform a long-term saf.. | 1 0.04 37.59 Commitment to support the availabilit.. | 1 0.04 37.63 Commits to performing a safety and ef.. | 1 0.04 37.67 Commits to performing an HPA axis sup.. | 1 0.04 37.71 Complete Clinical Trial C13008, an op.. | 1 0.04 37.74 Complete a clinical pharmacokinetic t.. | 1 0.04 37.78 Complete a clinical pharmacokinetic t.. | 1 0.04 37.82 Complete a clinical pharmacokinetic t.. | 1 0.04 37.86 Complete a clinical trial evaluating .. | 1 0.04 37.90 Complete a clinical trial to evaluate.. | 1 0.04 37.94 Complete a clinical trial to evaluate.. | 1 0.04 37.97 Complete a clinical trial to evaluate.. | 1 0.04 38.01 Complete a clinical trial to evaluate.. | 1 0.04 38.05 Complete a detailed analysis of the b.. | 1 0.04 38.09 Complete a pharmacokinetic trial to d.. | 1 0.04 38.13 Complete a pharmacokinetic trial to d.. | 1 0.04 38.17 Complete a pharmacokinetic trial to d.. | 1 0.04 38.20 Complete a randomized, multicenter, p.. | 1 0.04 38.24 Complete a study of long-term follow-.. | 1 0.04 38.28 Complete an adequate and well-control.. | 2 0.08 38.36 Complete and submit the final results.. | 1 0.04 38.40 Complete study of long-term follow-up.. | 1 0.04 38.43 Complete the ongoing clinical pharmac.. | 1 0.04 38.47 Complete the ongoing clinical pharmac.. | 1 0.04 38.51 Complete the ongoing drug-drug intera.. | 1 0.04 38.55 Complete the ongoing pharmacokinetic .. | 1 0.04 38.59 Complete the ongoing single-arm trial.. | 1 0.04 38.63 Complete the treatment and evaluation.. | 1 0.04 38.67 Complete the treatment and evaluation.. | 1 0.04 38.70 Complete the trial and submit the fin.. | 1 0.04 38.74 Complete the trial and submit the fin.. | 1 0.04 38.78 Complete the trial and submit the fin.. | 1 0.04 38.82 Completion of a controlled clinical s.. | 1 0.04 38.86 Completion of the clinical confirmato.. | 1 0.04 38.90 Completion of the planned mass balanc.. | 1 0.04 38.93 Conduct Study Hib-097, a comparative .. | 1 0.04 38.97 Conduct Study No. V71_18, a randomize.. | 1 0.04 39.01 Conduct Study Protocol P10-262, an 80.. | 1 0.04 39.05 Conduct US surveillance studies for f.. | 1 0.04 39.09 Conduct US surveillance studies for f.. | 2 0.08 39.16 Conduct a 12 month long-term safety a.. | 1 0.04 39.20 Conduct a 12 week randomized, double-.. | 1 0.04 39.24 Conduct a 12 week, randomized, open-l.. | 1 0.04 39.28 Conduct a 12-week, randomized, double.. | 1 0.04 39.32 Conduct a 12-week, randomized, double.. | 1 0.04 39.36 Conduct a 16-week, randomized (1:1), .. | 1 0.04 39.39 Conduct a 2-AB UHPLC assay on lots of.. | 1 0.04 39.43 Conduct a 2-week randomized, double-b.. | 1 0.04 39.47 Conduct a 2-year bioassay in the mous.. | 1 0.04 39.51 Conduct a 2-year bioassay in the rat .. | 1 0.04 39.55 Conduct a 2-year controlled trial in .. | 1 0.04 39.59 Conduct a 2-year rodent oral carcinog.. | 1 0.04 39.62 Conduct a 24-week, randomized, contro.. | 1 0.04 39.66 Conduct a 3 - arm randomized trial in.. | 1 0.04 39.70 Conduct a 48-week, randomized, double.. | 1 0.04 39.74 Conduct a 5-year, randomized, control.. | 1 0.04 39.78 Conduct a 52 week randomized, double .. | 1 0.04 39.82 Conduct a 52-week, randomized, double.. | 1 0.04 39.85 Conduct a 52-week, randomized, double.. | 1 0.04 39.89 Conduct a 6-month repeat-dose oral to.. | 1 0.04 39.93 Conduct a 6-month, open-label extensi.. | 1 0.04 39.97 Conduct a 6-week, double-blind, place.. | 1 0.04 40.01 Conduct a 6-week, randomized, double-.. | 1 0.04 40.05 Conduct a 9-month repeat-dose oral to.. | 1 0.04 40.08 Conduct a Field Study to evaluate the.. | 1 0.04 40.12 Conduct a Long term safety study to f.. | 1 0.04 40.16 Conduct a PK/PD study in adolescents .. | 1 0.04 40.20 Conduct a PK/PD study in adolescents .. | 1 0.04 40.24 Conduct a PK/safety study of SC abata.. | 1 0.04 40.28 Conduct a Pharmacokinetic study in At.. | 1 0.04 40.31 Conduct a Phase 1 Single-Dose Safety .. | 2 0.08 40.39 Conduct a Phase 1 Single-Dose Safety .. | 2 0.08 40.47 Conduct a Phase 1/2 single arm clinic.. | 1 0.04 40.51 Conduct a Phase 3 randomized controll.. | 1 0.04 40.54 Conduct a Phase 3, randomized, compar.. | 1 0.04 40.58 Conduct a Phase 3, randomized, compar.. | 1 0.04 40.62 Conduct a Phase 3, randomized, compar.. | 1 0.04 40.66 Conduct a Phase 4 study to evaluate t.. | 1 0.04 40.70 Conduct a Phase II open-label adminis.. | 1 0.04 40.74 Conduct a Phase IIIb open-label admin.. | 1 0.04 40.77 Conduct a Phase IV self-controlled ca.. | 1 0.04 40.81 Conduct a Phase IV, Multicentre, Open.. | 1 0.04 40.85 Conduct a Phase IV, descriptive, epid.. | 1 0.04 40.89 Conduct a Post Approval Safety Study .. | 1 0.04 40.93 Conduct a Postmarketing study to furt.. | 1 0.04 40.97 Conduct a Prospective, non-interventi.. | 1 0.04 41.00 Conduct a US surveillance study over .. | 1 0.04 41.04 Conduct a carcinogenicity assessment .. | 1 0.04 41.08 Conduct a carcinogenicity assessment .. | 1 0.04 41.12 Conduct a cell culture study to chara.. | 1 0.04 41.16 Conduct a cell-culture 2-drug combina.. | 1 0.04 41.20 Conduct a chronic (6-month) repeat-do.. | 1 0.04 41.24 Conduct a chronic (9-month) repeat-do.. | 1 0.04 41.27 Conduct a clinical PK trial evaluatin.. | 1 0.04 41.31 Conduct a clinical study to assess wh.. | 1 0.04 41.35 Conduct a clinical study to evaluate .. | 1 0.04 41.39 Conduct a clinical trial (PX-171-007).. | 1 0.04 41.43 Conduct a clinical trial (or trials) .. | 1 0.04 41.47 Conduct a clinical trial designed to .. | 1 0.04 41.50 Conduct a clinical trial designed to .. | 1 0.04 41.54 Conduct a clinical trial in patients .. | 1 0.04 41.58 Conduct a clinical trial in patients .. | 1 0.04 41.62 Conduct a clinical trial of patients .. | 3 0.12 41.73 Conduct a clinical trial to assess wh.. | 1 0.04 41.77 Conduct a clinical trial to assess wh.. | 1 0.04 41.81 Conduct a clinical trial to determine.. | 1 0.04 41.85 Conduct a clinical trial to determine.. | 1 0.04 41.89 Conduct a clinical trial to estimate .. | 16 0.61 42.50 Conduct a clinical trial to estimate .. | 16 0.61 43.11 Conduct a clinical trial to evaluate .. | 1 0.04 43.15 Conduct a clinical trial to evaluate .. | 1 0.04 43.19 Conduct a clinical trial to evaluate .. | 1 0.04 43.23 Conduct a clinical trial to evaluate .. | 1 0.04 43.27 Conduct a clinical trial to evaluate .. | 1 0.04 43.31 Conduct a clinical trial to evaluate .. | 1 0.04 43.34 Conduct a clinical trial to evaluate .. | 1 0.04 43.38 Conduct a clinical trial to evaluate .. | 1 0.04 43.42 Conduct a clinical trial to evaluate .. | 1 0.04 43.46 Conduct a clinical trial to evaluate .. | 1 0.04 43.50 Conduct a clinical trial to evaluate .. | 1 0.04 43.54 Conduct a clinical trial to evaluate .. | 1 0.04 43.57 Conduct a clinical trial to evaluate .. | 1 0.04 43.61 Conduct a clinical trial to evaluate .. | 1 0.04 43.65 Conduct a clinical trial to evaluate .. | 1 0.04 43.69 Conduct a clinical trial to evaluate .. | 1 0.04 43.73 Conduct a clinical trial to further a.. | 1 0.04 43.77 Conduct a clinical trial to test whet.. | 1 0.04 43.81 Conduct a clinical trial, per FDA gui.. | 1 0.04 43.84 Conduct a clinical trial, per FDA gui.. | 1 0.04 43.88 Conduct a clinical trial, per FDA gui.. | 1 0.04 43.92 Conduct a combination in vivo micronu.. | 1 0.04 43.96 Conduct a comparative single-dose pha.. | 1 0.04 44.00 Conduct a comparative, double-blind, .. | 1 0.04 44.04 Conduct a comparative, double-blind, .. | 1 0.04 44.07 Conduct a confirmatory randomized dou.. | 1 0.04 44.11 Conduct a controlled clinical trial t.. | 1 0.04 44.15 Conduct a controlled efficacy and pha.. | 1 0.04 44.19 Conduct a controlled postmarketing st.. | 1 0.04 44.23 Conduct a controlled trial (trial of .. | 1 0.04 44.27 Conduct a dedicated PK trial in patie.. | 1 0.04 44.30 Conduct a dedicated QT study in leish.. | 1 0.04 44.34 Conduct a deferred pediatric study (S.. | 1 0.04 44.38 Conduct a deferred pediatric study un.. | 1 0.04 44.42 Conduct a deferred pediatric study un.. | 1 0.04 44.46 Conduct a descriptive study of the us.. | 1 0.04 44.50 Conduct a descriptive study regarding.. | 1 0.04 44.53 Conduct a dose ranging study to deter.. | 1 0.04 44.57 Conduct a dose-exploration, multicent.. | 3 0.12 44.69 Conduct a dose-finding study (Phase 2.. | 1 0.04 44.73 Conduct a dose-ranging PK-PD euglycem.. | 1 0.04 44.76 Conduct a dose-ranging Pharmacokineti.. | 1 0.04 44.80 Conduct a dose-ranging study to deter.. | 1 0.04 44.84 Conduct a dose-ranging trial to deter.. | 1 0.04 44.88 Conduct a double-blind, randomized, p.. | 1 0.04 44.92 Conduct a double-blinded clinical tri.. | 1 0.04 44.96 Conduct a driving study in adolescent.. | 1 0.04 44.99 Conduct a drug interaction trial to e.. | 1 0.04 45.03 Conduct a drug interaction trial to e.. | 1 0.04 45.07 Conduct a drug interaction trial to e.. | 1 0.04 45.11 Conduct a drug interaction trial to e.. | 1 0.04 45.15 Conduct a drug-drug interaction clini.. | 1 0.04 45.19 Conduct a fertility and early embryon.. | 1 0.04 45.22 Conduct a fertility and early embryon.. | 1 0.04 45.26 Conduct a fertility and early embryon.. | 1 0.04 45.30 Conduct a fertility and early embryon.. | 1 0.04 45.34 Conduct a field study (protocol AX-00.. | 1 0.04 45.38 Conduct a field study to evaluate the.. | 4 0.15 45.53 Conduct a field study to evaluate the.. | 2 0.08 45.61 Conduct a field study to evaluate the.. | 1 0.04 45.65 Conduct a fixed-dose, placebo-control.. | 1 0.04 45.68 Conduct a fixed-dose, placebo-control.. | 1 0.04 45.72 Conduct a food effect clinical trial,.. | 1 0.04 45.76 Conduct a human factors validation st.. | 1 0.04 45.80 Conduct a juvenile animal toxicology .. | 1 0.04 45.84 Conduct a juvenile rat toxicology stu.. | 2 0.08 45.91 Conduct a juvenile rat toxicology stu.. | 1 0.04 45.95 Conduct a juvenile toxicity study in .. | 1 0.04 45.99 Conduct a labeling comprehension stud.. | 1 0.04 46.03 Conduct a large scale observational s.. | 1 0.04 46.07 Conduct a large, non-randomized, open.. | 1 0.04 46.11 Conduct a large, randomized, controll.. | 1 0.04 46.14 Conduct a large, randomized, controll.. | 1 0.04 46.18 Conduct a large-scale observational p.. | 1 0.04 46.22 Conduct a long-term evaluation of vac.. | 1 0.04 46.26 Conduct a long-term open label extens.. | 1 0.04 46.30 Conduct a long-term prospective obser.. | 1 0.04 46.34 Conduct a long-term safety study of a.. | 1 0.04 46.38 Conduct a long-term safety trial, inc.. | 1 0.04 46.41 Conduct a long-term stability evaluat.. | 1 0.04 46.45 Conduct a long-term, postmarketing, o.. | 1 0.04 46.49 Conduct a mass balance trial in human.. | 1 0.04 46.53 Conduct a maximum use pharmacokinetic.. | 1 0.04 46.57 Conduct a milk-only lactation study i.. | 1 0.04 46.61 Conduct a multi-center, randomized, b.. | 1 0.04 46.64 Conduct a multicenter, evaluator blin.. | 1 0.04 46.68 Conduct a multicenter, evaluator-blin.. | 1 0.04 46.72 Conduct a multicenter, evaluator-blin.. | 1 0.04 46.76 Conduct a multicenter, randomized, pl.. | 1 0.04 46.80 Conduct a multiple ascending dose cli.. | 1 0.04 46.84 Conduct a multiple dose trial in pati.. | 1 0.04 46.87 Conduct a multiple dose trial in pati.. | 1 0.04 46.91 Conduct a multiple dose trial to dete.. | 1 0.04 46.95 Conduct a multiple dose trial to dete.. | 1 0.04 46.99 Conduct a multiple-dose pharmacokinet.. | 1 0.04 47.03 Conduct a nationally representative d.. | 1 0.04 47.07 Conduct a nested case-control study a.. | 1 0.04 47.10 Conduct a non-inferiority immunogenic.. | 1 0.04 47.14 Conduct a non-interventional 2-arm st.. | 1 0.04 47.18 Conduct a non-interventional 2-arm st.. | 1 0.04 47.22 Conduct a non-interventional 2-armed .. | 1 0.04 47.26 Conduct a non-interventional, prospec.. | 2 0.08 47.33 Conduct a one-year, multi-center, ran.. | 1 0.04 47.37 Conduct a one-year, randomized, place.. | 1 0.04 47.41 Conduct a patient registry study for .. | 1 0.04 47.45 Conduct a pediatric pharmacokinetic, .. | 1 0.04 47.49 Conduct a pediatric pharmacokinetic, .. | 1 0.04 47.53 Conduct a pediatric safety and antivi.. | 1 0.04 47.56 Conduct a pediatric study under the P.. | 1 0.04 47.60 Conduct a pediatric study under the P.. | 1 0.04 47.64 Conduct a pediatric trial to evaluate.. | 1 0.04 47.68 Conduct a pediatric trial to evaluate.. | 1 0.04 47.72 Conduct a pediatric trial to evaluate.. | 1 0.04 47.76 Conduct a pediatric trial to evaluate.. | 1 0.04 47.79 Conduct a peri- and post-natal develo.. | 1 0.04 47.83 Conduct a peri- and post-natal develo.. | 1 0.04 47.87 Conduct a pharmacoepidemiology study .. | 1 0.04 47.91 Conduct a pharmacokinetic (PK) study .. | 1 0.04 47.95 Conduct a pharmacokinetic (PK) sub-tr.. | 1 0.04 47.99 Conduct a pharmacokinetic and safety .. | 1 0.04 48.02 Conduct a pharmacokinetic and safety .. | 1 0.04 48.06 Conduct a pharmacokinetic study in ad.. | 1 0.04 48.10 Conduct a pharmacokinetic study in ad.. | 1 0.04 48.14 Conduct a pharmacokinetic study in he.. | 1 0.04 48.18 Conduct a pharmacokinetic trial to de.. | 1 0.04 48.22 Conduct a pharmacokinetic trial to de.. | 1 0.04 48.25 Conduct a pharmacokinetic, pharmacody.. | 1 0.04 48.29 Conduct a pharmacokinetics (PK) study.. | 2 0.08 48.37 Conduct a pharmacokinetics, safety, a.. | 1 0.04 48.41 Conduct a phase 4 observational study.. | 1 0.04 48.45 Conduct a phase 4 observational study.. | 1 0.04 48.48 Conduct a phase 4 study to verify the.. | 1 0.04 48.52 Conduct a pilot trial of clinically m.. | 1 0.04 48.56 Conduct a placebo-controlled, randomi.. | 2 0.08 48.64 Conduct a placebo-controlled, randomi.. | 2 0.08 48.71 Conduct a post-market claims-based st.. | 1 0.04 48.75 Conduct a post-market electronic medi.. | 1 0.04 48.79 Conduct a post-marketing observationa.. | 1 0.04 48.83 Conduct a postmarketing clinical prog.. | 1 0.04 48.87 Conduct a postmarketing clinical tria.. | 1 0.04 48.91 Conduct a postmarketing clinical tria.. | 1 0.04 48.95 Conduct a postmarketing study to anal.. | 1 0.04 48.98 Conduct a postmarketing surveillance .. | 1 0.04 49.02 Conduct a pre- and post-natal develop.. | 1 0.04 49.06 Conduct a pre- and post-natal develop.. | 1 0.04 49.10 Conduct a pre- and post-natal develop.. | 1 0.04 49.14 Conduct a pre- and post-natal develop.. | 1 0.04 49.18 Conduct a pre- and post-natal develop.. | 1 0.04 49.21 Conduct a pre- and post-natal develop.. | 1 0.04 49.25 Conduct a pregnancy registry to evalu.. | 1 0.04 49.29 Conduct a prospective 5-year pre-OLT .. | 1 0.04 49.33 Conduct a prospective cohort study in.. | 1 0.04 49.37 Conduct a prospective cohort study us.. | 1 0.04 49.41 Conduct a prospective in vitro study .. | 1 0.04 49.44 Conduct a prospective observational c.. | 1 0.04 49.48 Conduct a prospective observational s.. | 1 0.04 49.52 Conduct a prospective observational s.. | 1 0.04 49.56 Conduct a prospective observational s.. | 1 0.04 49.60 Conduct a prospective observational s.. | 1 0.04 49.64 Conduct a prospective observational s.. | 1 0.04 49.67 Conduct a prospective randomized, con.. | 1 0.04 49.71 Conduct a prospective registry of bel.. | 1 0.04 49.75 Conduct a prospective registry-based .. | 1 0.04 49.79 Conduct a prospective study over a fi.. | 1 0.04 49.83 Conduct a prospective study over a fi.. | 1 0.04 49.87 Conduct a prospective study over a fi.. | 1 0.04 49.90 Conduct a prospective study over a fi.. | 1 0.04 49.94 Conduct a prospective study over a fi.. | 2 0.08 50.02 Conduct a prospective, 3-arm trial ev.. | 1 0.04 50.06 Conduct a prospective, double-blind, .. | 1 0.04 50.10 Conduct a prospective, long-term, obs.. | 1 0.04 50.13 Conduct a prospective, multi-center r.. | 1 0.04 50.17 Conduct a prospective, observational .. | 1 0.04 50.21 Conduct a prospective, observational .. | 1 0.04 50.25 Conduct a prospective, observational .. | 1 0.04 50.29 Conduct a prospective, observational .. | 1 0.04 50.33 Conduct a prospective, observational .. | 1 0.04 50.36 Conduct a prospective, observational .. | 1 0.04 50.40 Conduct a prospective, observational .. | 2 0.08 50.48 Conduct a prospective, observational .. | 1 0.04 50.52 Conduct a prospective, randomized cli.. | 1 0.04 50.56 Conduct a prospective, randomized tri.. | 2 0.08 50.63 Conduct a prospective, randomized tri.. | 1 0.04 50.67 Conduct a prospective, randomized, co.. | 1 0.04 50.71 Conduct a prospective, randomized, pl.. | 1 0.04 50.75 Conduct a prospective, randomized, pl.. | 1 0.04 50.79 Conduct a prospective, randomized, pl.. | 1 0.04 50.82 Conduct a randomized Phase 2 clinical.. | 1 0.04 50.86 Conduct a randomized Single-Blind, Mu.. | 2 0.08 50.94 Conduct a randomized masked trial tha.. | 1 0.04 50.98 Conduct a randomized multicenter, act.. | 1 0.04 51.02 Conduct a randomized phase 3 clinical.. | 1 0.04 51.05 Conduct a randomized placebo-controll.. | 1 0.04 51.09 Conduct a randomized study of the pro.. | 1 0.04 51.13 Conduct a randomized trial that will .. | 1 0.04 51.17 Conduct a randomized trial that will .. | 1 0.04 51.21 Conduct a randomized trial using two .. | 1 0.04 51.25 Conduct a randomized withdrawal trial.. | 1 0.04 51.29 Conduct a randomized, Single-Blind, M.. | 2 0.08 51.36 Conduct a randomized, active-controll.. | 3 0.12 51.48 Conduct a randomized, comparative tri.. | 1 0.04 51.52 Conduct a randomized, controlled clin.. | 1 0.04 51.55 Conduct a randomized, controlled clin.. | 1 0.04 51.59 Conduct a randomized, controlled tria.. | 1 0.04 51.63 Conduct a randomized, controlled, bli.. | 1 0.04 51.67 Conduct a randomized, controlled, dou.. | 1 0.04 51.71 Conduct a randomized, controlled, lon.. | 1 0.04 51.75 Conduct a randomized, controlled, lon.. | 1 0.04 51.78 Conduct a randomized, controlled, obs.. | 1 0.04 51.82 Conduct a randomized, dose-exploratio.. | 3 0.12 51.94 Conduct a randomized, dose-exploratio.. | 3 0.12 52.05 Conduct a randomized, double blind, d.. | 1 0.04 52.09 Conduct a randomized, double blind, m.. | 1 0.04 52.13 Conduct a randomized, double-blind st.. | 1 0.04 52.17 Conduct a randomized, double-blind, a.. | 1 0.04 52.21 Conduct a randomized, double-blind, p.. | 1 0.04 52.24 Conduct a randomized, multi-arm trial.. | 2 0.08 52.32 Conduct a randomized, multicenter, ac.. | 1 0.04 52.36 Conduct a randomized, observer-blind,.. | 1 0.04 52.40 Conduct a randomized, open-label, act.. | 1 0.04 52.44 Conduct a randomized, placebo-control.. | 1 0.04 52.47 Conduct a randomized, placebo-control.. | 1 0.04 52.51 Conduct a randomized, placebo-control.. | 1 0.04 52.55 Conduct a randomized, single-blind, m.. | 1 0.04 52.59 Conduct a randomized, single-blind, m.. | 1 0.04 52.63 Conduct a randomized, single-blind, m.. | 1 0.04 52.67 Conduct a randomized, single-blind, m.. | 1 0.04 52.70 Conduct a randomized, single-blind, m.. | 1 0.04 52.74 Conduct a randomized, single-blind, m.. | 1 0.04 52.78 Conduct a reactogenicity and immunoge.. | 1 0.04 52.82 Conduct a reactogenicity and immunoge.. | 1 0.04 52.86 Conduct a repeat dose, dose ranging p.. | 1 0.04 52.90 Conduct a repeat dose, pharmacokineti.. | 1 0.04 52.93 Conduct a retrospective cohort study .. | 1 0.04 52.97 Conduct a retrospective study to iden.. | 1 0.04 53.01 Conduct a safety and efficacy study i.. | 1 0.04 53.05 Conduct a safety and efficacy study i.. | 1 0.04 53.09 Conduct a safety and efficacy study i.. | 1 0.04 53.13 Conduct a safety and efficacy study i.. | 1 0.04 53.16 Conduct a safety and efficacy study o.. | 1 0.04 53.20 Conduct a safety, pharmacokinetics, a.. | 1 0.04 53.24 Conduct a single dose PK study in neo.. | 1 0.04 53.28 Conduct a single dose PK trial in neo.. | 1 0.04 53.32 Conduct a single dose pharmacokinetic.. | 1 0.04 53.36 Conduct a single dose pharmacokinetic.. | 1 0.04 53.39 Conduct a single open-label study to .. | 1 0.04 53.43 Conduct a single point vasoconstricti.. | 1 0.04 53.47 Conduct a single-center, open-label t.. | 1 0.04 53.51 Conduct a single-dose PK/PD and toler.. | 3 0.12 53.62 Conduct a single-dose pharmacokinetic.. | 1 0.04 53.66 Conduct a single-dose pharmacokinetic.. | 1 0.04 53.70 Conduct a single-dose pharmacokinetic.. | 1 0.04 53.74 Conduct a single-dose pharmacokinetic.. | 1 0.04 53.78 Conduct a study (Study V58_31) under .. | 1 0.04 53.82 Conduct a study consisting of establi.. | 1 0.04 53.86 Conduct a study exploring potential a.. | 1 0.04 53.89 Conduct a study in adult healthy volu.. | 1 0.04 53.93 Conduct a study in children 6 to less.. | 2 0.08 54.01 Conduct a study in collaboration with.. | 1 0.04 54.05 Conduct a study in pediatric patients.. | 1 0.04 54.09 Conduct a study investigating Epithel.. | 1 0.04 54.12 Conduct a study of Entereg (alvimopan.. | 1 0.04 54.16 Conduct a study of Entereg (alvimopan.. | 1 0.04 54.20 Conduct a study of Entereg for the ac.. | 1 0.04 54.24 Conduct a study of Entereg for the ac.. | 1 0.04 54.28 Conduct a study of pretreatment molec.. | 1 0.04 54.32 Conduct a study to analyze laboratory.. | 1 0.04 54.35 Conduct a study to assess inhibitory .. | 1 0.04 54.39 Conduct a study to assess the pharmac.. | 1 0.04 54.43 Conduct a study to assess the safety .. | 1 0.04 54.47 Conduct a study to assess the safety .. | 1 0.04 54.51 Conduct a study to assess the safety .. | 1 0.04 54.55 Conduct a study to assess the safety .. | 1 0.04 54.58 Conduct a study to characterize the c.. | 1 0.04 54.62 Conduct a study to characterize the i.. | 2 0.08 54.70 Conduct a study to characterize the l.. | 1 0.04 54.74 Conduct a study to characterize the s.. | 1 0.04 54.78 Conduct a study to compare exposure a.. | 1 0.04 54.81 Conduct a study to comprehensively ad.. | 1 0.04 54.85 Conduct a study to define and validat.. | 16 0.61 55.47 Conduct a study to determine an appro.. | 2 0.08 55.54 Conduct a study to determine if Tysab.. | 1 0.04 55.58 Conduct a study to determine the cros.. | 1 0.04 55.62 Conduct a study to determine the inci.. | 1 0.04 55.66 Conduct a study to evaluate T.R.U.E. .. | 1 0.04 55.70 Conduct a study to evaluate concomita.. | 1 0.04 55.73 Conduct a study to evaluate dapaglifl.. | 1 0.04 55.77 Conduct a study to evaluate pediatric.. | 1 0.04 55.81 Conduct a study to evaluate safety an.. | 1 0.04 55.85 Conduct a study to evaluate the effec.. | 3 0.12 55.96 Conduct a study to evaluate the effec.. | 1 0.04 56.00 Conduct a study to evaluate the effec.. | 1 0.04 56.04 Conduct a study to evaluate the effic.. | 2 0.08 56.12 Conduct a study to evaluate the immun.. | 1 0.04 56.16 Conduct a study to evaluate the pharm.. | 3 0.12 56.27 Conduct a study to evaluate the pharm.. | 1 0.04 56.31 Conduct a study to evaluate the pharm.. | 1 0.04 56.35 Conduct a study to evaluate the pharm.. | 1 0.04 56.39 Conduct a study to evaluate the pharm.. | 1 0.04 56.43 Conduct a study to evaluate the pharm.. | 1 0.04 56.46 Conduct a study to evaluate the pharm.. | 2 0.08 56.54 Conduct a study to evaluate the pharm.. | 1 0.04 56.58 Conduct a study to evaluate the pharm.. | 1 0.04 56.62 Conduct a study to evaluate the pharm.. | 1 0.04 56.66 Conduct a study to evaluate the safet.. | 1 0.04 56.69 Conduct a study to evaluate the safet.. | 1 0.04 56.73 Conduct a study to identify and quant.. | 1 0.04 56.77 Conduct a study to investigate the ca.. | 1 0.04 56.81 Conduct a study to validate an assay .. | 1 0.04 56.85 Conduct a study to validate an assay .. | 1 0.04 56.89 Conduct a study to validate coded med.. | 16 0.61 57.50 Conduct a study, based on a registry .. | 1 0.04 57.54 Conduct a study, based on a registry .. | 1 0.04 57.58 Conduct a study, using your establish.. | 1 0.04 57.61 Conduct a systemic bioavailability st.. | 1 0.04 57.65 Conduct a thorough QT trial in adults.. | 1 0.04 57.69 Conduct a trial in 100 evaluable pedi.. | 1 0.04 57.73 Conduct a trial in 100 evaluable pedi.. | 1 0.04 57.77 Conduct a trial in hepatitis C virus .. | 1 0.04 57.81 Conduct a trial in hepatitis C virus .. | 1 0.04 57.84 Conduct a trial in hepatitis C virus .. | 1 0.04 57.88 Conduct a trial in moderately to seve.. | 1 0.04 57.92 Conduct a trial in patients, ages 2 t.. | 1 0.04 57.96 Conduct a trial in patients, ages 2 t.. | 1 0.04 58.00 Conduct a trial in the >/=12 - 16 yea.. | 1 0.04 58.04 Conduct a trial or submit data from t.. | 1 0.04 58.07 Conduct a trial to assess ocular toxi.. | 1 0.04 58.11 Conduct a trial to assess the long-te.. | 1 0.04 58.15 Conduct a trial to assess the long-te.. | 1 0.04 58.19 Conduct a trial to assess the long-te.. | 2 0.08 58.27 Conduct a trial to assess the long-te.. | 1 0.04 58.30 Conduct a trial to characterize the p.. | 1 0.04 58.34 Conduct a trial to determine the effi.. | 1 0.04 58.38 Conduct a trial to determine the effi.. | 1 0.04 58.42 Conduct a trial to evaluate pediatric.. | 1 0.04 58.46 Conduct a trial to evaluate pediatric.. | 1 0.04 58.50 Conduct a trial to evaluate pediatric.. | 1 0.04 58.53 Conduct a trial to evaluate pediatric.. | 1 0.04 58.57 Conduct a trial to evaluate pediatric.. | 1 0.04 58.61 Conduct a trial to evaluate pediatric.. | 1 0.04 58.65 Conduct a trial to evaluate pediatric.. | 1 0.04 58.69 Conduct a trial to evaluate pediatric.. | 1 0.04 58.73 Conduct a trial to evaluate the pharm.. | 1 0.04 58.76 Conduct a trial to evaluate the pharm.. | 1 0.04 58.80 Conduct a trial to investigate the ef.. | 2 0.08 58.88 Conduct a trial to provide evidence s.. | 2 0.08 58.96 Conduct a trial to provide evidence s.. | 2 0.08 59.03 Conduct a trial to provide evidence s.. | 2 0.08 59.11 Conduct a trial to provide evidence s.. | 2 0.08 59.19 Conduct a trial to provide evidence s.. | 2 0.08 59.26 Conduct a trial to provide evidence s.. | 1 0.04 59.30 Conduct a trial to quantify efavirenz.. | 2 0.08 59.38 Conduct a two-year mouse carcinogenic.. | 2 0.08 59.46 Conduct a two-year rat carcinogenicit.. | 2 0.08 59.53 Conduct ado-trastuzumab emtansine exp.. | 1 0.04 59.57 Conduct an 18-month study in dogs to .. | 1 0.04 59.61 Conduct an Enhanced Pharmacovigilance.. | 1 0.04 59.65 Conduct an adequate extractable/leach.. | 1 0.04 59.69 Conduct an adequate leachable safety .. | 1 0.04 59.72 Conduct an adequate leachable safety .. | 1 0.04 59.76 Conduct an adequate leachable safety .. | 1 0.04 59.80 Conduct an analysis of data from ongo.. | 1 0.04 59.84 Conduct an analysis of safety in a ra.. | 1 0.04 59.88 Conduct an animal study that will mea.. | 1 0.04 59.92 Conduct an assessment and an analysis.. | 1 0.04 59.95 Conduct an assessment of neutralizing.. | 2 0.08 60.03 Conduct an efficacy and safety study .. | 1 0.04 60.07 Conduct an elotuzumab exposure-respon.. | 1 0.04 60.11 Conduct an embryo-fetal development s.. | 1 0.04 60.15 Conduct an embryo-fetal development s.. | 1 0.04 60.18 Conduct an embryo-fetal development s.. | 1 0.04 60.22 Conduct an embryo-fetal development s.. | 1 0.04 60.26 Conduct an embryo-fetal development s.. | 1 0.04 60.30 Conduct an embryo-fetal development s.. | 1 0.04 60.34 Conduct an embryo-fetal development s.. | 1 0.04 60.38 Conduct an embryo-fetal development s.. | 1 0.04 60.41 Conduct an embryo-fetal developmental.. | 1 0.04 60.45 Conduct an embryo-fetal developmental.. | 1 0.04 60.49 Conduct an embryo-fetal developmental.. | 1 0.04 60.53 Conduct an embryo-fetal developmental.. | 1 0.04 60.57 Conduct an embryo-fetal developmental.. | 1 0.04 60.61 Conduct an embryo-fetal developmental.. | 1 0.04 60.64 Conduct an enhanced pharmacovigilance.. | 2 0.08 60.72 Conduct an enhanced pharmacovigilance.. | 1 0.04 60.76 Conduct an epidemiologic study using .. | 1 0.04 60.80 Conduct an extension of the randomize.. | 1 0.04 60.84 Conduct an in vitro study evaluating .. | 1 0.04 60.87 Conduct an in vitro study to characte.. | 1 0.04 60.91 Conduct an in vitro study to determin.. | 1 0.04 60.95 Conduct an in vivo comet assay for [... | 2 0.08 61.03 Conduct an in vivo comet assay in liv.. | 1 0.04 61.07 Conduct an in vivo drug interaction t.. | 1 0.04 61.10 Conduct an in vivo drug interaction t.. | 1 0.04 61.14 Conduct an in vivo drug-drug interact.. | 1 0.04 61.18 Conduct an in vivo micronucleus genot.. | 1 0.04 61.22 Conduct an observational clinical stu.. | 1 0.04 61.26 Conduct an observational database stu.. | 1 0.04 61.30 Conduct an observational database stu.. | 1 0.04 61.33 Conduct an observational multi-site i.. | 1 0.04 61.37 Conduct an observational postmarketin.. | 1 0.04 61.41 Conduct an observational postmarketin.. | 1 0.04 61.45 Conduct an observational prospective .. | 1 0.04 61.49 Conduct an observational safety study.. | 1 0.04 61.53 Conduct an observational study (6096A.. | 1 0.04 61.57 Conduct an observational study to cha.. | 1 0.04 61.60 Conduct an observational study to inv.. | 1 0.04 61.64 Conduct an open label trial evaluatin.. | 1 0.04 61.68 Conduct an open label, single arm tri.. | 1 0.04 61.72 Conduct an open-Label, Multicenter St.. | 2 0.08 61.80 Conduct an open-label extension safet.. | 1 0.04 61.83 Conduct an open-label extension safet.. | 1 0.04 61.87 Conduct an open-label pharmacokinetic.. | 1 0.04 61.91 Conduct an open-label pharmacokinetic.. | 1 0.04 61.95 Conduct an open-label pilot study ass.. | 1 0.04 61.99 Conduct an open-label safety trial in.. | 1 0.04 62.03 Conduct an open-label study to assess.. | 1 0.04 62.06 Conduct an open-label study to evalua.. | 1 0.04 62.10 Conduct an open-label trial to assess.. | 1 0.04 62.14 Conduct an open-label trial to evalua.. | 2 0.08 62.22 Conduct an open-label, dose-finding, .. | 1 0.04 62.26 Conduct an open-label, multi-dose saf.. | 1 0.04 62.29 Conduct an open-label, multi-dose saf.. | 1 0.04 62.33 Conduct an open-label, multicenter, c.. | 1 0.04 62.37 Conduct an open-label, randomized, pa.. | 1 0.04 62.41 Conduct an open-label, repeated treat.. | 1 0.04 62.45 Conduct an open-label, single dose, s.. | 1 0.04 62.49 Conduct an open-label, single- and mu.. | 1 0.04 62.52 Conduct an open-label, single- and mu.. | 1 0.04 62.56 Conduct an open-label, single-arm tri.. | 2 0.08 62.64 Conduct an ophthalmologic study in pa.. | 1 0.04 62.68 Conduct analysis from the ongoing Tri.. | 1 0.04 62.72 Conduct and report the results of a p.. | 1 0.04 62.75 Conduct and submit a final report for.. | 1 0.04 62.79 Conduct and submit a final study repo.. | 2 0.08 62.87 Conduct and submit the results of a m.. | 1 0.04 62.91 Conduct and submit the results of a m.. | 2 0.08 62.98 Conduct and submit the results of a m.. | 2 0.08 63.06 Conduct and submit the results of a r.. | 1 0.04 63.10 Conduct and submit the results of at .. | 1 0.04 63.14 Conduct and submit the results of at .. | 1 0.04 63.18 Conduct and submit the results of at .. | 1 0.04 63.21 Conduct and submit the results of at .. | 1 0.04 63.25 Conduct case study analysis of report.. | 1 0.04 63.29 Conduct clinical trials of ropivacain.. | 1 0.04 63.33 Conduct epidemiologic investigations .. | 1 0.04 63.37 Conduct epidemiologic investigations .. | 1 0.04 63.41 Conduct epidemiologic investigations .. | 1 0.04 63.44 Conduct epidemiologic investigations .. | 1 0.04 63.48 Conduct formal observational studies .. | 1 0.04 63.52 Conduct formal observational studies .. | 1 0.04 63.56 Conduct formal observational studies .. | 1 0.04 63.60 Conduct formal observational studies .. | 1 0.04 63.64 Conduct in vitro assessments to evalu.. | 1 0.04 63.67 Conduct in vitro studies to properly .. | 1 0.04 63.71 Conduct in-vitro assessments to evalu.. | 1 0.04 63.75 Conduct one or more clinical trials i.. | 1 0.04 63.79 Conduct one or more studies to provid.. | 16 0.61 64.40 Conduct ongoing long term efficacy st.. | 1 0.04 64.44 Conduct ongoing long term efficacy st.. | 1 0.04 64.48 Conduct ongoing study D-QIV-004 under.. | 1 0.04 64.52 Conduct pediatric PK, dose selection,.. | 2 0.08 64.60 Conduct pediatric PK, dose selection,.. | 2 0.08 64.67 Conduct post-marketing assessments of.. | 1 0.04 64.71 Conduct prospective pregnancy exposur.. | 1 0.04 64.75 Conduct site-directed mutant phenotyp.. | 1 0.04 64.79 Conduct site-directed mutant phenotyp.. | 1 0.04 64.83 Conduct site-directed mutant phenotyp.. | 1 0.04 64.86 Conduct studies to define the mechani.. | 1 0.04 64.90 Conduct studies to evaluate the safet.. | 1 0.04 64.94 Conduct study 6096A1-4018, an ecologi.. | 1 0.04 64.98 Conduct study DoD Active Surveillance.. | 1 0.04 65.02 Conduct study IC51-325 " Long Term Im.. | 1 0.04 65.06 Conduct study Q-Pan H5N1=AS03-021 und.. | 1 0.04 65.09 Conduct study Q-Pan-023 under PREA to.. | 1 0.04 65.13 Conduct study Q-Pan-024 under PREA to.. | 1 0.04 65.17 Conduct study Q-Pan-025 under PREA to.. | 1 0.04 65.21 Conduct study, protocol #P008, under .. | 1 0.04 65.25 Conduct study, protocol #P009, under .. | 1 0.04 65.29 Conduct the DoD Pregnancy Surveillanc.. | 1 0.04 65.32 Conduct the analysis and submit the c.. | 1 0.04 65.36 Conduct the analysis and submit the c.. | 1 0.04 65.40 Conduct the deferred pediatric study .. | 1 0.04 65.44 Conduct the deferred pediatric study .. | 1 0.04 65.48 Conduct two clinical trials: Trial 1:.. | 1 0.04 65.52 Conduct your deferred pediatric study.. | 1 0.04 65.55 Conduct your deferred pediatric study.. | 1 0.04 65.59 Conduct your deferred pediatric study.. | 1 0.04 65.63 Conduct “A phase 3, multi-center, ope.. | 1 0.04 65.67 Conduct “A phase 3, prospective, open.. | 1 0.04 65.71 Conduct “A phase 3, prospective, rand.. | 1 0.04 65.75 Conduct “A phase 3b, prospective, ope.. | 1 0.04 65.78 Conduct “GO29294: A Phase 3, Open-lab.. | 1 0.04 65.82 Confirm the efficacy and safety of Tr.. | 1 0.04 65.86 Confirm the efficacy and safety of Tr.. | 1 0.04 65.90 Considering the relative complexity o.. | 1 0.04 65.94 Contingent on the outcome of the pilo.. | 1 0.04 65.98 Continuation and modification of your.. | 4 0.15 66.13 Continue follow-up of patients (on tr.. | 1 0.04 66.17 Continue the registry of patients wit.. | 1 0.04 66.21 Continue to evaluate the long-term ef.. | 1 0.04 66.24 Continue to follow patients en rolled.. | 1 0.04 66.28 Controlled clinical trial to evaluate.. | 1 0.04 66.32 Convene a panel of experts in oncolog.. | 1 0.04 66.36 Create adjunct instructions for use u.. | 1 0.04 66.40 Deferred 3-month cariprazine toxicity.. | 2 0.08 66.47 Deferred 6-month study in the juvenil.. | 2 0.08 66.55 Deferred Pediatric Studies Under PREA.. | 1 0.04 66.59 Deferred Pediatric Trial (V118_05) un.. | 1 0.04 66.63 Deferred clinical efficacy and safety.. | 1 0.04 66.67 Deferred controlled effectiveness stu.. | 1 0.04 66.71 Deferred controlled effectiveness stu.. | 1 0.04 66.74 Deferred long-term open label safety .. | 1 0.04 66.78 Deferred long-term open label safety .. | 1 0.04 66.82 Deferred long-term, open-label safety.. | 2 0.08 66.90 Deferred pediatric 12-month Open-Labe.. | 1 0.04 66.94 Deferred pediatric Placebo-Controlled.. | 1 0.04 66.97 Deferred pediatric assessment under P.. | 1 0.04 67.01 Deferred pediatric bioavailability st.. | 1 0.04 67.05 Deferred pediatric dose ranging, immu.. | 1 0.04 67.09 Deferred pediatric efficacy study und.. | 2 0.08 67.17 Deferred pediatric long-term safety s.. | 2 0.08 67.24 Deferred pediatric safety, immunogeni.. | 1 0.04 67.28 Deferred pediatric studies under PREA.. | 3 0.12 67.40 Deferred pediatric studies under PREA.. | 1 0.04 67.43 Deferred pediatric studies under PREA.. | 1 0.04 67.47 Deferred pediatric studies under PREA.. | 1 0.04 67.51 Deferred pediatric studies under PREA.. | 1 0.04 67.55 Deferred pediatric studies under PREA.. | 1 0.04 67.59 Deferred pediatric studies under PREA.. | 1 0.04 67.63 Deferred pediatric studies under PREA.. | 1 0.04 67.66 Deferred pediatric studies under PREA.. | 1 0.04 67.70 Deferred pediatric studies under PREA.. | 1 0.04 67.74 Deferred pediatric study (PSC17) unde.. | 1 0.04 67.78 Deferred pediatric study (PXVX-VC-200.. | 1 0.04 67.82 Deferred pediatric study (Study PSC08.. | 1 0.04 67.86 Deferred pediatric study (Study V130_.. | 2 0.08 67.93 Deferred pediatric study (Study V58_3.. | 1 0.04 67.97 Deferred pediatric study IB1001-02B u.. | 1 0.04 68.01 Deferred pediatric study of pharmacok.. | 1 0.04 68.05 Deferred pediatric study of pharmacok.. | 1 0.04 68.09 Deferred pediatric study of pharmacok.. | 2 0.08 68.16 Deferred pediatric study of pharmacok.. | 1 0.04 68.20 Deferred pediatric study of pharmacok.. | 2 0.08 68.28 Deferred pediatric study of pharmacok.. | 1 0.04 68.32 Deferred pediatric study of safety an.. | 1 0.04 68.35 Deferred pediatric study of safety an.. | 1 0.04 68.39 Deferred pediatric study of tizanidin.. | 1 0.04 68.43 Deferred pediatric study under PREA (.. | 2 0.08 68.51 Deferred pediatric study under PREA e.. | 1 0.04 68.55 Deferred pediatric study under PREA f.. | 1 0.04 68.58 Deferred pediatric study under PREA f.. | 1 0.04 68.62 Deferred pediatric study under PREA f.. | 1 0.04 68.66 Deferred pediatric study under PREA f.. | 1 0.04 68.70 Deferred pediatric study under PREA f.. | 1 0.04 68.74 Deferred pediatric study under PREA f.. | 1 0.04 68.78 Deferred pediatric study under PREA f.. | 1 0.04 68.81 Deferred pediatric study under PREA f.. | 1 0.04 68.85 Deferred pediatric study under PREA f.. | 1 0.04 68.89 Deferred pediatric study under PREA f.. | 1 0.04 68.93 Deferred pediatric study under PREA f.. | 1 0.04 68.97 Deferred pediatric study under PREA f.. | 1 0.04 69.01 Deferred pediatric study under PREA f.. | 1 0.04 69.04 Deferred pediatric study under PREA f.. | 1 0.04 69.08 Deferred pediatric study under PREA f.. | 1 0.04 69.12 Deferred pediatric study under PREA f.. | 1 0.04 69.16 Deferred pediatric study under PREA f.. | 1 0.04 69.20 Deferred pediatric study under PREA f.. | 1 0.04 69.24 Deferred pediatric study under PREA f.. | 1 0.04 69.28 Deferred pediatric study under PREA f.. | 1 0.04 69.31 Deferred pediatric study under PREA f.. | 1 0.04 69.35 Deferred pediatric study under PREA f.. | 1 0.04 69.39 Deferred pediatric study under PREA f.. | 1 0.04 69.43 Deferred pediatric study under PREA f.. | 1 0.04 69.47 Deferred pediatric study under PREA f.. | 1 0.04 69.51 Deferred pediatric study under PREA f.. | 1 0.04 69.54 Deferred pediatric study under PREA f.. | 1 0.04 69.58 Deferred pediatric study under PREA f.. | 2 0.08 69.66 Deferred pediatric study under PREA f.. | 2 0.08 69.74 Deferred pediatric study under PREA f.. | 2 0.08 69.81 Deferred pediatric study under PREA f.. | 1 0.04 69.85 Deferred pediatric study under PREA f.. | 1 0.04 69.89 Deferred pediatric study under PREA f.. | 1 0.04 69.93 Deferred pediatric study under PREA f.. | 1 0.04 69.97 Deferred pediatric study under PREA f.. | 1 0.04 70.00 Deferred pediatric study under PREA f.. | 1 0.04 70.04 Deferred pediatric study under PREA f.. | 1 0.04 70.08 Deferred pediatric study under PREA f.. | 1 0.04 70.12 Deferred pediatric study under PREA f.. | 1 0.04 70.16 Deferred pediatric study under PREA f.. | 1 0.04 70.20 Deferred pediatric study under PREA f.. | 1 0.04 70.23 Deferred pediatric study under PREA f.. | 1 0.04 70.27 Deferred pediatric study under PREA f.. | 1 0.04 70.31 Deferred pediatric study under PREA f.. | 1 0.04 70.35 Deferred pediatric study under PREA f.. | 2 0.08 70.43 Deferred pediatric study under PREA f.. | 1 0.04 70.46 Deferred pediatric study under PREA f.. | 1 0.04 70.50 Deferred pediatric study under PREA f.. | 1 0.04 70.54 Deferred pediatric study under PREA f.. | 1 0.04 70.58 Deferred pediatric study under PREA f.. | 1 0.04 70.62 Deferred pediatric study under PREA f.. | 1 0.04 70.66 Deferred pediatric study under PREA f.. | 1 0.04 70.69 Deferred pediatric study under PREA f.. | 1 0.04 70.73 Deferred pediatric study under PREA f.. | 2 0.08 70.81 Deferred pediatric study under PREA f.. | 1 0.04 70.85 Deferred pediatric study under PREA f.. | 1 0.04 70.89 Deferred pediatric study under PREA f.. | 1 0.04 70.92 Deferred pediatric study under PREA f.. | 1 0.04 70.96 Deferred pediatric study under PREA f.. | 1 0.04 71.00 Deferred pediatric study under PREA f.. | 1 0.04 71.04 Deferred pediatric study under PREA f.. | 1 0.04 71.08 Deferred pediatric study under PREA f.. | 1 0.04 71.12 Deferred pediatric study under PREA f.. | 2 0.08 71.19 Deferred pediatric study under PREA f.. | 2 0.08 71.27 Deferred pediatric study under PREA f.. | 2 0.08 71.35 Deferred pediatric study under PREA f.. | 2 0.08 71.42 Deferred pediatric study under PREA f.. | 1 0.04 71.46 Deferred pediatric study under PREA f.. | 1 0.04 71.50 Deferred pediatric study under PREA f.. | 1 0.04 71.54 Deferred pediatric study under PREA f.. | 2 0.08 71.61 Deferred pediatric study under PREA f.. | 2 0.08 71.69 Deferred pediatric study under PREA f.. | 1 0.04 71.73 Deferred pediatric study under PREA f.. | 1 0.04 71.77 Deferred pediatric study under PREA f.. | 1 0.04 71.81 Deferred pediatric study under PREA f.. | 1 0.04 71.85 Deferred pediatric study under PREA f.. | 2 0.08 71.92 Deferred pediatric study under PREA f.. | 1 0.04 71.96 Deferred pediatric study under PREA f.. | 1 0.04 72.00 Deferred pediatric study under PREA f.. | 1 0.04 72.04 Deferred pediatric study under PREA f.. | 1 0.04 72.08 Deferred pediatric study under PREA f.. | 1 0.04 72.11 Deferred pediatric study under PREA f.. | 1 0.04 72.15 Deferred pediatric study under PREA f.. | 1 0.04 72.19 Deferred pediatric study under PREA i.. | 1 0.04 72.23 Deferred pediatric study under PREA i.. | 1 0.04 72.27 Deferred pediatric study under PREA t.. | 1 0.04 72.31 Deferred pediatric study under PREA t.. | 1 0.04 72.34 Deferred pediatric study under PREA t.. | 1 0.04 72.38 Deferred pediatric study under PREA t.. | 2 0.08 72.46 Deferred pediatric study under PREA t.. | 1 0.04 72.50 Deferred pediatric study under PREA t.. | 1 0.04 72.54 Deferred pediatric study under PREA t.. | 1 0.04 72.57 Deferred pediatric study under PREA t.. | 1 0.04 72.61 Deferred pediatric study under PREA t.. | 1 0.04 72.65 Deferred pediatric study under PREA t.. | 1 0.04 72.69 Deferred pediatric study under PREA t.. | 1 0.04 72.73 Deferred pediatric study under PREA t.. | 3 0.12 72.84 Deferred pediatric study under PREA t.. | 1 0.04 72.88 Deferred pediatric study under PREA t.. | 1 0.04 72.92 Deferred pediatric study under PREA t.. | 1 0.04 72.96 Deferred pediatric study under PREA t.. | 1 0.04 73.00 Deferred pediatric study under PREA, .. | 1 0.04 73.03 Deferred pediatric study under PREA, .. | 1 0.04 73.07 Deferred pediatric study under PREA, .. | 1 0.04 73.11 Deferred pediatric study under PREA, .. | 1 0.04 73.15 Deferred pediatric study under PREA, .. | 1 0.04 73.19 Deferred pediatric study under PREA, .. | 1 0.04 73.23 Deferred pediatric study under PREA, .. | 1 0.04 73.26 Deferred pediatric study under PREA, .. | 1 0.04 73.30 Deferred pediatric study under PREA: .. | 1 0.04 73.34 Deferred pediatric study under PREA: .. | 1 0.04 73.38 Deferred pediatric study under PREA: .. | 1 0.04 73.42 Deferred pediatric study under PREA: .. | 1 0.04 73.46 Deferred pediatric study under PREA: .. | 1 0.04 73.49 Deferred pediatric study under PREA: .. | 1 0.04 73.53 Deferred pediatric study under PREA: .. | 1 0.04 73.57 Deferred pediatric study under PREA: .. | 1 0.04 73.61 Deferred pediatric study(ies) under P.. | 1 0.04 73.65 Deferred pediatric trial (V118_14) un.. | 1 0.04 73.69 Deferred pediatric trial (V118_19) un.. | 1 0.04 73.72 Deferred pediatric trial (V70_29) und.. | 1 0.04 73.76 Deferred pediatric trial under PREA t.. | 1 0.04 73.80 Deferred pediatric trial under PREA: .. | 1 0.04 73.84 Deferred pediatric trial under PREA: .. | 1 0.04 73.88 Deferred pediatric trial under PREA: .. | 1 0.04 73.92 Deferred pediatric trial under PREA: .. | 1 0.04 73.95 Deferred pharmacokinetics (PK) and sa.. | 1 0.04 73.99 Deferred randomized and controlled pe.. | 1 0.04 74.03 Deferred randomized and controlled pe.. | 1 0.04 74.07 Deferred requirement for development .. | 1 0.04 74.11 Deferred requirement for development .. | 1 0.04 74.15 Deferred safety and pharmacokinetic p.. | 1 0.04 74.18 Deferred safety and pharmacokinetic p.. | 1 0.04 74.22 Deferred study of efficacy, safety, a.. | 1 0.04 74.26 Deferred study of safety and pharmaco.. | 1 0.04 74.30 Deferred study under PREA to evaluate.. | 1 0.04 74.34 Deferred study under PREA to evaluate.. | 1 0.04 74.38 Deferred study under PREA to evaluate.. | 1 0.04 74.42 Deferred study under PREA to evaluate.. | 1 0.04 74.45 Deferred study under PREA to evaluate.. | 1 0.04 74.49 Deferred study under PREA to evaluate.. | 1 0.04 74.53 Deferred study under PREA to evaluate.. | 1 0.04 74.57 Deferred study under PREA to evaluate.. | 1 0.04 74.61 Deferred study under PREA to evaluate.. | 1 0.04 74.65 Deferred study under PREA to evaluate.. | 1 0.04 74.68 Deferred study under PREA to evaluate.. | 1 0.04 74.72 Deferred study under PREA to evaluate.. | 1 0.04 74.76 Deferred study under PREA to evaluate.. | 1 0.04 74.80 Deferred study under PREA to evaluate.. | 1 0.04 74.84 Deferred submission of pediatric stud.. | 1 0.04 74.88 Deferred submission of your pediatric.. | 2 0.08 74.95 Deferred, 1-year, pediatric efficacy .. | 1 0.04 74.99 Design and conduct a prospective tria.. | 2 0.08 75.07 Design and conduct a study and provid.. | 1 0.04 75.11 Determine the appropriate Trulance (p.. | 1 0.04 75.14 Determine the appropriate Trulance (p.. | 1 0.04 75.18 Determine the appropriate Trulance (p.. | 1 0.04 75.22 Determine the change in overall past .. | 1 0.04 75.26 Determine the change in the incidence.. | 1 0.04 75.30 Determine the change in the prevalenc.. | 1 0.04 75.34 Determine the change in the rate of p.. | 1 0.04 75.37 Determine the effect of a broad range.. | 1 0.04 75.41 Determine the effect of ibrutinib on .. | 1 0.04 75.45 Determine the no observable effect le.. | 1 0.04 75.49 Determine the safety and efficacy of .. | 1 0.04 75.53 Determine what dose adjustments are a.. | 1 0.04 75.57 Develop a formulation that would allo.. | 1 0.04 75.60 Develop a patient registry for bedaqu.. | 1 0.04 75.64 Develop a presentation that can be us.. | 1 0.04 75.68 Develop a presentation that can be us.. | 1 0.04 75.72 Develop a validated cross-reactive im.. | 1 0.04 75.76 Develop an Investigational Use Only, .. | 1 0.04 75.80 Develop an age appropriate formulatio.. | 1 0.04 75.83 Develop an age-appropriate formulatio.. | 1 0.04 75.87 Develop an assay to directly compare .. | 1 0.04 75.91 Develop an educational outreach progr.. | 1 0.04 75.95 Develop and maintain a prospective, o.. | 1 0.04 75.99 Develop and maintain a prospective, o.. | 1 0.04 76.03 Develop and test the stability of a l.. | 1 0.04 76.06 Develop and validate a sensitive and .. | 1 0.04 76.10 Develop and validate an appropriate a.. | 4 0.15 76.26 Develop and validate an appropriate a.. | 1 0.04 76.29 Develop and validate an appropriate a.. | 1 0.04 76.33 Develop and validate an appropriate a.. | 1 0.04 76.37 Develop and validate an appropriate a.. | 7 0.27 76.64 Develop and validate an assay that is.. | 1 0.04 76.68 Develop and validate an assay to eval.. | 1 0.04 76.72 Develop and validate an assay with im.. | 1 0.04 76.75 Develop and validate an assay with im.. | 1 0.04 76.79 Develop and validate an assay with im.. | 1 0.04 76.83 Develop and validate an improved assa.. | 1 0.04 76.87 Develop and validate an improved immu.. | 1 0.04 76.91 Develop and validate anti-ecallantide.. | 1 0.04 76.95 Develop and validate assays to evalua.. | 1 0.04 76.99 Develop and validate measures of the .. | 16 0.61 77.60 Develop and validate sensitive and pr.. | 1 0.04 77.64 Document the presence or absence of I.. | 1 0.04 77.68 Due to the complexity of on site prep.. | 1 0.04 77.71 During the conduct of the required po.. | 1 0.04 77.75 Efficacy and safety trial of Triferic.. | 2 0.08 77.83 Enhanced Pharmacovigilance Study to A.. | 1 0.04 77.87 Enhanced pharmacovigilance program fo.. | 1 0.04 77.91 Enhanced pharmacovigilance program fo.. | 1 0.04 77.94 Enhanced pharmacovigilance program fo.. | 1 0.04 77.98 Enhanced pharmacovigilance program fo.. | 1 0.04 78.02 Enhanced pharmacovigilance program fo.. | 1 0.04 78.06 Enroll 4,000 Stelara¿ (ustekinumab)-t.. | 1 0.04 78.10 Establish a Pregnancy Registry to col.. | 1 0.04 78.14 Establish a Pregnancy Registry to col.. | 1 0.04 78.17 Establish a U.S. pregnancy registry t.. | 1 0.04 78.21 Establish a U.S.-based prospective, o.. | 1 0.04 78.25 Establish a pregnancy registry in the.. | 1 0.04 78.29 Establish a pregnancy registry of pat.. | 1 0.04 78.33 Establish a pregnancy registry that w.. | 1 0.04 78.37 Establish a pregnancy registry that w.. | 1 0.04 78.40 Establish a pregnancy registry to col.. | 1 0.04 78.44 Establish a pregnancy registry to pro.. | 1 0.04 78.48 Establish a pregnancy registry to pro.. | 1 0.04 78.52 Establish a pregnancy registry to pro.. | 1 0.04 78.56 Establish a registry for children age.. | 1 0.04 78.60 Establish a registry for children age.. | 1 0.04 78.63 Establish a registry in order to perf.. | 1 0.04 78.67 Establish a registry in order to perf.. | 1 0.04 78.71 Establish a registry of children (age.. | 2 0.08 78.79 Establish a registry to collect and a.. | 2 0.08 78.86 Establish procedures for monitoring r.. | 1 0.04 78.90 Establish reliability requirements fo.. | 1 0.04 78.94 Establish reliability requirements fo.. | 1 0.04 78.98 Establish the efficacy and safety of .. | 1 0.04 79.02 Establish the optimal and safe dose o.. | 1 0.04 79.06 Establish the optimal and safe dose o.. | 1 0.04 79.09 Evaluate efficacy and safety for rout.. | 1 0.04 79.13 Evaluate efficacy and safety in the p.. | 1 0.04 79.17 Evaluate for cross-reactivity of anti.. | 1 0.04 79.21 Evaluate immunogenicity in patients w.. | 1 0.04 79.25 Evaluate in a step-wise approach the .. | 1 0.04 79.29 Evaluate long-term safety and activit.. | 1 0.04 79.32 Evaluate long-term safety and efficac.. | 1 0.04 79.36 Evaluate the effect of SLCO1B1 genoty.. | 1 0.04 79.40 Evaluate the effect of VENCLEXTA (ven.. | 1 0.04 79.44 Evaluate the effect of hepatic impair.. | 1 0.04 79.48 Evaluate the effect of hepatic impair.. | 1 0.04 79.52 Evaluate the effect of individual HCV.. | 1 0.04 79.56 Evaluate the impact of peramivir resi.. | 1 0.04 79.59 Evaluate the long-term safety of Vimi.. | 1 0.04 79.63 Evaluate the long-term safety of ecul.. | 1 0.04 79.67 Evaluate the long-term, prospective c.. | 1 0.04 79.71 Evaluate the occurrence of serious in.. | 1 0.04 79.75 Evaluate the pediatric pharmacokineti.. | 1 0.04 79.79 Evaluate the pharmacokinetics (PK), p.. | 2 0.08 79.86 Evaluate the pharmacokinetics, safety.. | 1 0.04 79.90 Evaluate the pharmacokinetics, safety.. | 1 0.04 79.94 Evaluate the pharmacokinetics, safety.. | 1 0.04 79.98 Evaluate the pharmacokinetics, safety.. | 1 0.04 80.02 Evaluate the pharmacokinetics, safety.. | 1 0.04 80.05 Evaluate the pharmacokinetics, safety.. | 1 0.04 80.09 Evaluate the pharmacokinetics, safety.. | 1 0.04 80.13 Evaluate the pharmacokinetics, safety.. | 1 0.04 80.17 Evaluate the pharmacokinetics, safety.. | 2 0.08 80.25 Evaluate the potential mechanism of b.. | 1 0.04 80.28 Evaluate the safety and efficacy of A.. | 1 0.04 80.32 Evaluate the safety and efficacy of A.. | 1 0.04 80.36 Evaluate the safety and efficacy of N.. | 1 0.04 80.40 Evaluate the safety and efficacy of N.. | 1 0.04 80.44 Evaluate the safety and pharmacokinet.. | 1 0.04 80.48 Evaluate the safety and treatment res.. | 1 0.04 80.51 Evaluation of long-term efficacy and .. | 1 0.04 80.55 Examine patients 0-23 months of age w.. | 1 0.04 80.59 Expand the Pediatric IBD Registry (DE.. | 1 0.04 80.63 Explore potential agonist (direct or .. | 1 0.04 80.67 Final Protocol Submission: November 3.. | 1 0.04 80.71 Firm commits to obtain pharmacokineti.. | 1 0.04 80.74 Follow-up for secondary malignancies .. | 1 0.04 80.78 Following completion of protocol ALID.. | 1 0.04 80.82 Following the assessment of data from.. | 1 0.04 80.86 Forteo User Registry Study (B3D-MC-GH.. | 1 0.04 80.90 Further explore the specific effects .. | 1 0.04 80.94 GENA-05: Evaluation of immunogenicity.. | 1 0.04 80.97 GENA-13: Evaluation of long-term immu.. | 1 0.04 81.01 GENA-15: Extension for subjects who c.. | 1 0.04 81.05 GENA-99: Post-licensure trial to docu.. | 1 0.04 81.09 Genzyme commits to designing and impl.. | 1 0.04 81.13 Genzyme commits to designing and impl.. | 1 0.04 81.17 Genzyme commits to designing and impl.. | 1 0.04 81.20 Genzyme commits to performing additio.. | 1 0.04 81.24 Gilead agrees to conduct a study exam.. | 1 0.04 81.28 Human pharmacokinetic study in adult .. | 2 0.08 81.36 Human pharmacokinetic study in pediat.. | 2 0.08 81.43 Identify an optimal dose of INJECTAFE.. | 1 0.04 81.47 Identify dosing adjustments needed in.. | 1 0.04 81.51 Identify the in vitro metabolic pathw.. | 1 0.04 81.55 If the studies conducted in children .. | 2 0.08 81.63 If the studies conducted in children .. | 2 0.08 81.70 Implement a myocarditis registry with.. | 1 0.04 81.74 Implement an enhanced surveillance pr.. | 1 0.04 81.78 In order to provide the baseline data.. | 1 0.04 81.82 In order to provide the baseline data.. | 1 0.04 81.86 In order to provide the baseline data.. | 1 0.04 81.89 In order to provide the baseline data.. | 1 0.04 81.93 In order to support safe use of cloni.. | 2 0.08 82.01 In order to verify the clinical benef.. | 1 0.04 82.05 In patients with CKD on dialysis, con.. | 1 0.04 82.09 In patients with CKD who are not on d.. | 1 0.04 82.13 In the context of a U.S. Centers for .. | 1 0.04 82.16 In vitro drug-drug interaction (DDI) .. | 1 0.04 82.20 In vitro studies to evaluate if Kuvan.. | 1 0.04 82.24 In vitro studies to evaluate the inhi.. | 1 0.04 82.28 In vitro studies to evaluate the pote.. | 1 0.04 82.32 In vitro studies to evaluate the pote.. | 1 0.04 82.36 In vitro study to evaluate the inhibi.. | 1 0.04 82.39 In vivo drug interaction study to eva.. | 1 0.04 82.43 In vivo drug interaction study with a.. | 1 0.04 82.47 In-vitro evaluation of: 1) inhibition.. | 2 0.08 82.55 In-vivo pharmacokinetic trial in subj.. | 1 0.04 82.59 Inclusion of a new target population,.. | 1 0.04 82.62 Inclusion of a new target population,.. | 1 0.04 82.66 Initiate a Registry to capture data f.. | 1 0.04 82.70 It is not apparent from the studies y.. | 1 0.04 82.74 It is not apparent from the trials yo.. | 1 0.04 82.78 Kamada Ltd. commits to conduct and re.. | 1 0.04 82.82 Long term extension study for PMR 209.. | 1 0.04 82.85 Long-term pediatric study in patients.. | 1 0.04 82.89 Long-term safety follow-up in patient.. | 1 0.04 82.93 Long-term safety study of brivaraceta.. | 3 0.12 83.05 Longer duration follow-up: Continue f.. | 1 0.04 83.08 Longitudinal studies involving follow.. | 2 0.08 83.16 Longitudinal studies involving follow.. | 1 0.04 83.20 Maternal-Fetal Outcome Study to Evalu.. | 1 0.04 83.24 Multicenter, randomized, double-blind.. | 1 0.04 83.28 Observational study of incidence and .. | 1 0.04 83.31 Observational study to collect long-t.. | 1 0.04 83.35 Obtain preliminary safety and activit.. | 1 0.04 83.39 Open label, 12-month study to evaluat.. | 1 0.04 83.43 Open label, baseline-controlled, mult.. | 1 0.04 83.47 Open label, multicenter single ascend.. | 1 0.04 83.51 Open label, single dose pharmacokinet.. | 1 0.04 83.54 Open-label long term extension study .. | 1 0.04 83.58 Open-label long term extension study .. | 1 0.04 83.62 Optimize the dosing regimen of Xofigo.. | 1 0.04 83.66 Oral absorption study of radiolabeled.. | 1 0.04 83.70 PK/Efficacy/Safety study in pediatric.. | 1 0.04 83.74 PMR-EC-1206 A Phase II, Open-Label, M.. | 1 0.04 83.77 Pediatric studies under PREA for the .. | 1 0.04 83.81 Pediatric studies under PREA for the .. | 1 0.04 83.85 Pediatric study in patients 10 years.. | 1 0.04 83.89 Pediatric study of an amoxicillin ext.. | 1 0.04 83.93 Perform a clinical trial to better ch.. | 1 0.04 83.97 Perform a milk-only lactation trial i.. | 1 0.04 84.00 Perform a randomized comparison of Te.. | 1 0.04 84.04 Perform a trial assessing the CSF con.. | 1 0.04 84.08 Perform genotypic (also phenotypic if.. | 1 0.04 84.12 Perform immunogenicity testing on ant.. | 1 0.04 84.16 Perform phenotypic resistance testing.. | 1 0.04 84.20 Perform, complete and submit the full.. | 1 0.04 84.23 Perform, complete and submit the full.. | 1 0.04 84.27 Pharmacokinetic and safety study in s.. | 2 0.08 84.35 Pharmacokinetic, efficacy, and safety.. | 2 0.08 84.43 Pharmacokinetic, safety, and efficacy.. | 3 0.12 84.54 Pharmacokinetic/safety study of tavab.. | 1 0.04 84.58 Phase 2 open-label follow-up trial to.. | 1 0.04 84.62 Phase 2 open-label trial to evaluate .. | 1 0.04 84.66 Phase 2 trial in 50 pediatric patient.. | 1 0.04 84.70 Phase 2, multicenter study to evaluat.. | 1 0.04 84.73 Phase 2, multicenter study to evaluat.. | 1 0.04 84.77 Phase 3 open-label follow-up extensio.. | 1 0.04 84.81 Phase 3 randomized, active-controlled.. | 1 0.04 84.85 Phenotype Week-48 virus samples from .. | 1 0.04 84.89 Post marketing comparative observatio.. | 1 0.04 84.93 Post-marketing observational study to.. | 1 0.04 84.96 Pre-/postnatal developmental toxicolo.. | 1 0.04 85.00 Pregnancy Registry Study to Evaluate .. | 1 0.04 85.04 Pregnancy registry to evaluate pregna.. | 1 0.04 85.08 Prepare and submit an integrated safe.. | 2 0.08 85.16 Propose and conduct an enhanced pharm.. | 2 0.08 85.23 Prospective Observational Study to Ev.. | 1 0.04 85.27 Prospective, randomized (1:1), open-l.. | 1 0.04 85.31 Provide a detailed and thoughtful ana.. | 1 0.04 85.35 Provide a rationale to support the sa.. | 1 0.04 85.39 Provide a study report that includes .. | 1 0.04 85.42 Provide an integrated safety analyses.. | 1 0.04 85.46 Provide clinical information from a 1.. | 1 0.04 85.50 Provide clinical information from a 1.. | 1 0.04 85.54 Provide data analyses from the Nordic.. | 1 0.04 85.58 Provide data analyses from the Pregna.. | 1 0.04 85.62 Provide data concerning duration of i.. | 1 0.04 85.65 Provide data on overall response rate.. | 1 0.04 85.69 Provide evidence sufficient to charac.. | 1 0.04 85.73 Provide information on maintenance of.. | 1 0.04 85.77 Provide long-term follow-up of all pa.. | 2 0.08 85.85 Provide nationally representative dru.. | 1 0.04 85.88 Provide quarterly reports on the stat.. | 1 0.04 85.92 Provide safety and efficacy data from.. | 1 0.04 85.96 Provide the results of an analytic va.. | 1 0.04 86.00 Randomized clinical trial comparing C.. | 1 0.04 86.04 Randomized clinical trial comparing S.. | 1 0.04 86.08 Randomized clinical trial in hospital.. | 1 0.04 86.11 Randomized clinical trial in hospital.. | 1 0.04 86.15 Randomized controlled trial in pediat.. | 1 0.04 86.19 Randomized controlled trial in pediat.. | 4 0.15 86.34 Randomized controlled trial in pediat.. | 1 0.04 86.38 Randomized controlled trial in pediat.. | 1 0.04 86.42 Randomized controlled trial in pediat.. | 1 0.04 86.46 Randomized controlled trial to evalua.. | 1 0.04 86.50 Randomized controlled trial to evalua.. | 1 0.04 86.54 Randomized, double-blind, adequate an.. | 1 0.04 86.57 Randomized, double-blind, adequate an.. | 1 0.04 86.61 Randomized, double-blind, adequate an.. | 1 0.04 86.65 Randomized, double-blind, adequate an.. | 1 0.04 86.69 Randomized, double-blind, adequately .. | 1 0.04 86.73 Randomized, double-blind, adequately .. | 1 0.04 86.77 Randomized, double-blind, dose-contro.. | 1 0.04 86.80 Randomized, double-blind, dose-contro.. | 1 0.04 86.84 Randomized, double-blind, dose-contro.. | 1 0.04 86.88 Randomized, double-blind, dose-contro.. | 1 0.04 86.92 Randomized, double-blind, placebo-con.. | 1 0.04 86.96 Randomized,-double-blind, adequately .. | 1 0.04 87.00 Regarding the hepatic impairment stud.. | 1 0.04 87.03 Regarding the requested renal impairm.. | 1 0.04 87.07 Review post-marketing adverse event s.. | 1 0.04 87.11 Shire commits to develop an assay to .. | 1 0.04 87.15 Shire commits to evaluating long-term.. | 1 0.04 87.19 Shire commits to re-assess the IgE cu.. | 1 0.04 87.23 Shire commits to revise the cut point.. | 1 0.04 87.27 Shire commits to utilize an antibody .. | 1 0.04 87.30 Single and multiple-dose pharmacokine.. | 1 0.04 87.34 Single and multiple-dose pharmacokine.. | 1 0.04 87.38 Six-month oral toxicology study of me.. | 1 0.04 87.42 Sponsor commits to determine if body .. | 1 0.04 87.46 Sponsor commits to undertake a Phase .. | 1 0.04 87.50 Studies to determine dosing for neona.. | 1 0.04 87.53 Study 1: A Phase 2, Open-Label, Multi.. | 1 0.04 87.57 Study 2: A Phase 2, Open-Label, Multi.. | 1 0.04 87.61 Submit a final report for ongoing obs.. | 1 0.04 87.65 Submit a final report for the long-te.. | 1 0.04 87.69 Submit a final report for the long-te.. | 1 0.04 87.73 Submit a final report for the long-te.. | 1 0.04 87.76 Submit a final report of follow-up sa.. | 1 0.04 87.80 Submit a final report of your analysi.. | 1 0.04 87.84 Submit a qualification report demonst.. | 1 0.04 87.88 Submit a report of the immunogenicity.. | 1 0.04 87.92 Submit an analysis of overall surviva.. | 1 0.04 87.96 Submit an analysis of secondary malig.. | 1 0.04 87.99 Submit an enhanced pre and post-natal.. | 1 0.04 88.03 Submit an enhanced pre and post-natal.. | 1 0.04 88.07 Submit an enhanced pre and post-natal.. | 1 0.04 88.11 Submit an enhanced pre and post-natal.. | 2 0.08 88.19 Submit an interim report from the ong.. | 1 0.04 88.22 Submit an interim report from the ong.. | 1 0.04 88.26 Submit and analyze quarterly reports .. | 1 0.04 88.30 Submit clinical data from an adequate.. | 1 0.04 88.34 Submit comparative LVEF and cardiac s.. | 2 0.08 88.42 Submit cumulative safety analyses ann.. | 1 0.04 88.45 Submit cumulative safety analyses ann.. | 1 0.04 88.49 Submit data from controlled extractio.. | 1 0.04 88.53 Submit data from the randomized withd.. | 3 0.12 88.65 Submit data to assess the pharmacokin.. | 2 0.08 88.72 Submit integrated analyses for genoty.. | 2 0.08 88.80 Submit integrated safety analyses and.. | 1 0.04 88.84 Submit integrated safety analyses fro.. | 1 0.04 88.88 Submit integrated safety analyses of .. | 1 0.04 88.91 Submit leachable data from long-term .. | 1 0.04 88.95 Submit results from your clinical stu.. | 1 0.04 88.99 Submit revised labeling, which accura.. | 1 0.04 89.03 Submit safety data assessing distant .. | 1 0.04 89.07 Submit safety data assessing distant .. | 1 0.04 89.11 Submit safety data assessing distant .. | 1 0.04 89.14 Submit safety data assessing distant .. | 1 0.04 89.18 Submit safety data assessing distant .. | 1 0.04 89.22 Submit safety data assessing distant .. | 1 0.04 89.26 Submit surveilance reports to evaluat.. | 1 0.04 89.30 Submit the Final Report for the clini.. | 1 0.04 89.34 Submit the clinical report at the tim.. | 1 0.04 89.37 Submit the comparative results for th.. | 1 0.04 89.41 Submit the complete final report and .. | 1 0.04 89.45 Submit the complete final report and .. | 1 0.04 89.49 Submit the complete final report and .. | 2 0.08 89.57 Submit the complete final report and .. | 2 0.08 89.64 Submit the final analysis of safety i.. | 1 0.04 89.68 Submit the final clinical report and .. | 1 0.04 89.72 Submit the final clinical report and .. | 1 0.04 89.76 Submit the final clinical report and .. | 1 0.04 89.80 Submit the final clinical report and .. | 1 0.04 89.84 Submit the final clinical report and .. | 1 0.04 89.87 Submit the final efficacy (disease-fr.. | 1 0.04 89.91 Submit the final overall survival (OS.. | 1 0.04 89.95 Submit the final overall survival ana.. | 1 0.04 89.99 Submit the final report and datasets .. | 1 0.04 90.03 Submit the final report and datasets .. | 1 0.04 90.07 Submit the final report and datasets .. | 1 0.04 90.10 Submit the final report and datasets .. | 1 0.04 90.14 Submit the final report and datasets .. | 1 0.04 90.18 Submit the final report and datasets .. | 1 0.04 90.22 Submit the final report and datasets .. | 1 0.04 90.26 Submit the final report and datasets .. | 1 0.04 90.30 Submit the final report and datasets .. | 1 0.04 90.33 Submit the final report and datasets .. | 1 0.04 90.37 Submit the final report and datasets .. | 1 0.04 90.41 Submit the final report and datasets .. | 1 0.04 90.45 Submit the final report and datasets .. | 1 0.04 90.49 Submit the final report and datasets .. | 1 0.04 90.53 Submit the final report and datasets .. | 1 0.04 90.56 Submit the final report and datasets .. | 1 0.04 90.60 Submit the final report and datasets .. | 1 0.04 90.64 Submit the final report and datasets .. | 1 0.04 90.68 Submit the final report and datasets .. | 1 0.04 90.72 Submit the final report and datasets .. | 1 0.04 90.76 Submit the final report and datasets .. | 1 0.04 90.79 Submit the final report and datasets .. | 1 0.04 90.83 Submit the final report and datasets,.. | 1 0.04 90.87 Submit the final report and datasets,.. | 1 0.04 90.91 Submit the final report and datasets,.. | 1 0.04 90.95 Submit the final report and efficacy .. | 2 0.08 91.02 Submit the final report and efficacy .. | 2 0.08 91.10 Submit the final report and efficacy .. | 1 0.04 91.14 Submit the final report for the pedia.. | 1 0.04 91.18 Submit the final report for trial D08.. | 1 0.04 91.22 Submit the final report for trial D08.. | 1 0.04 91.25 Submit the final report for your clin.. | 1 0.04 91.29 Submit the final report for your ongo.. | 1 0.04 91.33 Submit the final report including pri.. | 1 0.04 91.37 Submit the final report of a study co.. | 1 0.04 91.41 Submit the final report of ongoing ma.. | 1 0.04 91.45 Submit the final report of the comple.. | 1 0.04 91.48 Submit the final study report for the.. | 1 0.04 91.52 Submit the final study report for the.. | 1 0.04 91.56 Submit the hypothesis for the final O.. | 1 0.04 91.60 Submit the ledipasvir 2 year rat carc.. | 1 0.04 91.64 Submit the long-term efficacy, safety.. | 1 0.04 91.68 Submit the long-term safety and antiv.. | 1 0.04 91.71 Submit the median duration of respons.. | 1 0.04 91.75 Submit the per protocol overall survi.. | 1 0.04 91.79 Submit the progression free survival .. | 1 0.04 91.83 Submit the progression-free survival .. | 1 0.04 91.87 Submit the progression-free survival .. | 1 0.04 91.91 Submit the progression-free survival .. | 1 0.04 91.94 Submit the progression-free survival .. | 1 0.04 91.98 Submit the results of a single-dose p.. | 3 0.12 92.10 Submit the results of overall surviva.. | 2 0.08 92.17 Submit the results of the final analy.. | 1 0.04 92.21 Submit the results of the proposed ph.. | 1 0.04 92.25 Submit the results of the protocol-sp.. | 2 0.08 92.33 Submit the results of the protocol-sp.. | 1 0.04 92.37 Submit to FDA the appropriate analyti.. | 1 0.04 92.41 Subpart I Confirmatory Studies: We no.. | 1 0.04 92.44 Teriparatide Post-Approval Osteosarco.. | 1 0.04 92.48 Test for the individual component phy.. | 1 0.04 92.52 Test for the individual component phy.. | 1 0.04 92.56 Test for the individual component phy.. | 1 0.04 92.60 Test for the individual component phy.. | 1 0.04 92.64 Test the three registration stability.. | 1 0.04 92.67 Testicular toxicity trial to investig.. | 2 0.08 92.75 The applicant currently proposes to d.. | 1 0.04 92.79 The merged protocol, Study 191622-137.. | 1 0.04 92.83 The merged protocol, Study 191622-137.. | 1 0.04 92.87 The preclinical rodent studies found .. | 1 0.04 92.90 The sponsor commits to conduct a Phas.. | 1 0.04 92.94 There is some preliminary evidence of.. | 1 0.04 92.98 Three-month repeat dose toxicity and .. | 1 0.04 93.02 Through collaboration with the Antire.. | 1 0.04 93.06 To adequately assess photosafety to s.. | 1 0.04 93.10 To assess the adequacy of the current.. | 1 0.04 93.13 To assess the effect of the implant o.. | 1 0.04 93.17 To assess the incidence and titers of.. | 1 0.04 93.21 To assess the incidence and titers of.. | 1 0.04 93.25 To assess the risk of bladder cancer .. | 1 0.04 93.29 To assess the risk of breast cancer a.. | 1 0.04 93.33 To assess the risk of breast cancer a.. | 1 0.04 93.36 To assess the safety of long-term use.. | 1 0.04 93.40 To assess the serious risks of respir.. | 1 0.04 93.44 To change the text on the backing fil.. | 1 0.04 93.48 To collect additional efficacy and sa.. | 1 0.04 93.52 To commit to development and validati.. | 1 0.04 93.56 To commit to providing complete valid.. | 1 0.04 93.59 To commit to testing samples from pat.. | 1 0.04 93.63 To complete ongoing trial 8HA01EXT, A.. | 1 0.04 93.67 To complete the clinical follow-up st.. | 1 0.04 93.71 To complete the clinical trial of hyd.. | 1 0.04 93.75 To complete the data analysis for tri.. | 1 0.04 93.79 To complete the ongoing 10-year study.. | 1 0.04 93.82 To complete the ongoing clinical tria.. | 1 0.04 93.86 To complete the ongoing study V503-01.. | 1 0.04 93.90 To complete trial 99HA306, An Open-La.. | 1 0.04 93.94 To conduct a 10-year study extension .. | 1 0.04 93.98 To conduct a 5-month repeat-dose juve.. | 1 0.04 94.02 To conduct a Phase 1 study, Protocol .. | 1 0.04 94.05 To conduct a Pregnancy Pharmacovigila.. | 1 0.04 94.09 To conduct a clinical trial in pediat.. | 1 0.04 94.13 To conduct a clinical trial in pediat.. | 1 0.04 94.17 To conduct a clinical trial of Hercep.. | 1 0.04 94.21 To conduct a clinical trial that asse.. | 1 0.04 94.25 To conduct a clinical trial, per FDA .. | 1 0.04 94.28 To conduct a cohort study (B1971052) .. | 1 0.04 94.32 To conduct a confirmatory clinical ef.. | 1 0.04 94.36 To conduct a field study to evaluate .. | 3 0.12 94.48 To conduct a large, simple, randomize.. | 1 0.04 94.51 To conduct a long-term rodent carcino.. | 1 0.04 94.55 To conduct a minimal in vitro genetic.. | 1 0.04 94.59 To conduct a multi-center, dose-findi.. | 1 0.04 94.63 To conduct a multi-center, randomized.. | 1 0.04 94.67 To conduct a phase 4, randomized, con.. | 1 0.04 94.71 To conduct a post-marketing multi-cen.. | 1 0.04 94.74 To conduct a prospective epidemiologi.. | 1 0.04 94.78 To conduct a prospective, observation.. | 1 0.04 94.82 To conduct a prospective, observation.. | 1 0.04 94.86 To conduct a randomized, multicenter,.. | 1 0.04 94.90 To conduct a rodent carcinogenicity s.. | 1 0.04 94.94 To conduct a safety and immunogenicit.. | 1 0.04 94.98 To conduct a study in both adult and .. | 1 0.04 95.01 To conduct a study to assess for the .. | 1 0.04 95.05 To conduct a study to assess safety, .. | 1 0.04 95.09 To conduct a study to assess the immu.. | 1 0.04 95.13 To conduct a study to assess the neut.. | 1 0.04 95.17 To conduct a study to determine the i.. | 1 0.04 95.21 To conduct a study to determine wheth.. | 1 0.04 95.24 To conduct a study to evaluate the ef.. | 2 0.08 95.32 To conduct a study to evaluate the im.. | 1 0.04 95.36 To conduct a toxicology study of adeq.. | 1 0.04 95.40 To conduct a trial that will evaluate.. | 1 0.04 95.44 To conduct a verification trial to de.. | 1 0.04 95.47 To conduct an "Antibody Registry Stud.. | 1 0.04 95.51 To conduct an adequate and well-contr.. | 1 0.04 95.55 To conduct an animal study that will .. | 1 0.04 95.59 To conduct an assessment for neutrali.. | 1 0.04 95.63 To conduct an assessment for the pres.. | 1 0.04 95.67 To conduct an assessment of anti-drug.. | 1 0.04 95.70 To conduct an assessment of neutraliz.. | 1 0.04 95.74 To conduct an observational postmarke.. | 1 0.04 95.78 To conduct an observational postmarke.. | 1 0.04 95.82 To conduct an observational study to .. | 1 0.04 95.86 To conduct an open label, descriptive.. | 1 0.04 95.90 To conduct an open label, descriptive.. | 1 0.04 95.93 To conduct and submit a final study r.. | 1 0.04 95.97 To conduct clinical trial 20070782 en.. | 1 0.04 96.01 To conduct exposure-response analysis.. | 1 0.04 96.05 To conduct pharmacokinetic studies to.. | 1 0.04 96.09 To conduct pharmacokinetics studies i.. | 1 0.04 96.13 To conduct study V72_72 of BEXSERO am.. | 1 0.04 96.16 To conduct study protocol P06-134, a .. | 1 0.04 96.20 To conduct the confirmatory study (V1.. | 1 0.04 96.24 To conduct the ongoing controlled stu.. | 1 0.04 96.28 To conduct the ongoing safety and imm.. | 1 0.04 96.32 To conduct the ongoing study (B197100.. | 1 0.04 96.36 To conduct the ongoing study (B197101.. | 1 0.04 96.39 To conduct the ongoing study V102_16 .. | 1 0.04 96.43 To cooperate with U.S.-based public h.. | 3 0.12 96.55 To cooperate with U.S.-based public h.. | 3 0.12 96.66 To determine the approximate percent .. | 1 0.04 96.70 To determine the potential for pharma.. | 1 0.04 96.74 To determine the potential for pharma.. | 1 0.04 96.78 To develop a presentation that can be.. | 1 0.04 96.82 To develop a validated assay for iden.. | 1 0.04 96.85 To develop a validated cross-reactive.. | 1 0.04 96.89 To develop a validated, sensitive, an.. | 1 0.04 96.93 To develop an algorithm for decision-.. | 1 0.04 96.97 To develop and maintain a Pregnancy S.. | 1 0.04 97.01 To develop and maintain a prospective.. | 1 0.04 97.05 To develop and validate an assay to a.. | 2 0.08 97.12 To develop validated screening and co.. | 1 0.04 97.16 To develop, in consultation with CDRH.. | 1 0.04 97.20 To develop, in consultation with CDRH.. | 1 0.04 97.24 To develop, validate, and implement a.. | 1 0.04 97.28 To establish a pregnancy registry as .. | 1 0.04 97.31 To establish a pregnancy registry for.. | 1 0.04 97.35 To establish a pregnancy registry for.. | 1 0.04 97.39 To establish a pregnancy registry tha.. | 1 0.04 97.43 To establish a pregnancy registry to .. | 1 0.04 97.47 To establish a pregnancy registry to .. | 1 0.04 97.51 To establish a pregnancy registry to .. | 1 0.04 97.55 To evaluate a prophylactic immune tol.. | 1 0.04 97.58 To evaluate efficacy and safety of da.. | 1 0.04 97.62 To evaluate potential tenofovir alafe.. | 1 0.04 97.66 To evaluate potential tenofovir alafe.. | 1 0.04 97.70 To evaluate the effect of ELELYSO (ta.. | 1 0.04 97.74 To evaluate the long-term safety and .. | 1 0.04 97.78 To evaluate the potential for a serio.. | 1 0.04 97.81 To evaluate the safety and tolerabili.. | 1 0.04 97.85 To evaluate the safety of palifermin .. | 1 0.04 97.89 To evaluate the safety of the product.. | 1 0.04 97.93 To identify further genetic determina.. | 1 0.04 97.97 To modify acceptance criteria for the.. | 1 0.04 98.01 To perform Segment III (peri- and pos.. | 1 0.04 98.04 To perform a randomized, blinded, con.. | 1 0.04 98.08 To perform and submit the trial, pres.. | 1 0.04 98.12 To provide a ribavirin pregnancy regi.. | 1 0.04 98.16 To provide an update of efficacy from.. | 2 0.08 98.24 To provide information or conduct pha.. | 1 0.04 98.27 To provide literature data or perform.. | 1 0.04 98.31 To study the pharmacokinetics, effica.. | 1 0.04 98.35 To study the pharmacokinetics, effica.. | 1 0.04 98.39 To submit a final report that include.. | 1 0.04 98.43 To submit a protocol for review for a.. | 1 0.04 98.47 To submit a separate subsection in th.. | 1 0.04 98.50 To submit an efficacy supplement cont.. | 1 0.04 98.54 To submit annual progress reports as .. | 1 0.04 98.58 To submit the clinical study report a.. | 1 0.04 98.62 To submit the final trial report for .. | 1 0.04 98.66 To support the use of levomilnacipran.. | 1 0.04 98.70 To test all banked clinical samples f.. | 1 0.04 98.73 Trial1321.3 titled, “A Phase III, Cas.. | 1 0.04 98.77 Twenty-eight day, daily, repeat dose,.. | 1 0.04 98.81 Unless FDA agrees, based on your comp.. | 1 0.04 98.85 Unless FDA agrees, based on your comp.. | 1 0.04 98.89 Use the anti-reslizumab IgE assay dev.. | 1 0.04 98.93 Use the validated cross reactivity as.. | 1 0.04 98.96 Use the validated neutralizing antibo.. | 1 0.04 99.00 Using appropriate in vitro approaches.. | 2 0.08 99.08 Using data from agreed upon studies o.. | 1 0.04 99.12 Using the method developed under PMR .. | 4 0.15 99.27 Utilize the validated anti-adalimumab.. | 1 0.04 99.31 Utilizing a validated AAA assay as de.. | 1 0.04 99.35 We are deferring pediatric studies fo.. | 1 0.04 99.39 With respect to requested in vivo dru.. | 1 0.04 99.42 Work with the FDA, and other public a.. | 1 0.04 99.46 You agree to re-initiate the BAT pati.. | 1 0.04 99.50 You are required to assess the safety.. | 1 0.04 99.54 You are required to assess the safety.. | 1 0.04 99.58 You have committed to conduct a pharm.. | 1 0.04 99.62 You have committed to the conduct of .. | 1 0.04 99.65 You must conduct a PK trial in childr.. | 1 0.04 99.69 You must conduct a PK trial in childr.. | 1 0.04 99.73 You must conduct a PK trial in childr.. | 1 0.04 99.77 You must conduct a PK trial in childr.. | 1 0.04 99.81 You will perform a "Thorough QT Study.. | 1 0.04 99.85 You will submit a protocol for a pros.. | 2 0.08 99.92 Zeneca is in the process of gathering.. | 1 0.04 99.96 [...] Identify and quantitate the imp.. | 1 0.04 100.00 ----------------------------------------+----------------------------------- Total | 2,607 100.00 Frequencies for cmt_status_str variable in pmc_commitments dataset : Commitment | Status | Freq. Percent Cum. ------------+----------------------------------- D | 504 19.33 19.33 F | 233 8.94 28.27 O | 726 27.85 56.12 P | 835 32.03 88.15 R | 138 5.29 93.44 S | 151 5.79 99.23 T | 20 0.77 100.00 ------------+----------------------------------- Total | 2,607 100.00 Frequencies for cmt_status variable in pmc_commitments dataset : Commitment | Status | Freq. Percent Cum. ------------+----------------------------------- Ongoing | 726 27.85 27.85 Pending | 835 32.03 59.88 Delayed | 504 19.33 79.21 Terminated | 20 0.77 79.98 Submitted | 151 5.79 85.77 Fulfilled | 233 8.94 94.71 Released | 138 5.29 100.00 ------------+----------------------------------- Total | 2,607 100.00 Frequencies for cmt_status_desc variable in pmc_commitments dataset : Commitment Status Description | Freq. Percent Cum. ----------------------------------------+----------------------------------- | 1,402 53.78 53.78 "The draft protocol was submitted[..... | 1 0.04 53.82 105 patients out of the planned 120 p.. | 1 0.04 53.86 11/25/15, Semi-annual report submitte.. | 1 0.04 53.89 111 subjects enrolled. Study is compl.. | 1 0.04 53.93 16/20 subjects completed as of 10/6/2.. | 1 0.04 53.97 168 subjects have been treated: 113 (.. | 3 0.12 54.09 174 patients have been screened; 73 h.. | 1 0.04 54.12 2 patients have been enrolled into th.. | 1 0.04 54.16 2,402 patients have been enrolled in .. | 1 0.04 54.20 2354 patients enrolled of the total 2.. | 1 0.04 54.24 2nd Deferral Extension granting lette.. | 1 0.04 54.28 3 subjects have been treated since No.. | 6 0.23 54.51 35 subjects have been treated subject.. | 3 0.12 54.62 36 subjects have been enrolled, accru.. | 1 0.04 54.66 38 subjects have been enrolled, accru.. | 1 0.04 54.70 3835 patients out of the planned 4000.. | 1 0.04 54.74 421/596 subjects completed the study... | 1 0.04 54.78 52/40 subjects enrolled | 1 0.04 54.81 58/60 subjects completed the study. S.. | 1 0.04 54.85 64 subjects have been treated: 24 (12.. | 3 0.12 54.97 7 patients out of the planned 210 pat.. | 1 0.04 55.01 74 subjects enrolled. | 1 0.04 55.04 9 patients out of the planned 260 pat.. | 1 0.04 55.08 A protocol is being drafted and will .. | 1 0.04 55.12 A request for release from this study.. | 1 0.04 55.16 A total of 30 of the planned 100 pati.. | 1 0.04 55.20 A total of 34 patients were enrolled .. | 1 0.04 55.24 A total of 40 of the planned 240 pati.. | 1 0.04 55.27 A total of 81 pediatric patients have.. | 1 0.04 55.31 Additional rat toxicity study was req.. | 1 0.04 55.35 Agency issued communication on 14-OCT.. | 1 0.04 55.39 Applicant has not provided update | 1 0.04 55.43 Approximately 1013 subjects have been.. | 1 0.04 55.47 As of 2/26/2016, 2 patients enrolled. | 1 0.04 55.50 As of April 1, 2016, 12 investigators.. | 1 0.04 55.54 As of December 2013, 40 patients have.. | 1 0.04 55.58 As of March 2016, 109 prospective cas.. | 1 0.04 55.62 As of September 15, 2015, 38 of the 1.. | 1 0.04 55.66 As of the cutoff date, 3/20/16, 3 of .. | 1 0.04 55.70 Astellas is assessing a current body .. | 1 0.04 55.73 AstraZeneca submitted a proposal on J.. | 1 0.04 55.77 BIPI submitted the final report for s.. | 1 0.04 55.81 Based on review of your April 27, 201.. | 1 0.04 55.85 CSR withdrawn; applicant granted defe.. | 1 0.04 55.89 Complete recruitment was to be comple.. | 1 0.04 55.93 Deferral Extension Granted per FDA le.. | 1 0.04 55.96 Deferral Extension Granted per FDA le.. | 3 0.12 56.08 Deferral Extension Requested 02/08/20.. | 1 0.04 56.12 Deferral Extension Requested 03/01/20.. | 1 0.04 56.16 Deferral Extension Requested 03/11/20.. | 1 0.04 56.19 Deferral Extension Requested 03/23/20.. | 1 0.04 56.23 Deferral Extension Requested 04/15/20.. | 1 0.04 56.27 Deferral Extension Requested 05/12/20.. | 1 0.04 56.31 Deferral Extension Requested 05/25/20.. | 1 0.04 56.35 Deferral Extension Requested 06/08/20.. | 1 0.04 56.39 Deferral Extension Requested 06/29/20.. | 1 0.04 56.43 Deferral Extension Requested 07/26/20.. | 8 0.31 56.73 Deferral Extension Requested 07/28/20.. | 1 0.04 56.77 Deferral Extension Requested 08/23/20.. | 1 0.04 56.81 Deferral Extension Requested 09/30/20.. | 2 0.08 56.89 Deferral Extension Requested 10/07/20.. | 1 0.04 56.92 Deferral Extension Requested 11/10/20.. | 1 0.04 56.96 Deferral Extension Requested 5/31/201.. | 1 0.04 57.00 Deferral Extension Requested December.. | 1 0.04 57.04 Deferral Extension granted in FDA let.. | 1 0.04 57.08 Deferral extension granted 6/24/2013... | 2 0.08 57.15 Deferral extension granting letter is.. | 2 0.08 57.23 Deferral granted December 22, 2015 du.. | 1 0.04 57.27 Deferred Study completion was due Mar.. | 1 0.04 57.31 Deferred pediatric studies under PREA.. | 3 0.12 57.42 Deferred pediatric study under PREA. .. | 4 0.15 57.58 Deferred trial completion was due Mar.. | 1 0.04 57.61 Delayed due to study completion date .. | 1 0.04 57.65 Delayed in meeting the due date for t.. | 1 0.04 57.69 Difficulties in recruiting patients d.. | 1 0.04 57.73 Draft Protocol and Final Protocol sub.. | 1 0.04 57.77 Due to delay in enrollment, agreement.. | 1 0.04 57.81 Efforts toward developing an age appr.. | 1 0.04 57.84 Enrollment complete in the normal and.. | 1 0.04 57.88 Enrollment completed on 1/2014 (846 p.. | 1 0.04 57.92 Enrollment completed on 8/22/14 (944 .. | 1 0.04 57.96 Enrollment completion/observation com.. | 1 0.04 58.00 Enrollment for 6-17 year olds complet.. | 1 0.04 58.04 Enrollment for the study is currently.. | 3 0.12 58.15 Enrollment for the study is currently.. | 1 0.04 58.19 Enrollment for the study is currently.. | 2 0.08 58.27 Enrollment for the study is currently.. | 1 0.04 58.30 Enrollment for the study is currently.. | 1 0.04 58.34 Enrollment in the adolescent cohort (.. | 1 0.04 58.38 Enrollment is continuing in all age g.. | 2 0.08 58.46 Enrollment is ongoing. As of 07 March.. | 1 0.04 58.50 Enrollment is temporarily suspended. | 1 0.04 58.53 Enrollment not yet started. | 1 0.04 58.57 Enrollment scheduled to begin Septemb.. | 1 0.04 58.61 FDA has determined that you had good .. | 1 0.04 58.65 FDA issued a not fulfilled letter 6/2.. | 1 0.04 58.69 FDA issued a not fulfilled letter on .. | 1 0.04 58.73 FLUARIX PMR Final Study Report to ful.. | 1 0.04 58.76 FSR due December 31, 2016 | 1 0.04 58.80 Final Protocol Submission is due 12/1.. | 1 0.04 58.84 Final Protocol Submission is due Marc.. | 1 0.04 58.88 Final Protocol Submission was due Dec.. | 1 0.04 58.92 Final Protocol not yet submitted. Spo.. | 1 0.04 58.96 Final Protocol submitted after milest.. | 1 0.04 59.00 Final Protocol was due June 2013. Spo.. | 1 0.04 59.03 Final Report due 2017 | 1 0.04 59.07 Final Report due 2018 | 1 0.04 59.11 Final Report due 2020 | 1 0.04 59.15 Final Report due May 2016 | 1 0.04 59.19 Final Report was due March 2016. The .. | 1 0.04 59.23 Final Study Report submitted June 3, .. | 1 0.04 59.26 Final Study Report submitted March 11.. | 3 0.12 59.38 Final Study Report was submitted as 1.. | 1 0.04 59.42 Final Study report is deferred to Aug.. | 1 0.04 59.46 Final protocol due in December, 2016. | 1 0.04 59.49 Final protocol due on 04/17 | 2 0.08 59.57 Final protocol missed pending further.. | 1 0.04 59.61 Final protocol revisions submitted Ma.. | 2 0.08 59.69 Final protocol submission 18-DEC-15; .. | 1 0.04 59.72 Final protocol submission date is 12/.. | 1 0.04 59.76 Final protocol submission date is Sep.. | 1 0.04 59.80 Final protocol submission date is Sep.. | 1 0.04 59.84 Final protocol submission date is Sep.. | 1 0.04 59.88 Final protocol submission date of May.. | 1 0.04 59.92 Final protocol was due in March, 2015 | 1 0.04 59.95 Final report due 2017 | 1 0.04 59.99 Final report due 2018 | 1 0.04 60.03 Final report due 2019 | 2 0.08 60.11 Final report due 2020 | 1 0.04 60.15 Final report is deferred to August 20.. | 1 0.04 60.18 Final report submission date 11/2017 | 1 0.04 60.22 Final report submission date 11/2018 | 1 0.04 60.26 Final report submission date is 11/29.. | 1 0.04 60.30 Final report submission was due 12/31.. | 4 0.15 60.45 Final report submitted on 05/30/2008... | 1 0.04 60.49 Final report submitted on March 31, 2.. | 1 0.04 60.53 Final report submitted to FDA on 5/27.. | 1 0.04 60.57 Final report was due November 2015. O.. | 1 0.04 60.61 Final report was due on March 31, 201.. | 1 0.04 60.64 Final study report due on April 30, 2.. | 1 0.04 60.68 Final study report had been deferred .. | 1 0.04 60.72 Final study report submitted on 7/28/.. | 1 0.04 60.76 Final study report was due in June, 2.. | 1 0.04 60.80 First subject dosed on Nov 4, 2014; 8.. | 1 0.04 60.84 Forty-five subjects have been enrolle.. | 1 0.04 60.87 Forty-five subjects have been enrolle.. | 2 0.08 60.95 Fulfilled per the FDA letter dated 10.. | 1 0.04 60.99 GE noted in their submission dated Ma.. | 1 0.04 61.03 Good Cause letter sent to sponsor and.. | 2 0.08 61.10 Good cause granted per FDA letter dat.. | 1 0.04 61.14 January 5, 2009, FDA replaced PMC-1 w.. | 1 0.04 61.18 Lantheus report based on previous inf.. | 1 0.04 61.22 Milestone revised to have additional .. | 1 0.04 61.26 Milestone revised to have additional .. | 1 0.04 61.30 Missed final protocol submission date.. | 1 0.04 61.33 NDA WD 06/28/2012. Applicant does not.. | 4 0.15 61.49 NDA Withdrawn withdrawal requested Ap.. | 1 0.04 61.53 NDA product withdrawn from the market.. | 1 0.04 61.57 NDA product withdrawn from the market.. | 3 0.12 61.68 NDA product withdrawn from the market.. | 1 0.04 61.72 NDA product withdrawn from the market.. | 1 0.04 61.76 NDA request to WD received Feb 6, 201.. | 1 0.04 61.80 New pediatric studies to replace 572-.. | 1 0.04 61.83 New pediatric studies to replace 572-.. | 1 0.04 61.87 No longer enrolling for the study- Se.. | 1 0.04 61.91 No new information for this reporting.. | 1 0.04 61.95 On 18-FEB-14, Pfizer submitted a revi.. | 1 0.04 61.99 On 9/24/13 the sponsor requested for .. | 1 0.04 62.03 On August 26, 2015 (Sequence 0103), T.. | 1 0.04 62.06 On March 26, 2014, the FDA issued a l.. | 1 0.04 62.10 On November 18, 2013, Teva submitted .. | 1 0.04 62.14 Opthalmologic Study -Enrollment in th.. | 2 0.08 62.22 Original 3-year follow-up due 4Q 2015.. | 1 0.04 62.26 Original Final Report Due Date: 01/15.. | 4 0.15 62.41 Original Final Report Due Date: 01/31.. | 2 0.08 62.49 Original Final Report Due Date: 01/31.. | 1 0.04 62.52 Original Final Report Due Date: 02/28.. | 1 0.04 62.56 Original Final Report Due Date: 02/28.. | 1 0.04 62.60 Original Final Report Due Date: 03/31.. | 1 0.04 62.64 Original Final Report Due Date: 03/31.. | 1 0.04 62.68 Original Final Report Due Date: 03/31.. | 1 0.04 62.72 Original Final Report Due Date: 05/31.. | 1 0.04 62.75 Original Final Report Due Date: 06/01.. | 1 0.04 62.79 Original Final Report Due Date: 06/30.. | 1 0.04 62.83 Original Final Report Due Date: 06/30.. | 2 0.08 62.91 Original Final Report Due Date: 07/01.. | 1 0.04 62.95 Original Final Report Due Date: 07/25.. | 1 0.04 62.98 Original Final Report Due Date: 08/31.. | 1 0.04 63.02 Original Final Report Due Date: 08/31.. | 1 0.04 63.06 Original Final Report Due Date: 08/31.. | 1 0.04 63.10 Original Final Report Due Date: 08/31.. | 1 0.04 63.14 Original Final Report Due Date: 09/06.. | 1 0.04 63.18 Original Final Report Due Date: 09/30.. | 1 0.04 63.21 Original Final Report Due Date: 09/30.. | 2 0.08 63.29 Original Final Report Due Date: 09/30.. | 1 0.04 63.33 Original Final Report Due Date: 10/31.. | 1 0.04 63.37 Original Final Report Due Date: 10/31.. | 1 0.04 63.41 Original Final Report Due Date: 11/30.. | 1 0.04 63.44 Original Final Report Due Date: 11/30.. | 1 0.04 63.48 Original Final Report Due Date: 11/30.. | 2 0.08 63.56 Original Final Report Due Date: 12/30.. | 2 0.08 63.64 Original Final Report Due Date: 12/31.. | 1 0.04 63.67 Original Final Report Due Date: 12/31.. | 2 0.08 63.75 Original Final Report Due Date: 12/31.. | 2 0.08 63.83 Original Final Report Due Date: 12/31.. | 1 0.04 63.87 Original Final Report Due Date: 12/31.. | 1 0.04 63.90 Original Final Report Due Date:07/25/.. | 1 0.04 63.94 Original Final Report due date: 12/31.. | 1 0.04 63.98 Original Study report due December 31.. | 1 0.04 64.02 Original Trial Completion due date wa.. | 1 0.04 64.06 Original final report due date: 10/31.. | 1 0.04 64.10 Original milestone: January 1, 2009. .. | 1 0.04 64.14 Original milestone: March 1, 2008 Spo.. | 1 0.04 64.17 Original milestone: October 1, 2007. .. | 2 0.08 64.25 PMC not fulfilled letter signed on 8/.. | 1 0.04 64.29 PMCs in 6/28/13AP ltr. Status has not.. | 2 0.08 64.37 PMR Final Study Report submitted 30-N.. | 1 0.04 64.40 PMR Release pending publication of WD.. | 1 0.04 64.44 PMR fulfilled per FDA letter dated 7/.. | 1 0.04 64.48 PMR newly issued in FDA letter dated .. | 1 0.04 64.52 Patient accrual lagging | 3 0.12 64.63 Patient accrual lagging. | 2 0.08 64.71 Pediatric studies – PK and safety. Mi.. | 2 0.08 64.79 Peds study final study report due in .. | 1 0.04 64.83 Per AP Letter Aug 11, 2004, the proto.. | 2 0.08 64.90 Per AP Letter Aug 11, 2004, the proto.. | 2 0.08 64.98 Per AP Letter Aug 11, 2004, the proto.. | 2 0.08 65.06 Per Agency instruction, this study wa.. | 1 0.04 65.09 Per FDA letter dated 01/06/2017, this.. | 1 0.04 65.13 Per FDA letter dated 01/09/2017, this.. | 1 0.04 65.17 Per FDA letter dated 01/17/2017, this.. | 1 0.04 65.21 Per FDA letter dated 01/24/2017, this.. | 1 0.04 65.25 Per FDA letter dated 02-Feb-2016, thi.. | 1 0.04 65.29 Per FDA letter dated 02-Feb-2016, thi.. | 1 0.04 65.32 Per FDA letter dated 02/03/2016, this.. | 1 0.04 65.36 Per FDA letter dated 02/05/2016, this.. | 2 0.08 65.44 Per FDA letter dated 02/11/2016, this.. | 1 0.04 65.48 Per FDA letter dated 02/23/2016, this.. | 2 0.08 65.55 Per FDA letter dated 03/10/2016, this.. | 1 0.04 65.59 Per FDA letter dated 03/17/2016, this.. | 1 0.04 65.63 Per FDA letter dated 03/18/2016, this.. | 1 0.04 65.67 Per FDA letter dated 03/21/2016, this.. | 1 0.04 65.71 Per FDA letter dated 03/22/2016, this.. | 1 0.04 65.75 Per FDA letter dated 04/28/2016, this.. | 3 0.12 65.86 Per FDA letter dated 05/11/2016, this.. | 2 0.08 65.94 Per FDA letter dated 05/16/2016, this.. | 1 0.04 65.98 Per FDA letter dated 05/20/2016, this.. | 2 0.08 66.05 Per FDA letter dated 05/24/2016, this.. | 1 0.04 66.09 Per FDA letter dated 06/07/2016, this.. | 2 0.08 66.17 Per FDA letter dated 06/15/2016, this.. | 2 0.08 66.24 Per FDA letter dated 06/20/2016, this.. | 1 0.04 66.28 Per FDA letter dated 06/28/2016, this.. | 2 0.08 66.36 Per FDA letter dated 07/08/2016, this.. | 4 0.15 66.51 Per FDA letter dated 07/11/2016, this.. | 2 0.08 66.59 Per FDA letter dated 07/12/2016, this.. | 1 0.04 66.63 Per FDA letter dated 07/13/2016, this.. | 1 0.04 66.67 Per FDA letter dated 07/15/2016, this.. | 1 0.04 66.71 Per FDA letter dated 07/26/2016, this.. | 1 0.04 66.74 Per FDA letter dated 07/27/2016, this.. | 1 0.04 66.78 Per FDA letter dated 07/29/2016, this.. | 1 0.04 66.82 Per FDA letter dated 08/08/2016, this.. | 1 0.04 66.86 Per FDA letter dated 08/15/2016, this.. | 2 0.08 66.94 Per FDA letter dated 08/16/2016, this.. | 2 0.08 67.01 Per FDA letter dated 08/24/2016, this.. | 1 0.04 67.05 Per FDA letter dated 09/01/2016, this.. | 1 0.04 67.09 Per FDA letter dated 09/02/2016, this.. | 1 0.04 67.13 Per FDA letter dated 09/14/2016, this.. | 1 0.04 67.17 Per FDA letter dated 10/06/2016, this.. | 1 0.04 67.20 Per FDA letter dated 10/13/2016, this.. | 3 0.12 67.32 Per FDA letter dated 10/17/2016, this.. | 1 0.04 67.36 Per FDA letter dated 10/18/2016, this.. | 2 0.08 67.43 Per FDA letter dated 10/28/2016, this.. | 1 0.04 67.47 Per FDA letter dated 11/09/2016, this.. | 1 0.04 67.51 Per FDA letter dated 11/10/2016, this.. | 1 0.04 67.55 Per FDA letter dated 11/14/2016, this.. | 1 0.04 67.59 Per FDA letter dated 12/14/2016, this.. | 1 0.04 67.63 Per FDA letter dated 12/14/2016, this.. | 1 0.04 67.66 Per FDA letter dated 12/16/2016, this.. | 3 0.12 67.78 Per FDA letter dated 12/22/2016, this.. | 2 0.08 67.86 Per FDA letter dated 22-Dec-2016, thi.. | 2 0.08 67.93 Per FDA letter dated 23-May-2016, thi.. | 1 0.04 67.97 Per FDA letter dated May 23, 2016, th.. | 1 0.04 68.01 Per FDA letter dated October 7, 2016,.. | 2 0.08 68.09 Per FDA letter dated October 7, 2016,.. | 2 0.08 68.16 Per FDA letter dated September 9, 201.. | 1 0.04 68.20 Per FDA letter dated September 9, 201.. | 2 0.08 68.28 Plans to submit final study report pe.. | 1 0.04 68.32 Product is no longer marketed. | 1 0.04 68.35 Product withdrawn from US market. Stu.. | 1 0.04 68.39 Protocol is being revised for resubmi.. | 1 0.04 68.43 Protocol submitted | 2 0.08 68.51 Protocol submitted June 2015 | 1 0.04 68.55 Protocol submitted on March 31, 2015... | 1 0.04 68.58 Protocol submitted, final report due .. | 1 0.04 68.62 Protocol submitted. | 1 0.04 68.66 Protocol was due 9/2015. Sponsor did .. | 1 0.04 68.70 Protocol was submitted 31-Oct-2014.Pr.. | 1 0.04 68.74 Protocol was submitted on September 3.. | 1 0.04 68.78 Protocols have been submitted [...]. .. | 1 0.04 68.81 Recruitment is slow, but the FDA requ.. | 1 0.04 68.85 Recruitment ongoing, 738 subjects enr.. | 1 0.04 68.89 Replaced with 125103/52 PMC #1 and 12.. | 1 0.04 68.93 Reported 7 subjects as of this report.. | 1 0.04 68.97 Reported enrollment of 62 subjects as.. | 1 0.04 69.01 Reporting the enrollment in the study.. | 1 0.04 69.04 Reporting the study is progressing. | 2 0.08 69.12 Revised Schedule: In a letter dated 1.. | 1 0.04 69.16 Revised draft protocol submitted on 2.. | 1 0.04 69.20 Revised milestone date for protocol i.. | 1 0.04 69.24 S-010 submitted on June 18, 2015, but.. | 1 0.04 69.28 STN 125163/405 fulfills postmarketing.. | 1 0.04 69.31 STN 125163/405 fulfills postmarketing.. | 1 0.04 69.35 Schedule revised due to enrollment ra.. | 1 0.04 69.39 Sponsor discontinued enrollment in th.. | 1 0.04 69.43 Sponsor has been issued a PREA non-co.. | 3 0.12 69.54 Sponsor has not provided any update. .. | 1 0.04 69.58 Sponsor has not submitted an acceptab.. | 1 0.04 69.62 Sponsor has withdrawn this NDA and do.. | 3 0.12 69.74 Sponsor is awaiting for the Agency’s .. | 1 0.04 69.77 Sponsor notified Agency of likely del.. | 1 0.04 69.81 Sponsor requested a deferral extensio.. | 1 0.04 69.85 Sponsor requested withdrawal of the N.. | 2 0.08 69.93 Sponsor submitted new study protocol .. | 1 0.04 69.97 Sponsor sumitted studies to support t.. | 1 0.04 70.00 Status update on study was provided o.. | 1 0.04 70.04 Study 1 (pJIA), enrollment completed .. | 1 0.04 70.08 Study 191622-120 is ongoing with 61 s.. | 1 0.04 70.12 Study 191622-121 is ongoing with 39 s.. | 1 0.04 70.16 Study 191622-137 is a Multicenter, ra.. | 2 0.08 70.23 Study A0221047 has been initiated wit.. | 1 0.04 70.27 Study complete, Report submitted 2/12.. | 1 0.04 70.31 Study completed, results to be submit.. | 1 0.04 70.35 Study completion date 09/2016 | 1 0.04 70.39 Study completion date 12/2017 | 1 0.04 70.43 Study completion date is 09/17 | 2 0.08 70.50 Study completion date is 9/2016 | 1 0.04 70.54 Study completion date is December, 20.. | 1 0.04 70.58 Study completion date is December, 2019 | 1 0.04 70.62 Study completion date is June, 2017. | 1 0.04 70.66 Study completion date is March, 2017 | 1 0.04 70.69 Study completion date is May, 2017. | 1 0.04 70.73 Study completion date of July 31, 201.. | 1 0.04 70.77 Study enrollment has been initiated | 1 0.04 70.81 Study enrollment was initiated in Apr.. | 1 0.04 70.85 Study is ongoing. | 5 0.19 71.04 Study start date of 1/2/2009 was miss.. | 1 0.04 71.08 Study status: FMCNA requested that th.. | 1 0.04 71.12 Study terminated March 11, 2016. 295 .. | 4 0.15 71.27 Study terminated March 11, 2016. 457 .. | 2 0.08 71.35 Study terminated March 11, 2016. 475 .. | 2 0.08 71.42 Study terminated because the initial .. | 1 0.04 71.46 Study to start October 2016. | 1 0.04 71.50 Submission of the complete final stud.. | 1 0.04 71.54 Supplement STN 125254/642 submitted o.. | 1 0.04 71.58 Supplement submitted to fulfill the P.. | 1 0.04 71.61 Supplement submitted, but FDA did not.. | 1 0.04 71.65 The Applicant needs to run tests on p.. | 1 0.04 71.69 The Division agreed that the sponsor .. | 1 0.04 71.73 The FDA is currently reviewing the pr.. | 1 0.04 71.77 The Final Protocol Submission milesto.. | 1 0.04 71.81 The Final Protocol Submission milesto.. | 1 0.04 71.85 The Final Protocol Submission milesto.. | 1 0.04 71.88 The Final Protocol Submission milesto.. | 1 0.04 71.92 The Final Protocol Submission milesto.. | 1 0.04 71.96 The Final Report Submission milestone.. | 1 0.04 72.00 The Final Report Submission milestone.. | 1 0.04 72.04 The Final Report Submission milestone.. | 1 0.04 72.08 The Final Report Submission milestone.. | 1 0.04 72.11 The Final Report Submission milestone.. | 1 0.04 72.15 The Final Report was submitted to FDA.. | 2 0.08 72.23 The Final Report was submitted to FDA.. | 1 0.04 72.27 The Final Report was submitted to FDA.. | 1 0.04 72.31 The Final Study Report expected Decem.. | 1 0.04 72.34 The Final Study Report was submitted .. | 1 0.04 72.38 The Final protocol is due January 2017 | 1 0.04 72.42 The PK and Tolerability study compone.. | 1 0.04 72.46 The PMR was fulfilled per FDA letter .. | 1 0.04 72.50 The PREA Deferral Extension, requeste.. | 3 0.12 72.61 The Protocol Submission Date mileston.. | 1 0.04 72.65 The Sponsor did not meet the original.. | 1 0.04 72.69 The Sponsor had difficulties with pat.. | 1 0.04 72.73 The Sponsor has not started the study.. | 1 0.04 72.77 The Sponsor is currently negotiating .. | 1 0.04 72.80 The Sponsor is still having difficult.. | 1 0.04 72.84 The Sponsor met the goal of submittin.. | 1 0.04 72.88 The Sponsor reports that the study is.. | 2 0.08 72.96 The Sponsor submitted a request for w.. | 1 0.04 73.00 The Sponsor submitted the final repor.. | 2 0.08 73.07 The Sponsor submitted the study repor.. | 1 0.04 73.11 The Study Completion milestone was mi.. | 1 0.04 73.15 The applicant has not reported the st.. | 1 0.04 73.19 The bi-annual interim report was subm.. | 1 0.04 73.23 The clinical trial completion date mi.. | 3 0.12 73.34 The company submitted the Final Study.. | 1 0.04 73.38 The data included in the final report.. | 1 0.04 73.42 The drug product application Clonidin.. | 2 0.08 73.49 The final Protocol was submitted on 0.. | 2 0.08 73.57 The final analysis plan submission du.. | 1 0.04 73.61 The final protocol and study completi.. | 2 0.08 73.69 The final protocol due date has passe.. | 6 0.23 73.92 The final protocol due date of 06/20/.. | 1 0.04 73.95 The final protocol has been submitted.. | 1 0.04 73.99 The final protocol has not been submi.. | 1 0.04 74.03 The final protocol has not been submi.. | 6 0.23 74.26 The final protocol has not been submi.. | 1 0.04 74.30 The final protocol is due on 9/30/17 | 1 0.04 74.34 The final protocol milestone of this .. | 1 0.04 74.38 The final protocol milestone was 5/31.. | 2 0.08 74.45 The final protocol milestone was miss.. | 1 0.04 74.49 The final protocol milestone was miss.. | 2 0.08 74.57 The final protocol milestone was miss.. | 1 0.04 74.61 The final protocol milestone was miss.. | 1 0.04 74.65 The final protocol milestone was miss.. | 1 0.04 74.68 The final protocol milestone was miss.. | 1 0.04 74.72 The final protocol milestone was miss.. | 2 0.08 74.80 The final protocol milestone was miss.. | 14 0.54 75.34 The final protocol milestone was miss.. | 1 0.04 75.37 The final protocol milestone was miss.. | 5 0.19 75.57 The final protocol milestone was miss.. | 1 0.04 75.60 The final protocol milestone was miss.. | 2 0.08 75.68 The final protocol milestone was miss.. | 2 0.08 75.76 The final protocol submission milesto.. | 3 0.12 75.87 The final protocol submission milesto.. | 1 0.04 75.91 The final protocol submission milesto.. | 1 0.04 75.95 The final protocol submission milesto.. | 2 0.08 76.03 The final protocol submission milesto.. | 1 0.04 76.06 The final protocol submission milesto.. | 2 0.08 76.14 The final protocol submission milesto.. | 1 0.04 76.18 The final protocol submission milesto.. | 1 0.04 76.22 The final protocol submission milesto.. | 1 0.04 76.26 The final protocol submission milesto.. | 1 0.04 76.29 The final protocol submission milesto.. | 1 0.04 76.33 The final report (STN 125546/53) was .. | 1 0.04 76.37 The final report due date has passed .. | 1 0.04 76.41 The final report due date has passed .. | 6 0.23 76.64 The final report has not been submitt.. | 1 0.04 76.68 The final report is due in July, 2017 | 1 0.04 76.72 The final report is due on 9/30/17 | 1 0.04 76.75 The final report milestone was missed.. | 1 0.04 76.79 The final report milestone was missed.. | 1 0.04 76.83 The final report milestone was missed.. | 1 0.04 76.87 The final report milestone was missed.. | 1 0.04 76.91 The final report milestone was missed.. | 1 0.04 76.95 The final report milestone was missed.. | 2 0.08 77.02 The final report milestone was missed.. | 1 0.04 77.06 The final report milestone was missed.. | 1 0.04 77.10 The final report milestone was missed.. | 1 0.04 77.14 The final report milestone was missed.. | 1 0.04 77.18 The final report milestone was missed. | 2 0.08 77.25 The final report milestone was missed.. | 2 0.08 77.33 The final report milestone was missed.. | 1 0.04 77.37 The final report milestone was missed.. | 1 0.04 77.41 The final report milestone was missed.. | 1 0.04 77.45 The final report milestone was not mi.. | 2 0.08 77.52 The final report submission milestone.. | 1 0.04 77.56 The final report submission milestone.. | 1 0.04 77.60 The final report submission milestone.. | 1 0.04 77.64 The final report submission milestone.. | 1 0.04 77.68 The final report submission was due 3.. | 1 0.04 77.71 The final report was due in April, 20.. | 1 0.04 77.75 The final report was originally due D.. | 1 0.04 77.79 The final report was submitted on 10/.. | 1 0.04 77.83 The final report was submitted to FDA.. | 2 0.08 77.91 The final study protocol deadline has.. | 3 0.12 78.02 The final study report deadline has p.. | 2 0.08 78.10 The final study report deadline has p.. | 1 0.04 78.14 The final study report milestone was .. | 1 0.04 78.17 The final study report milestone was .. | 1 0.04 78.21 The final study report milestone was .. | 1 0.04 78.25 The final study report submitted with.. | 1 0.04 78.29 The final study report was submitted .. | 1 0.04 78.33 The final study report was submitted .. | 2 0.08 78.40 The final study report was submitted .. | 1 0.04 78.44 The final study reports for the remai.. | 47 1.80 80.25 The first interim report submission d.. | 3 0.12 80.36 The first interim report submission m.. | 1 0.04 80.40 The initial study submitted November .. | 1 0.04 80.44 The initiation of study CAIN457A2110 .. | 1 0.04 80.48 The interim report milestone was miss.. | 1 0.04 80.51 The original Final Report submission .. | 1 0.04 80.55 The original final study report due d.. | 2 0.08 80.63 The original milestone for the final .. | 1 0.04 80.67 The pilot study that will guide the d.. | 1 0.04 80.71 The protocol finalization milestone w.. | 1 0.04 80.74 The protocol finalization milestone w.. | 1 0.04 80.78 The protocol finalization milestone w.. | 2 0.08 80.86 The protocol finalization milestone w.. | 1 0.04 80.90 The protocols for the clinical safety.. | 1 0.04 80.94 The revised milestone proposal submit.. | 1 0.04 80.97 The sixth interim report was submitte.. | 1 0.04 81.01 The sponsor submitted on 11/23/15 pro.. | 2 0.08 81.09 The study completion (establishment o.. | 1 0.04 81.13 The study completion and final report.. | 1 0.04 81.17 The study completion and final study .. | 1 0.04 81.20 The study completion date has passed .. | 3 0.12 81.32 The study completion milestone was mi.. | 1 0.04 81.36 The study completion milestone was mi.. | 1 0.04 81.40 The study completion milestone was mi.. | 1 0.04 81.43 The study completion milestone was mi.. | 1 0.04 81.47 The study has been initiated | 3 0.12 81.59 The study has been initiated. | 6 0.23 81.82 The study has been initiated.85 patie.. | 1 0.04 81.86 The study has completed enrollment. | 2 0.08 81.93 The study has not been initiated but .. | 1 0.04 81.97 The study has not been initiated, but.. | 9 0.35 82.32 The study has not been initiated, but.. | 264 10.13 92.44 The study has not been initiated, but.. | 1 0.04 92.48 The study has not been initiated, but.. | 2 0.08 92.56 The study has not been initiated. | 1 0.04 92.60 The study has not begun but does not .. | 1 0.04 92.64 The study has not begun but does not .. | 5 0.19 92.83 The study has not begun but does not .. | 1 0.04 92.87 The study has not begun but does not .. | 1 0.04 92.90 The study has not begun but does not .. | 3 0.12 93.02 The study has not yet begun but does .. | 3 0.12 93.13 The study is delayed. Currently negot.. | 1 0.04 93.17 The study is proceeding according to .. | 1 0.04 93.21 The study is recruiting patients. Ori.. | 1 0.04 93.25 The study is terminated since the dru.. | 1 0.04 93.29 The study was initiated 2nd quarter o.. | 1 0.04 93.33 The study was initiated on September .. | 1 0.04 93.36 The study was initiated on September .. | 1 0.04 93.40 The study/trial has not begun but doe.. | 3 0.12 93.52 The study/trial has not begun but doe.. | 1 0.04 93.56 The study/trial has not begun but doe.. | 1 0.04 93.59 The supplement was approved on 3/22/1.. | 84 3.22 96.82 The supplements were approved. The PM.. | 48 1.84 98.66 The trial completion milestone was Ju.. | 1 0.04 98.70 The trial completion milestone was mi.. | 1 0.04 98.73 The trial has completed enrollment. T.. | 2 0.08 98.81 The trial has not been completed beca.. | 1 0.04 98.85 The trial has not begun but does not .. | 4 0.15 99.00 The trial has not begun but does not .. | 1 0.04 99.04 The trial is ongoing. Trial Completio.. | 1 0.04 99.08 The trial was initiated in April 2006.. | 1 0.04 99.12 The trial was terminated on the basis.. | 1 0.04 99.16 The trial will be extended for two ad.. | 1 0.04 99.19 There are 68 subjects currently enrol.. | 1 0.04 99.23 Thirty evaluable patients are enrolle.. | 1 0.04 99.27 This PMC final report was due on 3/31.. | 1 0.04 99.31 This PMC was to provide long-term saf.. | 1 0.04 99.35 This PMR replaces PMR 387-1. | 1 0.04 99.39 This PMR/PMC is ongoing. | 1 0.04 99.42 This study has not been initiated, bu.. | 1 0.04 99.46 This study is not scheduled to start .. | 1 0.04 99.50 This study titled “Provide clinical i.. | 1 0.04 99.54 To assess the effect of the implant o.. | 1 0.04 99.58 To date, 100 patients have been scree.. | 2 0.08 99.65 Trial completion milestone missed, FD.. | 6 0.23 99.88 Valeant anticipates initiating study .. | 1 0.04 99.92 study final study report due in 2020 | 1 0.04 99.96 “Good Cause justification was submitt.. | 1 0.04 100.00 ----------------------------------------+----------------------------------- Total | 2,607 100.00 Frequencies for study_type variable in pmc_commitments dataset : Study Type | Freq. Percent Cum. ------------+----------------------------------- . | 2,607 100.00 100.00 ------------+----------------------------------- Total | 2,607 100.00 Frequencies for study_start_date variable in pmc_commitments dataset : Study Start | Date | Freq. Percent Cum. ------------+----------------------------------- . | 2,607 100.00 100.00 ------------+----------------------------------- Total | 2,607 100.00 Frequencies for protocol_submission_date variable in pmc_commitments dataset : Protocol | Submission | Date | Freq. Percent Cum. ------------+----------------------------------- . | 2,607 100.00 100.00 ------------+----------------------------------- Total | 2,607 100.00 Frequencies for final_rpt_recv_date variable in pmc_commitments dataset : Final | Report | Received | Date | Freq. Percent Cum. ------------+----------------------------------- . | 2,607 100.00 100.00 ------------+----------------------------------- Total | 2,607 100.00 Frequencies for annual_rpt_due_date variable in pmc_commitments dataset : Annual | Repport Due | Date | Freq. Percent Cum. ------------+----------------------------------- . | 2,607 100.00 100.00 ------------+----------------------------------- Total | 2,607 100.00 Frequencies for annual_rpt_recv_datetime variable in pmc_commitments dataset : Annual | Report | Received | Date | Freq. Percent Cum. ------------+----------------------------------- 02aug2010 | 1 0.04 0.04 01nov2010 | 1 0.04 0.08 03dec2010 | 1 0.04 0.12 21dec2010 | 1 0.04 0.15 22dec2010 | 2 0.08 0.23 07feb2011 | 1 0.04 0.27 01mar2011 | 1 0.04 0.31 22apr2011 | 1 0.04 0.35 16may2011 | 1 0.04 0.38 07jun2011 | 1 0.04 0.42 10aug2011 | 1 0.04 0.46 21sep2011 | 1 0.04 0.50 17apr2012 | 1 0.04 0.54 18jun2012 | 1 0.04 0.58 02aug2012 | 1 0.04 0.61 13aug2012 | 3 0.12 0.73 26oct2012 | 6 0.23 0.96 02jan2013 | 3 0.12 1.07 16jan2013 | 2 0.08 1.15 27feb2013 | 3 0.12 1.27 01mar2013 | 1 0.04 1.30 19jun2013 | 22 0.84 2.15 02jul2013 | 3 0.12 2.26 16oct2013 | 6 0.23 2.49 13dec2013 | 1 0.04 2.53 06feb2014 | 2 0.08 2.61 10feb2014 | 5 0.19 2.80 14mar2014 | 1 0.04 2.84 04apr2014 | 1 0.04 2.88 12may2014 | 1 0.04 2.92 16may2014 | 1 0.04 2.95 22may2014 | 6 0.23 3.18 03jun2014 | 4 0.15 3.34 17jun2014 | 1 0.04 3.38 27jun2014 | 2 0.08 3.45 08aug2014 | 2 0.08 3.53 29sep2014 | 2 0.08 3.61 27oct2014 | 2 0.08 3.68 13nov2014 | 4 0.15 3.84 12dec2014 | 2 0.08 3.91 15dec2014 | 3 0.12 4.03 18dec2014 | 5 0.19 4.22 28jan2015 | 15 0.58 4.79 06feb2015 | 6 0.23 5.02 11feb2015 | 1 0.04 5.06 26feb2015 | 3 0.12 5.18 06mar2015 | 3 0.12 5.29 13mar2015 | 1 0.04 5.33 17mar2015 | 2 0.08 5.41 20mar2015 | 1 0.04 5.45 27mar2015 | 1 0.04 5.49 02apr2015 | 2 0.08 5.56 07apr2015 | 5 0.19 5.75 24apr2015 | 4 0.15 5.91 20may2015 | 1 0.04 5.95 28may2015 | 7 0.27 6.21 01jun2015 | 1 0.04 6.25 11jun2015 | 1 0.04 6.29 15jun2015 | 1 0.04 6.33 18jun2015 | 6 0.23 6.56 19jun2015 | 1 0.04 6.60 26jun2015 | 1 0.04 6.64 02jul2015 | 4 0.15 6.79 10jul2015 | 1 0.04 6.83 14jul2015 | 2 0.08 6.90 16jul2015 | 10 0.38 7.29 17jul2015 | 1 0.04 7.33 20jul2015 | 1 0.04 7.36 31jul2015 | 1 0.04 7.40 04aug2015 | 1 0.04 7.44 05aug2015 | 3 0.12 7.56 13aug2015 | 1 0.04 7.59 14aug2015 | 3 0.12 7.71 18aug2015 | 1 0.04 7.75 28aug2015 | 6 0.23 7.98 18sep2015 | 1 0.04 8.02 24sep2015 | 2 0.08 8.09 29sep2015 | 1 0.04 8.13 19oct2015 | 1 0.04 8.17 20oct2015 | 1 0.04 8.21 22oct2015 | 1 0.04 8.25 28oct2015 | 1 0.04 8.29 29oct2015 | 1 0.04 8.32 30oct2015 | 4 0.15 8.48 05nov2015 | 8 0.31 8.78 06nov2015 | 2 0.08 8.86 12nov2015 | 4 0.15 9.01 16nov2015 | 1 0.04 9.05 01dec2015 | 6 0.23 9.28 04dec2015 | 4 0.15 9.44 07dec2015 | 6 0.23 9.67 09dec2015 | 1 0.04 9.70 15dec2015 | 1 0.04 9.74 18dec2015 | 13 0.50 10.24 21dec2015 | 1 0.04 10.28 24dec2015 | 1 0.04 10.32 28dec2015 | 9 0.35 10.66 14jan2016 | 1 0.04 10.70 15jan2016 | 2 0.08 10.78 20jan2016 | 1 0.04 10.82 27jan2016 | 5 0.19 11.01 29jan2016 | 3 0.12 11.12 01feb2016 | 9 0.35 11.47 02feb2016 | 5 0.19 11.66 03feb2016 | 2 0.08 11.74 04feb2016 | 7 0.27 12.01 05feb2016 | 22 0.84 12.85 08feb2016 | 15 0.58 13.43 10feb2016 | 5 0.19 13.62 11feb2016 | 15 0.58 14.19 16feb2016 | 45 1.73 15.92 17feb2016 | 12 0.46 16.38 18feb2016 | 16 0.61 16.99 19feb2016 | 20 0.77 17.76 22feb2016 | 5 0.19 17.95 23feb2016 | 17 0.65 18.60 24feb2016 | 1 0.04 18.64 25feb2016 | 1 0.04 18.68 26feb2016 | 5 0.19 18.87 29feb2016 | 6 0.23 19.10 01mar2016 | 1 0.04 19.14 04mar2016 | 2 0.08 19.22 07mar2016 | 3 0.12 19.33 11mar2016 | 4 0.15 19.49 14mar2016 | 15 0.58 20.06 15mar2016 | 1 0.04 20.10 16mar2016 | 12 0.46 20.56 17mar2016 | 10 0.38 20.94 18mar2016 | 9 0.35 21.29 21mar2016 | 5 0.19 21.48 22mar2016 | 5 0.19 21.67 23mar2016 | 9 0.35 22.02 24mar2016 | 12 0.46 22.48 25mar2016 | 14 0.54 23.01 28mar2016 | 5 0.19 23.21 29mar2016 | 10 0.38 23.59 30mar2016 | 8 0.31 23.90 31mar2016 | 7 0.27 24.17 01apr2016 | 19 0.73 24.89 05apr2016 | 4 0.15 25.05 06apr2016 | 2 0.08 25.12 08apr2016 | 3 0.12 25.24 11apr2016 | 1 0.04 25.28 12apr2016 | 1 0.04 25.32 13apr2016 | 4 0.15 25.47 14apr2016 | 2 0.08 25.55 15apr2016 | 2 0.08 25.62 18apr2016 | 3 0.12 25.74 19apr2016 | 4 0.15 25.89 20apr2016 | 3 0.12 26.01 21apr2016 | 7 0.27 26.28 22apr2016 | 12 0.46 26.74 25apr2016 | 8 0.31 27.04 26apr2016 | 10 0.38 27.43 27apr2016 | 6 0.23 27.66 28apr2016 | 13 0.50 28.15 29apr2016 | 2 0.08 28.23 03may2016 | 2 0.08 28.31 05may2016 | 8 0.31 28.62 09may2016 | 8 0.31 28.92 10may2016 | 4 0.15 29.08 11may2016 | 3 0.12 29.19 12may2016 | 2 0.08 29.27 13may2016 | 9 0.35 29.61 16may2016 | 7 0.27 29.88 17may2016 | 6 0.23 30.11 18may2016 | 2 0.08 30.19 19may2016 | 3 0.12 30.30 20may2016 | 5 0.19 30.49 23may2016 | 7 0.27 30.76 24may2016 | 8 0.31 31.07 25may2016 | 11 0.42 31.49 26may2016 | 12 0.46 31.95 27may2016 | 3 0.12 32.07 31may2016 | 4 0.15 32.22 01jun2016 | 2 0.08 32.30 02jun2016 | 26 1.00 33.29 03jun2016 | 4 0.15 33.45 08jun2016 | 1 0.04 33.49 09jun2016 | 1 0.04 33.53 10jun2016 | 4 0.15 33.68 15jun2016 | 2 0.08 33.76 16jun2016 | 6 0.23 33.99 17jun2016 | 11 0.42 34.41 20jun2016 | 6 0.23 34.64 21jun2016 | 14 0.54 35.17 22jun2016 | 11 0.42 35.60 23jun2016 | 6 0.23 35.83 24jun2016 | 3 0.12 35.94 27jun2016 | 5 0.19 36.13 28jun2016 | 21 0.81 36.94 29jun2016 | 1 0.04 36.98 30jun2016 | 4 0.15 37.13 01jul2016 | 4 0.15 37.28 05jul2016 | 1 0.04 37.32 06jul2016 | 8 0.31 37.63 07jul2016 | 2 0.08 37.71 08jul2016 | 25 0.96 38.67 11jul2016 | 1 0.04 38.70 12jul2016 | 5 0.19 38.90 14jul2016 | 11 0.42 39.32 15jul2016 | 4 0.15 39.47 19jul2016 | 2 0.08 39.55 20jul2016 | 3 0.12 39.66 21jul2016 | 46 1.76 41.43 22jul2016 | 26 1.00 42.42 25jul2016 | 2 0.08 42.50 26jul2016 | 2 0.08 42.58 27jul2016 | 9 0.35 42.92 28jul2016 | 12 0.46 43.38 01aug2016 | 10 0.38 43.77 02aug2016 | 2 0.08 43.84 03aug2016 | 4 0.15 44.00 04aug2016 | 2 0.08 44.07 05aug2016 | 2 0.08 44.15 08aug2016 | 2 0.08 44.23 09aug2016 | 1 0.04 44.27 10aug2016 | 5 0.19 44.46 11aug2016 | 3 0.12 44.57 12aug2016 | 7 0.27 44.84 15aug2016 | 2 0.08 44.92 16aug2016 | 18 0.69 45.61 17aug2016 | 3 0.12 45.72 19aug2016 | 17 0.65 46.38 22aug2016 | 4 0.15 46.53 24aug2016 | 18 0.69 47.22 25aug2016 | 25 0.96 48.18 26aug2016 | 21 0.81 48.98 30aug2016 | 20 0.77 49.75 01sep2016 | 8 0.31 50.06 02sep2016 | 7 0.27 50.33 07sep2016 | 9 0.35 50.67 09sep2016 | 8 0.31 50.98 12sep2016 | 2 0.08 51.05 13sep2016 | 2 0.08 51.13 14sep2016 | 16 0.61 51.75 15sep2016 | 25 0.96 52.70 16sep2016 | 12 0.46 53.16 20sep2016 | 5 0.19 53.36 21sep2016 | 21 0.81 54.16 22sep2016 | 3 0.12 54.28 23sep2016 | 2 0.08 54.35 26sep2016 | 6 0.23 54.58 27sep2016 | 5 0.19 54.78 28sep2016 | 10 0.38 55.16 29sep2016 | 13 0.50 55.66 30sep2016 | 4 0.15 55.81 04oct2016 | 3 0.12 55.93 05oct2016 | 22 0.84 56.77 06oct2016 | 7 0.27 57.04 07oct2016 | 11 0.42 57.46 11oct2016 | 34 1.30 58.76 12oct2016 | 20 0.77 59.53 13oct2016 | 2 0.08 59.61 17oct2016 | 2 0.08 59.69 18oct2016 | 5 0.19 59.88 19oct2016 | 7 0.27 60.15 20oct2016 | 20 0.77 60.91 21oct2016 | 6 0.23 61.14 24oct2016 | 21 0.81 61.95 25oct2016 | 15 0.58 62.52 26oct2016 | 20 0.77 63.29 27oct2016 | 1 0.04 63.33 28oct2016 | 4 0.15 63.48 31oct2016 | 10 0.38 63.87 01nov2016 | 1 0.04 63.90 02nov2016 | 1 0.04 63.94 03nov2016 | 3 0.12 64.06 04nov2016 | 3 0.12 64.17 08nov2016 | 4 0.15 64.33 10nov2016 | 12 0.46 64.79 14nov2016 | 10 0.38 65.17 15nov2016 | 8 0.31 65.48 16nov2016 | 10 0.38 65.86 17nov2016 | 21 0.81 66.67 18nov2016 | 16 0.61 67.28 21nov2016 | 4 0.15 67.43 22nov2016 | 14 0.54 67.97 23nov2016 | 17 0.65 68.62 25nov2016 | 9 0.35 68.97 28nov2016 | 5 0.19 69.16 29nov2016 | 2 0.08 69.24 30nov2016 | 2 0.08 69.31 01dec2016 | 5 0.19 69.51 02dec2016 | 5 0.19 69.70 06dec2016 | 14 0.54 70.23 07dec2016 | 4 0.15 70.39 09dec2016 | 7 0.27 70.66 12dec2016 | 4 0.15 70.81 14dec2016 | 8 0.31 71.12 15dec2016 | 25 0.96 72.08 16dec2016 | 4 0.15 72.23 19dec2016 | 32 1.23 73.46 20dec2016 | 10 0.38 73.84 21dec2016 | 46 1.76 75.60 22dec2016 | 9 0.35 75.95 23dec2016 | 5 0.19 76.14 27dec2016 | 1 0.04 76.18 28dec2016 | 3 0.12 76.29 30dec2016 | 3 0.12 76.41 03jan2017 | 1 0.04 76.45 04jan2017 | 1 0.04 76.49 05jan2017 | 1 0.04 76.52 06jan2017 | 10 0.38 76.91 10jan2017 | 2 0.08 76.99 11jan2017 | 11 0.42 77.41 12jan2017 | 17 0.65 78.06 13jan2017 | 9 0.35 78.40 17jan2017 | 22 0.84 79.25 18jan2017 | 7 0.27 79.52 20jan2017 | 5 0.19 79.71 23jan2017 | 23 0.88 80.59 25jan2017 | 2 0.08 80.67 26jan2017 | 4 0.15 80.82 27jan2017 | 6 0.23 81.05 30jan2017 | 1 0.04 81.09 . | 493 18.91 100.00 ------------+----------------------------------- Total | 2,607 100.00 Frequencies for nda_bla_approval_datetime variable in pmc_commitments dataset : New Drug | Application | (NDA) | Biologic | License | Application | (BLA) | Approval | Date | Freq. Percent Cum. ------------+----------------------------------- 17jan1946 | 1 0.04 0.04 23apr1947 | 1 0.04 0.08 13aug1947 | 16 0.61 0.69 24dec1953 | 1 0.04 0.73 27apr1954 | 1 0.04 0.77 05jun1958 | 1 0.04 0.81 22jul1958 | 2 0.08 0.88 16aug1962 | 1 0.04 0.92 08jun1964 | 1 0.04 0.96 30jul1964 | 1 0.04 1.00 08oct1965 | 1 0.04 1.04 22dec1967 | 1 0.04 1.07 10sep1970 | 1 0.04 1.11 08dec1970 | 1 0.04 1.15 09dec1970 | 2 0.08 1.23 25jan1971 | 1 0.04 1.27 12feb1971 | 1 0.04 1.30 04mar1971 | 1 0.04 1.34 22mar1971 | 8 0.31 1.65 23mar1971 | 1 0.04 1.69 06aug1971 | 1 0.04 1.73 24sep1971 | 1 0.04 1.76 24feb1972 | 1 0.04 1.80 21dec1973 | 1 0.04 1.84 08apr1974 | 1 0.04 1.88 04jun1975 | 1 0.04 1.92 13aug1975 | 6 0.23 2.15 07oct1975 | 5 0.19 2.34 03dec1975 | 1 0.04 2.38 07jan1976 | 1 0.04 2.42 26jan1976 | 1 0.04 2.45 24mar1976 | 1 0.04 2.49 14may1976 | 1 0.04 2.53 02jun1976 | 1 0.04 2.57 12apr1977 | 1 0.04 2.61 03jan1978 | 1 0.04 2.65 16jan1978 | 1 0.04 2.69 06feb1978 | 1 0.04 2.72 08feb1978 | 2 0.08 2.80 10feb1978 | 1 0.04 2.84 16feb1978 | 1 0.04 2.88 24feb1978 | 1 0.04 2.92 24apr1978 | 1 0.04 2.95 15aug1978 | 2 0.08 3.03 01feb1979 | 4 0.15 3.18 02feb1979 | 7 0.27 3.45 04apr1979 | 1 0.04 3.49 06aug1979 | 1 0.04 3.53 28aug1979 | 2 0.08 3.61 15jan1980 | 1 0.04 3.64 18feb1980 | 1 0.04 3.68 22feb1980 | 2 0.08 3.76 17apr1980 | 1 0.04 3.80 16may1980 | 1 0.04 3.84 29may1980 | 3 0.12 3.95 10jun1980 | 1 0.04 3.99 11jul1980 | 1 0.04 4.03 05sep1980 | 1 0.04 4.07 28nov1980 | 1 0.04 4.10 23jan1981 | 5 0.19 4.30 19feb1982 | 1 0.04 4.33 23mar1982 | 5 0.19 4.53 06may1982 | 1 0.04 4.56 30jun1982 | 1 0.04 4.60 03aug1982 | 1 0.04 4.64 27oct1982 | 2 0.08 4.72 29oct1982 | 2 0.08 4.79 09nov1982 | 2 0.08 4.87 29nov1982 | 1 0.04 4.91 04may1983 | 1 0.04 4.95 10may1983 | 1 0.04 4.99 29jun1983 | 1 0.04 5.02 01nov1983 | 1 0.04 5.06 11jan1984 | 1 0.04 5.10 03apr1984 | 1 0.04 5.14 15jun1984 | 1 0.04 5.18 13jul1984 | 2 0.08 5.26 20jul1984 | 4 0.15 5.41 23aug1984 | 1 0.04 5.45 27aug1984 | 6 0.23 5.68 05sep1984 | 1 0.04 5.72 24sep1984 | 1 0.04 5.75 25sep1984 | 5 0.19 5.95 28sep1984 | 1 0.04 5.98 26jan1985 | 1 0.04 6.02 05apr1985 | 2 0.08 6.10 12jul1985 | 1 0.04 6.14 15jul1985 | 2 0.08 6.21 26jul1985 | 1 0.04 6.25 06sep1985 | 1 0.04 6.29 17sep1985 | 2 0.08 6.37 26dec1985 | 1 0.04 6.41 31dec1985 | 1 0.04 6.44 14jan1986 | 1 0.04 6.48 17jan1986 | 1 0.04 6.52 03apr1986 | 2 0.08 6.60 08may1986 | 3 0.12 6.71 03jun1986 | 1 0.04 6.75 26jun1986 | 4 0.15 6.90 17oct1986 | 1 0.04 6.94 08jan1987 | 1 0.04 6.98 29may1987 | 16 0.61 7.59 22oct1987 | 1 0.04 7.63 02dec1987 | 1 0.04 7.67 02feb1988 | 1 0.04 7.71 17feb1988 | 1 0.04 7.75 24feb1988 | 2 0.08 7.83 29feb1988 | 4 0.15 7.98 09mar1988 | 1 0.04 8.02 24mar1988 | 1 0.04 8.06 08jun1988 | 1 0.04 8.09 17oct1988 | 2 0.08 8.17 01nov1988 | 2 0.08 8.25 07nov1988 | 1 0.04 8.29 30dec1988 | 1 0.04 8.32 01jun1989 | 1 0.04 8.36 29sep1989 | 6 0.23 8.59 02oct1989 | 1 0.04 8.63 15dec1989 | 1 0.04 8.67 26dec1989 | 4 0.15 8.82 12jul1990 | 3 0.12 8.94 07aug1990 | 16 0.61 9.55 26dec1990 | 2 0.08 9.63 20feb1991 | 1 0.04 9.67 05mar1991 | 2 0.08 9.74 02jul1991 | 1 0.04 9.78 01nov1991 | 1 0.04 9.82 09dec1991 | 18 0.69 10.51 19dec1991 | 2 0.08 10.59 30dec1991 | 1 0.04 10.63 17apr1992 | 2 0.08 10.70 21apr1992 | 1 0.04 10.74 30nov1992 | 1 0.04 10.78 07dec1992 | 2 0.08 10.86 28may1993 | 1 0.04 10.89 10jun1993 | 4 0.15 11.05 26jul1993 | 1 0.04 11.09 09aug1993 | 1 0.04 11.12 20dec1993 | 1 0.04 11.16 30dec1993 | 5 0.19 11.35 01feb1994 | 3 0.12 11.47 25mar1994 | 8 0.31 11.78 12oct1994 | 1 0.04 11.81 22dec1994 | 1 0.04 11.85 03mar1995 | 2 0.08 11.93 10may1995 | 2 0.08 12.01 29sep1995 | 1 0.04 12.04 19oct1995 | 1 0.04 12.08 23oct1995 | 1 0.04 12.12 24oct1995 | 1 0.04 12.16 27oct1995 | 1 0.04 12.20 17nov1995 | 2 0.08 12.27 21dec1995 | 5 0.19 12.47 22mar1996 | 1 0.04 12.50 12jun1996 | 1 0.04 12.54 14jun1996 | 1 0.04 12.58 03jul1996 | 16 0.61 13.20 18jul1996 | 1 0.04 13.23 07aug1996 | 5 0.19 13.43 30aug1996 | 1 0.04 13.46 06sep1996 | 1 0.04 13.50 24sep1996 | 1 0.04 13.54 06dec1996 | 1 0.04 13.58 17dec1996 | 1 0.04 13.62 20dec1996 | 8 0.31 13.92 24dec1996 | 1 0.04 13.96 30jan1997 | 1 0.04 14.00 28feb1997 | 1 0.04 14.04 26mar1997 | 1 0.04 14.08 28mar1997 | 1 0.04 14.12 14may1997 | 1 0.04 14.15 15aug1997 | 1 0.04 14.19 29aug1997 | 1 0.04 14.23 26sep1997 | 1 0.04 14.27 29sep1997 | 1 0.04 14.31 14oct1997 | 1 0.04 14.35 20oct1997 | 1 0.04 14.38 25nov1997 | 1 0.04 14.42 26nov1997 | 4 0.15 14.58 24dec1997 | 4 0.15 14.73 31dec1997 | 1 0.04 14.77 13jan1998 | 1 0.04 14.81 29may1998 | 1 0.04 14.84 05jun1998 | 1 0.04 14.88 24aug1998 | 8 0.31 15.19 26aug1998 | 1 0.04 15.23 17sep1998 | 1 0.04 15.27 25sep1998 | 6 0.23 15.50 26oct1998 | 1 0.04 15.54 02nov1998 | 2 0.08 15.61 03nov1998 | 1 0.04 15.65 12nov1998 | 1 0.04 15.69 09jun1999 | 1 0.04 15.73 15jul1999 | 1 0.04 15.77 21oct1999 | 1 0.04 15.80 27oct1999 | 1 0.04 15.84 07dec1999 | 1 0.04 15.88 09dec1999 | 2 0.08 15.96 10dec1999 | 2 0.08 16.03 17dec1999 | 1 0.04 16.07 28jan2000 | 1 0.04 16.11 02feb2000 | 1 0.04 16.15 04feb2000 | 1 0.04 16.19 28feb2000 | 1 0.04 16.23 18jul2000 | 3 0.12 16.34 27jul2000 | 1 0.04 16.38 18aug2000 | 1 0.04 16.42 24aug2000 | 2 0.08 16.49 21sep2000 | 1 0.04 16.53 06nov2000 | 1 0.04 16.57 06dec2000 | 1 0.04 16.61 08dec2000 | 3 0.12 16.72 05jan2001 | 1 0.04 16.76 12jan2001 | 1 0.04 16.80 19jan2001 | 1 0.04 16.84 26jan2001 | 1 0.04 16.88 05feb2001 | 1 0.04 16.92 16feb2001 | 1 0.04 16.95 22mar2001 | 2 0.08 17.03 29mar2001 | 1 0.04 17.07 07may2001 | 4 0.15 17.22 11may2001 | 1 0.04 17.26 15aug2001 | 2 0.08 17.34 17sep2001 | 2 0.08 17.41 02oct2001 | 2 0.08 17.49 26oct2001 | 4 0.15 17.64 30nov2001 | 2 0.08 17.72 07dec2001 | 4 0.15 17.87 13dec2001 | 1 0.04 17.91 31jan2002 | 1 0.04 17.95 01feb2002 | 1 0.04 17.99 20mar2002 | 6 0.23 18.22 24may2002 | 3 0.12 18.34 24jul2002 | 1 0.04 18.37 14aug2002 | 2 0.08 18.45 29aug2002 | 1 0.04 18.49 30aug2002 | 1 0.04 18.53 20sep2002 | 1 0.04 18.57 08oct2002 | 6 0.23 18.80 16oct2002 | 1 0.04 18.83 18oct2002 | 1 0.04 18.87 31oct2002 | 1 0.04 18.91 15nov2002 | 1 0.04 18.95 26nov2002 | 2 0.08 19.03 27nov2002 | 2 0.08 19.10 03dec2002 | 1 0.04 19.14 23dec2002 | 2 0.08 19.22 31dec2002 | 12 0.46 19.68 05feb2003 | 1 0.04 19.72 26mar2003 | 1 0.04 19.75 18apr2003 | 3 0.12 19.87 24apr2003 | 2 0.08 19.95 30apr2003 | 4 0.15 20.10 17jun2003 | 2 0.08 20.18 19jun2003 | 1 0.04 20.21 20jun2003 | 1 0.04 20.25 08jul2003 | 2 0.08 20.33 25jul2003 | 1 0.04 20.37 12sep2003 | 2 0.08 20.44 30sep2003 | 2 0.08 20.52 02oct2003 | 2 0.08 20.60 19dec2003 | 1 0.04 20.64 05feb2004 | 3 0.12 20.75 12feb2004 | 2 0.08 20.83 26feb2004 | 2 0.08 20.91 26mar2004 | 1 0.04 20.94 20apr2004 | 2 0.08 21.02 10may2004 | 4 0.15 21.17 21may2004 | 1 0.04 21.21 25may2004 | 10 0.38 21.60 15jun2004 | 3 0.12 21.71 27jul2004 | 2 0.08 21.79 02aug2004 | 6 0.23 22.02 05aug2004 | 2 0.08 22.09 11aug2004 | 6 0.23 22.32 17sep2004 | 2 0.08 22.40 24sep2004 | 6 0.23 22.63 08oct2004 | 1 0.04 22.67 19oct2004 | 4 0.15 22.82 21oct2004 | 3 0.12 22.94 04nov2004 | 1 0.04 22.98 18nov2004 | 2 0.08 23.05 19nov2004 | 1 0.04 23.09 23nov2004 | 6 0.23 23.32 10dec2004 | 3 0.12 23.44 15dec2004 | 5 0.19 23.63 22dec2004 | 1 0.04 23.67 28dec2004 | 1 0.04 23.71 30dec2004 | 4 0.15 23.86 14jan2005 | 2 0.08 23.94 29mar2005 | 4 0.15 24.09 28apr2005 | 2 0.08 24.17 02may2005 | 1 0.04 24.20 05may2005 | 3 0.12 24.32 26may2005 | 3 0.12 24.43 31may2005 | 3 0.12 24.55 03jun2005 | 2 0.08 24.63 10jun2005 | 3 0.12 24.74 15jun2005 | 3 0.12 24.86 07jul2005 | 15 0.58 25.43 19aug2005 | 1 0.04 25.47 29aug2005 | 1 0.04 25.51 31aug2005 | 2 0.08 25.58 08sep2005 | 4 0.15 25.74 28oct2005 | 1 0.04 25.78 01dec2005 | 2 0.08 25.85 23dec2005 | 4 0.15 26.01 27dec2005 | 1 0.04 26.05 26jan2006 | 5 0.19 26.24 27jan2006 | 2 0.08 26.31 31jan2006 | 7 0.27 26.58 17feb2006 | 1 0.04 26.62 16mar2006 | 1 0.04 26.66 13apr2006 | 1 0.04 26.70 28apr2006 | 3 0.12 26.81 10may2006 | 4 0.15 26.97 16may2006 | 1 0.04 27.00 22may2006 | 1 0.04 27.04 25may2006 | 1 0.04 27.08 07jun2006 | 1 0.04 27.12 08jun2006 | 5 0.19 27.31 22jun2006 | 19 0.73 28.04 12jul2006 | 1 0.04 28.08 17jul2006 | 1 0.04 28.12 21jul2006 | 2 0.08 28.19 24jul2006 | 4 0.15 28.35 28jul2006 | 1 0.04 28.39 15sep2006 | 1 0.04 28.42 20sep2006 | 1 0.04 28.46 27sep2006 | 2 0.08 28.54 28sep2006 | 1 0.04 28.58 05oct2006 | 3 0.12 28.69 16oct2006 | 1 0.04 28.73 20oct2006 | 1 0.04 28.77 25oct2006 | 2 0.08 28.85 15dec2006 | 5 0.19 29.04 19dec2006 | 1 0.04 29.08 16jan2007 | 2 0.08 29.15 31jan2007 | 1 0.04 29.19 23feb2007 | 2 0.08 29.27 05mar2007 | 1 0.04 29.31 13mar2007 | 1 0.04 29.34 16mar2007 | 1 0.04 29.38 30mar2007 | 2 0.08 29.46 09may2007 | 1 0.04 29.50 11may2007 | 1 0.04 29.54 22may2007 | 2 0.08 29.61 15jun2007 | 2 0.08 29.69 26jul2007 | 1 0.04 29.73 06aug2007 | 2 0.08 29.80 31aug2007 | 3 0.12 29.92 28sep2007 | 4 0.15 30.07 12oct2007 | 4 0.15 30.23 17oct2007 | 2 0.08 30.30 19oct2007 | 1 0.04 30.34 14nov2007 | 7 0.27 30.61 13dec2007 | 5 0.19 30.80 18jan2008 | 1 0.04 30.84 23jan2008 | 1 0.04 30.88 25jan2008 | 4 0.15 31.03 21feb2008 | 1 0.04 31.07 27feb2008 | 1 0.04 31.11 29feb2008 | 2 0.08 31.19 17mar2008 | 4 0.15 31.34 20mar2008 | 2 0.08 31.42 03apr2008 | 1 0.04 31.45 15apr2008 | 4 0.15 31.61 22apr2008 | 5 0.19 31.80 23apr2008 | 1 0.04 31.84 24apr2008 | 1 0.04 31.88 09may2008 | 3 0.12 31.99 20may2008 | 4 0.15 32.14 13jun2008 | 4 0.15 32.30 20jun2008 | 1 0.04 32.34 01aug2008 | 1 0.04 32.37 15aug2008 | 2 0.08 32.45 22aug2008 | 3 0.12 32.57 12sep2008 | 2 0.08 32.64 10oct2008 | 1 0.04 32.68 28oct2008 | 22 0.84 33.53 31oct2008 | 2 0.08 33.60 20nov2008 | 1 0.04 33.64 12dec2008 | 6 0.23 33.87 30dec2008 | 3 0.12 33.99 14jan2009 | 1 0.04 34.02 16jan2009 | 4 0.15 34.18 23jan2009 | 1 0.04 34.22 27jan2009 | 1 0.04 34.25 30jan2009 | 9 0.35 34.60 06feb2009 | 1 0.04 34.64 13feb2009 | 1 0.04 34.68 30mar2009 | 7 0.27 34.94 07apr2009 | 2 0.08 35.02 24apr2009 | 14 0.54 35.56 28apr2009 | 2 0.08 35.63 29apr2009 | 7 0.27 35.90 30apr2009 | 2 0.08 35.98 05may2009 | 2 0.08 36.06 06may2009 | 2 0.08 36.13 12may2009 | 1 0.04 36.17 19may2009 | 2 0.08 36.25 11jun2009 | 1 0.04 36.29 16jun2009 | 3 0.12 36.40 17jun2009 | 10 0.38 36.79 30jun2009 | 2 0.08 36.86 16jul2009 | 2 0.08 36.94 29jul2009 | 2 0.08 37.02 31jul2009 | 2 0.08 37.09 12aug2009 | 1 0.04 37.13 13aug2009 | 20 0.77 37.90 19aug2009 | 1 0.04 37.94 21aug2009 | 1 0.04 37.97 27aug2009 | 2 0.08 38.05 28aug2009 | 1 0.04 38.09 11sep2009 | 2 0.08 38.17 24sep2009 | 7 0.27 38.43 25sep2009 | 6 0.23 38.67 29sep2009 | 2 0.08 38.74 02oct2009 | 1 0.04 38.78 09oct2009 | 3 0.12 38.90 16oct2009 | 3 0.12 39.01 30oct2009 | 2 0.08 39.09 04nov2009 | 3 0.12 39.20 05nov2009 | 3 0.12 39.32 27nov2009 | 4 0.15 39.47 01dec2009 | 2 0.08 39.55 03dec2009 | 2 0.08 39.62 04jan2010 | 4 0.15 39.78 08jan2010 | 4 0.15 39.93 25jan2010 | 4 0.15 40.08 02feb2010 | 3 0.12 40.20 19feb2010 | 5 0.19 40.39 22feb2010 | 1 0.04 40.43 24feb2010 | 4 0.15 40.58 26feb2010 | 4 0.15 40.74 01mar2010 | 17 0.65 41.39 18mar2010 | 3 0.12 41.50 24mar2010 | 5 0.19 41.70 05apr2010 | 22 0.84 42.54 12apr2010 | 2 0.08 42.62 16apr2010 | 1 0.04 42.65 20apr2010 | 11 0.42 43.08 29apr2010 | 1 0.04 43.11 30apr2010 | 1 0.04 43.15 06may2010 | 1 0.04 43.19 07may2010 | 3 0.12 43.31 14may2010 | 3 0.12 43.42 24may2010 | 4 0.15 43.57 27may2010 | 2 0.08 43.65 28may2010 | 2 0.08 43.73 01jun2010 | 7 0.27 44.00 17jun2010 | 2 0.08 44.07 22jun2010 | 3 0.12 44.19 30jun2010 | 17 0.65 44.84 01jul2010 | 4 0.15 44.99 02jul2010 | 4 0.15 45.15 28jul2010 | 2 0.08 45.22 30jul2010 | 8 0.31 45.53 05aug2010 | 4 0.15 45.68 13aug2010 | 2 0.08 45.76 30aug2010 | 1 0.04 45.80 14sep2010 | 2 0.08 45.88 21sep2010 | 4 0.15 46.03 06oct2010 | 2 0.08 46.11 19oct2010 | 3 0.12 46.22 20oct2010 | 4 0.15 46.38 28oct2010 | 9 0.35 46.72 29oct2010 | 4 0.15 46.87 02nov2010 | 2 0.08 46.95 05nov2010 | 1 0.04 46.99 10nov2010 | 2 0.08 47.07 23nov2010 | 1 0.04 47.10 29dec2010 | 1 0.04 47.14 14jan2011 | 1 0.04 47.18 21jan2011 | 2 0.08 47.26 03feb2011 | 2 0.08 47.33 25feb2011 | 2 0.08 47.41 28feb2011 | 1 0.04 47.45 09mar2011 | 9 0.35 47.79 16mar2011 | 1 0.04 47.83 25mar2011 | 7 0.27 48.10 06apr2011 | 8 0.31 48.41 18apr2011 | 1 0.04 48.45 29apr2011 | 1 0.04 48.48 02may2011 | 3 0.12 48.60 20may2011 | 1 0.04 48.64 27may2011 | 3 0.12 48.75 08jun2011 | 2 0.08 48.83 10jun2011 | 7 0.27 49.10 13jun2011 | 1 0.04 49.14 15jun2011 | 3 0.12 49.25 17jun2011 | 1 0.04 49.29 21jun2011 | 1 0.04 49.33 30jun2011 | 2 0.08 49.41 01jul2011 | 19 0.73 50.13 10aug2011 | 2 0.08 50.21 17aug2011 | 7 0.27 50.48 19aug2011 | 2 0.08 50.56 25aug2011 | 17 0.65 51.21 26aug2011 | 9 0.35 51.55 14oct2011 | 2 0.08 51.63 21oct2011 | 2 0.08 51.71 28oct2011 | 4 0.15 51.86 16nov2011 | 3 0.12 51.98 18nov2011 | 1 0.04 52.01 23nov2011 | 1 0.04 52.05 09dec2011 | 16 0.61 52.67 21dec2011 | 4 0.15 52.82 12jan2012 | 2 0.08 52.90 18jan2012 | 1 0.04 52.93 27jan2012 | 6 0.23 53.16 30jan2012 | 3 0.12 53.28 31jan2012 | 3 0.12 53.39 02feb2012 | 1 0.04 53.43 03feb2012 | 3 0.12 53.55 14feb2012 | 1 0.04 53.59 17feb2012 | 2 0.08 53.66 01mar2012 | 2 0.08 53.74 09mar2012 | 1 0.04 53.78 27mar2012 | 6 0.23 54.01 27apr2012 | 1 0.04 54.05 01may2012 | 8 0.31 54.35 17may2012 | 3 0.12 54.47 08jun2012 | 5 0.19 54.66 12jun2012 | 1 0.04 54.70 14jun2012 | 1 0.04 54.74 27jun2012 | 4 0.15 54.89 28jun2012 | 4 0.15 55.04 16jul2012 | 4 0.15 55.20 17jul2012 | 8 0.31 55.50 20jul2012 | 5 0.19 55.70 23jul2012 | 1 0.04 55.73 09aug2012 | 3 0.12 55.85 27aug2012 | 5 0.19 56.04 29aug2012 | 5 0.19 56.23 30aug2012 | 7 0.27 56.50 31aug2012 | 1 0.04 56.54 04sep2012 | 1 0.04 56.58 12sep2012 | 2 0.08 56.66 27sep2012 | 2 0.08 56.73 28sep2012 | 1 0.04 56.77 12oct2012 | 1 0.04 56.81 15oct2012 | 1 0.04 56.85 19oct2012 | 4 0.15 57.00 22oct2012 | 7 0.27 57.27 26oct2012 | 3 0.12 57.38 06nov2012 | 3 0.12 57.50 20nov2012 | 10 0.38 57.88 29nov2012 | 4 0.15 58.04 05dec2012 | 3 0.12 58.15 14dec2012 | 16 0.61 58.76 19dec2012 | 2 0.08 58.84 20dec2012 | 5 0.19 59.03 21dec2012 | 6 0.23 59.26 28dec2012 | 5 0.19 59.46 31dec2012 | 3 0.12 59.57 14jan2013 | 1 0.04 59.61 16jan2013 | 8 0.31 59.92 17jan2013 | 7 0.27 60.18 18jan2013 | 7 0.27 60.45 25jan2013 | 8 0.31 60.76 29jan2013 | 2 0.08 60.84 31jan2013 | 1 0.04 60.87 01feb2013 | 4 0.15 61.03 08feb2013 | 6 0.23 61.26 20feb2013 | 1 0.04 61.30 22feb2013 | 4 0.15 61.45 25feb2013 | 1 0.04 61.49 04mar2013 | 1 0.04 61.53 05mar2013 | 1 0.04 61.57 13mar2013 | 1 0.04 61.60 20mar2013 | 1 0.04 61.64 22mar2013 | 8 0.31 61.95 27mar2013 | 3 0.12 62.06 29mar2013 | 5 0.19 62.26 08apr2013 | 1 0.04 62.29 11apr2013 | 1 0.04 62.33 12apr2013 | 2 0.08 62.41 29apr2013 | 2 0.08 62.49 30apr2013 | 1 0.04 62.52 10may2013 | 3 0.12 62.64 15may2013 | 4 0.15 62.79 29may2013 | 10 0.38 63.18 21jun2013 | 3 0.12 63.29 26jun2013 | 1 0.04 63.33 03jul2013 | 1 0.04 63.37 10jul2013 | 1 0.04 63.41 12jul2013 | 1 0.04 63.44 18jul2013 | 1 0.04 63.48 19jul2013 | 2 0.08 63.56 25jul2013 | 5 0.19 63.75 06aug2013 | 4 0.15 63.90 12aug2013 | 7 0.27 64.17 16aug2013 | 4 0.15 64.33 23aug2013 | 1 0.04 64.37 30sep2013 | 5 0.19 64.56 03oct2013 | 6 0.23 64.79 11oct2013 | 1 0.04 64.83 15oct2013 | 2 0.08 64.90 18oct2013 | 5 0.19 65.09 21oct2013 | 1 0.04 65.13 24oct2013 | 1 0.04 65.17 25oct2013 | 25 0.96 66.13 01nov2013 | 2 0.08 66.21 08nov2013 | 13 0.50 66.71 13nov2013 | 7 0.27 66.97 14nov2013 | 5 0.19 67.17 22nov2013 | 10 0.38 67.55 25nov2013 | 2 0.08 67.63 27nov2013 | 1 0.04 67.66 06dec2013 | 9 0.35 68.01 20dec2013 | 1 0.04 68.05 23dec2013 | 1 0.04 68.09 08jan2014 | 7 0.27 68.35 28jan2014 | 1 0.04 68.39 14feb2014 | 3 0.12 68.51 18feb2014 | 1 0.04 68.55 24feb2014 | 9 0.35 68.89 05mar2014 | 1 0.04 68.93 11mar2014 | 6 0.23 69.16 13mar2014 | 2 0.08 69.24 19mar2014 | 4 0.15 69.39 21mar2014 | 1 0.04 69.43 24mar2014 | 1 0.04 69.47 28mar2014 | 2 0.08 69.54 01apr2014 | 2 0.08 69.62 11apr2014 | 2 0.08 69.70 15apr2014 | 4 0.15 69.85 17apr2014 | 4 0.15 70.00 21apr2014 | 1 0.04 70.04 23apr2014 | 1 0.04 70.08 25apr2014 | 2 0.08 70.16 29apr2014 | 6 0.23 70.39 20may2014 | 10 0.38 70.77 23may2014 | 7 0.27 71.04 28may2014 | 1 0.04 71.08 30may2014 | 1 0.04 71.12 04jun2014 | 1 0.04 71.15 06jun2014 | 5 0.19 71.35 20jun2014 | 12 0.46 71.81 27jun2014 | 9 0.35 72.15 03jul2014 | 8 0.31 72.46 07jul2014 | 1 0.04 72.50 16jul2014 | 1 0.04 72.54 23jul2014 | 38 1.46 73.99 01aug2014 | 5 0.19 74.18 06aug2014 | 7 0.27 74.45 08aug2014 | 5 0.19 74.65 15aug2014 | 2 0.08 74.72 19aug2014 | 2 0.08 74.80 20aug2014 | 4 0.15 74.95 22aug2014 | 3 0.12 75.07 25aug2014 | 1 0.04 75.11 04sep2014 | 8 0.31 75.41 05sep2014 | 1 0.04 75.45 10sep2014 | 8 0.31 75.76 12sep2014 | 3 0.12 75.87 16sep2014 | 2 0.08 75.95 18sep2014 | 5 0.19 76.14 23sep2014 | 2 0.08 76.22 24sep2014 | 9 0.35 76.56 07oct2014 | 1 0.04 76.60 10oct2014 | 19 0.73 77.33 15oct2014 | 1 0.04 77.37 23oct2014 | 1 0.04 77.41 29oct2014 | 11 0.42 77.83 14nov2014 | 2 0.08 77.91 20nov2014 | 22 0.84 78.75 03dec2014 | 1 0.04 78.79 10dec2014 | 5 0.19 78.98 19dec2014 | 30 1.15 80.13 22dec2014 | 9 0.35 80.48 23dec2014 | 10 0.38 80.86 07jan2015 | 2 0.08 80.94 08jan2015 | 3 0.12 81.05 21jan2015 | 7 0.27 81.32 23jan2015 | 12 0.46 81.78 29jan2015 | 7 0.27 82.05 30jan2015 | 1 0.04 82.09 03feb2015 | 5 0.19 82.28 13feb2015 | 2 0.08 82.36 23feb2015 | 2 0.08 82.43 25feb2015 | 5 0.19 82.62 26feb2015 | 1 0.04 82.66 04mar2015 | 2 0.08 82.74 06mar2015 | 9 0.35 83.08 10mar2015 | 5 0.19 83.28 17mar2015 | 1 0.04 83.31 24mar2015 | 2 0.08 83.39 30mar2015 | 9 0.35 83.74 31mar2015 | 3 0.12 83.85 17apr2015 | 3 0.12 83.97 29apr2015 | 2 0.08 84.04 30apr2015 | 1 0.04 84.08 14may2015 | 2 0.08 84.16 27may2015 | 4 0.15 84.31 22jun2015 | 2 0.08 84.39 02jul2015 | 1 0.04 84.43 07jul2015 | 2 0.08 84.50 10jul2015 | 10 0.38 84.89 24jul2015 | 19 0.73 85.62 29jul2015 | 1 0.04 85.65 18aug2015 | 7 0.27 85.92 26aug2015 | 5 0.19 86.11 27aug2015 | 4 0.15 86.27 01sep2015 | 6 0.23 86.50 04sep2015 | 5 0.19 86.69 09sep2015 | 2 0.08 86.77 15sep2015 | 2 0.08 86.84 17sep2015 | 20 0.77 87.61 22sep2015 | 2 0.08 87.69 25sep2015 | 7 0.27 87.96 02oct2015 | 15 0.58 88.53 16oct2015 | 3 0.12 88.65 19oct2015 | 3 0.12 88.76 20oct2015 | 1 0.04 88.80 21oct2015 | 3 0.12 88.91 23oct2015 | 19 0.73 89.64 27oct2015 | 2 0.08 89.72 04nov2015 | 2 0.08 89.80 05nov2015 | 2 0.08 89.87 06nov2015 | 1 0.04 89.91 10nov2015 | 3 0.12 90.03 13nov2015 | 14 0.54 90.56 16nov2015 | 6 0.23 90.79 18nov2015 | 4 0.15 90.95 24nov2015 | 5 0.19 91.14 30nov2015 | 1 0.04 91.18 04dec2015 | 3 0.12 91.29 08dec2015 | 1 0.04 91.33 11dec2015 | 2 0.08 91.41 15dec2015 | 4 0.15 91.56 22dec2015 | 1 0.04 91.60 26jan2016 | 6 0.23 91.83 27jan2016 | 5 0.19 92.02 28jan2016 | 9 0.35 92.37 05feb2016 | 1 0.04 92.41 18feb2016 | 12 0.46 92.87 23feb2016 | 3 0.12 92.98 24feb2016 | 1 0.04 93.02 01mar2016 | 1 0.04 93.06 16mar2016 | 2 0.08 93.13 18mar2016 | 1 0.04 93.17 22mar2016 | 5 0.19 93.36 23mar2016 | 3 0.12 93.48 30mar2016 | 1 0.04 93.52 04apr2016 | 2 0.08 93.59 08apr2016 | 4 0.15 93.75 11apr2016 | 3 0.12 93.86 15apr2016 | 1 0.04 93.90 25apr2016 | 3 0.12 94.02 26apr2016 | 14 0.54 94.55 29apr2016 | 11 0.42 94.98 18may2016 | 5 0.19 95.17 26may2016 | 4 0.15 95.32 27may2016 | 9 0.35 95.67 10jun2016 | 2 0.08 95.74 17jun2016 | 2 0.08 95.82 28jun2016 | 8 0.31 96.13 01jul2016 | 5 0.19 96.32 13jul2016 | 8 0.31 96.62 19jul2016 | 1 0.04 96.66 22jul2016 | 1 0.04 96.70 27jul2016 | 3 0.12 96.82 29jul2016 | 1 0.04 96.85 09aug2016 | 7 0.27 97.12 19aug2016 | 6 0.23 97.35 30aug2016 | 1 0.04 97.39 14sep2016 | 2 0.08 97.47 19sep2016 | 5 0.19 97.66 23sep2016 | 8 0.31 97.97 18oct2016 | 2 0.08 98.04 19oct2016 | 3 0.12 98.16 21oct2016 | 1 0.04 98.20 10nov2016 | 9 0.35 98.54 14dec2016 | 1 0.04 98.58 19dec2016 | 6 0.23 98.81 23dec2016 | 3 0.12 98.93 27dec2016 | 3 0.12 99.04 09jan2017 | 7 0.27 99.31 17jan2017 | 4 0.15 99.46 19jan2017 | 14 0.54 100.00 ------------+----------------------------------- Total | 2,607 100.00 Frequencies for orig_proj_compl_datetime variable in pmc_commitments dataset : Original | Project | Completion | Date | Freq. Percent Cum. ------------+----------------------------------- 18aug2001 | 1 0.04 0.04 31dec2003 | 2 0.08 0.12 30apr2004 | 2 0.08 0.19 31dec2004 | 1 0.04 0.23 17may2005 | 1 0.04 0.27 30nov2005 | 1 0.04 0.31 31dec2005 | 1 0.04 0.35 31mar2006 | 1 0.04 0.38 30apr2006 | 2 0.08 0.46 31oct2006 | 1 0.04 0.50 29dec2006 | 1 0.04 0.54 31dec2006 | 2 0.08 0.61 31jan2007 | 2 0.08 0.69 15jul2007 | 2 0.08 0.77 01oct2007 | 2 0.08 0.84 08oct2007 | 2 0.08 0.92 02jan2008 | 1 0.04 0.96 31jan2008 | 2 0.08 1.04 01mar2008 | 1 0.04 1.07 30apr2008 | 1 0.04 1.11 30may2008 | 1 0.04 1.15 30jun2008 | 1 0.04 1.19 31jul2008 | 1 0.04 1.23 19dec2008 | 1 0.04 1.27 26dec2008 | 1 0.04 1.30 31dec2008 | 2 0.08 1.38 01jan2009 | 1 0.04 1.42 31jan2009 | 3 0.12 1.53 01feb2009 | 1 0.04 1.57 13mar2009 | 1 0.04 1.61 30apr2009 | 1 0.04 1.65 01may2009 | 1 0.04 1.69 08may2009 | 1 0.04 1.73 30jun2009 | 1 0.04 1.76 19jul2009 | 1 0.04 1.80 31jul2009 | 1 0.04 1.84 24sep2009 | 1 0.04 1.88 20oct2009 | 1 0.04 1.92 30oct2009 | 1 0.04 1.96 31dec2009 | 4 0.15 2.11 31jan2010 | 1 0.04 2.15 31may2010 | 3 0.12 2.26 31aug2010 | 2 0.08 2.34 30sep2010 | 2 0.08 2.42 30nov2010 | 2 0.08 2.49 10dec2010 | 1 0.04 2.53 31dec2010 | 3 0.12 2.65 02jan2011 | 1 0.04 2.69 15feb2011 | 1 0.04 2.72 31mar2011 | 2 0.08 2.80 29apr2011 | 1 0.04 2.84 10may2011 | 1 0.04 2.88 01jun2011 | 1 0.04 2.92 30jun2011 | 3 0.12 3.03 01aug2011 | 1 0.04 3.07 31aug2011 | 1 0.04 3.11 30sep2011 | 1 0.04 3.15 31oct2011 | 4 0.15 3.30 30nov2011 | 1 0.04 3.34 03dec2011 | 2 0.08 3.41 31dec2011 | 6 0.23 3.64 31jan2012 | 1 0.04 3.68 31mar2012 | 2 0.08 3.76 01apr2012 | 1 0.04 3.80 30apr2012 | 1 0.04 3.84 31may2012 | 1 0.04 3.87 27jun2012 | 1 0.04 3.91 29jun2012 | 1 0.04 3.95 30jun2012 | 2 0.08 4.03 31jul2012 | 2 0.08 4.10 31aug2012 | 1 0.04 4.14 29sep2012 | 1 0.04 4.18 30sep2012 | 3 0.12 4.30 01oct2012 | 2 0.08 4.37 10oct2012 | 1 0.04 4.41 01nov2012 | 1 0.04 4.45 22nov2012 | 1 0.04 4.49 30nov2012 | 1 0.04 4.53 31jan2013 | 2 0.08 4.60 28feb2013 | 2 0.08 4.68 31mar2013 | 2 0.08 4.76 15apr2013 | 2 0.08 4.83 30apr2013 | 1 0.04 4.87 01may2013 | 1 0.04 4.91 31may2013 | 1 0.04 4.95 01jun2013 | 1 0.04 4.99 30jun2013 | 5 0.19 5.18 02jul2013 | 1 0.04 5.22 31jul2013 | 4 0.15 5.37 31aug2013 | 1 0.04 5.41 30sep2013 | 7 0.27 5.68 09oct2013 | 1 0.04 5.72 31oct2013 | 4 0.15 5.87 30nov2013 | 2 0.08 5.95 31dec2013 | 9 0.35 6.29 25jan2014 | 1 0.04 6.33 31jan2014 | 3 0.12 6.44 28feb2014 | 2 0.08 6.52 18mar2014 | 2 0.08 6.60 31mar2014 | 5 0.19 6.79 30apr2014 | 3 0.12 6.90 30may2014 | 1 0.04 6.94 31may2014 | 5 0.19 7.13 30jun2014 | 8 0.31 7.44 01jul2014 | 1 0.04 7.48 14jul2014 | 1 0.04 7.52 31jul2014 | 1 0.04 7.56 05aug2014 | 2 0.08 7.63 31aug2014 | 1 0.04 7.67 30sep2014 | 12 0.46 8.13 01oct2014 | 2 0.08 8.21 30oct2014 | 2 0.08 8.29 31oct2014 | 6 0.23 8.52 01nov2014 | 1 0.04 8.55 30nov2014 | 4 0.15 8.71 15dec2014 | 1 0.04 8.75 31dec2014 | 17 0.65 9.40 31jan2015 | 7 0.27 9.67 10feb2015 | 1 0.04 9.70 28feb2015 | 1 0.04 9.74 30mar2015 | 3 0.12 9.86 31mar2015 | 10 0.38 10.24 30apr2015 | 8 0.31 10.55 30may2015 | 1 0.04 10.59 31may2015 | 7 0.27 10.86 20jun2015 | 1 0.04 10.89 30jun2015 | 24 0.92 11.81 01jul2015 | 2 0.08 11.89 30jul2015 | 2 0.08 11.97 31jul2015 | 17 0.65 12.62 14aug2015 | 1 0.04 12.66 15aug2015 | 1 0.04 12.70 20aug2015 | 1 0.04 12.73 31aug2015 | 11 0.42 13.16 30sep2015 | 73 2.80 15.96 30oct2015 | 3 0.12 16.07 31oct2015 | 15 0.58 16.65 10nov2015 | 1 0.04 16.69 30nov2015 | 139 5.33 22.02 01dec2015 | 1 0.04 22.06 30dec2015 | 2 0.08 22.13 31dec2015 | 53 2.03 24.17 15jan2016 | 1 0.04 24.20 28jan2016 | 1 0.04 24.24 31jan2016 | 26 1.00 25.24 28feb2016 | 5 0.19 25.43 29feb2016 | 13 0.50 25.93 20mar2016 | 1 0.04 25.97 30mar2016 | 3 0.12 26.08 31mar2016 | 74 2.84 28.92 01apr2016 | 1 0.04 28.96 30apr2016 | 8 0.31 29.27 31may2016 | 12 0.46 29.73 30jun2016 | 29 1.11 30.84 06jul2016 | 2 0.08 30.92 31jul2016 | 8 0.31 31.22 01aug2016 | 1 0.04 31.26 31aug2016 | 7 0.27 31.53 16sep2016 | 1 0.04 31.57 30sep2016 | 16 0.61 32.18 31oct2016 | 12 0.46 32.64 30nov2016 | 22 0.84 33.49 15dec2016 | 1 0.04 33.53 29dec2016 | 1 0.04 33.56 30dec2016 | 1 0.04 33.60 31dec2016 | 69 2.65 36.25 30jan2017 | 1 0.04 36.29 31jan2017 | 41 1.57 37.86 26feb2017 | 1 0.04 37.90 28feb2017 | 49 1.88 39.78 15mar2017 | 1 0.04 39.82 31mar2017 | 41 1.57 41.39 23apr2017 | 2 0.08 41.47 30apr2017 | 10 0.38 41.85 03may2017 | 1 0.04 41.89 23may2017 | 1 0.04 41.93 31may2017 | 27 1.04 42.96 14jun2017 | 1 0.04 43.00 30jun2017 | 66 2.53 45.53 25jul2017 | 1 0.04 45.57 31jul2017 | 16 0.61 46.18 17aug2017 | 1 0.04 46.22 30aug2017 | 1 0.04 46.26 31aug2017 | 13 0.50 46.76 30sep2017 | 32 1.23 47.99 02oct2017 | 1 0.04 48.02 31oct2017 | 17 0.65 48.68 15nov2017 | 1 0.04 48.71 23nov2017 | 1 0.04 48.75 30nov2017 | 18 0.69 49.44 29dec2017 | 3 0.12 49.56 30dec2017 | 2 0.08 49.64 31dec2017 | 45 1.73 51.36 06jan2018 | 1 0.04 51.40 15jan2018 | 1 0.04 51.44 31jan2018 | 36 1.38 52.82 21feb2018 | 1 0.04 52.86 28feb2018 | 9 0.35 53.20 30mar2018 | 1 0.04 53.24 31mar2018 | 23 0.88 54.12 01apr2018 | 1 0.04 54.16 13apr2018 | 1 0.04 54.20 30apr2018 | 5 0.19 54.39 31may2018 | 9 0.35 54.74 01jun2018 | 1 0.04 54.78 28jun2018 | 2 0.08 54.85 30jun2018 | 56 2.15 57.00 23jul2018 | 1 0.04 57.04 31jul2018 | 14 0.54 57.58 01aug2018 | 1 0.04 57.61 22aug2018 | 1 0.04 57.65 30aug2018 | 2 0.08 57.73 31aug2018 | 7 0.27 58.00 28sep2018 | 2 0.08 58.07 30sep2018 | 24 0.92 59.00 30oct2018 | 1 0.04 59.03 31oct2018 | 10 0.38 59.42 30nov2018 | 13 0.50 59.92 01dec2018 | 3 0.12 60.03 06dec2018 | 1 0.04 60.07 14dec2018 | 1 0.04 60.11 15dec2018 | 1 0.04 60.15 30dec2018 | 1 0.04 60.18 31dec2018 | 66 2.53 62.72 16jan2019 | 1 0.04 62.75 30jan2019 | 2 0.08 62.83 31jan2019 | 8 0.31 63.14 01feb2019 | 1 0.04 63.18 27feb2019 | 1 0.04 63.21 28feb2019 | 18 0.69 63.90 31mar2019 | 27 1.04 64.94 30apr2019 | 14 0.54 65.48 10may2019 | 1 0.04 65.52 30may2019 | 1 0.04 65.55 31may2019 | 16 0.61 66.17 14jun2019 | 1 0.04 66.21 30jun2019 | 29 1.11 67.32 31jul2019 | 16 0.61 67.93 31aug2019 | 38 1.46 69.39 01sep2019 | 1 0.04 69.43 30sep2019 | 38 1.46 70.89 31oct2019 | 6 0.23 71.12 29nov2019 | 1 0.04 71.15 30nov2019 | 16 0.61 71.77 15dec2019 | 4 0.15 71.92 30dec2019 | 1 0.04 71.96 31dec2019 | 43 1.65 73.61 15jan2020 | 1 0.04 73.65 31jan2020 | 8 0.31 73.95 28feb2020 | 4 0.15 74.11 29feb2020 | 2 0.08 74.18 31mar2020 | 30 1.15 75.34 30apr2020 | 12 0.46 75.80 31may2020 | 6 0.23 76.03 30jun2020 | 23 0.88 76.91 15jul2020 | 1 0.04 76.95 30jul2020 | 1 0.04 76.99 31jul2020 | 5 0.19 77.18 10aug2020 | 1 0.04 77.22 31aug2020 | 6 0.23 77.45 25sep2020 | 1 0.04 77.48 30sep2020 | 14 0.54 78.02 31oct2020 | 8 0.31 78.33 30nov2020 | 10 0.38 78.71 01dec2020 | 1 0.04 78.75 15dec2020 | 2 0.08 78.83 31dec2020 | 30 1.15 79.98 31jan2021 | 8 0.31 80.28 27feb2021 | 1 0.04 80.32 28feb2021 | 9 0.35 80.67 31mar2021 | 21 0.81 81.47 17apr2021 | 1 0.04 81.51 30apr2021 | 8 0.31 81.82 31may2021 | 10 0.38 82.20 20jun2021 | 2 0.08 82.28 30jun2021 | 8 0.31 82.59 30jul2021 | 1 0.04 82.62 31jul2021 | 7 0.27 82.89 31aug2021 | 4 0.15 83.05 30sep2021 | 10 0.38 83.43 30oct2021 | 1 0.04 83.47 31oct2021 | 1 0.04 83.51 12nov2021 | 2 0.08 83.58 30nov2021 | 4 0.15 83.74 15dec2021 | 1 0.04 83.77 31dec2021 | 30 1.15 84.93 30jan2022 | 2 0.08 85.00 31jan2022 | 2 0.08 85.08 25feb2022 | 1 0.04 85.12 28feb2022 | 1 0.04 85.16 01mar2022 | 1 0.04 85.19 31mar2022 | 10 0.38 85.58 30apr2022 | 4 0.15 85.73 31may2022 | 8 0.31 86.04 30jun2022 | 24 0.92 86.96 31jul2022 | 4 0.15 87.11 31aug2022 | 10 0.38 87.50 01sep2022 | 2 0.08 87.57 30sep2022 | 11 0.42 87.99 31oct2022 | 3 0.12 88.11 30nov2022 | 2 0.08 88.19 01dec2022 | 1 0.04 88.22 30dec2022 | 2 0.08 88.30 31dec2022 | 11 0.42 88.72 31jan2023 | 10 0.38 89.11 28feb2023 | 4 0.15 89.26 31mar2023 | 8 0.31 89.57 20apr2023 | 1 0.04 89.60 30apr2023 | 4 0.15 89.76 31may2023 | 3 0.12 89.87 30jun2023 | 10 0.38 90.26 31jul2023 | 3 0.12 90.37 31aug2023 | 9 0.35 90.72 30sep2023 | 4 0.15 90.87 30oct2023 | 1 0.04 90.91 31oct2023 | 1 0.04 90.95 30nov2023 | 2 0.08 91.02 31dec2023 | 11 0.42 91.45 31jan2024 | 1 0.04 91.48 31mar2024 | 4 0.15 91.64 30apr2024 | 2 0.08 91.71 31may2024 | 3 0.12 91.83 01jun2024 | 1 0.04 91.87 30jun2024 | 4 0.15 92.02 31jul2024 | 7 0.27 92.29 31aug2024 | 1 0.04 92.33 30sep2024 | 3 0.12 92.44 31oct2024 | 1 0.04 92.48 30nov2024 | 3 0.12 92.60 31dec2024 | 5 0.19 92.79 31jan2025 | 1 0.04 92.83 28feb2025 | 1 0.04 92.87 31mar2025 | 3 0.12 92.98 25may2025 | 1 0.04 93.02 29may2025 | 1 0.04 93.06 31may2025 | 1 0.04 93.10 25jun2025 | 1 0.04 93.13 30jun2025 | 3 0.12 93.25 07jul2025 | 1 0.04 93.29 31jul2025 | 3 0.12 93.40 31aug2025 | 3 0.12 93.52 31oct2025 | 3 0.12 93.63 31dec2025 | 3 0.12 93.75 31jan2026 | 3 0.12 93.86 28feb2026 | 2 0.08 93.94 31mar2026 | 1 0.04 93.98 31may2026 | 1 0.04 94.02 15jun2026 | 1 0.04 94.05 30jun2026 | 3 0.12 94.17 31jul2026 | 1 0.04 94.21 30aug2026 | 1 0.04 94.25 31aug2026 | 1 0.04 94.28 15sep2026 | 1 0.04 94.32 30sep2026 | 1 0.04 94.36 31dec2026 | 3 0.12 94.48 31jan2027 | 3 0.12 94.59 30apr2027 | 2 0.08 94.67 29may2027 | 1 0.04 94.71 31may2027 | 1 0.04 94.74 15jun2027 | 1 0.04 94.78 30jun2027 | 1 0.04 94.82 31jul2027 | 1 0.04 94.86 18may2028 | 1 0.04 94.90 30jun2028 | 2 0.08 94.98 31aug2028 | 1 0.04 95.01 01sep2028 | 1 0.04 95.05 30sep2028 | 1 0.04 95.09 28feb2029 | 2 0.08 95.17 31mar2029 | 2 0.08 95.24 30jun2029 | 1 0.04 95.28 31dec2029 | 1 0.04 95.32 31mar2030 | 1 0.04 95.36 30apr2030 | 1 0.04 95.40 31may2030 | 5 0.19 95.59 30jun2030 | 1 0.04 95.63 31aug2030 | 1 0.04 95.67 30sep2030 | 1 0.04 95.70 31dec2030 | 3 0.12 95.82 30apr2031 | 1 0.04 95.86 30jun2031 | 2 0.08 95.93 30sep2031 | 1 0.04 95.97 31mar2032 | 1 0.04 96.01 31dec2045 | 2 0.08 96.09 . | 102 3.91 100.00 ------------+----------------------------------- Total | 2,607 100.00 Frequencies for current_proj_compl_date variable in pmc_commitments dataset : Current | Project | Completion | Date | Freq. Percent Cum. ------------+----------------------------------- . | 2,607 100.00 100.00 ------------+----------------------------------- Total | 2,607 100.00 Frequencies for nda_number variable in pmc_commitments dataset : New Drug | Application | (NDA) | Number | Freq. Percent Cum. ------------+----------------------------------- 4589 | 1 0.04 0.04 6134 | 16 0.61 0.65 6170 | 1 0.04 0.69 9165 | 1 0.04 0.73 9321 | 1 0.04 0.77 11287 | 1 0.04 0.81 11366 | 2 0.08 0.88 13295 | 1 0.04 0.92 13684 | 1 0.04 0.96 14738 | 1 0.04 1.00 16080 | 1 0.04 1.04 16269 | 1 0.04 1.07 16366 | 1 0.04 1.11 16367 | 1 0.04 1.15 16673 | 1 0.04 1.19 16677 | 1 0.04 1.23 16678 | 1 0.04 1.27 16679 | 1 0.04 1.30 16682 | 1 0.04 1.34 16683 | 1 0.04 1.38 16687 | 1 0.04 1.42 16689 | 1 0.04 1.46 16692 | 1 0.04 1.50 16693 | 1 0.04 1.53 16694 | 1 0.04 1.57 16695 | 1 0.04 1.61 16696 | 1 0.04 1.65 16697 | 1 0.04 1.69 16730 | 1 0.04 1.73 16734 | 1 0.04 1.76 16741 | 1 0.04 1.80 16772 | 1 0.04 1.84 16784 | 1 0.04 1.88 16822 | 1 0.04 1.92 16983 | 1 0.04 1.96 17378 | 1 0.04 1.99 17385 | 1 0.04 2.03 17390 | 1 0.04 2.07 17438 | 1 0.04 2.11 17451 | 1 0.04 2.15 17464 | 1 0.04 2.19 17484 | 1 0.04 2.22 17493 | 1 0.04 2.26 17510 | 1 0.04 2.30 17514 | 1 0.04 2.34 17521 | 1 0.04 2.38 17533 | 1 0.04 2.42 17585 | 1 0.04 2.45 17586 | 1 0.04 2.49 17606 | 1 0.04 2.53 17607 | 1 0.04 2.57 17608 | 1 0.04 2.61 17609 | 1 0.04 2.65 17610 | 1 0.04 2.69 17634 | 1 0.04 2.72 17641 | 1 0.04 2.76 17643 | 5 0.19 2.95 17648 | 1 0.04 2.99 17656 | 1 0.04 3.03 17673 | 1 0.04 3.07 17766 | 1 0.04 3.11 17789 | 1 0.04 3.15 17799 | 1 0.04 3.18 17957 | 1 0.04 3.22 17995 | 1 0.04 3.26 18008 | 1 0.04 3.30 18016 | 1 0.04 3.34 18037 | 1 0.04 3.38 18080 | 1 0.04 3.41 18090 | 1 0.04 3.45 18161 | 1 0.04 3.49 18233 | 1 0.04 3.53 18251 | 1 0.04 3.57 18254 | 1 0.04 3.61 18258 | 1 0.04 3.64 18268 | 1 0.04 3.68 18314 | 1 0.04 3.72 18316 | 1 0.04 3.76 18362 | 1 0.04 3.80 18365 | 1 0.04 3.84 18371 | 1 0.04 3.87 18376 | 1 0.04 3.91 18404 | 1 0.04 3.95 18429 | 1 0.04 3.99 18449 | 5 0.19 4.18 18523 | 1 0.04 4.22 18561 | 1 0.04 4.26 18562 | 1 0.04 4.30 18563 | 1 0.04 4.33 18564 | 1 0.04 4.37 18582 | 1 0.04 4.41 18629 | 1 0.04 4.45 18632 | 1 0.04 4.49 18676 | 1 0.04 4.53 18684 | 1 0.04 4.56 18701 | 1 0.04 4.60 18722 | 1 0.04 4.64 18725 | 1 0.04 4.68 18735 | 1 0.04 4.72 18744 | 1 0.04 4.76 18800 | 1 0.04 4.79 18801 | 1 0.04 4.83 18802 | 1 0.04 4.87 18803 | 1 0.04 4.91 18840 | 1 0.04 4.95 18876 | 1 0.04 4.99 18892 | 1 0.04 5.02 18893 | 1 0.04 5.06 18895 | 1 0.04 5.10 18896 | 1 0.04 5.14 18897 | 1 0.04 5.18 18905 | 1 0.04 5.22 18921 | 1 0.04 5.26 18931 | 1 0.04 5.29 18947 | 1 0.04 5.33 18956 | 1 0.04 5.37 18959 | 1 0.04 5.41 18960 | 1 0.04 5.45 18961 | 1 0.04 5.49 18962 | 1 0.04 5.52 18969 | 1 0.04 5.56 18970 | 5 0.19 5.75 18991 | 5 0.19 5.95 18997 | 1 0.04 5.98 19018 | 1 0.04 6.02 19022 | 1 0.04 6.06 19034 | 1 0.04 6.10 19047 | 1 0.04 6.14 19217 | 1 0.04 6.18 19222 | 1 0.04 6.21 19292 | 1 0.04 6.25 19308 | 1 0.04 6.29 19345 | 1 0.04 6.33 19367 | 1 0.04 6.37 19374 | 1 0.04 6.41 19398 | 1 0.04 6.44 19437 | 1 0.04 6.48 19438 | 1 0.04 6.52 19445 | 1 0.04 6.56 19465 | 1 0.04 6.60 19466 | 1 0.04 6.64 19479 | 1 0.04 6.67 19480 | 1 0.04 6.71 19492 | 1 0.04 6.75 19513 | 1 0.04 6.79 19514 | 1 0.04 6.83 19515 | 1 0.04 6.87 19516 | 16 0.61 7.48 19531 | 1 0.04 7.52 19537 | 1 0.04 7.56 19599 | 2 0.08 7.63 19603 | 1 0.04 7.67 19626 | 1 0.04 7.71 19627 | 1 0.04 7.75 19630 | 1 0.04 7.79 19631 | 1 0.04 7.83 19632 | 1 0.04 7.86 19633 | 1 0.04 7.90 19634 | 1 0.04 7.94 19635 | 1 0.04 7.98 19681 | 1 0.04 8.02 19682 | 1 0.04 8.06 19683 | 1 0.04 8.09 19685 | 1 0.04 8.13 19686 | 1 0.04 8.17 19691 | 1 0.04 8.21 19696 | 1 0.04 8.25 19699 | 1 0.04 8.29 19708 | 1 0.04 8.32 19710 | 1 0.04 8.36 19711 | 1 0.04 8.40 19718 | 1 0.04 8.44 19759 | 1 0.04 8.48 19813 | 16 0.61 9.09 19815 | 1 0.04 9.13 19832 | 1 0.04 9.17 19839 | 1 0.04 9.21 19843 | 1 0.04 9.24 19844 | 1 0.04 9.28 19847 | 1 0.04 9.32 19857 | 1 0.04 9.36 19864 | 1 0.04 9.40 19867 | 1 0.04 9.44 19869 | 1 0.04 9.47 19870 | 1 0.04 9.51 19873 | 1 0.04 9.55 19893 | 1 0.04 9.59 19894 | 1 0.04 9.63 19904 | 1 0.04 9.67 19942 | 5 0.19 9.86 19999 | 3 0.12 9.97 20000 | 1 0.04 10.01 20002 | 1 0.04 10.05 20004 | 1 0.04 10.09 20006 | 1 0.04 10.13 20015 | 1 0.04 10.16 20041 | 1 0.04 10.20 20047 | 1 0.04 10.24 20084 | 8 0.31 10.55 20120 | 1 0.04 10.59 20161 | 1 0.04 10.63 20173 | 1 0.04 10.66 20177 | 1 0.04 10.70 20178 | 1 0.04 10.74 20179 | 1 0.04 10.78 20181 | 1 0.04 10.82 20220 | 1 0.04 10.86 20248 | 5 0.19 11.05 20281 | 2 0.08 11.12 20287 | 1 0.04 11.16 20292 | 1 0.04 11.20 20316 | 5 0.19 11.39 20327 | 1 0.04 11.43 20351 | 1 0.04 11.47 20406 | 1 0.04 11.51 20410 | 1 0.04 11.55 20414 | 1 0.04 11.58 20415 | 1 0.04 11.62 20416 | 1 0.04 11.66 20427 | 1 0.04 11.70 20453 | 1 0.04 11.74 20489 | 1 0.04 11.78 20505 | 1 0.04 11.81 20511 | 1 0.04 11.85 20533 | 1 0.04 11.89 20564 | 1 0.04 11.93 20570 | 1 0.04 11.97 20596 | 1 0.04 12.01 20608 | 1 0.04 12.04 20610 | 3 0.12 12.16 20616 | 16 0.61 12.77 20622 | 2 0.08 12.85 20634 | 3 0.12 12.97 20635 | 3 0.12 13.08 20652 | 1 0.04 13.12 20678 | 1 0.04 13.16 20699 | 1 0.04 13.20 20711 | 1 0.04 13.23 20725 | 2 0.08 13.31 20732 | 3 0.12 13.43 20733 | 3 0.12 13.54 20734 | 1 0.04 13.58 20753 | 1 0.04 13.62 20780 | 1 0.04 13.66 20786 | 4 0.15 13.81 20808 | 1 0.04 13.85 20825 | 1 0.04 13.89 20831 | 1 0.04 13.92 20844 | 1 0.04 13.96 20849 | 1 0.04 14.00 20862 | 1 0.04 14.04 20866 | 2 0.08 14.12 20899 | 1 0.04 14.15 20923 | 1 0.04 14.19 20947 | 3 0.12 14.31 20972 | 1 0.04 14.35 20987 | 1 0.04 14.38 20988 | 2 0.08 14.46 20990 | 1 0.04 14.50 21015 | 1 0.04 14.54 21038 | 1 0.04 14.58 21044 | 6 0.23 14.81 21073 | 1 0.04 14.84 21077 | 2 0.08 14.92 21085 | 2 0.08 15.00 21087 | 1 0.04 15.04 21097 | 1 0.04 15.07 21098 | 1 0.04 15.11 21117 | 1 0.04 15.15 21123 | 2 0.08 15.23 21135 | 1 0.04 15.27 21200 | 1 0.04 15.30 21208 | 1 0.04 15.34 21217 | 17 0.65 16.00 21225 | 1 0.04 16.03 21227 | 1 0.04 16.07 21234 | 1 0.04 16.11 21243 | 1 0.04 16.15 21247 | 2 0.08 16.23 21252 | 1 0.04 16.26 21260 | 6 0.23 16.49 21264 | 2 0.08 16.57 21266 | 1 0.04 16.61 21267 | 1 0.04 16.65 21277 | 2 0.08 16.72 21302 | 1 0.04 16.76 21304 | 1 0.04 16.80 21306 | 17 0.65 17.45 21318 | 2 0.08 17.53 21322 | 1 0.04 17.57 21323 | 2 0.08 17.64 21324 | 2 0.08 17.72 21338 | 1 0.04 17.76 21345 | 4 0.15 17.91 21356 | 4 0.15 18.07 21360 | 1 0.04 18.11 21361 | 9 0.35 18.45 21365 | 2 0.08 18.53 21415 | 2 0.08 18.60 21425 | 1 0.04 18.64 21428 | 1 0.04 18.68 21436 | 1 0.04 18.72 21446 | 4 0.15 18.87 21447 | 1 0.04 18.91 21450 | 2 0.08 18.99 21451 | 1 0.04 19.03 21454 | 1 0.04 19.06 21463 | 1 0.04 19.10 21472 | 1 0.04 19.14 21494 | 1 0.04 19.18 21511 | 1 0.04 19.22 21513 | 1 0.04 19.26 21518 | 1 0.04 19.29 21529 | 1 0.04 19.33 21543 | 1 0.04 19.37 21549 | 1 0.04 19.41 21551 | 4 0.15 19.56 21572 | 2 0.08 19.64 21588 | 3 0.12 19.75 21606 | 3 0.12 19.87 21610 | 17 0.65 20.52 21611 | 2 0.08 20.60 21626 | 2 0.08 20.68 21632 | 1 0.04 20.71 21636 | 3 0.12 20.83 21641 | 1 0.04 20.87 21644 | 3 0.12 20.98 21647 | 1 0.04 21.02 21673 | 1 0.04 21.06 21692 | 4 0.15 21.21 21693 | 3 0.12 21.33 21704 | 4 0.15 21.48 21710 | 2 0.08 21.56 21713 | 1 0.04 21.60 21721 | 3 0.12 21.71 21724 | 2 0.08 21.79 21729 | 1 0.04 21.83 21737 | 1 0.04 21.86 21743 | 2 0.08 21.94 21745 | 3 0.12 22.06 21749 | 3 0.12 22.17 21751 | 3 0.12 22.29 21752 | 6 0.23 22.52 21756 | 2 0.08 22.59 21768 | 2 0.08 22.67 21773 | 2 0.08 22.75 21775 | 4 0.15 22.90 21797 | 2 0.08 22.98 21798 | 2 0.08 23.05 21821 | 3 0.12 23.17 21825 | 2 0.08 23.25 21829 | 1 0.04 23.28 21842 | 1 0.04 23.32 21845 | 2 0.08 23.40 21846 | 1 0.04 23.44 21856 | 1 0.04 23.48 21864 | 2 0.08 23.55 21866 | 1 0.04 23.59 21870 | 1 0.04 23.63 21875 | 1 0.04 23.67 21876 | 1 0.04 23.71 21877 | 1 0.04 23.74 21879 | 1 0.04 23.78 21880 | 1 0.04 23.82 21882 | 15 0.58 24.40 21883 | 7 0.27 24.66 21892 | 1 0.04 24.70 21894 | 2 0.08 24.78 21897 | 1 0.04 24.82 21908 | 7 0.27 25.09 21919 | 2 0.08 25.16 21923 | 2 0.08 25.24 21925 | 1 0.04 25.28 21926 | 4 0.15 25.43 21928 | 4 0.15 25.58 21929 | 2 0.08 25.66 21937 | 1 0.04 25.70 21938 | 4 0.15 25.85 21945 | 2 0.08 25.93 21957 | 1 0.04 25.97 21964 | 1 0.04 26.01 21968 | 1 0.04 26.05 21977 | 2 0.08 26.12 21983 | 1 0.04 26.16 21985 | 1 0.04 26.20 21992 | 2 0.08 26.28 21995 | 1 0.04 26.31 22000 | 2 0.08 26.39 22003 | 1 0.04 26.43 22007 | 1 0.04 26.47 22008 | 2 0.08 26.54 22011 | 2 0.08 26.62 22020 | 4 0.15 26.77 22023 | 4 0.15 26.93 22024 | 1 0.04 26.97 22030 | 1 0.04 27.00 22041 | 5 0.19 27.20 22044 | 1 0.04 27.23 22056 | 1 0.04 27.27 22059 | 1 0.04 27.31 22081 | 1 0.04 27.35 22087 | 1 0.04 27.39 22106 | 2 0.08 27.46 22108 | 1 0.04 27.50 22110 | 2 0.08 27.58 22113 | 2 0.08 27.66 22117 | 2 0.08 27.73 22122 | 2 0.08 27.81 22127 | 1 0.04 27.85 22128 | 2 0.08 27.92 22145 | 2 0.08 28.00 22148 | 2 0.08 28.08 22154 | 2 0.08 28.15 22156 | 1 0.04 28.19 22159 | 2 0.08 28.27 22165 | 6 0.23 28.50 22175 | 3 0.12 28.62 22180 | 2 0.08 28.69 22181 | 5 0.19 28.88 22185 | 1 0.04 28.92 22187 | 1 0.04 28.96 22192 | 2 0.08 29.04 22195 | 2 0.08 29.11 22198 | 2 0.08 29.19 22200 | 6 0.23 29.42 22202 | 3 0.12 29.54 22204 | 1 0.04 29.57 22205 | 3 0.12 29.69 22207 | 2 0.08 29.77 22210 | 2 0.08 29.84 22219 | 1 0.04 29.88 22222 | 2 0.08 29.96 22225 | 4 0.15 30.11 22233 | 1 0.04 30.15 22244 | 6 0.23 30.38 22249 | 1 0.04 30.42 22252 | 1 0.04 30.46 22253 | 11 0.42 30.88 22254 | 11 0.42 31.30 22255 | 11 0.42 31.72 22256 | 1 0.04 31.76 22257 | 1 0.04 31.80 22268 | 2 0.08 31.88 22271 | 4 0.15 32.03 22272 | 22 0.84 32.87 22275 | 2 0.08 32.95 22279 | 2 0.08 33.03 22287 | 9 0.35 33.37 22301 | 1 0.04 33.41 22304 | 1 0.04 33.45 22309 | 1 0.04 33.49 22318 | 1 0.04 33.53 22321 | 18 0.69 34.22 22328 | 1 0.04 34.25 22331 | 2 0.08 34.33 22334 | 3 0.12 34.45 22341 | 4 0.15 34.60 22345 | 7 0.27 34.87 22348 | 1 0.04 34.91 22350 | 2 0.08 34.98 22352 | 2 0.08 35.06 22362 | 1 0.04 35.10 22370 | 3 0.12 35.21 22372 | 4 0.15 35.37 22382 | 3 0.12 35.48 22393 | 3 0.12 35.60 22396 | 3 0.12 35.71 22399 | 6 0.23 35.94 22402 | 2 0.08 36.02 22404 | 1 0.04 36.06 22405 | 2 0.08 36.13 22406 | 19 0.73 36.86 22407 | 3 0.12 36.98 22410 | 1 0.04 37.02 22411 | 2 0.08 37.09 22416 | 13 0.50 37.59 22426 | 1 0.04 37.63 22439 | 1 0.04 37.67 22442 | 1 0.04 37.71 22445 | 7 0.27 37.97 22450 | 2 0.08 38.05 22454 | 1 0.04 38.09 22458 | 8 0.31 38.40 22468 | 7 0.27 38.67 22472 | 4 0.15 38.82 22474 | 2 0.08 38.90 22488 | 4 0.15 39.05 22496 | 4 0.15 39.20 22499 | 2 0.08 39.28 22504 | 1 0.04 39.32 22505 | 2 0.08 39.39 22511 | 1 0.04 39.43 22512 | 3 0.12 39.55 22518 | 3 0.12 39.66 22522 | 1 0.04 39.70 22523 | 2 0.08 39.78 22524 | 4 0.15 39.93 22526 | 7 0.27 40.20 22527 | 4 0.15 40.35 22529 | 4 0.15 40.51 22549 | 3 0.12 40.62 22554 | 5 0.19 40.81 22555 | 2 0.08 40.89 22562 | 3 0.12 41.00 22563 | 2 0.08 41.08 22565 | 2 0.08 41.16 22567 | 2 0.08 41.24 22571 | 2 0.08 41.31 22575 | 4 0.15 41.47 22577 | 1 0.04 41.50 22580 | 8 0.31 41.81 22581 | 1 0.04 41.85 50670 | 1 0.04 41.89 50710 | 1 0.04 41.93 50711 | 1 0.04 41.96 50730 | 1 0.04 42.00 50733 | 1 0.04 42.04 50777 | 1 0.04 42.08 50779 | 1 0.04 42.12 50784 | 1 0.04 42.16 50797 | 1 0.04 42.19 50809 | 1 0.04 42.23 50813 | 1 0.04 42.27 50814 | 1 0.04 42.31 90067 | 1 0.04 42.35 102475 | 2 0.08 42.42 103000 | 18 0.69 43.11 103123 | 1 0.04 43.15 103174 | 1 0.04 43.19 103234 | 1 0.04 43.23 103353 | 1 0.04 43.27 103362 | 2 0.08 43.34 103411 | 3 0.12 43.46 103694 | 1 0.04 43.50 103705 | 3 0.12 43.61 103738 | 1 0.04 43.65 103772 | 8 0.31 43.96 103792 | 6 0.23 44.19 103795 | 2 0.08 44.27 103821 | 1 0.04 44.30 103837 | 1 0.04 44.34 103846 | 2 0.08 44.42 103914 | 2 0.08 44.50 103948 | 4 0.15 44.65 103949 | 1 0.04 44.69 103951 | 2 0.08 44.76 103964 | 1 0.04 44.80 103976 | 1 0.04 44.84 103979 | 2 0.08 44.92 125020 | 2 0.08 44.99 125031 | 1 0.04 45.03 125039 | 2 0.08 45.11 125057 | 12 0.46 45.57 125058 | 4 0.15 45.72 125062 | 1 0.04 45.76 125063 | 1 0.04 45.80 125078 | 2 0.08 45.88 125084 | 2 0.08 45.95 125085 | 2 0.08 46.03 125089 | 2 0.08 46.11 125103 | 5 0.19 46.30 125104 | 6 0.23 46.53 125109 | 1 0.04 46.57 125117 | 3 0.12 46.68 125118 | 4 0.15 46.84 125123 | 1 0.04 46.87 125126 | 5 0.19 47.07 125127 | 2 0.08 47.14 125141 | 3 0.12 47.26 125145 | 1 0.04 47.30 125147 | 2 0.08 47.37 125151 | 4 0.15 47.53 125158 | 3 0.12 47.64 125160 | 5 0.19 47.83 125163 | 3 0.12 47.95 125164 | 3 0.12 48.06 125166 | 1 0.04 48.10 125197 | 1 0.04 48.14 125201 | 1 0.04 48.18 125234 | 1 0.04 48.22 125249 | 1 0.04 48.25 125254 | 4 0.15 48.41 125259 | 3 0.12 48.52 125261 | 6 0.23 48.75 125264 | 1 0.04 48.79 125265 | 1 0.04 48.83 125267 | 1 0.04 48.87 125268 | 2 0.08 48.95 125274 | 7 0.27 49.21 125276 | 4 0.15 49.37 125277 | 2 0.08 49.44 125280 | 4 0.15 49.60 125284 | 1 0.04 49.64 125285 | 8 0.31 49.94 125287 | 3 0.12 50.06 125288 | 3 0.12 50.17 125289 | 14 0.54 50.71 125291 | 4 0.15 50.86 125293 | 2 0.08 50.94 125294 | 5 0.19 51.13 125296 | 1 0.04 51.17 125297 | 4 0.15 51.32 125300 | 5 0.19 51.52 125317 | 4 0.15 51.67 125319 | 4 0.15 51.82 125320 | 7 0.27 52.09 125324 | 4 0.15 52.24 125325 | 4 0.15 52.40 125338 | 1 0.04 52.44 125347 | 1 0.04 52.47 125348 | 1 0.04 52.51 125349 | 2 0.08 52.59 125360 | 8 0.31 52.90 125363 | 1 0.04 52.93 125370 | 9 0.35 53.28 125377 | 7 0.27 53.55 125387 | 1 0.04 53.59 125388 | 2 0.08 53.66 125389 | 2 0.08 53.74 125390 | 6 0.23 53.97 125392 | 3 0.12 54.09 125398 | 1 0.04 54.12 125400 | 1 0.04 54.16 125402 | 3 0.12 54.28 125408 | 10 0.38 54.66 125409 | 5 0.19 54.85 125416 | 4 0.15 55.01 125419 | 5 0.19 55.20 125421 | 2 0.08 55.27 125426 | 1 0.04 55.31 125427 | 4 0.15 55.47 125431 | 4 0.15 55.62 125433 | 1 0.04 55.66 125444 | 2 0.08 55.73 125446 | 1 0.04 55.77 125460 | 3 0.12 55.89 125462 | 3 0.12 56.00 125466 | 2 0.08 56.08 125469 | 5 0.19 56.27 125471 | 2 0.08 56.35 125472 | 1 0.04 56.39 125473 | 2 0.08 56.46 125476 | 10 0.38 56.85 125477 | 1 0.04 56.89 125478 | 4 0.15 57.04 125486 | 2 0.08 57.12 125487 | 3 0.12 57.23 125495 | 1 0.04 57.27 125496 | 1 0.04 57.31 125499 | 2 0.08 57.38 125504 | 6 0.23 57.61 125506 | 1 0.04 57.65 125508 | 5 0.19 57.84 125509 | 1 0.04 57.88 125510 | 5 0.19 58.07 125511 | 4 0.15 58.23 125512 | 1 0.04 58.27 125513 | 3 0.12 58.38 125514 | 8 0.31 58.69 125516 | 5 0.19 58.88 125518 | 2 0.08 58.96 125521 | 5 0.19 59.15 125522 | 4 0.15 59.30 125523 | 1 0.04 59.34 125526 | 2 0.08 59.42 125527 | 2 0.08 59.49 125546 | 6 0.23 59.72 125549 | 10 0.38 60.11 125553 | 1 0.04 60.15 125554 | 9 0.35 60.49 125555 | 4 0.15 60.64 125557 | 1 0.04 60.68 125559 | 5 0.19 60.87 125561 | 1 0.04 60.91 125562 | 2 0.08 60.99 125566 | 7 0.27 61.26 125574 | 2 0.08 61.33 125597 | 2 0.08 61.41 200063 | 8 0.31 61.72 200327 | 3 0.12 61.83 200533 | 17 0.65 62.49 200534 | 2 0.08 62.56 200535 | 2 0.08 62.64 200603 | 9 0.35 62.98 200656 | 1 0.04 63.02 200677 | 3 0.12 63.14 200678 | 1 0.04 63.18 200796 | 2 0.08 63.25 201023 | 2 0.08 63.33 201194 | 2 0.08 63.41 201280 | 3 0.12 63.52 201292 | 1 0.04 63.56 201635 | 4 0.15 63.71 201655 | 16 0.61 64.33 201688 | 5 0.19 64.52 201699 | 3 0.12 64.63 201803 | 1 0.04 64.67 201820 | 1 0.04 64.71 202022 | 1 0.04 64.75 202067 | 2 0.08 64.83 202080 | 1 0.04 64.86 202088 | 1 0.04 64.90 202107 | 2 0.08 64.98 202123 | 2 0.08 65.06 202155 | 2 0.08 65.13 202192 | 3 0.12 65.25 202207 | 1 0.04 65.29 202211 | 1 0.04 65.32 202245 | 2 0.08 65.40 202270 | 1 0.04 65.44 202276 | 1 0.04 65.48 202278 | 3 0.12 65.59 202292 | 3 0.12 65.71 202293 | 7 0.27 65.98 202317 | 1 0.04 66.01 202342 | 4 0.15 66.17 202429 | 7 0.27 66.44 202450 | 1 0.04 66.47 202497 | 3 0.12 66.59 202535 | 4 0.15 66.74 202570 | 9 0.35 67.09 202611 | 4 0.15 67.24 202714 | 5 0.19 67.43 202763 | 1 0.04 67.47 202799 | 6 0.23 67.70 202806 | 7 0.27 67.97 202810 | 4 0.15 68.12 202811 | 7 0.27 68.39 202834 | 7 0.27 68.66 202872 | 1 0.04 68.70 202880 | 25 0.96 69.66 202992 | 2 0.08 69.74 203045 | 2 0.08 69.81 203085 | 2 0.08 69.89 203093 | 1 0.04 69.93 203094 | 8 0.31 70.23 203098 | 1 0.04 70.27 203100 | 5 0.19 70.46 203188 | 3 0.12 70.58 203202 | 1 0.04 70.62 203214 | 3 0.12 70.73 203284 | 3 0.12 70.85 203312 | 2 0.08 70.92 203313 | 3 0.12 71.04 203314 | 4 0.15 71.19 203324 | 1 0.04 71.23 203341 | 1 0.04 71.27 203388 | 3 0.12 71.38 203389 | 1 0.04 71.42 203414 | 2 0.08 71.50 203415 | 1 0.04 71.54 203441 | 1 0.04 71.58 203469 | 11 0.42 72.00 203565 | 2 0.08 72.08 203567 | 1 0.04 72.11 203568 | 2 0.08 72.19 203585 | 3 0.12 72.31 203595 | 7 0.27 72.57 203629 | 1 0.04 72.61 203634 | 1 0.04 72.65 203684 | 1 0.04 72.69 203756 | 4 0.15 72.84 203791 | 2 0.08 72.92 203794 | 1 0.04 72.96 203826 | 5 0.19 73.15 203858 | 2 0.08 73.23 203971 | 4 0.15 73.38 204026 | 6 0.23 73.61 204031 | 3 0.12 73.72 204042 | 5 0.19 73.92 204063 | 3 0.12 74.03 204096 | 2 0.08 74.11 204114 | 3 0.12 74.22 204141 | 1 0.04 74.26 204150 | 1 0.04 74.30 204153 | 5 0.19 74.49 204168 | 3 0.12 74.61 204242 | 1 0.04 74.65 204275 | 3 0.12 74.76 204300 | 5 0.19 74.95 204307 | 1 0.04 74.99 204326 | 3 0.12 75.11 204353 | 5 0.19 75.30 204369 | 1 0.04 75.34 204370 | 20 0.77 76.10 204384 | 3 0.12 76.22 204399 | 1 0.04 76.26 204410 | 2 0.08 76.33 204412 | 1 0.04 76.37 204427 | 1 0.04 76.41 204442 | 4 0.15 76.56 204447 | 5 0.19 76.75 204508 | 6 0.23 76.99 204553 | 3 0.12 77.10 204592 | 3 0.12 77.22 204629 | 5 0.19 77.41 204630 | 4 0.15 77.56 204671 | 9 0.35 77.91 204683 | 1 0.04 77.94 204684 | 4 0.15 78.10 204760 | 2 0.08 78.17 204768 | 3 0.12 78.29 204781 | 1 0.04 78.33 204790 | 7 0.27 78.60 205003 | 1 0.04 78.63 205053 | 2 0.08 78.71 205103 | 2 0.08 78.79 205109 | 1 0.04 78.83 205122 | 3 0.12 78.94 205123 | 5 0.19 79.13 205175 | 1 0.04 79.17 205208 | 1 0.04 79.21 205223 | 1 0.04 79.25 205266 | 5 0.19 79.44 205353 | 2 0.08 79.52 205388 | 1 0.04 79.56 205395 | 3 0.12 79.67 205422 | 10 0.38 80.05 205435 | 6 0.23 80.28 205436 | 6 0.23 80.51 205437 | 1 0.04 80.55 205474 | 2 0.08 80.63 205488 | 1 0.04 80.67 205494 | 2 0.08 80.74 205525 | 5 0.19 80.94 205551 | 3 0.12 81.05 205552 | 7 0.27 81.32 205583 | 1 0.04 81.36 205596 | 2 0.08 81.43 205613 | 1 0.04 81.47 205625 | 4 0.15 81.63 205636 | 3 0.12 81.74 205637 | 1 0.04 81.78 205641 | 2 0.08 81.86 205649 | 1 0.04 81.89 205718 | 4 0.15 82.05 205739 | 2 0.08 82.13 205750 | 1 0.04 82.16 205755 | 6 0.23 82.39 205777 | 20 0.77 83.16 205786 | 1 0.04 83.20 205831 | 3 0.12 83.31 205832 | 1 0.04 83.35 205834 | 14 0.54 83.89 205836 | 4 0.15 84.04 205837 | 4 0.15 84.20 205838 | 4 0.15 84.35 205858 | 9 0.35 84.70 205874 | 1 0.04 84.73 206038 | 1 0.04 84.77 206073 | 1 0.04 84.81 206088 | 2 0.08 84.89 206099 | 2 0.08 84.96 206111 | 5 0.19 85.16 206162 | 5 0.19 85.35 206192 | 3 0.12 85.46 206229 | 1 0.04 85.50 206256 | 8 0.31 85.81 206316 | 2 0.08 85.88 206317 | 2 0.08 85.96 206321 | 7 0.27 86.23 206323 | 2 0.08 86.31 206333 | 1 0.04 86.34 206334 | 7 0.27 86.61 206353 | 4 0.15 86.77 206426 | 7 0.27 87.03 206488 | 5 0.19 87.23 206494 | 5 0.19 87.42 206500 | 6 0.23 87.65 206544 | 15 0.58 88.22 206545 | 9 0.35 88.57 206619 | 15 0.58 89.14 206627 | 22 0.84 89.99 206628 | 1 0.04 90.03 206829 | 3 0.12 90.14 206843 | 6 0.23 90.37 206910 | 9 0.35 90.72 206940 | 4 0.15 90.87 206947 | 2 0.08 90.95 207070 | 2 0.08 91.02 207071 | 1 0.04 91.06 207103 | 5 0.19 91.25 207154 | 1 0.04 91.29 207318 | 3 0.12 91.41 207500 | 4 0.15 91.56 207501 | 4 0.15 91.71 207561 | 2 0.08 91.79 207589 | 2 0.08 91.87 207620 | 2 0.08 91.94 207621 | 6 0.23 92.17 207648 | 8 0.31 92.48 207695 | 1 0.04 92.52 207931 | 3 0.12 92.64 207932 | 14 0.54 93.17 207953 | 2 0.08 93.25 207960 | 3 0.12 93.36 207975 | 4 0.15 93.52 207981 | 2 0.08 93.59 207988 | 1 0.04 93.63 207999 | 4 0.15 93.79 208010 | 2 0.08 93.86 208030 | 2 0.08 93.94 208056 | 6 0.23 94.17 208065 | 7 0.27 94.44 208079 | 1 0.04 94.48 208090 | 14 0.54 95.01 208114 | 1 0.04 95.05 208147 | 3 0.12 95.17 208169 | 1 0.04 95.21 208183 | 1 0.04 95.24 208215 | 2 0.08 95.32 208246 | 3 0.12 95.44 208261 | 9 0.35 95.78 208271 | 1 0.04 95.82 208277 | 1 0.04 95.86 208289 | 7 0.27 96.13 208341 | 8 0.31 96.43 208351 | 1 0.04 96.47 208401 | 1 0.04 96.51 208411 | 4 0.15 96.66 208434 | 2 0.08 96.74 208464 | 9 0.35 97.08 208471 | 3 0.12 97.20 208551 | 2 0.08 97.28 208573 | 3 0.12 97.39 208603 | 7 0.27 97.66 208624 | 1 0.04 97.70 208692 | 1 0.04 97.74 208745 | 14 0.54 98.27 209115 | 6 0.23 98.50 209531 | 3 0.12 98.62 209862 | 2 0.08 98.70 761024 | 4 0.15 98.85 761025 | 1 0.04 98.89 761029 | 5 0.19 99.08 761033 | 3 0.12 99.19 761034 | 5 0.19 99.39 761035 | 1 0.04 99.42 761036 | 6 0.23 99.65 761038 | 1 0.04 99.69 761041 | 2 0.08 99.77 761042 | 1 0.04 99.81 761044 | 4 0.15 99.96 761046 | 1 0.04 100.00 ------------+----------------------------------- Total | 2,607 100.00 Frequencies for applicant variable in pmc_commitments dataset : Applicant | Freq. Percent Cum. ----------------------------------------+----------------------------------- ABBVIE INC | 29 1.11 1.11 ACADIA PHARMACEUTICALS INC | 3 0.12 1.23 ACORDA THERAPEUTICS INC | 1 0.04 1.27 ACTELION PHARMACEUTICALS LTD | 3 0.12 1.38 ADAPT PHARMA OPERATIONS LTD | 4 0.15 1.53 AEGERION PHARMACEUTICALS INC | 2 0.08 1.61 ALEMBIC PHARMACEUTICALS LTD | 1 0.04 1.65 ALEXZA PHARMACEUTICALS INC | 3 0.12 1.76 ALKERMES INC | 1 0.04 1.80 ALLERGAN HOLDINGS UNLIMITED CO | 4 0.15 1.96 ALLERGAN INC | 1 0.04 1.99 ALLERGAN PHARMACEUTICALS INTERNATIONA.. | 2 0.08 2.07 ALLERGAN SALES LLC | 20 0.77 2.84 ALLOS THERAPEUTICS INC | 7 0.27 3.11 ALPHARMA PHARMACEUTICALS LLC | 18 0.69 3.80 AMAG PHARMA USA INC | 2 0.08 3.87 AMAG PHARMACEUTICALS INC | 4 0.15 4.03 ANACOR PHARMACEUTICALS INC | 2 0.08 4.10 ANGELINI PHARMA INC | 2 0.08 4.18 ANI PHARMACEUTICALS INC | 1 0.04 4.22 APOPHARMA INC | 4 0.15 4.37 ARALEZ PHARMACEUTICALS TRADING DAC | 2 0.08 4.45 ARBOR PHARMACEUTICALS LLC | 8 0.31 4.76 ARIAD PHARMACEUTICALS INC | 11 0.42 5.18 ASTELLAS PHARMA GLOBAL DEVELOPMENT INC | 4 0.15 5.33 ASTELLAS PHARMA US INC | 12 0.46 5.79 ASTRAZENECA AB | 21 0.81 6.60 ASTRAZENECA PHARMACEUTICALS LP | 20 0.77 7.36 AUXILIUM PHARMACEUTICALS INC | 2 0.08 7.44 AVADEL LEGACY PHARMACEUTICALS LLC | 5 0.19 7.63 AVANIR PHARMACEUTICALS | 3 0.12 7.75 AVEDRO INC | 1 0.04 7.79 AYTU BIOSCIENCE INC | 1 0.04 7.83 AbbVie Inc. | 12 0.46 8.29 Aegerion Pharmaceuticals, Inc | 6 0.23 8.52 Alexion Pharmaceuticals, Inc. | 4 0.15 8.67 Allergan, Inc. | 18 0.69 9.36 Amgen, Inc. | 27 1.04 10.40 Aptevo BioTherapeutics LLC | 1 0.04 10.43 Auxilium Pharmaceuticals, Inc. | 1 0.04 10.47 B BRAUN MEDICAL INC | 48 1.84 12.31 BAUSCH AND LOMB INC | 2 0.08 12.39 BAXTER HEALTHCARE CORP | 54 2.07 14.46 BAYER HEALTHCARE PHARMACEUTICALS INC | 23 0.88 15.34 BIOCRYST PHARMACEUTICALS INC | 7 0.27 15.61 BIODELIVERY SCIENCES INTERNATIONAL INC | 15 0.58 16.19 BIOGEN IDEC INC | 6 0.23 16.42 BIOMARIN PHARMACEUTICAL INC | 5 0.19 16.61 BIONPHARMA INC | 1 0.04 16.65 BOEHRINGER INGELHEIM | 2 0.08 16.72 BOEHRINGER INGELHEIM PHARMACEUTICALS .. | 19 0.73 17.45 BRACCO DIAGNOSTICS INC | 4 0.15 17.61 BRAEBURN PHARMACEUTICALS INC | 4 0.15 17.76 BRAINTREE LABORATORIES INC | 16 0.61 18.37 BRISTOL-MYERS SQUIBB CO | 18 0.69 19.06 Baxalta US Inc. | 19 0.73 19.79 Bayer HealthCare LLC | 2 0.08 19.87 Bio Products Laboratory | 1 0.04 19.91 Biogen Inc. | 18 0.69 20.60 Biomarin Pharmaceutical Inc. | 10 0.38 20.98 Biotest Pharmaceuticals Corporation | 2 0.08 21.06 Boehringer Ingelheim Pharmaceuticals,.. | 1 0.04 21.10 Bristol-Myers Squibb Company | 26 1.00 22.09 CELGENE CORP | 13 0.50 22.59 CEPHALON INC | 2 0.08 22.67 CEREXA INC | 8 0.31 22.98 CHIESI USA INC | 2 0.08 23.05 CIPHER PHARMACEUTICALS INC | 3 0.12 23.17 CIPHER PHARMACEUTICALS US LLC | 2 0.08 23.25 CITIUS PHARMACEUTICALS LLC | 1 0.04 23.28 CLOVIS ONCOLOGY INC | 6 0.23 23.51 COLLEGIUM PHARMACEUTICAL INC | 14 0.54 24.05 CONCORDIA PHARMACEUTICALS INC | 3 0.12 24.17 CORCEPT THERAPEUTICS INC | 2 0.08 24.24 CP PHARMACEUTICALS INTERNATIONAL CV | 5 0.19 24.43 CSL Behring AG | 1 0.04 24.47 CSL Behring GmbH | 9 0.35 24.82 CSL Behring LLC | 2 0.08 24.89 CUBIST PHARMACEUTICALS INC | 4 0.15 25.05 CUBIST PHARMACEUTICALS LLC | 20 0.77 25.82 CUMBERLAND PHARMACEUTICALS INC | 1 0.04 25.85 CYPRESS BIOSCIENCE INC | 1 0.04 25.89 CYPRESS PHARMACEUTICAL INC | 3 0.12 26.01 Cangene Corporation | 6 0.23 26.24 DAIICHI SANKYO INC | 18 0.69 26.93 DENTSPLY PHARMACEUTICAL | 1 0.04 26.97 DEPOMED INC | 28 1.07 28.04 DIGESTIVE CARE INC | 3 0.12 28.15 DOW PHARMACEUTICAL SCIENCES INC | 1 0.04 28.19 DUCHESNAY INC | 1 0.04 28.23 DURATA THERAPEUTICS INTERNATIONAL BV | 7 0.27 28.50 Dendreon Corporation | 1 0.04 28.54 Dyax Corp. | 2 0.08 28.62 EGALET CORP | 7 0.27 28.88 EGALET US INC | 4 0.15 29.04 EISAI INC | 20 0.77 29.80 ELI LILLY AND CO | 5 0.19 30.00 EMD SERONO INC | 1 0.04 30.03 ENDO PHARMACEUTICALS INC | 38 1.46 31.49 EXELIXIS INC | 5 0.19 31.68 EXELTIS SUISSE SA | 1 0.04 31.72 Eli Lilly and Company | 14 0.54 32.26 Elusys Therapeutics, Inc. | 1 0.04 32.30 Emergent BioDefense Operations Lansin.. | 1 0.04 32.34 Ethicon, Inc. | 3 0.12 32.45 FEINSTEIN INSTITUTE MEDICAL RESEARCH | 1 0.04 32.49 FERRING PHARMACEUTICALS INC | 4 0.15 32.64 FLAMEL IRELAND LIMITED | 7 0.27 32.91 FOREST LABORATORIES INC | 7 0.27 33.18 FOREST LABORATORIES LLC | 16 0.61 33.79 FOREST RESEARCH INSTITUTE INC | 20 0.77 34.56 FOUGERA PHARMACEUTICALS INC | 1 0.04 34.60 FRESENIUS KABI DEUTSCHLAND GMBH | 20 0.77 35.37 FRESENIUS KABI USA LLC | 12 0.46 35.83 FRESENIUS MEDICAL CARE NORTH AMERICA | 1 0.04 35.86 Fibrocell Technologies, Inc. | 1 0.04 35.90 GALDERMA LABORATORIES INC | 3 0.12 36.02 GALDERMA LABORATORIES LP | 3 0.12 36.13 GATOR PHARMACEUTICALS INC | 3 0.12 36.25 GE HEALTHCARE INC | 7 0.27 36.52 GENENTECH INC | 6 0.23 36.75 GENZYME CORP | 8 0.31 37.05 GILEAD SCIENCES INC | 93 3.57 40.62 GLAXO GROUP LTD ENGLAND DBA GLAXOSMIT.. | 5 0.19 40.81 GLAXOSMITHKLINE | 1 0.04 40.85 GLAXOSMITHKLINE CONSUMER HEALTHCARE | 2 0.08 40.93 GLAXOSMITHKLINE INTELLECTUAL PROPERTY.. | 4 0.15 41.08 GLAXOSMITHKLINE INTELLECTUAL PROPERTY.. | 7 0.27 41.35 GLAXOSMITHKLINE LLC | 2 0.08 41.43 GUERBET LLC | 7 0.27 41.70 Genentech, Inc. | 35 1.34 43.04 Genzyme Corporation | 13 0.50 43.54 GlaxoSmithKline Biologicals | 19 0.73 44.27 GlaxoSmithKline LLC | 6 0.23 44.50 Grifols Biologicals Inc. | 2 0.08 44.57 Grifols Therapeutics Inc. | 1 0.04 44.61 HAMELN PHARMA PLUS GMBH | 6 0.23 44.84 HELSINN HEALTHCARE SA | 5 0.19 45.03 HERON THERAPEUTICS INC | 7 0.27 45.30 HEYL CHEMISCH PHARMAZEUTISHE FABRIK | 2 0.08 45.38 HOFFMANN-LA ROCHE INC | 14 0.54 45.91 HORIZON PHARMA USA INC | 1 0.04 45.95 HORIZON THERAPEUTICS INC | 3 0.12 46.07 HOSPIRA INC | 93 3.57 49.64 HQ SPECIALTY PHARMA CORP | 1 0.04 49.67 Hoffmann-La Roche Inc. | 1 0.04 49.71 Horizon Pharma Rheumatology LLC | 2 0.08 49.79 Human Genome Sciences, Inc. | 11 0.42 50.21 IBSA INSTITUT BIOCHIMIQUE SA | 1 0.04 50.25 ID Biomedical Corporation of Quebec | 8 0.31 50.56 IMPAX LABORATORIES INC | 2 0.08 50.63 INCYTE CORP | 3 0.12 50.75 INDIVIOR INC | 7 0.27 51.02 INSYS DEVELOPMENT CO INC | 5 0.19 51.21 INTERCEPT PHARMACEUTICALS INC | 4 0.15 51.36 IPR PHARMACEUTICALS INC | 2 0.08 51.44 IROKO PHARMACEUTICALS LLC | 6 0.23 51.67 IRONWOOD PHARMACEUTICALS INC | 1 0.04 51.71 Immunex Corporation | 2 0.08 51.78 Ipsen Biopharm Limited | 7 0.27 52.05 JANSSEN PHARMACEUTICALS INC | 63 2.42 54.47 JANSSEN PRODUCTS LP | 12 0.46 54.93 JANSSEN RESEARCH AND DEVELOPMENT LLC | 3 0.12 55.04 JAVELIN PHARMACEUTICALS INC A WHOLLY .. | 3 0.12 55.16 JAZZ PHARMACEUTICALS INC | 1 0.04 55.20 Janssen Biotech, Inc. | 40 1.53 56.73 KALEO INC | 2 0.08 56.81 KASTLE THERAPEUTICS LLC | 2 0.08 56.89 KERYX BIOPHARMACEUTICALS INC | 1 0.04 56.92 KING PHARMACEUTICALS LLC | 6 0.23 57.15 KNIGHT THERAPEUTICS USA INC | 4 0.15 57.31 KYOWA KIRIN INC | 2 0.08 57.38 KYTHERA BIOPHARMACEUTICALS INC | 1 0.04 57.42 Kamada Ltd. | 4 0.15 57.58 LABORATOIRE HRA PHARMA | 2 0.08 57.65 LANTHEUS MEDICAL IMAGING INC | 1 0.04 57.69 LEHIGH VALLEY TECHNOLOGIES INC | 4 0.15 57.84 LEO PHARMA AS | 4 0.15 58.00 LIEBEL-FLARSHEIM CO LLC | 5 0.19 58.19 LUITPOLD PHARMACEUTICALS INC | 3 0.12 58.30 LUNDBECK NA LTD | 1 0.04 58.34 LUNDBECK PHARMACEUTICALS LLC | 3 0.12 58.46 LUPIN ATLANTIS HOLDING SA SWITZERLAND | 1 0.04 58.50 MALLINCKRODT INC | 3 0.12 58.61 MALLINCKRODT INC THE PHARMACEUTICALS .. | 17 0.65 59.26 MALLINCKRODT IP | 2 0.08 59.34 MANNKIND CORP | 4 0.15 59.49 MAYNE PHARMA LLC | 2 0.08 59.57 MEDA PHARMACEUTICALS | 2 0.08 59.65 MEDICINES360 | 1 0.04 59.69 MEDICIS PHARMACEUTICALS A DIV OF VALE.. | 5 0.19 59.88 MERCK SHARP AND DOHME CORP | 34 1.30 61.18 MERCK SHARP AND DOHME CORP A SUBSIDIA.. | 2 0.08 61.26 MERIDIAN MEDICAL TECHNOLOGIES INC | 4 0.15 61.41 MERZ PHARMACEUTICALS LLC | 2 0.08 61.49 METUCHEN PHARMACEUTICALS LLC | 1 0.04 61.53 MICROBIX BIOSYSTEMS INC | 1 0.04 61.57 MIDATECH PHARMA US INC | 5 0.19 61.76 MISSION PHARMACAL CO | 2 0.08 61.83 MYLAN INSTITUTIONAL INC | 1 0.04 61.87 MYLAN IRELAND LTD | 4 0.15 62.03 MYLAN SPECIALTY LP | 1 0.04 62.06 MedImmune, LLC | 2 0.08 62.14 Merck Sharp & Dohme Corp. | 27 1.04 63.18 Merz Pharmaceuticals GmbH c/o Merz Ph.. | 8 0.31 63.48 NAPO PHARMACEUTICALS INC | 3 0.12 63.60 NAVIDEA BIOPHARMACEUTICALS INC | 1 0.04 63.64 NEOS THERAPEUTICS | 3 0.12 63.75 NODEN PHARMA DAC | 1 0.04 63.79 NOVARTIS PHARMACEUTICALS CORP | 76 2.92 66.71 NOVO NORDISK INC | 18 0.69 67.40 NPS PHARMACEUTICALS INC | 1 0.04 67.43 NPS Pharmaceuticals | 4 0.15 67.59 NUVO RESEARCH INC | 3 0.12 67.70 Novartis Pharmaceuticals Corporation | 10 0.38 68.09 Novo Nordisk Inc. | 3 0.12 68.20 OMEROS CORP | 1 0.04 68.24 ONYX THERAPEUTICS INC A WHOLLY OWNED .. | 5 0.19 68.43 OPKO IRELAND GLOBAL HOLDINGS LTD | 2 0.08 68.51 OREXIGEN THERAPEUTICS INC | 8 0.31 68.81 OREXO US INC | 1 0.04 68.85 ORGANON USA INC A SUBSIDIARY OF MERCK.. | 5 0.19 69.04 ORPHAN EUROPE | 3 0.12 69.16 OSI PHARMACEUTICALS LLC | 2 0.08 69.24 OSMOTICA PHARMACEUTICAL CORP | 1 0.04 69.28 OTSUKA AMERICA PHARMACEUTICAL INC | 2 0.08 69.35 OTSUKA PHARMACEUTICAL CO LTD | 14 0.54 69.89 OTSUKA PHARMACEUTICAL DEVELOPMENT AND.. | 1 0.04 69.93 Octapharma Pharmazeutika Produktionsg.. | 9 0.35 70.27 Organogenesis, Inc. | 1 0.04 70.31 PACIRA PHARMACEUTICALS INC | 4 0.15 70.46 PERNIX IRELAND LTD | 4 0.15 70.62 PERNIX IRELAND PAIN LIMITED | 25 0.96 71.58 PERRIGO ISRAEL PHARMACEUTICALS LTD | 1 0.04 71.61 PERRIGO PHARMA INTERNATIONAL DAC | 2 0.08 71.69 PF PRISM CV | 29 1.11 72.80 PFIZER CENTRAL RESEARCH | 1 0.04 72.84 PFIZER CHEMICALS DIV PFIZER INC | 2 0.08 72.92 PFIZER INC | 42 1.61 74.53 PFIZER PHARMACEUTICALS INC | 2 0.08 74.61 PHARMACIA AND UPJOHN CO | 2 0.08 74.68 PHARMACYCLICS LLC | 7 0.27 74.95 PHARMALUCENCE INC | 8 0.31 75.26 PHOTOCURE ASA | 2 0.08 75.34 PROMIUS PHARMA LLC | 1 0.04 75.37 PROVEPHARM SAS | 4 0.15 75.53 PURDUE PHARMA LP | 97 3.72 79.25 PURDUE PHARMA PRODUCTS LP | 4 0.15 79.40 PURDUE PHARMACEUTICAL PRODUCTS LP | 1 0.04 79.44 Pax Vax Bermuda Ltd. | 2 0.08 79.52 PaxVax berna GmbH | 1 0.04 79.56 ProFibrix, BV. | 1 0.04 79.59 Protein Sciences Corporation | 8 0.31 79.90 R2 PHARMA LLC | 4 0.15 80.05 RAPTOR PHARMACEUTICALS INC | 1 0.04 80.09 RELYPSA INC | 2 0.08 80.17 RETROPHIN INC | 1 0.04 80.21 RHODES PHARMACEUTICALS LP | 9 0.35 80.55 ROCKWELL MEDICAL INC | 4 0.15 80.71 Regeneron Pharmaceuticals, Inc. | 2 0.08 80.78 SALIX PHARMACEUTICALS INC | 18 0.69 81.47 SANOFI-AVENTIS US LLC | 15 0.58 82.05 SANTARUS INC | 3 0.12 82.16 SAREPTA THERAPEUTICS INC | 5 0.19 82.36 SEBELA IRELAND LTD | 2 0.08 82.43 SEPTODONT HOLDING SAS | 2 0.08 82.51 SERB SA | 5 0.19 82.70 SHIONOGI INC | 5 0.19 82.89 SHIRE DEVELOPMENT LLC | 5 0.19 83.08 SHIRE HUMAN GENETIC THERAPIES INC | 4 0.15 83.24 SILVERGATE PHARMACEUTICALS INC | 1 0.04 83.28 SOVEREIGN PHARMACEUTICALS LLC | 2 0.08 83.35 SPECTRUM PHARMACEUTICALS INC | 8 0.31 83.66 SPRIASO LLC | 2 0.08 83.74 SPROUT PHARMACEUTICALS INC | 7 0.27 84.00 STRONGBRIDGE US INC | 2 0.08 84.08 SUCAMPO PHARMA AMERICAS LLC | 7 0.27 84.35 SUN PHARMA GLOBAL FZE | 1 0.04 84.39 SUN PHARMACEUTICAL INDUSTRIES INC | 1 0.04 84.43 SUNOVION PHARMACEUTICALS INC | 22 0.84 85.27 SUPERNUS PHARMACEUTICALS INC | 8 0.31 85.58 SYMPLMED PHARMACEUTICALS LLC | 1 0.04 85.62 SYNERGY PHARMACEUTICALS INC | 14 0.54 86.15 Sandoz Inc. | 2 0.08 86.23 Sanofi Pasteur Biologics, LLC | 3 0.12 86.34 Sanofi Pasteur Inc. | 4 0.15 86.50 Sanofi Pasteur Limited | 1 0.04 86.54 Santarus, Inc. | 1 0.04 86.57 Seattle Genetics, Inc. | 2 0.08 86.65 Seqirus Inc. | 19 0.73 87.38 Seqirus Pty Ltd. | 4 0.15 87.53 Seqirus Vaccines Limited | 1 0.04 87.57 Shire Human Genetic Therapies, Inc. | 4 0.15 87.73 Sicor Biotech UAB | 5 0.19 87.92 SmartPractice Denmark ApS | 1 0.04 87.96 Solstice NeuroSciences, LLC | 2 0.08 88.03 Stallergenes, S.A. | 2 0.08 88.11 Swedish Orphan Biovitrum AB (publ) | 5 0.19 88.30 Synageva BioPharma Corp | 1 0.04 88.34 TAIHO ONCOLOGY INC | 2 0.08 88.42 TAKEDA PHARMACEUTICALS USA INC | 42 1.61 90.03 TALON THERAPEUTICS INC | 3 0.12 90.14 TARO PHARMACEUTICALS USA INC | 1 0.04 90.18 TERUMO BCT | 1 0.04 90.22 TESARO INC | 6 0.23 90.45 TEVA BRANDED PHARMACEUTICAL PRODUCTS .. | 10 0.38 90.83 TEVA NEUROSCIENCE INC | 1 0.04 90.87 TEVA PARENTERAL MEDICINES INC | 1 0.04 90.91 TEVA PHARMACEUTICALS INTERNATIONAL GMBH | 3 0.12 91.02 TEVA PHARMACEUTICALS USA | 2 0.08 91.10 TEVA PHARMACEUTICALS USA INC | 1 0.04 91.14 THE MEDICINES CO | 8 0.31 91.45 THERATECHNOLOGIES INC | 2 0.08 91.52 THERAVANCE BIOPHARMA ANTIBIOTICS INC | 5 0.19 91.71 TRIS PHARMA INC | 5 0.19 91.91 Takeda Pharmaceuticals U.S.A., Inc. | 10 0.38 92.29 Teva Respiratory, LLC | 3 0.12 92.41 Teva Women's Health, Inc. | 1 0.04 92.44 UCB INC | 46 1.76 94.21 UCB, Inc. | 5 0.19 94.40 ULURU INC | 1 0.04 94.44 UNITED STATES ARMY OFFICE SURGEON GEN.. | 1 0.04 94.48 UPSHER-SMITH LABORATORIES INC | 4 0.15 94.63 US WORLDMEDS LLC | 3 0.12 94.74 United Therapeutics Corporation | 5 0.19 94.94 VALEANT PHARMACEUTICALS INTERNATIONAL | 9 0.35 95.28 VALEANT PHARMACEUTICALS INTERNATIONAL.. | 2 0.08 95.36 VALEANT PHARMACEUTICALS NORTH AMERICA.. | 8 0.31 95.67 VALIDUS PHARMACEUTICALS INC | 2 0.08 95.74 VANDA PHARMACEUTICALS INC | 2 0.08 95.82 VERNALIS R AND D LTD | 1 0.04 95.86 VEROSCIENCE LLC | 2 0.08 95.93 VERTEX PHARMACEUTICALS INC | 4 0.15 96.09 VICURON HOLDINGS LLC | 1 0.04 96.13 VIFOR FRESENIUS MEDICAL CARE RENAL PH.. | 1 0.04 96.16 VIIV HEALTHCARE CO | 14 0.54 96.70 VISTAPHARM INC | 2 0.08 96.78 VIVUS INC | 8 0.31 97.08 Valneva Austria GmbH | 4 0.15 97.24 Vifor (International) Inc. | 3 0.12 97.35 ViroPharma Biologics, Inc. | 1 0.04 97.39 WEILL MEDICAL COLLEGE CORNELL UNIV | 2 0.08 97.47 WELLSTAT THERAPEUTICS CORP | 1 0.04 97.51 WEST WARD PHARMACEUTICAL CORP | 5 0.19 97.70 WEST-WARD PHARMACEUTICALS INTERNATION.. | 24 0.92 98.62 WYETH PHARMACEUTICALS INC | 11 0.42 99.04 WYETH PHARMACEUTICALS INC A SUBSIDIAR.. | 1 0.04 99.08 Wyeth Pharmaceuticals Inc. | 16 0.61 99.69 rEVO Biologics, Inc. | 1 0.04 99.73 sanofi-aventis U.S. LLC | 7 0.27 100.00 ----------------------------------------+----------------------------------- Total | 2,607 100.00 Frequencies for product variable in pmc_commitments dataset : Product | Freq. Percent Cum. ----------------------------------------+----------------------------------- 0.9% SODIUM CHLORIDE IRRIGATION, USP | 1 0.04 0.04 ACAM2000, Smallpox (Vaccinia) Vaccine.. | 3 0.12 0.15 ACETATED RINGER'S INJ (PLASTIC CONT) | 1 0.04 0.19 ADD-Vantage® (Sodium Chloride) | 1 0.04 0.23 ADYNOVATE, Antihemophilic Factor (Rec.. | 7 0.27 0.50 AFLURIA; Afluria Quadrivalent, Influe.. | 4 0.15 0.65 ALPROLIX, Coagulation Factor IX (Reco.. | 2 0.08 0.73 APHTHASOL | 1 0.04 0.77 ATryn, Antithrombin (Recombinant) | 1 0.04 0.81 Abilify® (Aripiprazole) | 3 0.12 0.92 Acetic Acid | 4 0.15 1.07 Actemra® (Tocilizumab) | 5 0.19 1.27 ActoPlus Met® (Pioglitazone and Metfo.. | 2 0.08 1.34 Actos® (Pioglitazone Hydrochloride) | 1 0.04 1.38 Aczone® (Dapsone) | 1 0.04 1.42 Adalimumab (ABP 501) | 4 0.15 1.57 Adasuve® (Loxapine) | 3 0.12 1.69 Adcetris® (Brentuximab Vedotin) | 2 0.08 1.76 AddyiI® (Flibanserin) | 7 0.27 2.03 Adenovirus Type 4 and Type 7 Vaccine,.. | 1 0.04 2.07 Adlyxin (lixisenatide) injection | 3 0.12 2.19 Advair® Diskus® (Fluticasone Propiona.. | 2 0.08 2.26 Advate, Antihemophilic Factor (Recomb.. | 1 0.04 2.30 Advil® (Iboprofen Sodium) | 1 0.04 2.34 Advil® Allergy and Congestion Relief .. | 2 0.08 2.42 Advil® Congestion Relief (Ibuprofen a.. | 2 0.08 2.49 Adzenys™ XR-ODT (Amphetamine) | 3 0.12 2.61 Aerospan® (Flunisolide) Inhalation Ae.. | 2 0.08 2.69 Afinitor® (Everolimus) | 3 0.12 2.80 Afrezza® (Human Insulin) | 4 0.15 2.95 Agriflu, Influenza Virus Vaccine | 4 0.15 3.11 Akovaz™ (Ephedrine Sulfate) | 7 0.27 3.38 Akynzeo® (Netupitant and Palonosetron.. | 4 0.15 3.53 Alcohol in Dextrose | 1 0.04 3.57 Aldurazyme® (Laronidase) | 4 0.15 3.72 Alecensa® (Alectinib) | 2 0.08 3.80 Allegra–D® Allergy and Congestion (Fe.. | 8 0.31 4.10 AllerNaze™ | 1 0.04 4.14 Aloxi® (Palonosetron Hydrochloride) | 1 0.04 4.18 Alphanate, Antihemophilic Factor/von .. | 2 0.08 4.26 Amino Acids | 2 0.08 4.33 Amino Acids and Electrolytes | 2 0.08 4.41 Aminosyn™ (Amino Acid) | 2 0.08 4.49 Aminosyn™ HBC (Amino Acid) | 1 0.04 4.53 Aminosyn™ II (Amino Acid and Electrol.. | 4 0.15 4.68 Aminosyn™ II (Amino Acid) | 3 0.12 4.79 Aminosyn™ PF (Dobutamine in Dextrose ) | 2 0.08 4.87 Aminosyn™ RF (Amino Acid) | 1 0.04 4.91 Amitiza® (Lubiprostone) | 7 0.27 5.18 AndroGel® (Testosterone) | 3 0.12 5.29 Androderm® (Testosterone) | 1 0.04 5.33 Anthim (obiltoxaximab) | 1 0.04 5.37 Anthrasil, Anthrax Immune Globulin In.. | 2 0.08 5.45 Aplenzin® (Bupropion Hydrobromide) | 1 0.04 5.49 Apokyn® (Apomorphine Hydrochloride) | 2 0.08 5.56 Apremilast | 2 0.08 5.64 Apriso® (Mesalamine) | 1 0.04 5.68 Aptensio XR® (Methylphenidate Hydroc.. | 3 0.12 5.79 Aptiom® (Eslicarbazepine Acetate) | 13 0.50 6.29 Aptryxol | 1 0.04 6.33 Aralast; Aralast NP, Alpha-1-Proteina.. | 2 0.08 6.41 Aranesp® (Darbepoetin Alpha) | 2 0.08 6.48 Arcalyst® (Rilonacept) | 1 0.04 6.52 Aripiprazole | 1 0.04 6.56 Arixtra® (Fondaparinux Sodium) | 4 0.15 6.71 Arnuity® Ellipta® (Fluticasone Furoate) | 4 0.15 6.87 Aromasin® (Exemestane) | 1 0.04 6.90 Arranon® (Nelarabine) | 1 0.04 6.94 Arymo™ ER (Morphine Sulfate) | 7 0.27 7.21 Asmanex® HFA (Mometasone Furoate) | 2 0.08 7.29 Astagraf™ XL (Tacrolimus) | 2 0.08 7.36 Atripla® (Efavirenz, Emtricitabine, a.. | 1 0.04 7.40 Aubagio® (Teriflunomide) | 2 0.08 7.48 Auryxia® (Ferric Citrate) | 1 0.04 7.52 Avanafil | 1 0.04 7.56 Avastin® (Bevacizumab) | 2 0.08 7.63 Aveed® (Testosterone Undecanoate) | 1 0.04 7.67 Avelox® (Moxifloxacin Hydrochloride) | 2 0.08 7.75 Avelox® IV (Moxifloxacin Hydrochloride) | 2 0.08 7.83 Avinza® (Morphine Sulfate) | 6 0.23 8.06 Avycaz® (Ceftazidime and Avibactam) | 5 0.19 8.25 Axid® (Nizatidine) | 1 0.04 8.29 Axiron® (Testosterone) | 1 0.04 8.32 Azilect® (Rasagiline Mesylate) | 1 0.04 8.36 Azithromycin | 1 0.04 8.40 Azulfidine EN-Tabs® | 1 0.04 8.44 BACTERIOSTATIC WATER FOR INJECTION | 1 0.04 8.48 BAT, Botulism Antitoxin Heptavalent (.. | 3 0.12 8.59 BEXSERO, Meningococcal Group B Vaccine | 6 0.23 8.82 BEYODYM ; PERJETA | 5 0.19 9.01 BRANCHAMIN 4% IN PLASTIC CONTAINER | 1 0.04 9.05 Baraclude® (Entecavir) | 4 0.15 9.21 Belbuca® (Buprenorphine Hydrochloride) | 14 0.54 9.74 Beleodaq® (Belinostat) | 8 0.31 10.05 Belviq® (Lorcaserin Hydrochloride) | 4 0.15 10.20 Benlysta® (Belimumab) | 9 0.35 10.55 Berinert, C1 Esterase Inhibitor (Human) | 3 0.12 10.66 Bethkis™ (Tobramycin) | 1 0.04 10.70 BioThrax, Anthrax Vaccine Adsorbed | 1 0.04 10.74 Bivigam, Immune Globulin Intravenous .. | 2 0.08 10.82 Blincyto® (Blinatumomab) | 1 0.04 10.86 Bosulif® (Bosutinib Monohydrate) | 1 0.04 10.89 Botox® and Botox® Cosmetic (Onabotuli.. | 18 0.69 11.58 Brelsina™ (Etanercept) | 1 0.04 11.62 Breo® Ellipta® (Fluticasone Furoate a.. | 3 0.12 11.74 Bridion® (Sugammadex) | 4 0.15 11.89 Briviact™ (Brivaracetam) | 12 0.46 12.35 Bunavail® (Buprenorphine and Naloxone) | 1 0.04 12.39 Butrans® (Buprenorphine) | 17 0.65 13.04 Bydureon® (Exenatide) | 6 0.23 13.27 Byetta® (Exenatide) | 4 0.15 13.43 CARBAGLU (CARGLUMIC ACID) | 3 0.12 13.54 CHOLOGRAFIN MEGLUMINE | 1 0.04 13.58 CHROMIC CHLORIDE IN PLASTIC CONTAINER | 1 0.04 13.62 CLINIMIX E 2.75/10 SULFITE-FREE W/ EL.. | 1 0.04 13.66 CNJ-016, Vaccinia Immune Globulin Int.. | 1 0.04 13.69 COAGADEX, Coagulation Factor X (Human) | 1 0.04 13.73 CODEINE SULFATE TABLETS 15,30,60 MG | 2 0.08 13.81 COSENTYX | 6 0.23 14.04 Cabotetyx™ (Cabozantinib) | 1 0.04 14.08 Calcium Chloride | 1 0.04 14.12 Calcium Chloride and Magnesium Chlori.. | 1 0.04 14.15 Calcium Choride and Potassium Chlorid.. | 2 0.08 14.23 Caldolor® (Ibuprofen) | 1 0.04 14.27 Cambia® (Diclofenac Potassium) | 6 0.23 14.50 Canasa® (Mesalamine) | 1 0.04 14.54 Cancidas® (Caspofungin Acetate) | 1 0.04 14.58 Caprelsa® (Vandetanib) | 2 0.08 14.65 Cayston® (Aztreonam) | 1 0.04 14.69 Cefazolin Sodium | 1 0.04 14.73 Ceprotin, Protein C Concentrate (Human) | 1 0.04 14.77 Cerdelga (eliglustat) | 2 0.08 14.84 Cervarix, Human Papillomavirus Bivale.. | 3 0.12 14.96 Chantix® (Varenicline Tartrate) | 4 0.15 15.11 Cholbam® (Cholic Acid) | 1 0.04 15.15 Cimzia® (Certolizumab Pegol) | 5 0.19 15.34 Cinqair™ (Reslizumab) | 3 0.12 15.46 Cinryze, C1 Esterase Inhibitor (Human) | 1 0.04 15.50 Cipro® (Ciprofloxacin Hydrochloride) | 2 0.08 15.57 Cipro® IV (Ciprofloxacin) | 2 0.08 15.65 Cleviprex® (Clevidipine Butyrate) | 1 0.04 15.69 Clinimix® Sulfite-Free (Amino Acids i.. | 1 0.04 15.73 Clinolipid™ (Lipid Emulsion) | 6 0.23 15.96 Clobex® (Clobetasol Propionate) | 3 0.12 16.07 Clolar® (Clofarabine) | 1 0.04 16.11 Coartem® (Artemether and Lumefantrine) | 2 0.08 16.19 Codeine Sulfate | 2 0.08 16.26 ColPrep Kit® (Sodium Sulfate, Potassi.. | 3 0.12 16.38 Colazal® (Balsalazide Disodium) | 3 0.12 16.49 Colcrys® (Colchicine) | 2 0.08 16.57 Cometriq® (Cabozantinib) | 4 0.15 16.72 Complera® (Emtricitabine, Rilpivirine.. | 2 0.08 16.80 Conray™ 30 | 1 0.04 16.84 Conray™ and Conray™ 43 | 1 0.04 16.88 Contrave® (Naltrexone Hydrochloride a.. | 8 0.31 17.18 Conzip® (Tramadol Hydrochloride) | 3 0.12 17.30 Copaxone® (Glatiramer Acetate) | 2 0.08 17.38 Copegus® (Ribavirin) | 1 0.04 17.41 Cotellic® (Cobimetinib) | 3 0.12 17.53 Creon® (Pancrelipase) | 2 0.08 17.61 Cresemba™ (Isavuconazonium Sulfate) | 8 0.31 17.91 Cubicin® (Daptomycin) | 2 0.08 17.99 Cupric Chloride | 1 0.04 18.03 Cuvposa® (Glycopyrrolate) | 2 0.08 18.11 Cyanokit® (hydroxocabalamin) | 5 0.19 18.30 Cycloset® (Bromocriptine Mesylate) | 2 0.08 18.37 Cymbalta® (Duloxetine Hydrochloride) | 2 0.08 18.45 Cyramza® (Ramucirumab) | 1 0.04 18.49 Cysview® (Hexaminolevulinate) | 2 0.08 18.57 DISTILLED WATER IN POLYALLOMER CONT. | 1 0.04 18.60 DaTscan™ (Ioflupane I-123) | 1 0.04 18.64 Daklinza® (Daclatasvir Dihydrochloride) | 6 0.23 18.87 Daliresp® (Roflumilast) | 1 0.04 18.91 Dalvance® | 7 0.27 19.18 Darzalex® (Daratumumab) | 6 0.23 19.41 Defitelio™ (Defibrotide Sodium) | 1 0.04 19.45 Delatestryl® (Testosterone Enanthate) | 1 0.04 19.49 Delzicol™ (Mesalamine) | 1 0.04 19.52 Descovy® (Emtricitabine and Tenofovir.. | 2 0.08 19.60 Desvenlafaxine | 1 0.04 19.64 Desvenlafaxine Fumarate | 1 0.04 19.68 Dexilant® (Dexlansoprazole) | 9 0.35 20.02 Dexilant® SoluTab (Dexlansoprazole) | 6 0.23 20.25 Dexmedetomidine Hydrochloride | 1 0.04 20.29 Dextrose | 21 0.81 21.10 Dextrose and Electrolytes | 2 0.08 21.17 Dextrose and Electrolyte® No 48 (Dext.. | 1 0.04 21.21 Dextrose and Multi-Electrolytes | 1 0.04 21.25 Dextrose and Ringer's® in Plastic Con.. | 1 0.04 21.29 Dextrose in Lactated Ringer's | 2 0.08 21.37 Dextrose in Ringer's Injection in EXC.. | 1 0.04 21.40 Dextrose, Electrolytes, and Potassium.. | 1 0.04 21.44 Diclegis® (Doxylamine Succinate and P.. | 1 0.04 21.48 Dificid® (Fidaxomicin) | 3 0.12 21.60 Dilaudid® and Dilaudid® HP (Hydromorp.. | 1 0.04 21.63 Diprivan® (Propofol) | 1 0.04 21.67 Dolophine® (Methadone Hydrochloride) | 16 0.61 22.29 Doribax (doripenem) | 2 0.08 22.36 Dotarem® (Gadoterate Meglumine) | 1 0.04 22.40 Duetact® (Glimepiride and Pioglitazon.. | 1 0.04 22.44 Dulera® (Formoterol Fumarate and Mome.. | 3 0.12 22.55 DuoDote® (Atropine and Pralidoxime Ch.. | 1 0.04 22.59 Duragesic® (Fentanyl Citrate) | 16 0.61 23.21 Dyanavel® XR (Amphetamine) | 3 0.12 23.32 Dyloject® (Diclofenac Sodium) | 3 0.12 23.44 Dysport® (AbobotulinumtoxinA) | 7 0.27 23.71 ELOCTATE, Antihemophilic Factor (Reco.. | 3 0.12 23.82 ERAXIS (anidulafungin) | 1 0.04 23.86 EVARREST, Fibrin Sealant Patch | 3 0.12 23.97 Ecoza (econazole nitrate) Foam | 1 0.04 24.01 Edarbi® (Azilsartan Kamedoxomil) | 2 0.08 24.09 Edurant (rilpivirine) | 1 0.04 24.13 Effexor® XR (Venlafaxine Hydrochloride) | 1 0.04 24.17 Egrifta® (Tesamorelin Acetate) | 2 0.08 24.24 Elaprase® (Idursulfase) | 4 0.15 24.40 Elelyso® (Taliglucerase Alfa) | 8 0.31 24.70 Elidel® (Pimecrolimus) | 1 0.04 24.74 Eliquis® (Apixaban) | 2 0.08 24.82 Ella® (Ulipristal Acetate) | 2 0.08 24.89 Embeda™ (Morphine Sulfate and Naltrex.. | 18 0.69 25.58 Emend® (Aprepitant, Fosaprepitant Dim.. | 5 0.19 25.78 Empliciti™ (Elotuzumab) | 1 0.04 25.82 Enablex® (Darifenacin) | 1 0.04 25.85 Enbrel® (Etanercept) | 2 0.08 25.93 Enstilar® | 2 0.08 26.01 Entereg® (Alvimopan) | 4 0.15 26.16 Entocort® EC (Budesonide) | 2 0.08 26.24 Entresto™ (Sacubutril and Valsartan) .. | 2 0.08 26.31 Entyvio® (Vedolizumab) | 10 0.38 26.70 Epclusa™ (Sofosbuvir and Velpatasvir) | 8 0.31 27.00 Epivir® (Lamivudine) | 2 0.08 27.08 Equetro® (Carbamazepine) | 2 0.08 27.16 Erbitux® (Cetuximab) | 2 0.08 27.23 Erivedge® (Vismodegib) | 3 0.12 27.35 Esomeprazole Strontium | 4 0.15 27.50 Eucrisa™ (Crisaborole) | 1 0.04 27.54 Evotaz® (Atazanavir and Cobicistat) | 4 0.15 27.69 Evzio® (Naloxone Hydrochloride) | 2 0.08 27.77 Exalgo® (Hydromorphone Hydrochloride) | 17 0.65 28.42 Exjade® (Deferasirox) | 15 0.58 29.00 Exondys 51™ (Eteplirsen) | 5 0.19 29.19 Exparel® | 4 0.15 29.34 Eylea® (Aflibercept) | 1 0.04 29.38 FERRISELTZ | 1 0.04 29.42 FLUAD, Influenza Vaccine, Adjuvanted | 5 0.19 29.61 FLUARIX; FLUARIX Quadrivalent, Influe.. | 2 0.08 29.69 FREAMINE III 10% | 1 0.04 29.73 Fabrazyme® (Agalsidase Beta) | 2 0.08 29.80 Fanapt® (Iloperidone) | 2 0.08 29.88 Farxiga® (Dapagliflozin) | 7 0.27 30.15 Farydak® (Panobinostat, LBH589) | 2 0.08 30.23 Feraheme® (Ferumoxytol) | 2 0.08 30.30 Feridex® IV (Ferumoxides) | 1 0.04 30.34 Ferriprox® (Deferiprone) | 4 0.15 30.49 Fetzima® (Levomilnacipran) | 3 0.12 30.61 Finacea® (Azelaic Acid) | 1 0.04 30.65 Flector® (Diclofenac Epolamine) | 1 0.04 30.69 FluBlok, Influenza Vaccine | 8 0.31 30.99 FluLaval; FluLaval Quadrivalent, Infl.. | 3 0.12 31.11 FluMist; FluMist Quad, Influenza Vacc.. | 2 0.08 31.19 FluVirin, Influenza Virus Vaccine | 1 0.04 31.22 Flucelvax; Flucelvax Quadrivalent, In.. | 10 0.38 31.61 Fludeoxyglucose F 18 | 3 0.12 31.72 Fluzone; Fluzone High Dose; Fluzone I.. | 2 0.08 31.80 Folotyn® (Pralatrexate) | 7 0.27 32.07 Foradil® Aerolizer® (Formoterol Fumar.. | 1 0.04 32.11 Forteo® (Teriparatide) | 2 0.08 32.18 Fortesta® (Testosterone) | 1 0.04 32.22 Fragmin® (Dalteparin Sodium) | 1 0.04 32.26 Fulyzaq® (Crofelemer) | 3 0.12 32.37 Fycompa® (Perampanel) | 8 0.31 32.68 GARDASIL, Human Papillomavirus Quadri.. | 5 0.19 32.87 GINTUIT, Allogeneic Cultured Keratino.. | 1 0.04 32.91 GLYCINE 1.5% IN PLASTIC CONTAINER | 1 0.04 32.95 GRASTEK, Timothy Grass Pollen Allerge.. | 2 0.08 33.03 Gardasil 9, Human Papillomavirus 9-va.. | 5 0.19 33.22 Gastromark™ (Ferumoxsil) | 1 0.04 33.26 Gattex® (Teduglutide) | 1 0.04 33.29 Gazyva® (GA101, Obinutuzumab, RO50727.. | 2 0.08 33.37 Gelnique® (Oxybutynin Chloride) | 1 0.04 33.41 Genvoya® (Elvitegravir, Cobicistat, E.. | 2 0.08 33.49 Geodon® (Ziprasidone Hydrochloride) | 1 0.04 33.53 Giazo® (Balsalazide Disodium) | 3 0.12 33.64 Gilenya® (Fingolimod) | 4 0.15 33.79 Gilotrif® | 1 0.04 33.83 Glassia, Alpha-1-Proteinase Inhibitor.. | 4 0.15 33.99 Gleevec® (Imatinib Mesylate) | 3 0.12 34.10 Glyxambi (Empagliflozin and Linaglipt.. | 1 0.04 34.14 Granix® (Tbo-Filgrastim) | 5 0.19 34.33 HEPATAMINE 8% | 1 0.04 34.37 HEXABRIX INJECTION | 1 0.04 34.41 HYPROTIGEN INJ 5%/GLASS | 1 0.04 34.45 HYQVIA, Immune Globulin Infusion (Hum.. | 3 0.12 34.56 Haldol® (Haloperidol Decanoate) | 1 0.04 34.60 HalfLytely® and Bisacodyl Tablet (PEG.. | 4 0.15 34.75 Harvoni® (Ledipasvir and Sofosbuvir) | 14 0.54 35.29 Hectorol® (Doxercalciferol) | 1 0.04 35.33 Herceptin® (Trastuzumab) | 6 0.23 35.56 Hiberix, Haemophilus b Conjugate Vacc.. | 1 0.04 35.60 Horizant® (Gabapentin Enacarbil) | 6 0.23 35.83 Humira® (Adalimumab) | 12 0.46 36.29 Hycofenix® (Hydrocodone, Pseudoephedr.. | 2 0.08 36.36 Hysingla® ER | 22 0.84 37.21 IMLYGIC, Talimogene laherparepvec | 2 0.08 37.28 IXINITY, Coagulation Factor IX (Recom.. | 1 0.04 37.32 Ibrance® (Palbociclib) | 5 0.19 37.51 Iclusig® (Ponatinib) | 11 0.42 37.94 Ilaris® (Canakinumab) | 4 0.15 38.09 Imbruvica® (Ibrutinib) | 7 0.27 38.36 Impavido® (Miltefosine) | 4 0.15 38.51 Injectafer® (Ferric Carboxymaltose) | 2 0.08 38.59 Intelence® (Etravirine) | 1 0.04 38.63 Intermezzo® (Zolpidem Tartrate) | 1 0.04 38.67 Intralipid® 10% (Fat Emulsion) | 5 0.19 38.86 Intralipid® 20% (Fat Emulsion) | 10 0.38 39.24 Intralipid® 30% (Fat Emulsion) | 5 0.19 39.43 Invokamet™ (Canagliflozin and Metform.. | 5 0.19 39.62 Invokana® (Canagloflozin) | 5 0.19 39.82 Iobenguane Sulfate I 131 | 8 0.31 40.12 Ionsys® (Fentanyl Iontophoretic) | 1 0.04 40.16 Isentress® (Raltegravir Potassium) | 3 0.12 40.28 Isentress® (Raltegravir) | 2 0.08 40.35 Isolyte® E in EXCEL® Pastic Container.. | 1 0.04 40.39 Isolyte® H in EXCEL® Plastic Containe.. | 1 0.04 40.43 Isolyte® P in EXCEL® Pastic Container.. | 1 0.04 40.47 Isolyte® R in EXCEL® Plastic Containe.. | 1 0.04 40.51 Isolyte® S in EXCEL® Plastic Containe.. | 1 0.04 40.54 Isoplate Solution, unidentifiable pro.. | 1 0.04 40.58 Isovue® (Iopamidol) | 2 0.08 40.66 Istodax® (Romidepsin) | 3 0.12 40.77 Ixiaro, Japanese Encephalitis Vaccine.. | 4 0.15 40.93 Jadenu® (Deferasirox) | 9 0.35 41.27 Jakafi® (Ruxolitinib Phosphate) | 3 0.12 41.39 Janumet® (Metformin Hydrochloride and.. | 1 0.04 41.43 Janumet® XR (Metformin Hydrochloride .. | 1 0.04 41.47 Januvia® (Sitagliptin Phosphate) | 1 0.04 41.50 Jardiance® (Empagliflozin) | 5 0.19 41.70 Jevtana® (Cabazitaxel, XPR6258) | 2 0.08 41.77 Jublia® (Efinaconazole) | 1 0.04 41.81 Juxtapid® (Lomitapide Mesylate) | 2 0.08 41.89 KOVALTRY, Antihemophilic Factor (Reco.. | 2 0.08 41.96 Kabiven® and Perikabiven® | 1 0.04 42.00 Kadcyla® (Ado-Trastuzumab Emtansine) | 4 0.15 42.16 Kadian® (Morphine Sulfate) | 16 0.61 42.77 Kalbitor® (Ecallantide) | 2 0.08 42.85 Kalydeco® (Ivacaftor) | 3 0.12 42.96 Kanuma™ (Sebelipase Alfa) | 1 0.04 43.00 Kapvay® (Clonidine Hydrochloride) | 2 0.08 43.08 Kayexalate® (Sodium Polystyrene Sulfo.. | 1 0.04 43.11 Kazano® (Alogliptin and Metformin Hyd.. | 2 0.08 43.19 Kcentra, Prothrombin Complex Concentr.. | 2 0.08 43.27 Kepivance® (Palifermin) | 5 0.19 43.46 Kerydin® (Tavaborole) | 1 0.04 43.50 Keveyis® (Dichlorphenamide) | 2 0.08 43.57 Keytruda® (Pembrolizumab) | 8 0.31 43.88 Khedezla™ (Desvenlafaxine) | 1 0.04 43.92 Kinlytic® (Urokinase) | 1 0.04 43.96 Klonopin® (Clonazepam) | 1 0.04 44.00 Kombiglyze® XR (Saxagliptin and Metfo.. | 1 0.04 44.04 Korlym® (Mifepristone) | 2 0.08 44.11 Krystexxa® (Pegloticase) | 2 0.08 44.19 Kuvan® (Sapropterin Dihydrochloride) | 5 0.19 44.38 Kybella™ (Deoxycholic Acid) | 1 0.04 44.42 Kynamro® (Mipomersen Sodium) | 2 0.08 44.50 Kyprolis® (Carfilzomib) | 5 0.19 44.69 LACTATED RINGER'S | 2 0.08 44.76 LACTATED RINGER'S INJ IN PLASTIC(PL-1.. | 1 0.04 44.80 LACTATED RINGER'S IRRIGATION | 1 0.04 44.84 LaViv, Azficel-T | 1 0.04 44.88 Lartruvo™ (Olaratumab) | 1 0.04 44.92 Latuda® (Lurasidone Hydrochloride) | 9 0.35 45.26 Lemtrada® (Alemtuzumab)/Campath® (Ale.. | 4 0.15 45.42 Lenvima® (Lenvatinib Mesylate) | 2 0.08 45.49 Letairis® (Ambrisentan) | 1 0.04 45.53 Leukine® (Sargramostim) | 2 0.08 45.61 Levaquin® (Levofloxacin) | 9 0.35 45.95 Lexapro® (Escitalopram Oxalate ) | 4 0.15 46.11 Lialda® (Mesalamine) | 2 0.08 46.18 Liletta® (Levonorgestrel) | 1 0.04 46.22 Linzess® (Linaclotide) | 7 0.27 46.49 Liposyn® II (Safflower Oil and Soybea.. | 6 0.23 46.72 Liposyn® III (Soybean Oil [Fat Emulsi.. | 7 0.27 46.99 Lonsurf® (Trifluridine and Tipiracil) | 2 0.08 47.07 Lotemax® (Loteprednol Etabonatel) | 1 0.04 47.10 Lumason® (Sulfur Hexafluoride Lipid-T.. | 1 0.04 47.14 Lumizyme™ (Alglucosidase Alfa) | 4 0.15 47.30 Lusedra® (Fospropofol Disodium) | 6 0.23 47.53 Luveris® (Lutropin Alfa) | 1 0.04 47.56 Luzu® (Luliconazole) | 5 0.19 47.76 Lybrel® (Levonorgestrel and Ethinyl E.. | 2 0.08 47.83 Lymphoseek™ (Technetium Tc 99m Tilman.. | 1 0.04 47.87 Lynparza® (Olaparib) | 5 0.19 48.06 Lyrica® (Pregabalin) | 10 0.38 48.45 MANGANESE CHLORIDE IN PLASTIC CONTAINER | 1 0.04 48.48 MD-76R (Diatrizoate Meglumine and Dia.. | 1 0.04 48.52 MENHIBRIX, Meningococcal Groups C and.. | 1 0.04 48.56 METVIXIA (METHYL AMINOLEVULINATE HCL) | 2 0.08 48.64 MS Contin® (Morphine Sulfate) | 16 0.61 49.25 Macugen® | 2 0.08 49.33 Magnesium Chloride and Potassium in D.. | 2 0.08 49.41 Makena® (Hydroxyprogesterone Caproate) | 2 0.08 49.48 Mannitol | 5 0.19 49.67 Mannitol and Sorbitol | 1 0.04 49.71 Marqibo® (Vincristine Sulfate Liposom.. | 3 0.12 49.83 Mechlorethamine | 1 0.04 49.87 Mekinist® (Trametinib) | 3 0.12 49.98 Menactra, Meningococcal Groups (A, C,.. | 2 0.08 50.06 Menveo, Meningococcal (Groups A, C, Y.. | 5 0.19 50.25 Midol® Liquid Gels (Ibuprofen) | 1 0.04 50.29 Mircera® (Methoxy Polyethylene Glycol.. | 3 0.12 50.40 Mirena® (Levonorgestrel-Releasing Int.. | 1 0.04 50.44 MorphaBond™ ER (Morphine Sulfate) | 15 0.58 51.02 Morphine Sulfate | 7 0.27 51.29 Movantik™ (Naloxegol) | 2 0.08 51.36 Moxatag® (Amoxicillin) | 1 0.04 51.40 Multiple Electrolytes Type 1 | 2 0.08 51.48 Multiple Electrolytes Type 2 | 1 0.04 51.52 Myalept™ (Metreleptin) | 6 0.23 51.75 Myobloc® (RimabotulinumtoxinB) | 2 0.08 51.82 Myozyme™ (Alglucosidase Alfa) | 3 0.12 51.94 Myrbetriq® (Mirabegron) | 4 0.15 52.09 NEPHRAMINE 5.4% | 1 0.04 52.13 Naftin® (Naftifine Hydrochloride) | 2 0.08 52.21 Naglazyme® (Galsulfase) | 3 0.12 52.32 Naloxone Hydrochloride | 4 0.15 52.47 Naropin® (Ropivacaine Hydrochloride) | 1 0.04 52.51 Natazia® (Estradiol Valerate; and Est.. | 1 0.04 52.55 Natesto™ (Testosterone) | 1 0.04 52.59 Natpara® (Parathyroid Hormone) | 4 0.15 52.74 Neostigmine Methylsulfate | 1 0.04 52.78 Nesina® (Alogliptin Benzoate) | 4 0.15 52.93 Neulasta® (Pegfilgrastim) | 1 0.04 52.97 Neumega® (Oprelvekin) | 1 0.04 53.01 Neupogen® (Filgrastim) | 1 0.04 53.05 Neupro® (Rotigotine) | 1 0.04 53.09 Nexavar® (Sorafenib Tosylate) | 2 0.08 53.16 Nexiclon XR® (Clonidine) | 2 0.08 53.24 Nexium® (Esomeprazole Magnesium) | 1 0.04 53.28 Nexplanon® (Etonogestrel) | 1 0.04 53.32 Normosol®-R and Normosol®-R pH 7.4 (M.. | 1 0.04 53.36 Normosol™ M and Dextrose (Dextrose an.. | 1 0.04 53.39 Normosol™ R and Dextrose (Dextrose an.. | 1 0.04 53.43 Northera® (Droxidopa) | 1 0.04 53.47 Novamine® (Amino Acids) | 1 0.04 53.51 Novoeight, Antihemophilic Factor (Rec.. | 2 0.08 53.59 Noxafil® (Posaconazole) | 5 0.19 53.78 Nplate® (Romiplostim) | 2 0.08 53.86 Nucala® (Mepolizumab) | 2 0.08 53.93 Nucynta® (Tapentadol) | 2 0.08 54.01 Nucynta® ER (Tapentadol) | 17 0.65 54.66 Nuedexta® (Dextromethorphan Hydrobrom.. | 1 0.04 54.70 Nulojix® (Belatacept) | 3 0.12 54.81 Nuplazid™ (Pimavanserin) | 3 0.12 54.93 Nuvessa™ (Metronidazole) | 1 0.04 54.97 Nuvigil® (Armodafinil) | 1 0.04 55.01 Nuwiq, Antihemophilic Factor (Recombi.. | 4 0.15 55.16 OBIZUR, Antihemophilic Factor (Recomb.. | 1 0.04 55.20 OCTAGAM, Immune Globulin Intravenous .. | 1 0.04 55.24 OCTAPLAS, Pooled Plasma (Human), Solv.. | 4 0.15 55.39 ORALAIR, Sweet Vernal, Orchard, Peren.. | 2 0.08 55.47 OSMITROL 10% IN WATER | 1 0.04 55.50 OSMOPREP | 1 0.04 55.54 Obredon® (Hydrocodone Bitartrate and .. | 2 0.08 55.62 Ocaliva™ (Obeticholic Acid) | 4 0.15 55.77 Odefsey® (Emtricitabine, Rilpivirine,.. | 1 0.04 55.81 Odomzo™ (Sonidegib) | 5 0.19 56.00 Ofev | 1 0.04 56.04 Ofirmev® (Acetaminophen) | 2 0.08 56.12 Oleptro® (Trazodone Hydrochloride) | 2 0.08 56.19 Olysio® (Simeprevir) | 5 0.19 56.39 Omidria® (Phenylephrine and Ketorolac) | 1 0.04 56.43 Omnipaque™ (Iohexol) | 2 0.08 56.50 Omontys (peginesatide) | 6 0.23 56.73 Oncaspar® (Pegaspargase) | 3 0.12 56.85 Onfi® (Clobazam) | 2 0.08 56.92 Onglyza® (Saxagliptin) | 2 0.08 57.00 Onzetra™ and Xsail™ (Sumatriptan Succ.. | 2 0.08 57.08 Opana® (Oxymorphone Hydrochloride) | 2 0.08 57.15 Opana® ER (Oxymorphone Hydrochloride) | 33 1.27 58.42 Opdivo® (Nivolumab) | 11 0.42 58.84 Opsumit® (Macitentan) | 2 0.08 58.92 Optiray™ 240, Optiray™ 300, Optiray™ .. | 1 0.04 58.96 Optiray™ 300 PBP, Optiray™ 320 PBP, O.. | 1 0.04 59.00 Optison® (Human Albumin) | 1 0.04 59.03 OraVerse® (Phentolamine Mesylate) | 2 0.08 59.11 Oraqix™ (Lidocaine and Prilocaine) | 1 0.04 59.15 Oravig® (Miconazole) | 1 0.04 59.19 Orbactiv® (Oritavancin Diphosphate) | 7 0.27 59.46 Orencia® (Abatacept [BMS-188667]) | 4 0.15 59.61 Orkambi™ (Lumacaftor and Ivacaftor) | 1 0.04 59.65 Oseni® (Alogliptin and Pioglitazone) | 1 0.04 59.69 Otezla® (Apremilast) | 1 0.04 59.72 Oxaydo® (Oxycodone Hydrochloride) | 1 0.04 59.76 Oxilan® (Ioxilan) | 5 0.19 59.95 Oxtellar® XR (Oxcarbazepine) | 4 0.15 60.11 OxyContin® (Oxycodone Hydrochloride) | 22 0.84 60.95 Oxycodone Hydrochloride | 6 0.23 61.18 Oxytrol® for Women (Oxybutynin) | 1 0.04 61.22 PLASMA LYTE 56 INJ IN VIAFLEX | 1 0.04 61.26 PLASMA LYTE-R IN PL-146 | 1 0.04 61.30 PROCALAMINE | 1 0.04 61.33 Palladone® (Hydromorphone Hydrochlori.. | 6 0.23 61.57 Pancreaze® (Pancrelipase) | 2 0.08 61.64 Pandel® ((Hydrocortisone Probutate) | 1 0.04 61.68 Pegasys® | 1 0.04 61.72 Pegintron® (Peginterferon Alfa-2b) | 1 0.04 61.76 Pennsaid® (Diclofenac Sodium) | 3 0.12 61.87 Pentacel, Haemophilus b Conjugate Vac.. | 1 0.04 61.91 Pentetate Calcium Trisodium | 3 0.12 62.03 Pentetate Zinc Trisodium | 3 0.12 62.14 Perforomist® (Formoterol Fumarate) | 1 0.04 62.18 Pertzye® (Pancrelipase) | 3 0.12 62.29 Phenylephrine Hydrochloride | 5 0.19 62.49 Phoslyra™ (Calcium Acetate) | 1 0.04 62.52 Photrexa® Viscous (Riboflavin 5'-Phos.. | 1 0.04 62.56 Plasma-Lyte® 148 Injection in Plastic.. | 1 0.04 62.60 Plasma-Lyte® 56 in 5% Dextrose Inject.. | 1 0.04 62.64 Plegridy® (Pegylated Interferon Beta-.. | 2 0.08 62.72 Pomalyst® (Pomalidomide) | 6 0.23 62.95 Potassium Acetate | 1 0.04 62.98 Potassium Chloride | 2 0.08 63.06 Potassium Chloride and Sodium Chlorid.. | 10 0.38 63.44 Potassium Chloride in Dextrose | 6 0.23 63.67 Potassium Chloride in Dextrose in Lac.. | 2 0.08 63.75 Potassium Chloride in Sodium Chloride | 4 0.15 63.90 Potiga® (Ezogabine) | 7 0.27 64.17 Pradaxa® (Dabigatran Etexilate Mesyla.. | 3 0.12 64.29 Praluent® (Alirocumab) | 5 0.19 64.48 Praxbind® (Idarucizumab) | 1 0.04 64.52 Precedex® (Dexmedetomidine Hydrochlor.. | 1 0.04 64.56 Prepopik™(Sodium Picosulfate, Magnesi.. | 4 0.15 64.71 Prestalia® (Perindopril Arginine and .. | 1 0.04 64.75 Prevacid® (Lansoprazole) | 1 0.04 64.79 Prevacid® SoluTab (Lansoprazole ) | 1 0.04 64.83 Prevnar 13, Pneumococcal 13-valent Co.. | 4 0.15 64.98 Prezcobix® | 3 0.12 65.09 Prilosec® (Omeprazole) | 1 0.04 65.13 Pristiq® (Desvenlafaxine) | 2 0.08 65.21 Privigen, Immune Globulin Intravenous.. | 1 0.04 65.25 ProAir® RespiClick® (Albuterol Sulfate) | 3 0.12 65.36 ProAmatine® | 1 0.04 65.40 Probuphine® (Buprenorphine) Implant | 4 0.15 65.55 Procrit® (Epoetin Alfa) | 1 0.04 65.59 Procysbi® (Cysteamine Bitartrate) | 1 0.04 65.63 Prolastin; Prolastin-C, Alpha-1-Prote.. | 1 0.04 65.67 Prolia® (Denosumab, AMG 162) | 7 0.27 65.94 Prosol® (Amino Acid) | 1 0.04 65.98 Protonix® (Pantoprazole Sodium) | 5 0.19 66.17 Protonix® IV (Pantoprazole Sodium) | 2 0.08 66.24 Protopic® (Tacrolimus) | 1 0.04 66.28 ProvayBlue™ (Methylene Blue) | 4 0.15 66.44 Provenge, sipuleucel-T | 1 0.04 66.47 Pyridostigmine Bromide | 1 0.04 66.51 Q-Pan, Influenza A (H5N1) Virus Monov.. | 5 0.19 66.71 Qbrelis™ (Lisinopril) | 1 0.04 66.74 Qsymia™ (Phentermine and Topiramate) | 8 0.31 67.05 Quadramet® (Samarium Sm 153 Lexidronam) | 1 0.04 67.09 Qudexy® XR (Topiramate) | 3 0.12 67.20 QuilliChew ER™ | 3 0.12 67.32 RADIOGARDASE (PRUSSIAN BLUE) 500MG CAPS | 2 0.08 67.40 RAGWITEK, Short Ragweed Pollen Allerg.. | 4 0.15 67.55 RAPLIXA, Fibrin Sealant (Human) | 1 0.04 67.59 RINGER'S INJECTION | 2 0.08 67.66 RIXUBIS, Coagulation Factor IX (Recom.. | 1 0.04 67.70 RUCONEST, C1 Esterase Inhibitor (Reco.. | 1 0.04 67.74 Rapivab® (Peramivir) | 7 0.27 68.01 Ravicti™ (Glycerol Phenylbutyrate) | 3 0.12 68.12 Raxibacumab | 2 0.08 68.20 Rayaldee (calcifediol) extended-relea.. | 2 0.08 68.28 Relistor® (Methylnaltrexone Bromide) | 2 0.08 68.35 Remeron® (Mirtazapine) | 1 0.04 68.39 Remeron® SolTab® (Mirtazapine) | 1 0.04 68.43 Remicade® (Infliximab) | 8 0.31 68.74 Renvela® (Sevelamer Carbonate) | 2 0.08 68.81 Repatha™ (Evolocumab) | 4 0.15 68.97 Requip® XL (Ropinirole Hydrochloride) | 2 0.08 69.04 Resectisol® (Mannitol Irrigation) in .. | 1 0.04 69.08 Retisert® (Fluocinolone Acetonide) | 1 0.04 69.12 Revatio® (Sildenafil Citrate) | 2 0.08 69.20 Revlimid® (Lenalidomide) | 1 0.04 69.24 Rexulti® (Brexpiprazole) | 10 0.38 69.62 Rezira® (Hydrocodone Bitartrate and P.. | 1 0.04 69.66 RiaSTAP, Fibrinogen Concentrate (Human) | 4 0.15 69.81 Ringers Injection | 1 0.04 69.85 Rituxan® (Rituximab) | 3 0.12 69.97 Rotarix, Rotavirus Vaccine, Live, Oral | 1 0.04 70.00 Rubraca™ (Rucaparib) | 6 0.23 70.23 Rybix® ODT (Tramadol Hydrochloride) | 3 0.12 70.35 Rytary™ (Carbidopa and Levodopa) | 2 0.08 70.43 Ryzodeg® 70/30 (Insulin Degludec and .. | 3 0.12 70.54 Ryzolt™ (Tramadol Hydrochloride) | 3 0.12 70.66 SMOFlipid™ (Soybean Oil, Medium Chain.. | 8 0.31 70.96 SODIUM ACETATE IN PLASTIC VIALS | 1 0.04 71.00 SODIUM CHLORIDE 0.45% IN PLASTIC CONT.. | 1 0.04 71.04 SODIUM CHLORIDE 0.9% ABBOJECT 10ML | 1 0.04 71.08 SODIUM CHLORIDE 0.9% IN PLASTIC CONTA.. | 1 0.04 71.12 SODIUM CHLORIDE 3% & 5% INJ USP (PL 1.. | 1 0.04 71.15 SODIUM CHLORIDE 50MEQ,100MEQ IN PLAST V | 1 0.04 71.19 SODIUM LACTATE INJECTION IN PLASTIC V.. | 1 0.04 71.23 SODIUM LACTATE M/6 IN PLAST CONT INJ | 1 0.04 71.27 SODIUM PHOSPHATE IN PLASTIC VIALS | 1 0.04 71.31 SORBITOL 3.3% IRRIGATION IN PLASTIC | 1 0.04 71.35 SOY BEAN OIL | 1 0.04 71.38 Sabril® (Vigabatrin) | 1 0.04 71.42 Samsca® (Tolvaptan) | 2 0.08 71.50 Sancuso® (Granisetron) | 2 0.08 71.58 Saphris® (Asenapine Maleate) | 2 0.08 71.65 Savaysa™ (Edoxaban Tosylate) | 2 0.08 71.73 Savella® (Milnacipran Hydrochloride) | 1 0.04 71.77 Saxenda® (Liraglutide) | 7 0.27 72.04 Selzentry® (Maraviroc) | 2 0.08 72.11 Sernivo™ (Betamethasone Dipropionate) | 1 0.04 72.15 Signifor® (Pasireotide) | 3 0.12 72.27 Simponi® (Golimumab) | 14 0.54 72.80 Simponi® Aria™ (Golimumab) | 1 0.04 72.84 Sirturo® (Bedaquiline) | 3 0.12 72.96 Sitavig® (Acyclovir) | 2 0.08 73.03 Sivextro™ (Tedizolid Phosphate) | 12 0.46 73.49 Sodium Chloride | 10 0.38 73.88 Sodium Chloride in Dextrose | 12 0.46 74.34 Sodium Lactate | 1 0.04 74.38 Soliris® (Eculizumab) | 1 0.04 74.42 Sorilux™ (Calcipotriene) | 2 0.08 74.49 Sovaldi® (Sofosbuvir) | 9 0.35 74.84 Spinraza™ (Nusinersen) | 3 0.12 74.95 Spiriva® Respimat® (Tiotropium Bromide) | 2 0.08 75.03 Sprix® (Ketorolac Tromethamine) | 3 0.12 75.14 Stelara® (Ustekinumab) | 10 0.38 75.53 Sterile Water | 5 0.19 75.72 Stivarga® (Regorafenib) | 3 0.12 75.83 Strensiq® (Asfotase Alfa) | 3 0.12 75.95 Striant® (Testosterone) | 1 0.04 75.99 Stribild® (Elvitegravir, Cobicistat, .. | 5 0.19 76.18 Suboxone® (Buprenorphine and Naloxone) | 4 0.15 76.33 Subutex® (Buprenorphine Hydrochloride) | 3 0.12 76.45 Suclear™ (Sodium Sulfate, Potassium S.. | 7 0.27 76.72 Sulfamylon® (Mafenide Acetate) | 1 0.04 76.75 Suprenza™ (Phentermine Hydrochloride) | 1 0.04 76.79 Suprep® Bowel Prep Kit (Sodium Sulfat.. | 4 0.15 76.95 Sustiva® (Efavirenz) | 2 0.08 77.02 Sustol® (Granisetron) | 7 0.27 77.29 Sutent® (Sunitinib Malate) | 5 0.19 77.48 Sylvant® (Siltuximab) | 1 0.04 77.52 Symbicort® pMDI (Budesonide and Formo.. | 2 0.08 77.60 Syndros™ (Dronabinol) | 5 0.19 77.79 Synjardy® (Empagliflozin and Metformi.. | 5 0.19 77.98 Synribo® (Omacetaxine Mepesuccinate) | 3 0.12 78.10 T.R.U.E. TEST, Thin-Layer Rapid Use E.. | 1 0.04 78.14 TPN ELECTROLYTES IN PLASTIC VIALS | 1 0.04 78.17 TRETTEN, Coagulation Factor XIII A-Su.. | 1 0.04 78.21 TROPHAMINE | 1 0.04 78.25 TROXYCA ER | 6 0.23 78.48 TRUMENBA, Meningococcal Group B Vaccine | 10 0.38 78.86 Taclonex® (Calcipotriene and Betameth.. | 1 0.04 78.90 Tafinlar® (Dabrafenib) | 7 0.27 79.17 Tagrisso™ (Osimertinib) | 7 0.27 79.44 Taltz™ (Ixekizumab) | 5 0.19 79.63 Tamiflu® (Oseltamivir Phosphate) | 1 0.04 79.67 Tanzeum® (Albiglutide) | 4 0.15 79.82 Tarceva® (Erlotinib Hydrochloride) | 2 0.08 79.90 Targiniq™ ER (Oxycodone Hydrochloride.. | 20 0.77 80.67 Tecentriq™ (Atezolizumab) | 7 0.27 80.94 Tecfidera® (Dimethyl Fumarate) | 3 0.12 81.05 Technivie® (Ombitasvir, Paritaprevir,.. | 3 0.12 81.17 Teflaro® (Ceftaroline Fosamil) | 3 0.12 81.28 Tekturna® (Aliskiren) | 1 0.04 81.32 Teslascan™ | 1 0.04 81.36 Testim® (Testosterone) | 1 0.04 81.40 Testosterone | 1 0.04 81.43 Tivicay® (Dolutegravir) | 7 0.27 81.70 Tivorbex™ (Indomethacin) | 3 0.12 81.82 Tobi Podhaler (Tobramycin) | 5 0.19 82.01 Topamax® (Topiramate) | 2 0.08 82.09 Topicort® (Desoximetasone) | 1 0.04 82.13 Toviaz® (Fesoterodine Fumarate) | 1 0.04 82.16 Tradjenta® (Linagliptin) | 3 0.12 82.28 Treanda® (Bendamustine Hydrochloride) | 1 0.04 82.32 Tresiba (Insulin Degludec Injection) | 4 0.15 82.47 Treximet® (Sumatriptan and Naproxen S.. | 4 0.15 82.62 Triferic™ (Ferric Pyrophosphate Citra.. | 4 0.15 82.78 Trintellix™ (Vortioxetine) | 5 0.19 82.97 Triumeq® | 3 0.12 83.08 Trokendi XR® (Topiramate) | 4 0.15 83.24 Trulance™ (Plecanatide) | 14 0.54 83.77 Trulicity® (Dulaglutide) | 5 0.19 83.97 Truvada® (Emtricitabine and Tenofovir.. | 6 0.23 84.20 Tudorza™ Pressair™ (Aclidinium Bromide) | 1 0.04 84.23 Tuxarin™ ER (Codeine Phosphate and Ch.. | 2 0.08 84.31 Tybost® (Cobicistat) | 8 0.31 84.62 Tygacil® (Tigecycline) | 3 0.12 84.73 Tykerb® (Lapatinib) | 1 0.04 84.77 Tysabri® (Natalizumab) | 6 0.23 85.00 Tyzeka® (Telbivudine) | 4 0.15 85.16 Uceris® (Budesonide) | 2 0.08 85.23 Uloric® (Febuxostat) | 1 0.04 85.27 Ultracet® (Acetaminophen and Tramadol.. | 2 0.08 85.35 Ultram® (Tramadol Hydrochloride) | 2 0.08 85.42 Ultram® ER (Tramadol Hydrochloride) | 4 0.15 85.58 Ultravate® (Halobetasol Propionate) | 1 0.04 85.62 Ultravist® (Iopromide) | 1 0.04 85.65 Ultravist® Injection Pharmacy Bulk Pack | 1 0.04 85.69 Ultresa® (Pancrelipase) | 2 0.08 85.77 Unituxin® (Dinutuximab) | 5 0.19 85.96 VELAGLUCERASE ALFA | 4 0.15 86.11 VESIcare® (Solifenacin Succinate) | 1 0.04 86.15 Valcyte® (Valganciclovir Hydrochloride) | 2 0.08 86.23 Vantrela ER (hydrocodone bitartrate) .. | 4 0.15 86.38 Varubi™ (Rolapitant) | 6 0.23 86.61 Vaxchora, Cholera Vaccine Live Oral | 2 0.08 86.69 Vazculep® (Phenylephrine Hydrochloride) | 5 0.19 86.88 Vectibix® (Panitumumab) | 2 0.08 86.96 Vectical™ (Calcitriol) | 1 0.04 87.00 Velphoro® (Sucroferric Oxyhydroxide) | 1 0.04 87.03 Veltassa® (Patiromer) | 2 0.08 87.11 Vemlidy® (Tenofovir Alafenamide) | 9 0.35 87.46 Venclexta™ (Venetoclax) | 3 0.12 87.57 Venofer® (Iron Sucrose) | 1 0.04 87.61 Vfend® (Voriconazole) | 2 0.08 87.69 Vibativ® | 3 0.12 87.80 Vibativ® (Telavancin Hydrochloride) | 2 0.08 87.88 Viberzi® (Eluxadoline) | 4 0.15 88.03 Victoza® (Liraglutide) | 4 0.15 88.19 Viekira Pak® (Ombitasvir, Paritaprevi.. | 15 0.58 88.76 Viekira® XR (Dasabuvir, Ombitasvir, P.. | 1 0.04 88.80 Viibryd® (Vilazodone Hydrochloride) | 2 0.08 88.88 Vimizim® (Elosulfase Alfa) | 3 0.12 88.99 Vimovo® (Esomeprazole Magnesium and N.. | 1 0.04 89.03 Vimpat® (Lacosamide) | 33 1.27 90.30 Vioxx™ (Rofecoxib) | 1 0.04 90.33 Viread® (Tenofovir Disoproxil Fumarate) | 5 0.19 90.53 Visicol® (Sodium Phosphate Monobasic .. | 1 0.04 90.56 Visipaque™ (Iohexol) | 2 0.08 90.64 Vitekta® (Elvitegravir) | 1 0.04 90.68 Vituz® (Hydrocodone Bitartrate and Ch.. | 1 0.04 90.72 Vivitrol® (Naltrexone Hydrochloride) | 1 0.04 90.76 Vivotif, Typhoid Vaccine Live Oral Ty.. | 1 0.04 90.79 Vogelxo™(Testosterone) | 1 0.04 90.83 Voltaren® (Diclofenac Sodium) | 2 0.08 90.91 Vraylar® (Cariprazine) | 20 0.77 91.68 Vyvanse® (Lisdexamfetamine Dimesylate) | 2 0.08 91.75 WelChol® (Colesevelam Hydrochloride) | 1 0.04 91.79 XYNTHA; XYNTHA SOLOFUSE, Antihemophil.. | 1 0.04 91.83 Xalkori® (Crizotinib) | 9 0.35 92.17 Xarelto® (Rivaroxaban) | 19 0.73 92.90 Xartemis™ XR (Acetaminophen and Oxyco.. | 3 0.12 93.02 Xeljanz® (Tofacitinib) | 3 0.12 93.13 Xeljanz® XR (Tofacitinib) | 3 0.12 93.25 Xenazine® (Tetrabenazine) | 2 0.08 93.33 Xeomin™ (IncobotulinumtoxinA) | 8 0.31 93.63 Xiaflex® (Collagenase Clostridium His.. | 1 0.04 93.67 Xifaxan® | 5 0.19 93.86 Xifaxan® (Rifaximin) | 9 0.35 94.21 Xigduo™ (Dapagliflozin and Metformin) | 1 0.04 94.25 Xofigo® (Radium Ra 223 Dichchoride) | 4 0.15 94.40 Xolair® (Omalizumab) | 1 0.04 94.44 Xtampza ER™ (Oxycodone) | 14 0.54 94.98 Xtandi® (Enzalutamide) | 1 0.04 95.01 Xuriden™ (Uridine Triacetate) | 1 0.04 95.05 Yasmin® (Drospirenone and Ethinyl Est.. | 1 0.04 95.09 Yervoy® (Ipilimumab) | 7 0.27 95.36 Yondelis™ (Trabectedin) | 2 0.08 95.44 Yosprala™ (Aspirin and Omeprazole) | 2 0.08 95.51 ZIinbryta™ (Daclizumab) | 5 0.19 95.70 Zanaflex® (Tizanidine Hydrochloride) | 1 0.04 95.74 Zarxio™ (Filgrastim) | 1 0.04 95.78 Zecuity™ (Sumatriptan) | 3 0.12 95.90 Zegerid® (Omeprazole and Sodium Bicar.. | 3 0.12 96.01 Zelboraf® (Vemurafenib) | 7 0.27 96.28 Zelnorm® (Tegaserod Maleate) | 1 0.04 96.32 Zemaira, Alpha-1-Proteinase Inhibitor.. | 2 0.08 96.39 Zemplar® (Paricalcitol) | 3 0.12 96.51 Zenpep® (Pancrelipase) | 2 0.08 96.59 Zepatier® (Elbasvir and Grazoprevir) | 9 0.35 96.93 Zerbaxa® (Ceftolozane Sulfate and Taz.. | 3 0.12 97.05 Zinc Chloride | 1 0.04 97.08 Zinplava™ (Bezlotoxumab) | 1 0.04 97.12 Zipsor® (Diclofenac Potassium) | 3 0.12 97.24 Zithromax® (Azithromycin) | 6 0.23 97.47 Zmax® (Azithromycin) | 1 0.04 97.51 Zohydro® ER (Hydrocodone Bitartrate) | 25 0.96 98.47 Zoloft® (Sertraline Hydrochloride) | 2 0.08 98.54 Zomig® Nasal Spray (Zolmitriptan) | 2 0.08 98.62 Zorvolex® (Diclofenac) | 3 0.12 98.73 Zostavax, Zoster Vaccine Live | 1 0.04 98.77 Zubsolv® (Buprenorphine Hydrochloride.. | 1 0.04 98.81 Zuplenz™ (Ondansetron) | 4 0.15 98.96 Zurampic® (Lesinurad) | 1 0.04 99.00 Zutripro® (Hydrocodone Bitartrate, Ch.. | 1 0.04 99.04 Zyban® (Bupropion Hydrochloride) | 1 0.04 99.08 Zydelig® (Idelalisib) | 18 0.69 99.77 Zykadia® (Ceritinib) | 6 0.23 100.00 ----------------------------------------+----------------------------------- Total | 2,607 100.00 Frequencies for public_flag variable in pmc_commitments dataset : Public Flag | Freq. Percent Cum. ------------+----------------------------------- Y | 2,607 100.00 100.00 ------------+----------------------------------- Total | 2,607 100.00 Frequencies for cder_or_cber variable in pmc_commitments dataset : Center for | Biologics | Evaluation | & Research | (CBER) or | Center for | Drug | Evaluation | Freq. Percent Cum. ------------+----------------------------------- CB | 190 7.29 7.29 CD | 2,417 92.71 100.00 ------------+----------------------------------- Total | 2,607 100.00 Frequencies for subpart_flag variable in pmc_commitments dataset : Subpart Flag | Freq. Percent Cum. ----------------------------------------+----------------------------------- Food and Drug Administration Amendments | 1,242 47.64 47.64 Accelerated Approval | 95 3.64 51.29 Deferred pediatric under Pediatric Rese | 784 30.07 81.36 . | 486 18.64 100.00 ----------------------------------------+----------------------------------- Total | 2,607 100.00 Frequencies for subpart_flagstr variable in pmc_commitments dataset : Subpart | Flag | Freq. Percent Cum. ------------+----------------------------------- | 466 17.87 17.87 E | 20 0.77 18.64 F | 1,242 47.64 66.28 H | 95 3.64 69.93 P | 784 30.07 100.00 ------------+----------------------------------- Total | 2,607 100.00 by Jean Roth , jroth@nber.org , 3 Feb 2017